

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
8 April 2004 (08.04.2004)

PCT

(10) International Publication Number
WO 2004/029220 A2

- (51) International Patent Classification⁷: **C12N**
- (21) International Application Number:
PCT/US2003/030940
- (22) International Filing Date:
26 September 2003 (26.09.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/414,085 26 September 2002 (26.09.2002) US
- (71) Applicant (*for all designated States except US*): **KOSAN BIOSCIENCES, INC.** [US/US]; 3832 Bay Center Place, Hayward, CA 94545 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **SANTI, Daniel, V.** [IN/US]; 211 Belgrave Avenue, San Francisco, CA 94117 (US). **REID, Ralph, C.** [US/US]; 600 Galcitra Way, San Rafael, CA 94903 (US). **KODUMAL, Sarah, J.** [US/US]; 3933 Harrison Street, Apartment # 102, Oakland, CA 94611 (US). **JAYARAJ, Sebastian** [IN/US]; 1709 Shattuck Avenue, Apartment # 214, Berkeley, CA 94709 (US).
- (74) Agents: **APPLE, Randolph, Ted et al.**; Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, CA 94304 (US).
- (81) Designated States (*national*): AE, AG, AI, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SI, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— *without international search report and to be republished upon receipt of that report*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: **SYNTHETIC GENES**

(57) Abstract: The invention provides strategies, methods, vectors, reagents, and systems for production of synthetic genes, production of libraries of such genes, and manipulation and characterization of the genes and corresponding encoded polypeptides. In one aspect, the synthetic genes can encode polyketide synthase polypeptides and facilitate production of therapeutically or commercially important polyketide compounds.



WO 2004/029220 A2

SYNTHETIC GENES

STATEMENT CONCERNING GOVERNMENT SUPPORT

[0001] Subject matter disclosed in this application was made, in part, with government support under National Institute of Standards and Technology ATP Grant No. 70NANB2H3014. As such, the United States government may have certain rights in this invention.

CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims benefit under 35 U.S.C. § 119(e) of provisional application No. 60/414,085, filed 26 September 2002, the contents of which are incorporated herein by reference.

FIELD OF THE INVENTION

[0003] The invention provides strategies, methods, vectors, reagents, and systems for production of synthetic genes, production of libraries of such genes, and manipulation and characterization of the genes and corresponding encoded polypeptides. In one aspect, the synthetic genes can encode polyketide synthase polypeptides and facilitate production of therapeutically or commercially important polyketide compounds. The invention finds application in the fields of human and veterinary medicine, pharmacology, agriculture, and molecular biology.

BACKGROUND

[0004] Polyketides represent a large family of compounds produced by fungi, mycelial bacteria, and other organisms. Numerous polyketides have therapeutically relevant and/or commercially valuable activities. Examples of useful polyketides include erythromycin, FK-506, FK-520, megalomycin, narbomycin, oleandomycin, picromycin, rapamycin, spinocyn, and tylosin.

[0005] Polyketides are synthesized in nature from 2-carbon units through a series of condensations and subsequent modifications by polyketide synthases (PKSs). Polyketide

synthases are multifunctional enzyme complexes composed of multiple large polypeptides. Each of the polypeptide components of the complex is encoded by a separate open reading frame, with the open reading frames corresponding to a particular PKS typically being clustered together on the chromosome. The structure of PKSs and the mechanisms of polyketide synthesis are reviewed in Cane et al., 1998, "Harnessing the biosynthetic code: combinations, permutations, and mutations" *Science* 282:63-8.

[0006] PKS polypeptides comprise numerous enzymatic and carrier domains, including acyltransferase (AT), acyl carrier protein (ACP), and beta-ketoacylsynthase (KS) activities, involved in loading and condensation steps; ketoreductase (KR), dehydratase (DH), and enoylreductase (ER) activities, involved in modification at β -carbon positions of the growing chain, and thioesterase (TE) activities involved in release of the polyketide from the PKS. Various combinations of these domains are organized in units called "modules." For example, the 6-deoxyerythronolide B synthase ("DEBS"), which is involved in the production of erythromycin, comprises 6 modules on three separate polypeptides (2 modules per polypeptide). The number, sequence, and domain content of the modules of a PKS determine the structure of the polyketide product of the PKS.

[0007] Given the importance of polyketides, the difficulty in producing polyketide compounds by traditional chemical methods, and the typically low production of polyketides in wild-type cells, there has been considerable interest in finding improved or alternate means for producing polyketide compounds. This interest has resulted in the cloning, analysis and manipulation by recombinant DNA technology of genes that encode PKS enzymes. The resulting technology allows one to manipulate a known PKS gene cluster to produce the polyketide synthesized by that PKS at higher levels than occur in nature, or in hosts that otherwise do not produce the polyketide. The technology also allows one to produce molecules that are structurally related to, but distinct from, the polyketides produced from known PKS gene clusters by inactivating a domain in the PKS and/or by adding a domain not normally found in the PKS through manipulation of the PKS gene.

[0008] While the detailed understanding of the mechanisms by which PKS enzymes function and the development of methods for manipulating PKS genes have facilitated the creation of novel polyketides, there are presently limits to the creation of novel polyketides by genetic engineering. One such limit is the availability of PKS genes. Many polyketides are known but

only a relatively small portion of the corresponding PKS genes have been cloned and are available for manipulation. Moreover, in many instances the organism producing an interesting polyketide is obtainable only with great difficulty and expense, and techniques for its growth in the laboratory and, production of the polyketide it produces are unknown or difficult or time-consuming to practice. Also, even if the PKS genes for a desired polyketide have been cloned, those genes may not serve to drive the level of production desired in a particular host cell.

[0009] If there was a method to produce a desired polyketide without having to access the genes that encode the PKS that produces the polyketide, then many of these difficulties could be ameliorated or avoided altogether. The present invention meets this and other needs.

BRIEF SUMMARY OF THE INVENTION

[0010] In one aspect, the invention provides a synthetic gene encoding a polypeptide segment that corresponds to a reference polypeptide segment encoded by a naturally occurring gene. The polypeptide segment-encoding sequence of the synthetic gene is different from the polypeptide segment-encoding sequence of the naturally occurring gene. In one aspect, the polypeptide segment-encoding sequence of the synthetic gene is less than about 90% identical to the polypeptide segment-encoding sequence of the naturally occurring gene, or in some embodiments, less than about 85% or less than about 80% identical. In one aspect, the polypeptide segment-encoding sequence of the synthetic gene comprises at least one (and in other embodiments, more than one, e.g., at least two, at least three, or at least four) unique restriction sites that are not present or are not unique in the polypeptide segment-encoding sequence of the naturally occurring gene. In an aspect, the polypeptide segment-encoding sequence of the synthetic gene is free from at least one restriction site that is present in the polypeptide segment-encoding sequence of the naturally occurring gene. In an embodiment of the invention, the polypeptide segment encoded by the synthetic gene corresponds to at least 50 contiguous amino acid residues encoded by the naturally occurring gene.

[0011] In an embodiment, the polypeptide segment is from a polyketide synthase (PKS) and may be or include a PKS domain (e.g., AT, ACP, KS, KR, DH, ER, and/or TE) or one or more PKS modules. In some embodiments, the synthetic PKS gene has, at most, one copy per module-encoding sequence of a restriction enzyme recognition site selected from the group consisting of Spe I, Mfe I, Afi II, Bsi WI, Sac II, Ngo MIV, Nhe I, Kpn I, Msc I, Bgl II, Bss HII,

Sac II, Age I, Pst I, Kas I, Mlu I, Xba I, Sph I, Bsp E, and Ngo MIV recognition sites. In an embodiment, the polypeptide segment-encoding sequence of the synthetic gene is free from at least one Type IIS enzyme restriction site (e.g., Bci VI, Bmr I, Bpm I, Bpu EI, Bse RI, Bsg I, Bsr DI, Bts I, Eci I, Ear I, Sap I, Bsm BI, Bsp MI, Bsa I, Bbs I, Bfu AI, Fok I and Alw I) present in the polypeptide segment-encoding sequence of the naturally occurring gene.

[0012] In a related embodiment, the invention provides a synthetic gene encoding a polypeptide segment that corresponds to a reference polypeptide segment encoded by a naturally occurring PKS gene, where the polypeptide segment-encoding sequence of the synthetic gene is different from the polypeptide segment-encoding sequence of the naturally occurring PKS gene and comprises at least two of (a) a Spe I site near the sequence encoding the amino-terminus of the module; (b) a Mfe I site near the sequence encoding the amino-terminus of a KS domain; (c) a Kpn I site near the sequence encoding the carboxy-terminus of a KS domain; (d) a Msc I site near the sequence encoding the amino-terminus of an AT domain; (e) a Pst I site near the sequence encoding the carboxy-terminus of an AT domain; (f) a Bsr BI site near the sequence encoding the amino-terminus of an ER domain; (g) an Age I site near the sequence encoding the amino-terminus of a KR domain; and (h) an Xba I site near the sequence encoding the amino-terminus of an ACP domain.

[0013] In related aspects, the invention provides a vector (e.g., cloning or expression vector) comprising a synthetic gene of the invention. In an embodiment, the vector comprises an open reading frame encoding a first PKS module and one or more of (a) a PKS extension module; (b) a PKS loading module; (c) a releasing (e.g., thioesterase) domain; and (d) an interpolypeptide linker.

[0014] Cells that comprise or express a gene or vector of the invention are provided, as well as a cell comprising a polypeptide encoded by the vector or, a functional polyketide synthase, wherein the PKS comprises a polypeptide encoded by the vector. In one aspect, a PKS polypeptide having a non-natural amino sequence is provided, such as a polypeptide characterized by a KS domain comprising the dipeptide Leu-Gln at the carboxy-terminal edge of the domain; and/or an ACP domain comprising the dipeptide Ser-Ser at the carboxy-terminal edge of the domain. A method is provided for making a polyketide comprising culturing a cell comprising a synthetic DNA of the invention under conditions in which a polyketide is produced, wherein the polyketide would not be produced by the cell in the absence of the vector.

[0015] In one aspect, the invention provides a method for high throughput synthesis of a plurality of different DNA units comprising different polypeptide encoding sequences comprising: for each DNA unit, performing polymerase chain reaction (PCR) amplification of a plurality of overlapping oligonucleotides to generate a DNA unit encoding a polypeptide segment and adding UDG-containing linkers to the 5' and 3' ends of the DNA unit by PCR amplification, thereby generating a linkered DNA unit, wherein the same UDG-containing linkers are added to said different DNA units. In embodiments, the plurality comprises more than 50 different DNA units, more than 100 different DNA units, or more than 500 different DNA units (synthons). In a related aspect, the invention provides a method for producing a vector comprising a polypeptide encoding sequence comprising cloning the linkered DNA unit into a vector using a ligation-independent-cloning method.

[0016] The invention provides gene libraries. In one embodiment, a gene library is provided that contains a plurality of different PKS module-encoding genes, where the module-encoding genes in the library have at least one (or more than one, such as at least 3, at least 4, at least 5 or at least 6) restriction site(s) in common, the restriction site is found no more than one time in each module, and the modules encoded in the library correspond to modules from five or more different polyketide synthase proteins. Vectors for gene libraries include cloning and expression vectors. In some embodiments, a library includes open reading frames that contain an extension module and at least one of a second PKS extension module, a PKS loading module, a thioesterase domain, and an interpolypeptide linker.

[0017] In a related aspect, the invention provides a method for synthesis of an expression library of PKS module-encoding genes by making a plurality of different PKS module-encoding genes as described above and cloning each gene into an expression vector. The library may include, for example, at least about 50 or at least about 100 different module-encoding genes.

[0018] The invention provides a variety of cloning vectors useful for stitching (e.g., a vector comprising, in the order shown, SM4 – SIS – SM2 – R₁ or L – SIS – SM2 – R₁ where SIS is a synthon insertion site, SM2 is a sequence encoding a first selectable marker, SM4 is a sequence encoding a second selectable marker different from the first, R₁ is a recognition site for a restriction enzyme, and L is a recognition site for a different restriction enzyme. The invention further provides vectors comprising synthon sequences, e.g. comprising, in the order shown, SM4 – 2S₁ – Sy₁ – 2S₂ – SM2 – R₁ or L – 2S₁ – Sy₂ – 2S₂ – SM2 – R₁ where 2S₁ is a

recognition site for first Type IIS restriction enzyme, $2S_2$ is a recognition site for a different Type IIS restriction enzyme, and Sy is synthon coding region. Also provided are compositions of a vector and a Type IIS or other restriction enzyme that recognizes a site on the vector, compositions comprising cognate pairs of vectors, kits, and the like.

[0019] In one embodiment, the invention provides a vector comprising a first selectable marker, a restriction site (R_1) recognized by a first restriction enzyme, and a synthon coding region that is flanked by a restriction site recognized by a first Type IIS restriction enzyme and a restriction site recognized by a second Type IIS restriction enzyme, wherein digestion of the vector with the first restriction enzyme and the first Type IIS restriction enzyme produces a fragment comprising the first selectable marker and the synthon coding region, and digestion of the vector with the first restriction enzyme and the second Type IIS restriction enzyme produces a fragment comprising the synthon coding region and not comprising the first selectable marker. In an embodiment, the vector comprising a second selectable marker wherein digestion of the vector with the first restriction enzyme and the first Type IIS restriction enzyme produces a fragment comprising the first selectable marker and the synthon coding region, and not comprising the second selectable marker, digestion of the vector with the first restriction enzyme and the second Type IIS restriction enzyme produces a fragment comprising the second selectable marker and the synthon coding region, and not comprising the first selectable marker. The invention provides methods of stitching adjacent DNA units (synthons) to synthesize a larger unit. For example, the invention provides a method for making a synthetic gene encoding a PKS module by producing a plurality (i.e., at least 3) of DNA units by assembly PCR, wherein each DNA unit encodes a portion of the PKS module and combining the plurality of DNA units in a predetermined sequence to produce PKS module-encoding gene. In an embodiment, the method includes combining the module-encoding gene in-frame with a nucleotide sequence encoding a PKS extension module, a PKS loading module, a thioesterase domain, or an PKS interpolypeptide linker, to produce a PKS open reading frame.

[0020] In a related embodiment, the invention provides a method for joining a series of DNA units using a vector pair by a) providing a first set of DNA units, each in a first-type selectable vector comprising a first selectable marker and providing a second set of DNA units, each in a second-type selectable vector comprising a second selectable marker different from the first, wherein the first-type and second-type selectable vectors can be selected based on the

different selectable markers, b) recombinantly joining a DNA unit from the first set with an adjacent DNA unit from the second set to generate a first-type selectable vector comprising a third DNA unit, and obtaining a desired clone by selecting for the first selectable marker c) recombinantly joining the third DNA unit with an adjacent DNA unit from the second set to generate a first-type selectable vector comprising a fourth DNA unit, and obtaining a desired clone by selecting for the first selectable marker, or recombinantly joining the third DNA unit with an adjacent DNA unit from the second set to generate a second-type selectable vector comprising a fourth DNA unit, and obtaining a desired clone by selecting for the second selectable marker. In an embodiment, the step (c) comprises recombinantly joining the third DNA unit with an adjacent DNA unit from the second set to generate a first-type selectable vector comprising a fourth DNA unit, and obtaining a desired clone by selecting for the first selectable marker, the method further comprising recombinantly combining the fourth DNA unit with an adjacent DNA unit from the second set to generate a first-type selectable vector comprising a fifth DNA unit, and obtaining a desired clone by selecting for the first selection marker, or recombinantly combining the third DNA unit with an adjacent DNA unit from the second set to generate a second-type selectable vector comprising a fifth DNA unit, and obtaining a desired clone by selecting for the second selection marker. In an embodiment, step (c) comprises recombinantly joining the third DNA unit with an adjacent DNA unit from the second series to generate a second-type selectable vector comprising a fourth DNA unit, and obtaining a desired clone by selecting for the second selectable marker, the method further comprising recombinantly joining the fourth DNA unit with an adjacent DNA unit from the first set to generate a first-type selectable vector comprising a fifth DNA unit, and obtaining a desired clone by selecting for the first selection marker, or recombinantly joining the third DNA unit with an adjacent DNA unit from the second set to generate a first-type selectable vector comprising a fifth DNA unit and obtaining a desired clone by selecting for the first selection marker.

[0021] In a related aspect, the invention provides a method for joining a series of DNA units to generate a DNA construct by (a) providing a first plurality of vectors, each comprising a DNA unit and a first selectable marker; (b) providing a second plurality of vectors, each comprising a DNA unit and a second selectable marker; (c) digesting a vector from (a) to produce a first fragment containing a DNA unit and at least one additional fragment not containing the DNA

unit; (d) digesting a DNA from (b) to produce a second fragment containing a DNA unit and at least one additional fragment not containing the DNA unit, where only one of the first and second fragments contains an origin of replication; ligating the fragments to generate a product vector comprising a DNA unit from (c) ligated to a DNA unit from (d); selecting the product vector by selecting for either the first or second selectable marker; (e) digesting the product vector to produce a third fragment containing a DNA unit and at least one additional fragment not containing the DNA unit; (d) digesting a DNA from (a) or (b) to produce a fourth fragment containing a DNA unit and at least one additional fragment not containing the DNA unit, where only one of the third and fourth fragments contains an origin of replication; (f) ligating the third and fourth fragments to generate a product vector comprising a DNA unit from (e) ligated to a DNA unit from (d) and selecting the product vector by selecting for either the first or second selectable marker.

[0022] In another aspect, an open reading frame vector is provided, which has an internal type {4-[7-*]-[*-8]-3}, left-edge type {4-[7-1]-[*-8]-3} or right-edge type {4-[7-*]-[6-8]-3} architecture where 7 and 8 are recognition sites for Type IIS restriction enzymes which cut to produce compatible overhangs “*”; 1 and 6 are Type II restriction enzyme sites that are optionally present; and 3 and 4 are recognition sites for restriction enzymes with 8-base pair recognition sites. In various embodiments, 1 is Nde I and/or 6 is Eco RI and/or 4 is Not I and/or 3 is Pac I.

[0023] In another aspect, a method for identifying restriction enzyme recognition sites useful for design of synthetic genes is provided. The method includes the steps of obtaining amino acid sequences for a plurality of functionally related polypeptide segments; reverse-translating the amino acid sequences to produce multiple polypeptide segment-encoding nucleic acid sequences for each polypeptide segment; and identifying restriction enzyme recognition sites that are found in at least one polypeptide segment-encoding nucleic acid sequence of at least about 50% of the polypeptide segments. In certain embodiments, the functionally related polypeptide segments are polypeptide synthase modules or domains, such as regions of high homology in PKS modules or domains.

[0024] In a method for designing a synthetic gene in accordance with the present invention a reference amino acid sequence is provided and reverse translated to a randomized nucleotide sequence which encodes the amino acid sequence using a random selection of codons which,

optionally, have been optimized for a codon preference of a host organism. One or more parameters for positions of restriction sites on a sequence of the synthetic gene are provided and occurrences of one or more selected restriction sites from the randomized nucleotide sequence are removed. One or more selected restriction sites are inserted at selected positions in the randomized nucleotide sequence to generate a sequence of the synthetic gene.

[0025] In one aspect of the invention, a set of overlapping oligonucleotide sequences which together comprise a sequence of the synthetic gene are generated.

[0026] In another aspect of the invention, one or more parameters for positions of restriction sites on a sequence of the synthetic gene comprise one or more preselected restriction sites at selected positions.

[0027] In another aspect of the invention, the selected position of the preselected restrictions site corresponds to a positions selected from the group consisting of a synthon edge, a domain edge and a module edge.

[0028] In another aspect of the invention, providing one or more parameters for positions of restriction sites on a sequence of the synthetic gene is followed by predicting all possible restriction sites that can be inserted in the randomized nucleotide sequence and optionally, identifying one or more unique restriction sites.

[0029] In another aspect of the invention, the sequence of the synthetic gene is divided into a series of synthons of selected length and then a set of overlapping oligonucleotide sequences is generated which together comprise a sequence of each synthon.

[0030] In another aspect of the invention, the set of overlapping oligonucleotide sequences comprise (a) oligonucleotide sequences which together comprise a synthon coding region corresponding to the synthetic gene, and (b) oligonucleotide sequences which comprise one or more synthon flanking sequences.

[0031] In another aspect of the invention, one or more quality tests are performed on the set of overlapping oligonucleotide sequences, wherein the tests are selected from the group consisting of: translational errors, invalid restriction sites, incorrect positions of restriction sites, and aberrant priming.

[0032] In another aspect of the invention, each oligonucleotide sequence is of a selected length and comprises an overlap of a predetermined length with adjacent oligonucleotides of the set of oligonucleotides which together comprise the sequence of the synthetic gene.

[0033] In another aspect of the invention, each oligonucleotide is about 40 nucleotides in length and comprises overlaps of between about 17 and 23 nucleotides with adjacent oligonucleotides.

[0034] In another aspect of the invention, a set of overlapping oligonucleotide sequences are selected wherein each oligonucleotide anneals with its adjacent oligonucleotide within a selected temperature range.

[0035] In another aspect of the invention, generating a set of overlapping oligonucleotide sequences includes providing an alignment cutoff value for sequence specificity, aligning each oligonucleotide sequence with the sequence of the synthetic gene and determining its alignment value, and identifying and rejecting oligonucleotides comprising alignment values lower than the alignment cutoff value.

[0036] In another aspect of the invention, a region of error in a rejected oligonucleotide is identified and optionally, one or more nucleotides in the region of error are substituted such that the alignment value of the rejected oligonucleotide is raised above the alignment cutoff value.

[0037] In another aspect of the invention, an order list of oligonucleotides which comprise a synthetic gene or a synthon is generated.

[0038] In another aspect of the invention, removing of restriction sites includes

[0039] identifying positions of preselected restriction sites in the randomized nucleotide sequence, identifying an ability of one or more codons comprising the nucleotide sequence of the restriction site for accepting a substitution in the nucleotide sequence of the restriction site wherein such substitution will (a) remove the restriction site and (b) create a codon encoding an amino acid identical to the codon whose sequence has been changed, and changing the sequence of the restriction site at the identified codon.

[0040] In another aspect of the invention, inserting of restriction sites includes identifying selected positions for insertion of a selected restriction site in the randomized nucleotide sequence, performing a substitution in the nucleotide sequence at the selected position such that the selected restriction site sequence is created at the selected position, translating the substituted sequence to an amino acid sequence, and accepting a substitution wherein the translated amino acid sequence is identical to the reference amino acid sequence at the selected position and rejecting a substitution wherein the translated amino acid sequence is different from the reference amino acid sequence at the selected position.

[0041] In another aspect of the invention, a translated amino acid sequence identical to the reference amino acid sequence comprises substitution of an amino acid with a similar amino acid at the selected position.

[0042] In another aspect of the invention, the synthetic gene encodes a PKS module.

[0043] In another aspect of the invention, the reference amino acid sequence is of a naturally occurring polypeptide segment.

[0044] In another aspect of the invention, one or more steps of the method may be performed by a programmed computer.

[0045] In another aspect of the invention, a computer readable storage medium contains computer executable code for carrying out the method of the present invention.

[0046] In a method for analyzing a nucleotide sequence of a synthon in accordance with the present invention, a sequence of a synthetic gene is provided, wherein the synthetic gene is divided into a plurality of synthons. Sequences of a plurality of synthon samples are also provided wherein each synthon of the plurality of synthons is cloned in a vector. And, a sequence of the vector without an insert is provided. Vector sequences from the sequence of the cloned synthon are eliminated and a contig map of sequences of the plurality of synthons is constructed. The contig map of sequences is aligned with the sequence of the synthetic gene; and a measure of alignment for each of the plurality of synthons is identified.

[0047] In another aspect of the invention, errors in one or more synthon sequences are identified; and one or more informations are reported, the informations selected from the group consisting of: a ranking of synthon samples by degree of alignment, an error in the sequence of a synthon sample, and identity of a synthon that can be repaired.

[0048] In another aspect of the invention, a statistical report on a plurality of alignment errors is prepared.

[0049] A system for high through-put synthesis of synthetic genes in accordance with the present invention includes a source microwell plate containing oligonucleotides for assembly PCR, a first source for amplification mixture including polymerase and buffers useable for assembly PCR, a second source for LIC extension primer mixture, and a PCR microwell plate for amplification of oligonucleotides. A liquid handling device retrieves a plurality of predetermined sets of oligonucleotides from the source microwell plate(s), combines the predetermined sets and the amplification mixture in wells of the PCR microwell plate, LIC

extension primer mixture, and combines the LIC extension primer mixture and amplicons in a well of the PCR microwell plate. The system also includes a heat source for PCR amplification configured to accept the at least one PCR microwell plate.

BRIEF DESCRIPTION OF THE FIGURES

[0050] FIGURE 1 shows a UDG-cloning cassette ("cloning linker") and a scheme of vector preparation for ligation-independent cloning (LIC) using the nicking endonuclease N. BbvC IA. FIGURE 1A. UDG-cloning cassette. *Sac* I and nicking enzyme sites used in vector preparation are labeled. FIGURE 1B. Scheme of vector preparation for LIC using nicking endonuclease N. BbvC IA.

[0051] FIGURE 2 illustrates the Method S joining method using Bbs I and Bsa I as the Type IIS restriction enzymes.

[0052] FIGURE 3A shows the Method S joining method using Vector Pair I. FIGURE 3B shows the Method S joining using Vector Pair II. 2S₁₋₄ are recognition sites for Type IIS restriction enzymes, and A, B, B and C, respectively, are the cleavage sites for the enzymes.

[0053] FIGURE 4 shows a vector pair useful for stitching. FIGURE 4A: Vector pKos293-172-2. FIGURE 4B: Vector pKos293-172-A76. Both vectors contain a UDG-cloning cassette with N.Bbv C IA recognition sites, a "right restriction site" common to both vectors (Xho I site), a "left restriction site" different for each vector (e.g., Eco RV or Stu I site), a first selection marker common to both vectors (carbenicillin resistance marker) and second selection markers that are different in each vector (chloramphenicol resistance marker or kanamycin resistance marker).

[0054] FIGURE 5 shows the Method R joining using Vector Pair II.

[0055] FIGURE 6A shows a composite restriction map with a complete complement of six PKS domains as in ery module 4. Approximate sizes are KS = 1.2, KS/AT linker = 0.3, AT = 1.0, AT/DH linker = 0.03, DH = 0.6, DH/ER linker = 0.8, ER = 0.8, ER/KR linker = 0.02, KR = 0.8, KR/ACP linker = 0.2, ACP = 0.2. 1 Unit = 1 kb; FIGURE 6B shows exemplary restriction sites for synthon edges with reference to DEBS2.

[0056] FIGURE 7 shows a non-pairwise selection strategy for stitching of synthons 1-9 to make module 1-2-3-4-5-6-7-8-9. Parentheticals show the selection marker (K=kanamycin resistant, Cm=chloramphenicol resistant) and the left restriction sites, L and L', (S=Stu I

restriction site, E= Eco RV restriction site) for the vector in which the synthon or desired multisynthon is cloned. The synthons are joined at the following cohesive ends: 1-2 NgoM IV; 2-3 Nhe I; 3-4 Kpn I; 4-5 Bgl II; 5-6 Age I/Ngo MIV; 6-7 Pst I; 7-8 Age I; 8-9 Bgl II.

[0057] FIGURE 8 is a flowchart showing the GeMS process.

[0058] FIGURE 9 is a flowchart showing a GeMS algorithm.

[0059] FIGURE 10A is a flowchart showing generation of codon preference table for a synthetic gene; and FIGURE 10B is a flowchart showing an algorithm for generating a randomized and codon optimized gene sequence.

[0060] FIGURE 11 is a flowchart showing a restriction site removal algorithm.

[0061] FIGURE 12 is a flowchart showing a restriction site insertion algorithm.

[0062] FIGURE 13 is a flowchart showing an algorithm for oligonucleotide design.

[0063] FIGURE 14 is a flowchart showing an algorithm for rapid analysis of synthon DNA sequences.

[0064] FIGURE 15 shows a PAGE analysis of DEBS. Soluble protein extracts from synthetic (sMod2) and natural sequence (nMod2) Mod2 strains were sampled 42 h after induction and analyzed by 3-8% SDS-PAGE. Positions of MW standards are indicated at the right. The gel was stained with Sypro Red (Molecular Probes).

[0065] FIGURE 16 shows restriction sites and synthons used in construction of a synthetic DEBS gene. 16A DEBS1 ORF; 16B, DEBS2 ORF, 16C DEBS3 ORF.

[0066] FIGURE 17 shows the stitching and selection strategy for construction of synthetic DEBS genes. A = synthon cloning vector 293-172-A76; B = synthon cloning vector 293-172-2. (A) Mod006 (DEBS mod1); (B) Mod007 (DEBS mod3); (C) Mod008 (DEBS mod4); (D) Mod009 (DEBS mod5); (E) Mod010 (DEBS mod6).

[0067] FIGURE 18 shows restriction sites and synthons used in construction of a synthetic Epothilone PKS gene.

[0068] FIGURE 19 shows an automated system for high throughput gene synthesis and analysis.

DETAILED DESCRIPTION

[0069] The outline below is provided to assist the reader. The organization of the disclosure below is for convenience, and disclosure of an aspect of the invention in a particular section, does not imply that the aspect is not related to disclosure in other, differently labeled, sections.

1. Definitions
2. Introduction
3. Design of Synthetic Genes
4. Synthesis of Genes
 - 4.1 Synthesis of Synthons
 - 4.2 Synthesis of Module Genes (Stitching)
 - 4.2.1 Cloning Synthons In Assembly Vectors
 - 4.2.2 Validation of Synthons
 - 4.2.3 Method S: Joining Strategies, Assembly Vectors, & Selection Schemes
 - 4.2.3.1 Joining Strategies
 - 4.2.3.2 Assembly Vectors
 - 4.2.3.3 Selection Schemes
 - 4.2.4 Method R: Joining Strategies, Assembly Vectors, & Selection Schemes
 - 4.2.4.1 Joining Strategies
 - 4.2.4.2 Assembly Vectors
 - 4.2.4.3 Selection Schemes
5. Gene Design and Gems (Gene Morphing System) Algorithm
 - 5.1 Gems - Overview
 - 5.2 Gems Algorithms
 - 5.3 Software Implementation
6. Multimodule Constructs And Libraries
 - 6.1 Introduction
 - 6.2 Exemplary Uses Of ORF Vector Libraries
 - 6.3 Module And Linker Combinations
 - 6.4 Exemplary Orf Vector Constructs
 - 6.4.1 Orf Vectors Comprising Amino- And- Carboxy Terminal Accessory Units or Other Polypeptide Sequences
 - 6.4.2 Orf Vector Synthesis
 - 6.4.3 Exemplary Orf Vector Construction Methods
7. Multimodule Design Based On Naturally Occurring Combinations
8. Domain Substitution
9. Exemplary Products
 - 9.1 Synthetic PKS Module Genes
 - 9.2 Vectors
 - 9.3 Libraries
 - 9.4 Databases
10. High Throughput Synthon Synthesis And Analysis
 - 10.1 Automation of Synthesis
 - 10.2 Rapid Analysis of Chromatograms (Racoon)
- 11 Examples

1. Gene Assembly and Amplification Protocols
2. Ligation Independent Cloning
3. Characterization and Correction of Cloned Synthons
4. Identification of Useful Restriction Sites in PKS Modules
5. Synthesis of Debs Module 2
6. Expression of Synthetic Debs Module 2 In E. Coli
7. Synthetic DEBS Gene Expression In E. Coli
8. Method for Quantitative Determination of Relative Amounts of Two Proteins
9. Synthesis of Epothilone Synthase Genes

1. DEFINITIONS

[0070] As used herein, a “protein” or “polypeptide” is a polymer of amino acids of any length, but usually comprising at least about 50 residues.

[0071] As used herein, the term “polypeptide segment” can be used to refer a polypeptide sequence of interest. A polypeptide segment can correspond to a naturally occurring polypeptide (e.g., the product of the DEBS ORF 1 gene), to a fragment or region of a naturally occurring polypeptide (e.g., a DEBS module 1, the KS domain of DEBS module 1, linkers, functionally defined regions, and arbitrarily defined regions not corresponding to any particular function or structure), or a synthetic polypeptide not necessarily corresponding to a naturally occurring polypeptide or region. A “polypeptide segment-encoding sequence” can be the portion of a nucleotide sequence (either in isolated form or contained within a longer nucleotide sequence) that encodes a polypeptide segment (for example, a nucleotide sequence encoding a DEBS1 KS domain); the polypeptide segment can be contained in a larger polypeptide or an entire polypeptide. In general, the term “polypeptide segment-encoding sequence” is intended to encompass any polypeptide-encoding nucleotide sequence that can be made using the methods of the present invention.

[0072] As used herein, the terms “synthon” and “DNA unit” refer to a double-stranded polynucleotide that is combined with other double-stranded polynucleotides to produce a larger macromolecule (e.g., a PKS module-encoding polynucleotide). Synthons are not limited to polynucleotides synthesized by any particular method (e.g., assembly PCR), and can encompass synthetic, recombinant, cloned, and naturally occurring DNAs of all types. In some cases, three different regions of a synthon can be distinguished (a coding region and two flanking regions). The portion of the synthon that is incorporated into the final DNA product of synthon stitching

(e.g., a module gene) can be referred to as the “synthon coding region.” The regions of the synthon that flank the synthon coding region, and which do not become part of the product DNA can be referred to as the “synthon flanking regions.” As is described below, the *synthon flanking regions* are physically separated from the *synthon coding region* during stitching by cleavage using restriction enzymes.

[0073] As used herein, “multisynthon” refers to a polynucleotide formed by the combination (e.g., ligation) of two or more synthons (usually four or more synthons). A “multisynthon” can also be referred to as a “synthon” (see definition above).

[0074] As used herein, a “module” is functional unit of a polypeptide. As used herein, “PKS module” refers to a naturally occurring, artificial or hybrid PKS extension module. PKS extension modules comprise KS and ACP domains (usually one KS and one ACP per module), often comprise an AT domain (usually one AT domain and sometimes two AT domains) where the AT activity is not supplied in *trans* or from an adjacent module, and sometimes comprising one or more of KR, DH, ER, MT (methyltransferase), A (adenylation), or other domains. In describing a naturally occurring PKS extension module other than at the amino terminus of a polypeptide, the term “module” can refer to the set of domains and interdomain linking regions extending approximately from the C terminus of one ACP domain to the C terminus of the next ACP domain (i.e., including a sequence linking the modules, corresponding to the Spe I-Mfe I region of the module shown in Figure 6) linker or, alternatively can refer to the set *not* including the linker sequence (e.g., corresponding roughly to the Mfe I-Xba I region of the module shown in Figure 6).

[0075] As used herein, the term “module” is more general than “PKS module” in two senses. First, “module” can be any type of functional unit including units that are not from a PKS. Second, when from a PKS, a “module” can encompass functional units of a PKS polypeptide, such as linkers, domains (including thioesterase or other releasing domains) not usually referred to in the PKS art as “PKS modules.”

[0076] As used herein, “multimodule” refers to a single polypeptide comprising two or more modules.

[0077] As used herein, the term “PKS accessory unit” (or “accessory unit”) refers to regions or domains of PKS polypeptides (or which function in polyketide synthesis) other than extension modules or domains of extension modules. Examples of PKS accessory units include loading

modules, interpolypeptide linkers, and releasing domains. PKS accessory units are known in the art. The sequences for PKS loading domains are publicly available (see Table 12). Generally, the loading module is responsible for binding the first building block used to synthesize the polyketide and transferring it to the first extension module. Exemplary loading modules consist of an acyltransferase (AT) domain and an acyl carrier protein (ACP) domain (e.g., of DEBS); an KS^Q domain, an AT domain, and an ACP domain (e.g., of tylosin synthase or oleandrolide synthase); a CoA ligase activity domain (avermectin synthase, rapamycin or FK-520 PKS) or a NRPS-like module (e.g., epothilone synthase). Linkers, both naturally occurring and artificial are also known. Naturally occurring PKS polypeptides are generally viewed as containing two types of linkers: "interpolypeptide linkers" and "intrapolypeptide linkers." See, e.g., Broadhurst et al., 2003, "The structure of docking domains in modular polyketide synthases" *Chem Biol.* 10:723-31; Wu et al. 2002, "Quantitative analysis of the relative contributions of donor acyl carrier proteins, acceptor ketosynthases, and linker regions to intermodular transfer of intermediates in hybrid polyketide synthases" *Biochemistry* 41:5056-66; Wu et al., 2001, "Assessing the balance between protein-protein interactions and enzyme-substrate interactions in the channeling of intermediates between polyketide synthase modules," *J Am Chem Soc.* 123:6465-74; Gokhale et al., 2000, "Role of linkers in communication between protein modules" *Curr Opin Chem Biol.* 4:22-7. For convenience, certain intrapolypeptide sequences linking extension modules (e.g., corresponding to the Spe I-Mfe I region of the module shown in Figure 6) are referred to as the "ACP-KS Linker Region" or AKL. The thioesterase domain (TE) can be found in most naturally occurring PKS molecules, e.g. in DEBS, tylosin synthase, epothilone synthase, pikromycin synthase, and soraphen synthase. Other chain-releasing activities are also accessory units, e.g. amino acid-incorporating activities such as those encoded by the *rapP* gene from the rapamycin cluster and its homologs from FK506, FK520, and the like; the amide-forming activities such as those found in the rifamycin and geldanamycin PKS; and hydrolases or linear ester-forming enzymes.

[0078] As used herein, a "gene" is a DNA sequence that encodes a polypeptide or polypeptide segment. A gene may also comprise additional sequences, such as for transcription regulatory elements, introns, 3'-untranslated regions, and the like.

[0079] As used herein, a "synthetic gene" is a gene comprising a polypeptide segment-encoding sequence not found in nature, where the polypeptide segment-encoding sequence

encodes a polypeptide or fragment or domain at least about 30, usually at least about 40, and often at least about 50 amino acid residues in length.

[0080] As used herein, "module gene" or "module-encoding gene" refers to a gene encoding a module; a "PKS module gene" refers to a gene encoding PKS module.

[0081] As used herein, "multimodule gene" refers to a gene encoding a multimodule.

[0082] A "naturally occurring" PKS, PKS module, PKS domain, and the like is a PKS, module, or domain having the amino acid sequence of a PKS found in nature.

[0083] A "naturally occurring" PKS gene *or* PKS module gene *or* PKS domain gene is a gene having the nucleotide sequence of a PKS gene found in nature. Sequences of exemplary naturally occurring PKS genes are known (see, e.g., Table 12).

[0084] A "gene library" means a collection of individually accessible polynucleotides of interest. The polynucleotides can be maintained in vectors (e.g., plasmid or phage), cells (e.g., bacterial cells), as purified DNA, or in other forms. Library members (variously referred to as clones, constructs, polynucleotides, etc.) can be stored in a variety of ways for retrieval and use, including for example, in multiwell culture or microtiter plates, in vials, in a suitable cellular environment (e.g., *E. coli* cells), as purified DNA compositions on suitable storage media (e.g., the Storage IsoCode® ID™ DNA library card; Schleicher & Schuell BioScience), or a variety of other art-known library forms. Typically a library has at least about 10 members, more often at least about 100, preferably at least about 500, and even more preferably at least about 1000 members. By "individually accessible" is meant that the location of the selected library member is known such that the member can be retrieved from the library.

[0085] As used herein, the terms "corresponds" or "corresponding" describe a relationship between polypeptides. A polypeptide (e.g., a PKS module or domain) encoded by a synthetic gene corresponds to a naturally occurring polypeptide when it has substantially the same amino acid sequence. For example, a KS domain encoded by a synthetic gene would correspond to the KS domain of module 1 of DEBS if the KS domain encoded by a synthetic gene has substantially the same amino acid sequence as the KS domain of module 1 of DEBS.

[0086] As used herein, when describing recombinant manipulations of polynucleotides "joined to," "combined with," and grammatical equivalents of each, refer to ligation (i.e., the formation of covalent 5' to 3' nucleic acid linkage) of two DNA molecules (or two ends of the same DNA molecule).

[0087] As used herein, “adjacent,” when referring to adjacent DNA units such as adjacent synthons, refers to sequences that are contiguous (or overlapping) in a naturally occurring or synthetic gene. In the case of “adjacent synthons,” the sequences of the synthon coding regions are contiguous or overlapping in the synthetic gene encoded in the synthons.

[0088] As used herein, “edge,” in the context of a polynucleotide or a polypeptide segment, refers to the region at the terminus of a polynucleotide or a polypeptide (i.e., physical edge) or near a boundary delimiting a region of the polypeptide (e.g., domain) or polynucleotide (e.g., domain-encoding sequence).

[0089] The term “junction edge” is used to describe the region of a synthon that is joined to an adjacent synthon (e.g., by formation of compatible ligatable ends in each synthon). Thus, reference to “a ligatable end at a junction end” of a synthon means the end that is (or will become) ligated to the compatible ligatable end of the adjacent synthon. It will be appreciated that in a construct with five or more synthons, most synthons will have two junction edges. The junction edge(s) being referred to will be apparent from context. A sequence motif or restriction enzyme site is “near” the nucleotide sequence encoding an amino- or carboxy-terminus of a PKS domain in a module when the motif or site is closer to the specified terminus (boundary) than to the terminus (boundary) of any other domain in the module. A sequence motif or restriction enzyme site is “near” the nucleotide sequence encoding an amino- or carboxy-terminus of a PKS module when the motif or site is closer to the specified terminus (boundary) than to the terminus of any domain in the module. The boundaries of PKS domains can be determined by methods known in the art by aligning the sequence of a subject domain with the sequences of other PKS domains of a similar type (e.g., KS, ER, etc.) and identifying boundaries between regions of relatively high and relatively low sequence identity. See Donadio and Katz, 1992, “Organization of the enzymatic domains in the multifunctional polyketide synthase involved in erythromycin formation in *Saccharopolyspora erythraea*” *Gene* 111:51-60. Programs such as BLAST, CLUSTALW and those available at <http://www.nii.res.in/pksdb.html> can be used for alignment. In some embodiments, a motif or restriction enzyme site that is near a boundary is not more than about 20 amino acid residues from the boundary.

[0090] As used herein, “overhang” when referring to a double-stranded polynucleotide, has its usual meaning and refers to a unpaired single-strand extension at the terminus of a double-stranded polynucleotide.

[0091] A “sequence-specific nicking endonuclease” or “sequence-specific nicking enzyme” is an enzyme that recognizes a double-stranded DNA sequence, and cleaves only one strand of DNA. Exemplary nicking endonucleases are described in U.S. Patent Application 20030100094 A1 “Method for engineering strand-specific, sequence-specific, DNA-nicking enzymes.” Exemplary nicking enzymes include N.Bbv C IA, N.BstNB I and N.Alw I (New England Biolabs).

[0092] As used herein, “restriction endonuclease” or “restriction enzyme” has its usual meaning in the art. Restriction endonucleases can be referred to by describing their properties and/or using a standard nomenclature (see Roberts et al., 2002, “A nomenclature for restriction enzymes, DNA methyltransferases, homing endonucleases and their genes,” *Nucleic Acids Res.* 31:1805-12). Generally, “Type II” restriction endonucleases recognize specific DNA sequences and cleave at constant positions at or close to that sequence to produce 5'-phosphates and 3'-hydroxyls. “Type II” restriction endonucleases that recognize palindromic sequences are sometimes referred to herein as “conventional restriction endonucleases.” “Type IIA” restriction endonucleases are a subset of type II in which the recognition site is asymmetric. Generally, “Type IIS” restriction endonucleases is a subset of type IIA in which at least one cleavage site is outside the recognition site. As used herein, reference to “Type IIS” restriction enzymes, unless otherwise noted, refers to those Type IIS enzymes for which both DNA strands are cut outside the recognition site and on the same side of the restriction site. In one embodiment of the invention, Type IIS enzymes are selected that produce an overhang of 2 to 4 bases. Exemplary restriction endonucleases include Aat II, Acl I, Afe I, Afl II, Age I, Ahd I, Alw 26I, Alw NI, Apa I, Apa LI, Asc I, Ase I, Avr II, Bam HI, Bbs I, Bbv CI, Bci VI, Bcl I, Bfu AI, Bgl I, Bgl II, Blp I, Bpl I, Bpm I, Bpu 10I, Bsa I, Bsa BI, Bsa MI, Bse RI, Bsg I, Bsi WI, Bsm BI, Bsm I, Bsp EI, Bsp HI, Bsr BI, Bsr DI, Bsr GI, Bss HII, Bss SI, Bst API, Bst BI, Bst EII, Bst XI, Bsu 36I, Cla I, Dra I, Dra III, Drd I, Eag I, Ear I, Eco NI, Eco RI, Eco RV, Fse I, Fsp I, Hin dIII, Hpa I, Kas I, Kpn I, Mfe I, Mlu I, Msc I, Nco I, Nde I, Ngo MIV, Nhe I, Not I, Nru I, Nsi I, Pac I, Pci I, Pfl MI, Pme I, Pml I, Psh AI, Psi I, Pst I, Pvu I, Pvu II, Rsr II, Sac I, Sac II, Sal I, San DI, Sap I, Sbf I, Sca I, Sex AI, Sfi I, Sgf I, Sgr AI, Sma I, Smi I, Sml I, Sna BI, Spe I, Sph I, Srf I, Ssp I, Stu I, Sty I, Swa I, Tat I, Tsp 509I, Tth 111I, Xba I, Xcm I, Xho I, Xmn I, those listed in Table 2, and others.e.g., <http://rebase.neb.com>).

[0093] As used herein, the terms “ligatable ends” refers to ends of two DNA fragments (ends of the same molecule) that can be ligated. “Ligatable ends” include blunt ends and “cohesive ends” (having single-stranded overhangs). Two cohesive ends are “compatible” when they can be anneal and be ligated (e.g., when each overhang is of the 3'-hydroxyl end; each is of the same length, e.g., 4 nucleotide units, and the sequences of the two overhangs are reverse complements of each other).

[0094] As used herein, unless otherwise indicated or apparent from context, a “restriction site” refers to a recognition site that is at least 5, and usually at least 6 basepairs in length.

[0095] As used herein, a “unique restriction site” refers to a restriction site that exists only once in a specified polynucleotide (e.g., vector) or specified region of a polynucleotide (e.g., module-encoding portion, specified vector region, etc.).

[0096] As used herein, a “useful restriction site” refers to a restriction site that is either unique or, if not unique, exists in a pattern and number in a specified polynucleotide or specified region of a polynucleotide such that digestion at all the of the sites in a specified polynucleotide (e.g., vector) or specified region of a polynucleotide (e.g., module gene) would achieve essentially the same result as if the site was unique.

[0097] As used herein, “vector” refers to polynucleotide elements that are used to introduce recombinant nucleic acid into cells for either expression or replication and which have an origin of replication and appropriate transcriptional and/or translational control sequences, such as enhancers and promoters, and other elements for vector maintenance. In one embodiment vectors are self-replicating circular extrachromosomal DNAs. Selection and use of such vehicles is routine in the art. An “expression vector” includes vectors capable of expressing a DNA inserted into the vector (e.g., a DNA sequence operatively linked with regulatory sequences, such as promoter regions). Thus, an expression vector refers to a recombinant DNA or RNA construct, such as a plasmid, a phage, recombinant virus or other vector that, upon introduction into an appropriate host cell, results in expression of the cloned DNA.

[0098] As used herein, a specified amino acid is “similar” to a reference amino acid in a protein when substitution of the specified amino acid for the reference amino does not substantially modify the function (e.g., biological activity) of the protein. Amino acids that are similar are often conservative substitutions for each other. The following six groups contain amino acids that are conservative substitutions for one another: [alanine; serine; threonine];

[aspartic acid, glutamic acid], [asparagine, glutamine], [arginine, lysine], [isoleucine, leucine, methionine, valine], and [phenylalanine, tyrosine, and tryptophan]. Also see Creighton, 1984, PROTEINS, W.H. Freeman and Company.

[0099] A nonribosomal peptide synthase, or "NRPS" is an enzyme that produces a peptide product by joining individual amino acids through a ribosome-independent process. Examples of NRPS include gramicidin synthetase, cyclosporin synthetase, surfactin synthetase, and others. For reviews, see Weber and Marahiel, 2001, "Exploring the domain structure of modular nonribosomal peptide synthetases" Structure (Camb). 9:R3-9; Mootz et al., 2002, "Ways of assembling complex natural products on modular nonribosomal peptide synthetases" Chembiochem. 3:490-504.

Conventions

[0100] Use of the terms "for example," "such as," "exemplary," "examples include," "*exempli gratia* (e.g.)," "typically," and the like are intended to illustrate aspects of the invention but are not intended to limit the invention to the particular examples described. Thus, each instance of such phrases can be read as if the phrase "*but not for limitation*," (e.g., "for example, but not for limitation, . . .") is present.

[0101] The terms "module" and "domain" generally refers to polypeptides or regions of polypeptides, while the terms "module gene" and "domain gene," or grammatical equivalents, refer to a DNA encoding the protein. Inadvertent exceptions to this convention will be apparent from context. For example, it will be clear that "restriction sites at module edges" refers to restriction sites in the region of the module gene encoding the edge of the module polypeptide sequence.

2. INTRODUCTION

[0102] The present invention relates to strategies, methods, vectors, reagents, and systems for synthesis of genes, production of libraries of such genes, and manipulation and characterization of the genes and corresponding encoded polypeptides. In particular, the invention provides new methods and tools for synthesis of genes encoding large polypeptides. Examples of genes that may be synthesized include those encoding domains, modules or polypeptides of a polyketide synthase (PKS), genes encoding domains, modules or polypeptides

of a non-ribosomal peptide synthase (NRPS), hybrids containing elements of both PKSs and NRPSs, viral genomes, and others. Genes encoding polyketide synthase modules are of particular interest and, for convenience, throughout this disclosure reference will often be made to design and synthesis of genes encoding PKS modules, domains and polypeptides. However, unless stated or otherwise apparent from context, aspects of the invention are not limited to any single class of genes or polypeptides. It will be understood by the reader that the methods of the present invention are useful for the design and synthesis of a large variety of polynucleotides.

[0103] The methods of the invention for producing synthetic genes encoding polypeptides of interest can include the following steps:

- a) Designing a gene that encodes a polypeptide segment of interest;
- b) Designing component polypeptide for synthesis of the gene;
- c) Synthesizing the oligopeptide-segment encoding gene by:
 - i) making synthons encoding portions of the module gene; and,
 - ii) "stitching" synthons together to produce multisynthons (i.e., larger DNA

units) that encode the polypeptide segment of interest. It will be appreciated by the reader that the polypeptide of interest can be expressed, recombinantly manipulated, and the like.

[0104] The methods and tools disclosed herein have particular application for the synthesis of polyketide synthase genes, and provide a variety of new benefits for synthesis of polyketides. As is discussed above, the order, number and domain content of modules in a polyketide synthase determine the structure of its polyketide product. Using the methods disclosed herein, genes encoding polypeptides comprising essentially any combination of PKS modules (themselves comprising a variety of combinations of domains) can be synthesized, cloned, and evaluated, and used for production of functional polyketide synthases. Such polyketide synthases can be used for production of naturally occurring polyketides without cloning and sequencing the corresponding gene cluster (useful in cases where PKS genes are inaccessible, as from unculturable or rare organisms); production of novel polyketides not produced (or not known to be produced by any naturally occurring PKS); more efficient production of analogs of known polyketides; production of gene libraries, and other uses.

[0105] In a related aspect, the invention relates to a universal design of genes encoding PKS modules (or other polypeptides) in which useful restriction sites flank functionally defined coding regions (e.g., sequence encoding modules, domains, linker regions, or combinations of

these). The design allows numerous different modules to be cloned into a common set of vectors for or manipulation (e.g., by substitution of domains) and/or expression of diverse multi-modular proteins.

[0106] In a related aspect, the invention provides large libraries of PKS modules.

[0107] In a related aspect, the invention provides vectors and methods useful for gene synthesis.

[0108] In a related aspect, the invention provides algorithms useful for design of synthetic genes.

[0109] In a related aspect, the invention provides automated systems useful for gene synthesis.

[0110] The invention provides a method for making a synthetic gene encoding a PKS module by producing a plurality of DNA units by assembly PCR or other method (where each DNA unit encodes a portion of the PKS module) and combining the DNA units in a predetermined sequence to produce a PKS module-encoding gene. In one embodiment, the method includes combining the module-encoding gene in-frame with a nucleotide sequence encoding a PKS extension module, a PKS loading module, a thioesterase domain, or an PKS interpolypeptide linker, thereby producing a PKS open reading frame.

[0111] The methods of the invention for synthesis of genes encoding PKS modules can include the following steps:

- a) Designing a PKS module (e.g., for production of a specific polyketide, or for inclusion in a library of modules);
- b) Designing a synthetic gene encoding the desired PKS module;
- c) Designing component oligonucleotides for synthesis of the gene;
- d) Synthesizing the module gene by:
 - i) making synthons encoding portions of the module gene; and,
 - ii) "stitching" synthons together;
- e) modifying module genes;
making open reading frames comprising module gene(s) and/or accessory unit gene(s);
producing libraries of module-encoding genes;

- f) expressing a module gene from (d) or (e) in a host cell, optionally in combination with other polypeptides.

Each of these steps is described in detail in the following sections.

3. DESIGN OF SYNTHETIC GENES

[0112] The nucleotide sequence of a synthetic gene of the invention will vary depending on the nature and intended uses of the gene. In general, the design of the genes will reflect the amino acid sequence of the polypeptide or fragment (e.g., PKS module or domain) to be encoded by the gene, and all or some of:

- a) the codon preference of intended expression host(s).
- b) the presence (introduction) of useful restriction sites in specified locations of the synthetic gene.
- c) the absence (removal) of undesired restriction sites in the gene or in specified regions of the gene.
- d) compatibility with synthetic methods disclosed herein, especially high-throughput methods.

[0113] A variety of criteria are available to the practitioner for selecting the gene(s) to be synthesized by the methods of the invention. The chief consideration is usually the protein encoded by the gene. For example, a gene can be synthesized that encodes a protein at least a portion of which has a sequence the same or substantially the same as a naturally occurring domain, module, linker, or other polypeptide unit, or combinations of the foregoing.

[0114] Having selected the polypeptide of interest, numerous nucleic acid sequences that encode the protein can be determined by reverse-translating the amino acid sequence. Methods for reverse translation are well known. As described below, according to the invention, reverse translation can be carried out in a fashion that "randomizes" the codon usage and optionally reflects a selected codon preference or bias. Since the synthetic genes of the invention may be expressed in a variety of hosts consideration of the codon preferences of the intended expression host may be have benefits for the efficiency of expression.

[0115] In considering codon preferences, preference tables may be obtained from publicly available sources or may be generated by the practitioner. Codon preference tables can be generated based on all reported or predicted sequences for an organism, or, alternatively, for a

subset of sequences (e.g., housekeeping genes). Codon preference tables for a wide variety of species are publicly available. Tables for many organisms are available at through links from a site maintained at the Kazusa DNA Research Institute (<http://www.kazusa.or.jp/codon/>). An exemplary codon preference for *E. coli* is shown in Table 1. Codon tables for *Saccharomyces cerevisiae* can be found in http://www.yeastgenome.org/codon_usage.shtml. In the event that no codon table is available for a particular host, the table(s) available for the most closely related organism(s) can be used.

TABLE 1
E. COLI CODON PREFERENCES*

UUU 22.4 (35982)	UCU 8.5 (13687)	UAU 16.3 (26266)	UGU 5.2 (8340)
UUC 16.6 (26678)	UCC 8.6 (13849)	UAC 12.3 (19728)	UGC 6.4 (10347)
UUA 13.9 (22376)	UCA 7.2 (11511)	UAA 2.0 (3246)	UGA 0.9 (1468)
UUG 13.7 (22070)	UCG 8.9 (14379)	UAG 0.2 (378)	UGG 15.3 (24615)
CUU 11.0 (17754)	CCU 7.1 (11340)	CAU 12.9 (20728)	CGU 21.0 (33694)
CUC 11.0 (17723)	CCC 5.5 (8915)	CAC 9.7 (15595)	CGC 22.0 (35306)
CUA 3.9 (6212)	CCA 8.5 (13707)	CAA 15.4 (24835)	CGA 3.6 (5716)
CUG 52.7 (84673)	CCG 23.2 (37328)	CAG 28.8 (46319)	CGG 5.4 (8684)
AUU 30.4 (48818)	ACU 9.0 (14397)	AAU 17.7 (28465)	AGU 8.8 (14092)
AUC 25.0 (40176)	ACC 23.4 (37624)	AAC 21.7 (34912)	AGC 16.1 (25843)
AUA 4.3 (6962)	ACA 7.1 (11366)	AAA 33.6 (54097)	AGA 2.1 (3337)
AUG 27.7 (44614)	ACG 14.4 (23124)	AAG 10.2 (16401)	AGG 1.2 (1987)
GUU 18.4 (29569)	GCU 15.4 (24719)	GAU 32.2 (51852)	GGU 24.9 (40019)
GUC 15.2 (24477)	GCC 25.5 (40993)	GAC 19.0 (30627)	GGC 29.4 (47309)
GUA 10.9 (17508)	GCA 20.3 (32666)	GAA 39.5 (63517)	GGA 7.9 (12776)
GUG 26.2 (42212)	GCG 33.6 (53988)	GAG 17.7 (28522)	GGG 11.0 (17704)

*fields: [triplet] [frequency: per thousand] [(number)]

[0116] In addition to accounting for the codon preferences of a specified host (expression organism, the nucleotide acid sequence of the synthetic gene may be designed to avoid clusters of adjacent rare codons, or regions of sequence duplication.

[0117] Suitable expression hosts will depend on the protein encoded. For PKS proteins, suitable hosts include cells that natively produce modular polyketides or have been engineered so as to be capable of producing modular polyketides. Hosts include, but are not limited to, actinomycetes such as *Streptomyces coelicolor*, *Streptomyces venezuelae*, *Streptomyces fradiae*, *Streptomyces ambofaciens*, and *Saccharopolyspora erythraea*, eubacteria such as *Escherichia*

coli, myxobacteria such as *Myxococcus xanthus*, and yeasts such as *Saccharomyces cerevisiae*. See, for example, Kealey et al., 1998, "Production of a polyketide natural product in nonpolyketide-producing prokaryotic and eukaryotic hosts" *Proc Natl Acad Sci USA* 95:505-9; Dayem et al, 2002, "Metabolic engineering of a methylmalonyl-CoA mutase-epimerase pathway for complex polyketide biosynthesis in *Escherichia coli*" *Biochemistry* 41:5193-201.

[0118] Codon optimization may be employed throughout the gene, or, alternatively, only in certain regions (e.g., the first few codons of the encoded polypeptide). In a different embodiment, codon optimization for a particular host is not considered in design of the gene, but codon randomization is used.

[0119] In an alternative embodiment, the DNA sequence of a naturally occurring gene encoding the protein is used to design the synthetic gene. In this embodiment the naturally occurring DNA sequence is modified as described below (e.g., to remove and introduce restriction sites) to provide the sequence of the synthetic gene.

[0120] The design of synthetic genes of the invention also involves the inclusion of desired restriction sites at certain locations in the gene, and exclusion of undesired restriction sites in the gene or in specified regions of the gene, as well as compatibility with synthetic methods used to make the gene(s). Often, an "undesired" restriction site (e.g., Eco RI site) is removed from one location to ensure that the same site is unique (for example) in another location of the gene, synthon, etc. These considerations will be more easily described and understood following a description of methods and tools employed in the synthesis and use of the synthetic genes of the invention. These methods and tools are described, in part, in Section 4, below, and further aspects of gene design are discussed in Section 5.

4. SYNTHESIS OF GENES

[0121] This section describes methods for production of synthetic genes. As noted above, in one aspect of the invention production of synthetic genes comprises combining ("stitching") two or more double-stranded, polynucleotides (referred to here as "synthons") to produce larger DNA units (i.e., multisynthons). The larger DNA unit can be virtually any length clonable in recombinant vectors but usually has a length bounded by a lower limit of about 500, 1000, 2000, 3000, 5000, 8000, or 10000 base pairs and an independently selected upper limit of about 5000, 10000, 20000 or 50000 base pairs (where the upper limit is greater than the lower limit). For

purposes of illustration, the following discussion generally refers to production of synthetic genes in which the larger DNA units encode *PKS modules*. However, it is contemplated that the methods and materials described herein may be used for synthesis of any number of polypeptide-segment encoding nucleotide sequences, including sequences encoding NRPS modules and synthetic variants, polypeptide segments of other modular proteins, polypeptide segments from other protein families, or any functional or structural DNA unit of interest.

[0122] According to the invention, typically, synthetic PKS module genes are produced by combining synthons ranging in length from about 300 to about 700 bp, more often from about 400 to about 600 bp, and usually about 500 bp. In the case of PKS modules, naturally occurring PKS module genes (and corresponding synthetic genes) are in the neighborhood of about 5000 bp in length. More generally, modules produce by synthon Allowing for some overlap between sequences of adjacent synthons, ten to twelve 500-bp synthons are typically combined to produce a 5000 bp module gene encoding a naturally occurring module or variant thereof. In various aspects of the invention, the number of synthons that are "stitched" together can be at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10, or can be a range delimited by a first integer selected from 2, 3, 4, 5, 6, 7, 8, 9, or 10 and a second selected from 5, 10, 20, 30 or 50 (where the second integer is greater than the first integer).

[0123] The next section describes synthon production. The following section, §4.2, describes the synthesis of module genes by stitching synthons, as well as vectors useful for stitching.

4.1 SYNTHESIS OF SYNTHONS

[0124] Synthons can be produced in a variety of ways. Just as module genes are produced by combining several synthons, synthons are generally produced by combining several shorter polynucleotides (i.e. oligonucleotides). Generally synthons are produced using assembly PCR methods. Useful assembly PCR strategies are known and involve PCR amplification of a set of overlapping single-stranded polynucleotides to produce a longer double-stranded polynucleotide (see e.g., Stemmer *et al.*, 1995, "Single-step assembly of a gene and entire plasmid from large numbers of oligodeoxyribonucleotides" *Gene* 164:49-53; Withers-Martinez *et al.*, 1999, "PCR-based gene synthesis as an efficient approach for expression of the A+T-rich malaria genome" *Protein Eng.* 12:1113-20; and Hoover and Lubkowski, 2002, "DNAWorks: An automated

method for designing oligonucleotides for PCR-based gene synthesis" *Nucleic Acids Res.* 30:43). Alternatively, synthons can be prepared by other methods, such as ligase-based methods (e.g., Chalmer and Curnow, 2001, "Scaling Up the Ligase Chain Reaction-Based Approach to Gene Synthesis" *Biotechniques* 30:249-252).

[0125] It will become apparent to the reader that the sequences of the oligonucleotide components of a synthon determines the sequence of the synthon, and ultimately the synthetic gene generated using the synthon. Thus, the sequences of the oligonucleotide components (1) encode the desired amino acid sequence, (2) usually reflect the codon preferences for the expression host, (3) contain restriction sites used during synthesis or desired in the synthetic gene, (4) are designed to exclude from the synthetic gene restriction sites that are not desired, (5) have annealing, priming and other characteristics consistent with the synthetic method (e.g. assembly PCR), and (6) reflect other design considerations described herein.

[0126] Synthons about 500 bp in length are conveniently prepared by assembly amplification of about twenty-five 40-base oligonucleotides ("40-mers"). In some embodiments of the invention, uracil-containing oligonucleotides are added to the ends of synthons (i.e., synthon flanking regions) to facilitate ligation independent cloning. (See Example 1). The oligonucleotides themselves are designed according to the principles described herein, can be prepared using by conventional methods (e.g., phosphoramidite synthesis) and/or can be obtained from a number of commercial sources (e.g., Sigma-Genosys, Operon). Although purified oligonucleotides can be used for synthon assembly, for high-throughput methods the oligonucleotide preparation usually is desalted but not gel purified (See Example 1). Assembly and amplification conditions are selected to minimize introduction of mutations (sequence errors).

4.2 SYNTHESIS OF MODULE GENES (STITCHING)

[0127] The process of combining synthons to produce module genes is referred to as "stitching." Usually at least three synthons are combined, more often at least five synthons, and most often at least eight synthons are combined. The stitching methods of the invention are suitable for high-throughput systems, avoid the need for purification of synthon fragments, and have other advantages. As previously noted, although stitching is described in the context of synthesis of PKS gene modules (ca. 5000 bp) it can be used for synthesis of any large gene. For

example, stitching can be used to combine two or more PKS module genes to prepare multimodule genes or to combine any of a variety of other combinations of polynucleotides (e.g., a promoter sequence and a RNA encoding sequence).

[0128] Stitching involves joining adjacent DNA units (e.g., synthons) by a process in which a first DNA unit (e.g., a first synthon or multisynthon) in a first vector is combined with an adjacent DNA unit (e.g., an adjacent synthon or multisynthon) in a second vector that is differently selectable from the first vector. Each of the two vectors contains an origin of replication (as used herein, reference to a “vector” indicates the presence of an origin of replication). The two vectors containing the adjacent DNA units (hereinafter, “synthons”) are sometimes referred to as a “cognate pair” or as the “donor” and “acceptor” vectors. In the stitching process, each of the two vectors is digested with restriction enzymes to generate fragments with compatible (usually cohesive) ligatable ends in the synthon sequences (allowing the synthons to be joined by ligation) and to generate compatible (usually cohesive) ligatable ends outside the synthon sequences such that the two synthon-containing vector fragments can be ligated to generate a new, selectable, vector containing the joined synthon sequences (multisynthon). As described in detail below, the invention provides methods for *rapid* cloning of large genes without the need for fragment purification steps during synthesis. Stitching methods are described below and illustrated in Figures 3, 5 and 7.

[0129] In one aspect of the invention, a method is provided for joining several DNA units in sequence, the method by

a) carrying out a first round of stitching comprising ligating an acceptor vector fragment comprising a first synthon SA_0 , a ligatable end LA_0 at the junction end of synthon SA_0 and an adjacent synthon SD_0 , and another ligatable end la_0 , and a donor vector fragment comprising a second synthon SD_0 , a ligatable end LD_0 at the junction end of synthon SD_0 and synthon SA_0 , wherein LD_0 and LA_0 are compatible, another ligatable end ld_0 , wherein ld_0 and la_0 are compatible, and a selectable marker, wherein LA_0 and LD_0 are ligated and la_0 and ld_0 are ligated, thereby joining the first and second synthons, and thereby generating a first vector comprising synthon coding sequence S_1 ;

b) selecting for the first vector by selecting for the selectable marker in (a);
and,

c) carrying out a number n additional rounds of stitching, wherein n is an integer from 1 to 20, wherein S_n is the synthon coding sequence generated by joining synthons in the previous round of stitching, and wherein each round n of stitching comprises: 1) designating the first or a subsequent vector as either an acceptor vector A_n or a donor vector D_n ; 2) digesting acceptor vector A_n with restriction enzymes to produce an acceptor vector fragment comprising a synthon coding sequence S_n , a ligatable end LA_n at the junction end of synthon S_n and an adjacent synthon SD_{n+100} , and another ligatable end la_n ; and, ligating the acceptor vector fragment to a donor vector fragment comprising synthon SD_{n+100} , a ligatable end LD_{n+100} at the junction end of synthon SD_{n+100} and synthon S_n , wherein LA_n and LD_{n+100} are compatible, another ligatable end ld_{n+100} , wherein la_n and ld_{n+100} are compatible, and a selectable marker, wherein LA_n and LD_{n+100} are ligated and la_n and ld_{n+100} are ligated, thereby generating a subsequent vector, or digesting donor vector D_n with restriction enzymes to produce a donor vector fragment comprising a synthon coding sequence S_n , a ligatable end LD_n at the junction end of synthon S_n and an adjacent synthon SA_{n+100} , another ligatable end ld_n , and a selectable marker; and ligating the donor vector fragment to an acceptor vector fragment comprising synthon SA_{n+100} , a ligatable end LA_{n+100} at the junction end of synthon SA_{n+100} and synthon S_n , and another ligatable end la_{n+100} wherein LA_{n+100} and LD_n are compatible and are ligated and la_{n+100} and ld_n are compatible and are ligated, thereby generating a subsequent vector

d) selecting the subsequent vector by selecting for the selectable marker of the donor vector fragment of step (c)

e) repeating steps (c) and (d) $n-1$ times thereby producing a multisynthon.

[0130] In various embodiments, the selectable marker of step (d) is not the same as the selectable marker of the preceding stitching step and/or is not the same as the selectable marker of the subsequent stitching step; la_0 , ld_0 , la_n , ld_n are the same and/or LA_0 , LD_0 , LA_n , and LD_n are created by a Type IIS restriction enzyme; the synthons SA_0 , SD_0 , SA_{n+100} , and SD_{n+100} are synthetic DNAs; any one or more of synthons SA_0 , SD_0 , SA_{n+100} , or SD_{n+100} is a multisynthon; and/or the multisynthon product of step (e) encodes a polypeptide comprising a PKS domain.

[0131] Two related approaches for stitching have been used by the inventors, each involving (1) cloning synthons into assembly vectors, (2) joining adjacent synthons, and (3) selecting desired constructs. The first stitching approach, referred to as "Method S," is facilitated by use of recognition sites for Type IIS restriction enzymes (as defined above). The second stitching

approach, referred to as “Method R,” is facilitated by recognition sites for conventional (Type II) restriction enzymes.

[0132] The two stitching approaches described here differ in the joining step, but use similar methods for cloning into assembly vectors and selection. Each of these steps is discussed below.

4.2.1 CLONING SYNTHONS IN ASSEMBLY VECTORS

[0133] The term “assembly vector” is used to refer to vectors used for the stitching step of gene synthesis. In one aspect of the invention, an assembly vector has a site, the “synthon insertion site” or “SIS,” into which synthons can be cloned (inserted). The structure of the SIS will depend on the cloning method used. An assembly vector comprising a synthon sequence can be called an “occupied” assembly vector. An assembly vector into which no synthon sequence has been cloned can be called an “empty” assembly vector.

[0134] Although any method of cloning the synthon can be used to introduce the synthon into the SIS of the vector, for automated high-throughput cloning, ligation-independent cloning (LIC) methods are preferred. Several methods for LIC are known, including single-strand extension based methods and topoisomerase-based methods (see, e.g., Chen *et al.*, 2002, “Universal Restriction Site-Free Cloning Method Using Chimeric Primers” *BioTech* 32:516-20; Rashchian *et al.*, 1992, “Uracil DNA glycosylase-mediated cloning of polymerase chain reaction-amplified DNA: application to genomic and cDNA cloning” *Anal Biochem* 206:91-97; and TOPO-cloning by Invitrogen Corp.). One LIC method involves creating single-strand complementary overhangs sufficiently long for annealing to each other (often 12 to 20 bases) on (a) the synthon and (b) the vector. When the synthon and vector are annealed and transformed into a host (e.g., *E. coli*) a closed, circular plasmid is generated with high efficiency.

[0135] In one embodiment, 3'-overhangs, or “LIC extensions” are introduced to the synthon using PCR primers that are later partially destroyed. This can be accomplished by incorporating uracil (U) residues (instead of thymidine) into a PCR primer, linking the primer onto the 3' ends of the product of assembly PCR described above, and digesting with Uracil-DNA Glycosidase (UDG). UDG cleaves the uracil residues from the sugar backbone, leaving the bases of the other strand free to interact with the complementary strand on the vector (see, e.g., Rashchian *et al.*, 1992). An alternative method involves incorporating a primer containing a ribonucleotide that is cleaved with mild base or RNase.

[0136] Because the sequences at synthon edges can be controlled by the practitioner, a single pair of UDG primers can be used for LIC of a large number of different synthons allowing automated and high-throughput LIC cloning of synthons.

[0137] There are also several options for generating the 3'-overhang on the vector. As above, it can be produced using primers containing U instead of T to replicate the entire plasmid, followed by treatment with UDG. Alternatively, a double-stranded fragment containing U's on one strand can be ligated to the vector followed by treatment with UDG. A particularly useful method for producing an LIC extension by digesting an appropriately designed SIS with a restriction enzyme that cleaves double-stranded DNA and with sequence-specific nicking endonuclease(s). Figure 1 illustrates this technique using, as an example, the UDG-LIC synthon insertion site from the vector pKOS293-88-1. Also see Example 2. The nicked, linearized, DNA is treated with exonuclease III to remove the small oligonucleotides (exonuclease III cleaves 3'→5', providing there are no 3'-overhangs). In an alternative method, the 3'-overhang on the vector is generated by the action of endonuclease VIII (see Example 2). The "central" restriction site is positioned such that cleavage with the restriction endonuclease and nicking endonuclease(s), followed by digestion with the exo- or endo-nuclease results in 3' overhangs suitable for annealing to a fragment with complementary 3' overhangs. Usually the central restriction site is a single, unique, site in the vector. However, the reader will immediately recognize that pairs or combinations of restriction sites can be used to accomplish the same result.

[0138] In an alternative embodiment, the SIS can have other recognition sites for one or more restriction enzymes that cleave both strands (e.g., a conventional "polylinker") and synthons can be inserted by ligase-mediated cloning.

4.2.2 VALIDATION OF SYNTHONS

[0139] High-throughput synthesis of libraries of large genes requires an enormous number of synthetic steps (beginning, for example, with synthesis of oligonucleotides). To maximize the frequency of a successful outcome (i.e., a gene having the desired sequence) the present invention provides optional validation steps throughout the synthetic process. To identify clones containing a synthon having the expected sequence (e.g. following oligonucleotide synthesis, assembly PCR, and LIC), assembly vector DNA is usually isolated from several (typically five


or more) clones and sequenced. See Example 3. Synthon samples can be sequenced until a clone with the desired sequence is found. Alternatively, clones with a small number of errors (e.g., only 1 or 2 point mutations) can be corrected using site-directed mutagenesis (SDM). One method for SDM is PCR-based site-directed mutagenesis using the 40-mer oligonucleotides used in the original gene synthesis.

4.2.3 METHOD S: JOINING STRATEGIES, ASSEMBLY VECTORS, & SELECTION SCHEMES

[0140] As noted above, two different stitching methods, "Method S" and "Method R," have been used by the inventors. This section describes Method S.

4.2.3.1 JOINING STRATEGIES

[0141] Method S entails the use of Type IIS restriction enzyme recognition sites (as defined above) usually *outside* the coding sequences of the synthons (i.e., in the synthon flanking region). In Method S, recognition sites for Type IIS restriction enzymes can be incorporated into the synthon flanking regions (e.g., during assembly PCR). The sites are positioned so that addition of the corresponding restriction enzyme results in cleavage in the synthon coding region and creation of ligatable ends. For illustration and not limitation, this is diagrammed below (R1, R2, R3, and R4 = recognition sites for Type IIS restriction enzymes and digestion with R2 and R3 produce compatible cohesive ends [(same length and orientation) overhangs], vvvvvvv = assembly vector region, sssssss = synthon coding region, s = sequence that is the same in the two synthons, ooo = synthon flanking regions).



[0142] In one embodiment of this method, R1 and R3 are the same and R2 and R4 are the same. This approach simplifies the design of the vectors used and the stitching process. In an

alternative embodiment, the Type IIS recognition sites can be present in the synthon coding region, rather than the flanking regions, provided the sites can be introduced consistent with the codon requirements of the coding region.

[0143] The sequence that is the same in the two synthons ("S") usually comprises at least 3 base pairs, and often comprises at least 4 base pairs. In an embodiment, the sequence is 5'-GATC-3'. Table 2 shows exemplary Type IIS restriction enzymes and recognition sites. Figure 2 illustrates the Method S joining method using Bbs I and Bsa I as enzymes.

TABLE 2
EXEMPLARY TYPE IIS RESTRICTION ENZYMES AND RECOGNITION SITES

Restriction Enzymes	Recognition Site	Cut Site	Overhang
BclV I	GTATCC	N6, N5	-1
Bmr I	ACTGGG	N5, N4	-1
Bpm I	CTGGAG	N16, N14	-2
BpuEI	CTTGAG	N16, N14	-2
BscR I	GAGGAG	N10, N8	-2
Bsg I	GTATCC	N16, N14	-2
BsrDI	GCAATG	N2, N0	-2
Bts I	GCAGTG	N2, N0	-2
Eci I	GGCGGA	N11, N9	-2
Ear I	CTCTTC	N1, N4	3
Sap I	GCTCTTC	N1, N4	3
BsmB I	CGTCTC	N1, N5	4
BspM I	ACCTGC	N4, N8	4
Bsa I	GGTCTC	N1, N5	4
Bbs I	GAAGAC	N2/N6	4
BfuA I	ACCTGC	N4, N8	4
Fok I	GGATG	N9/N13	
Alw I	GGATC	N4/N5	

4.3.2.2 ASSEMBLY VECTORS

[0144] Figure 3 illustrates how the joining method described above can be combined with a selection strategy to efficiently link a series of adjacent synthons. In this embodiment, pairs of adjacent synthons (or adjacent multisynthons) are cloned into the SIS sites of cognate pairs of vectors, where the two members of the pair are differently selectable. These selection strategies are discussed in greater detail in the next section (4.3.2.3). In this section, exemplary cognate vector pairs that can be used in stitching are described, as well as certain intermediates (occupied assembly vectors) created during the stitching process.

Vector Pair I

[0145] In one embodiment, the stitching vectors have i) a synthon insertion site (SIS); ii) a "right" restriction site (R_1) common to both vectors or, alternatively, that is different in each vector but which produce compatible ends; iii) a first selection marker (SM2 or SM3) that is different in each vector; iv) a second selection marker (SM4 or SM5) that is different in each vector; and, v) optionally a third selection marker (SM1) common to both vectors. The convention used here is that SM2 and SM4 lie on the first vector of the pair, and SM3 and SM5 lie on the second vector of the pair, and none of SM2-5 are the same.

[0146] The spatial arrangement of these elements can be


$$(SM2 \text{ or } SM3) - SIS - (SM4 \text{ or } SM5) - R_1 \quad [I]$$

[0147] In Vector I, the *right restriction site* is usually a unique site in the vector. In cases in which there is more than one site, the additional sites are positioned so that the additional copies do not interfere with the strategy described below and illustrated in Figure 3A. [For example, in an acceptor vector, the R_1 site can be unique or, if not unique, absent from the portion of the vector containing the SIS (or synthon), the SM2/SM3, and delimited by the SIS (or the junction edge of the synthon) and the R_1 site (i.e., the R_1 that is cleaved to result in the ligatable end). In a donor vector, the R_1 site can be unique or, if not unique, absent from the portion of the vector containing the SIS (or synthon) and the SM4/SM5 site, and delimited by the SIS (or the junction edge of the synthon) and the R_1 site (e.g., the R_1 that is cleaved to result in the ligatable end)].


[0148] The R_1 site can be a recognition sites for any Type II restriction enzyme that forms a ligatable end (e.g., usually cohesive ends). Usually the recognition sequence is at least 5-bp, and often is at least 6-bp. In one embodiment, the right restriction site is about 1 kb downstream of the SIS. In one embodiment of the invention, the R_1 sites of the donor and acceptor vectors are not the same, but simply produce compatible cohesive ends when each is cleaved by a restriction enzyme.

[0149] In one embodiment of the invention, the SIS is a site suitable for LIC having a sequence with a pair of nicking sites recognized by a site-specific nicking endonuclease (usually the same endonuclease recognizes both nicking sites) and, positioned between the nicking sites, a restriction site recognized by a restriction endonuclease (to linearize the nicked SIS, consistent


with the LIC strategy described above). In one embodiment, the nicking endonuclease is N.BbvC IA, which recognizes the sequence (∇ = nicking site):



[0150] Accordingly, in one embodiment, a Vector Pair I vector has the following structure, where N_1 and N_2 are recognition sites for nicking enzymes (usually the same enzyme), R_2 is an SIS restriction site as discussed above, and R_1 and SM1-5 are as described above, e.g.,



[0151] In one embodiment of the invention, a Vector Pair I vector is "occupied" by a synthon, and has the following structure, where $2S_1$ and $2S_2$ are recognition sites for Type IIS restriction enzymes, S_y is synthon coding region, and R_1 and SM1-5 are as described above, e.g.,




This is an intermediate construct useful for stitching.

Vector Pair II

[0152] Vector pair II requires only one unique selectable marker on each vector in the pair (i.e., an SM found on one vector and not the other) although additional selectable markers may optionally be included. In one embodiment, the stitching vectors have

- i) a synthon insertion site (SIS);
- ii) a "right" restriction site (R_1) as described above for Vector I, usually common to both vectors;
- iii) a "left restriction site" on each vector that may be the same or different (L or L');
- iv) a first selection marker ($SM2$ or $SM3$) that is different in each vector
- vi) optionally a second selection marker ($SM4$ or $SM5$) that is different in each vector; and,
- vi) optionally a third selection marker ($SM1$), common to both vectors.

[0153] The spatial arrangement of these elements can be



[0154] In this embodiment, the *right restriction site* (R_1) and *left restriction site* (L or L') are usually unique sites in the vector. In cases in which they are not unique, the additional sites are positioned so they do not interfere with the strategy described below and illustrated in Figure 3B.

Recognition sites for any Type II restriction enzyme may be used, although typically the recognition sequence is at least 5-bp, often at least 6-bp. In one embodiment, the right restriction site is about 1 kb downstream of the SIS.

[0155] The vectors also contain the conventional elements required for vector function in the host cell or useful for vector maintenance (for example, they may contain one or more of an origin of replication, transcriptional and/or translational control sequences, such as enhancers and promoters, and other elements).

[0156] In one embodiment of the invention, the SIS is a site suitable for LIC having a sequence with a pair of nicking sites recognized by a site-specific nicking endonuclease as described above in the description of Vector Pair I. Accordingly, in one embodiment, a Vector Pair II vector has the following structure, where N_1 and N_2 , R_1 , R_2 , L , L' , and SM2 and 3 and SM1-5 are as described above, e.g.,

$$(L \text{ or } L') - N_1 - R_2 - N_2 - (SM2 \text{ or } SM3) - R_1 \quad [V]$$

[0157] In one embodiment of the invention, a Vector Pair II vector comprises a synthon cloned at the SIS site and has the following structure, where $2S_1$ and $2S_2$, S_y , R_1 , L , L' , SM2 and 3 are described above, e.g.,

$$(L \text{ or } L') - 2S_1 - S_y - 2S_2 - (SM2 \text{ or } SM3) - R_1 \quad [VI]$$

[0158] Figure 4 is a diagram of exemplary stitching vectors pKos293-172-2 and pKos293-172-A76.

4.2.3.3 SELECTION SCHEMES

Two-Selection Marker Scheme

[0159] As noted, Figure 3 illustrates how the joining method shown above can be combined with a selection strategy to efficiently link a series of adjacent synthons (or other DNA units). Using Vector Pair I (Figure 3A), the vectors of the pair into which adjacent synthons have been cloned are digested with R_1 (e.g., Xho I) and with either $2S_1$ or $2S_2$ (the site closest to the junction edges), and the products ligated. Thus, the vector containing the first synthon (acceptor vector) is restricted at the 3'-synthon edge and R_1 downstream of the 3' synthon edge). The vector containing the second, 3' adjacent synthon (donor vector) is restricted at the 5'-synthon edge and R_1 . The resulting products are ligated to reconstruct the vector containing 2 synthons,

and selection is by antibiotic resistance markers SM2 and SM5. By selecting for positive clones with a unique selection marker from both the donor and the acceptor plasmid, only the correct clones will have the two markers.

[0160] By running parallel reactions, four 2-synthon vectors are prepared simultaneously to prepare four 2-synthon vectors. Next, using the same approach, four 2-synthon fragments are stitched to make two 4-synthon fragments, and then the two 4-synthon fragments are stitched together to make an 8-synthon product. For illustration, consider a vector pair each having two unique SMs (SM2, SM4 and SM3, SM5). To make a hypothetical 8-synthon module of sequence S1-S2-S3-S4-S5-S6-S7-S8 where S1-8 are synthons, synthons 1, 4, 6, and 7 can be cloned into the vector with the SM2+SM4 markers, and 2, 3, 5, and 8 can be cloned into the vector with the SM3+SM5 markers as summarized in Table 3.

TABLE 3
SELECTION STRATEGY

Synthon→	1	2	3	4	5	6	7	8				
1-syn ¹	SM2	SM3	SM3	SM2	SM3	SM2	SM2	SM3				
	SM4	SM5	SM5	SM4	SM5	SM4	SM4	SM5				
2-syn ²	SM2 + SM5		SM3 + SM4		SM3 + SM4		SM2 + SM5					
4-syn ²	SM2 + SM4				SM3 + SM5							
8-syn ²	SM2 + SM5											

¹Shows unique marker of vector into which synthon is cloned.

²Shows marker selected for after of synthons are combined.

[0161] The same procedure is applied to the two vectors containing synthon 3 (SM3, SM5) and synthon 4 (SM2, SM4). This would produce a 2-synthon vector containing SM3 and SM4 and selectable for these markers. Next, the 2-synthon insert containing synthons 3 and 4 are cloned into the first 2-synthon containing synthons 1 and 2 to give a 4-synthon product (1-2-3-4) in a SM2 + SM4 vector. This could be repeated with the synthons 5, 6, 7, and 8 to give a 4-synthon insert (5-6-7-8) in a SM3 + SM5 vector. The two would then be combined as before to give an 8-synthon module in an SM3 vector.

[0162] It can be seen that by designing modules to contain 2ⁿ synthons, and parallel-processing the synthon stitching reactions, a complete module can be assembled in n operations.

[0163] Although pairwise combining minimizes ligation steps, and is thus particularly efficient, other combination strategies, such as that illustrated in Figure 7 for Method R, can be used.

[0164] A wide variety of selection markers and selection methods are known in molecular biology and can be used for selection. Typically, the marker is a gene for drug resistance such as *carb* (carbenicillin resistance), *tet* (tetracycline resistance), *kan* (kanamycin resistance), *strep* (streptomycin resistance) or *cm* (chloramphenicol resistance). Other suitable selection markers include counterselectable markers (csm) such as *sacB* (sucrose sensitivity), *araB* (ribulose sensitivity), and *tetAR* (codes for tetracycline resistance/fusaric acid hypersensitivity). Many other selectable markers are known in the art and could be employed.

One-Marker Scheme

[0165] An alternative selection strategy uses Vector Pair II. According to this strategy, at each round, the two vectors are mixed in equal amounts, and simultaneously digested to completion with restriction enzymes R_1 , L (or L'), and the Type IIS enzyme corresponding to the restriction site at the two synthon edges to be joined, followed by ligation. In Figure 3B, the vector containing synthon 1 + SM2 is cut at right edge of the synthon and at R_1 , and the vector containing synthon 2 + SM3 is cut at the left edge of the synthon and at R_1 and at L' . Cleavage at L' is intended to prevent re-ligation of this fragment. The mixture of fragments are ligated, transformed, and cells grown on antibiotics to select for SM1 and SM3. Under these selection conditions, the predominant clones are the desired 2-synthon product.

[0166] Table 3 shows a selection scheme for stitching a hypothetical 8-synthon module of sequence 1-2-3-4-5-6-7-8 using Vector Pair II. Synthons 1, 4, 6, and 7 can be cloned into the vector with the SM2 marker, and 2, 3, 5, and 8 can be cloned into the vector with the SM3 marker as summarized in Table 4.

TABLE 4
SELECTION STRATEGY

Synthon→	1	2	3	4	5	6	7	8
1-syn	SM2	SM3	SM3	SM2	SM3	SM2	SM2	SM3
2-syn	SM3		SM2		SM2		SM3	
4-syn	SM2				SM3			
8-syn	SM3							

4.2.4 METHOD R: ASSEMBLY VECTORS, JOINING STRATEGIES, & SELECTION SCHEMES

4.2.4.1 JOINING STRATEGIES

[0167] Method R entails the use of recognition sites for Type II restriction enzymes at the *edges* of the coding sequences of the synthons. Compatible (e.g. identical) restriction sites at the edges of adjacent synthons are cleaved and ligated together. For illustration and not limitation, this is diagrammed below (R1, R2 and R3 = recognition sites for different Type II restriction enzymes, vvvvvvvv = assembly vector region, ssssssss = synthon coding region, ooo = synthon flanking regions).

$$\begin{array}{l}
 \text{vvvvvvvvvooor1ssssssssssssssssssR2ooovvvvvvvvv} + \text{vvvvvvvvvooor2ssssssssssssssssssR3ooovvvvvvvvv} \\
 \quad \quad \quad \blacktriangledown \text{ digest with R2} \\
 \text{vvvvvvvvvooor1ssssssssssssssssssR2} \quad \quad \quad + \quad \quad \quad \text{R2ssssssssssssssssssR3ooovvvvvvvvv} \\
 \quad \quad \quad \blacktriangledown \text{ ligate} \\
 \text{vvvvvvvvvooor1ssssssssssssssssssR2ssssssssssssssssssR3ooovvvvvvvvv}
 \end{array}$$


[0168] Both the association of specific synthons (depending on their position in the module) with SM2 or SM3 and the selection of restriction sites in the synthons is important. As noted above, synthons are designed with useful restriction sites at both the left and right edges of the synthons, and the sites are selected so that adjacent synthon edges share a common (or compatible) restriction site. For example, to prepare a module with a sequence 1-2-3-4-5-6-7-8 by stitching of synthons comprising the sequences 1, 2, 3, 4, 5, 6, 7, and 8, the adjacent synthon

edges can share common sites B, C, D, E, F, G and H as follows: A-1-B, B-2-C, C-3-D, D-4-E, E-5-F, F-6-G, G-7-H, H-8-X. See Figure 5.

[0169] The basis for this method is the design of synthons (and component oligonucleotides) that contain unique restriction sites at the edges of the synthon. This requires both the presence (insertion) of useful restriction sites (at the synthon edges) and absence (removal) of these sites in the interior of the synthon. Example 4 describes a strategy for identifying useful restriction sites that can be engineered at synthon and module without resulting in a disruptive change in the module amino acid sequence, and provides exemplary results from an analysis of 140 PKS modules (see Figure 6 and Tables 8-12). Section 5, below, describes computer implementable algorithms for the design of oligonucleotides that can be used to produce synthons with the desired patterns of restriction sites.

4.2.4.2 ASSEMBLY VECTORS

[0170] Method R can be carried out using the same vector pairs as are useful for Method S. Using Method R, a Vector Pair I vector comprises a synthon cloned at the SIS site can have the following structure (where R_3 and R_4 are restriction sites at the edges of the synthon, and the other abbreviations are as described previously):



This is an intermediate construct useful for stitching.

4.2.4.3 SELECTION SCHEMES

[0171] The selection schemes described for Method S can be used for Method R. It will be appreciated that the restrictions sites at the ends of synthons must be designed so they are compatible with the digestion at vector restriction sites L and L'.

5. GENE DESIGN AND GEMS (GENE MORPHING SYSTEM) ALGORITHM

[0172] Design of the synthetic genes of the invention, as well as the design of oligonucleotides that can be used for gene synthesis, requires concomitant consideration of a large number of factors. For example, the synthetic module genes of the invention will encode a polypeptide with a desired amino acid sequence and/or activity, and typically

- use the codon preference of a specified expression host,

- are free from restriction sites that are inconsistent with the stitching method (e.g., the Type IIS sites used in stitching Method S) and/or are comprised of synthons free from restriction sites that are inconsistent with the stitching method (e.g., the Type II sites used in stitching Method R) and/or are free from restriction sites that are inconsistent with the construction of open reading frames and gene libraries (as described below),

- contain useful (e.g., unique) restriction sites or sequence motifs at specific locations (e.g., region encoding domain edges, synthon edges, module boundaries, and within synthons). Without limitation, restriction sites within synthons are used for correction of errors in gene synthesis or other modifications of large genes; restriction sites and/or sequence motifs at synthon edges are used for LIC cloning (e.g., addition of UDG-linkers), stitching; restriction sites at domain edges are used for domain “swaps;” restriction sites at module edges are useful for cloning module genes into vectors and synthesis of multimodule genes. By incorporating these sites into a number of different PKS module-encoding genes, the “modules” can readily be cloned into a common set of vectors, domains (or combinations of domains) can be readily moved between modules, and other gene modifications can be made.

[0173] Challenges encountered during synthetic design of large genes include efficient codon optimization for the host organism, restriction site insertion and elimination without affecting protein sequence and design of high quality oligonucleotide components for synthesis.

[0174] A computer implementable algorithm for design of synthetic genes (and component synthons and oligonucleotides) is described in this section. A Gene Morphing System (“GeMS”) is aimed at simplifying the gene design process.

5.1 GeMS - OVERVIEW

[0175] The GeMS process was initially developed for designing PKS genes is described below. The process includes components for the design of any gene. For convenience, the GeMS process will be described with reference to a gene encoding a specified polypeptide segment. The polypeptide segment can be a complete protein, a structurally or functionally defined fragment (e.g., module or domain), a segment encoded by the synthon coding region of a particular synthon, or any other useful segment of a polypeptide of interest.

[0176] A GeMS process generically applicable to the design of any gene has several of the following features: (i) restriction site prediction algorithms; (ii) host organism based codon optimization; (iii) automated assignment of restriction sites; (iv) ability to accept DNA or protein sequence as input; (v) oligonucleotide design and testing algorithm; (vi) input generation for robotic systems; and (vii) generation of spreadsheets of oligonucleotides.

[0177] GeMS executes several steps to build a synthetic gene and generate oligonucleotides for in vitro assembly. Each of these steps are closely connected in the overall program execution pipeline. This allows the gene design to be executed in a high-throughput process as shown in Figure 8.

[0178] Briefly, a GeMS process initiates with an input 800 of (i) an amino acid sequence of a reference polypeptide and (ii) parameters for positioning and identity of restriction sites or desired sequence motifs. In one embodiment a DNA sequence of the reference polypeptide is input and translated to the corresponding amino acid sequence. While the amino acid/DNA sequence are input from publicly available databases (e.g., GenBank), in one embodiment the sequence is verified (by independent sequencing) for accuracy prior to input in the GeMS process. In the example of Figure 8, a GeMS process according to the present invention comprises a first series of steps 810 wherein the amino acid sequence is used as a reference to generate a-corresponding nucleotide sequence which encodes the reference polypeptide ("reverse translated"). Further processes in the first series of steps include codon randomization wherein additional nucleotide sequences are generated which encode a same (or similar) amino acid sequence as the reference polypeptide using a random selection of degenerate codons for each amino acid at a position in the sequence. The process may optionally include optimization of codon usage based on a known bias of a host expression organism for codon usage. The codon-randomized DNA sequence generated by the software is further processed for introduction of restriction sites at specific location, and removal of undesired occurrences of sites in subsequent steps.

[0179] A series of steps 820 and 830 comprise restriction site removal and insertion in response to a selection of restriction sites and identification of their positions in the sequence. In one embodiment, the process uses the GeMS restriction site prediction algorithms to predict all possible restriction sites in the sequence. Based on a combination of pre-determined parameters, user input and internal decisions, the algorithm suggests optimally positioned (or spaced)

restriction sites that can be introduced into the nucleic acid sequence. These sites may be unique (within the entire gene, or a portion of the gene) or useful based on position and spacing (e.g., sites useful for synthon stitching using Method R, which need not necessarily be unique). In another embodiment, an user inputs positions of preferred restriction sites in the sequence.

[0180] In a series of steps 820 the GeMS software removes occurrences of restriction sites from unwanted locations. This process preserves the unique positions of certain restriction sites in the sequence. Following removal, a third series of steps 830 inserts selected restriction sites at specific locations in the sequence. The nucleotide sequence is then divided into a series of overlapping oligonucleotides which are synthesized for assembly *in vitro* into a series of synthons which are then stitched together to comprise the final synthetic gene. The design of the oligonucleotides in step 840 and synthons are guided by a number of criteria that are discussed in greater detail below. Following design the oligonucleotide sequences are tested in step 840 for their ability to meet the criteria. In the event of a failure of an oligo or synthon to pass the stringent quality tests of GeMS, the entire gene sequence is re-optimized to produce a unique new sequence which is subjected to the various design stages.

[0181] Successful designs are validated in step 850 by verifying sequence integrity relative to the amino acid sequence of the reference polypeptide, restriction site errors and silent mutations. The software also produces a spreadsheet of the oligonucleotides that are in a format that can be used for commercial orders and as input to automated systems.

[0182] The overall scheme for synthon design by GeMS software is shown in the flow diagram of Figure 9. The inputs 910 for the GeMS software include a file (e.g., GenBank derived information) containing the amino acid sequence of a reference polypeptide segment (or a DNA sequence encoding a polypeptide segment, usually the sequence of a naturally occurring gene). When a DNA sequence is input into GeMS, a translation of the open reading frame (ORF) to the corresponding amino acid sequence is performed. The input optionally comprises the identity of an appropriate host organism for expression of the synthetic gene and its preference for codon usage. The input may optionally include one or more lists of annotated restriction sites or other sequence motifs desired to be incorporated in the nucleotide sequence of the gene (e.g., at module/domain/synthon edges), and annotated restriction sites to be removed or excluded from the gene (e.g., recognition sites for Type IIS enzymes used in stitching). The user may input acceptable ranges of synthon sizes (typically about 300 to about 700 basepairs), number of

synthons (e.g., $2n$, where $n = 2-5$), and synthon flanking sequences (e.g., sequences useful for ligation independent cloning, for example, annealing of “universal” UDG primers).

[0183] In step 920, the amino acid sequence of the reference polypeptide segment is converted (reverse-translated) to a DNA sequence using randomly selected codons, such that the second DNA sequence codes for essentially the same protein (i.e., coding for the same or a similar amino acids at corresponding positions). In one embodiment, the random choice of codons reflects a codon preference of the selected host organism. In one embodiment, the codon optimization and randomization are omitted and the DNA sequence derived from the database is directly processed in the subsequent steps. The codon randomization and optimization processes are described in greater detail in Figures 10A and 10B and the accompanying text.

[0184] In one embodiment, preselected restriction sites and their positions are input in step 930. In step 932, the GeMS program then identifies positions for insertions of the specified sites and identifies positions from which unwanted occurrences of specific restriction sites are to be removed. In another embodiment following step, one or more parameters for positions of restriction sites and specified characteristics of the sites are input in step 934. GeMS identifies all possible restriction sites within the sequence in step 936. The program also suggests a unique set of restriction sites according to the predetermined parameters (such as spacing, recognition site, type, etc.) in step 936. In one embodiment, the regions suggested are selected for their presence within or adjacent to synthon fragment boundaries. Common unique restriction sites or related defined sequences for modules, domain ends, synthon junctions and their positions (based on the above design principles) are identified by the program in step 936. The user accepts or rejects the suggested restrictions sites and positions in step 938. In one embodiment, the user may manually input proposed restriction sites.

[0185] In step 940 uniqueness of restriction sites at specific positions (e.g., the edges) is preserved by eliminating all unwanted occurrences of these sites in the sequence. Selected codons at specified positions are replaced with alternate codons specifying the same (or similar) amino acid to remove undesirable restriction sites.

[0186] This step is followed by insertion of selected codons at the specified positions to create restriction sites in step 950. In one embodiment, the user retains the option to include additional sites and/or to eliminate specific sites from the DNA sequence.

[0187] The DNA sequence generated following removal and insertion of restriction sites is then divided in step 960 into fragments of synthon coding regions having predetermined size and number. Synthon flanking sequences are added for determination of each synthon sequence additino of sequence motifs for addition of LIC primers, restriction sites or other motifs.

[0188] In one embodiment, specific intra-synthon sites are introduced into the DNA sequence in step 950 which are unique within the synthon. These may be used for repairs within a synthon, or for future mutagenesis. Each synthon sequence is generated as overlapping oligonucleotides of a specified length with a specified amount of overlap with its two adjacent oligonucleotides in step 970. Several factors enter into the determination of the length of the oligonucleotides and the length of the overlap (e.g., efficiency of synthesis, annealing conditions, aberrant priming, etc.). The length of the oligonucleotides may be about 10, 15, 20, 30, 40, 50, 60, 70, 80, 90 or 100 nucleotides. The length of the overlap may be about 5, 10, 15, 20, 25, 30, 35, 40 or 50 nucleotides. the lengths of the overlap may not be precise and a variation by 1, 2, 3, 4 or 5 between several oligonucleotides comprising adjacent synthons is acceptable. In one embodiment, each synthon is designed as oligonucleotides of overlapping 40-mers with about a 20 base overlap among adjacent oligonucleotides. The overlap may vary between 17 and 23 nucleotides throughout the set of oligonucleotides. An option to design these oligonucleotides based on an uniform annealing temperature is also available.

[0189] As discussed in detail below, each set of oligonucleotides used for synthesis of a synthon (synthon coding region and synthon flanking sequence) can be subjected to one or more quality tests in step 980. The oligonucleotides are tested under one or more criteria of primer specificity including absence of secondary structur predicted to interfere with amplification, and fidelity with respect to the reference sequence. As discussed below, validatino is also carried out for the assembled gene.

[0190] Any failures trigger a user-selected choice of two strategies in step 982: 1) repeat the random codon generation protocol 984 and continue the process from codon removal 940 and insertion 950; and/or 2) manually adjust the sequence to conform better to the predetermined parameters in the problematic region in step 984. The process may be repeated (starting with the codon optimization and randomization step 920) for a particular synthon that does not pass the test or may be run *de novo* for the entire polypeptide segment sequence. The candidate oligonucleotide sequences generated by this process are in turn tested again. When an entire set

of oligonucleotides for 10 to 12 synthon sequences has been successfully generated, the entire candidate module sequence can be checked in any way desired (repeats, etc.), with the possibility of triggering redesign of individual synthons. Optionally, duplicated regions are removed although the random choice procedure makes occurrence of substantial repeats unlikely. Optionally, the software also edits the sequence to remove clustered positioning of rare codons. Since each redesign uses a random set of codons, synthon fragments pass these tests in relatively few iterations.

[0191] Once all fragments have passed the tests, GeMS reassembles the fragments in predetermined order and validates the restriction sites and DNA sequence by comparison with the original input sequence. This integrity check ensures that the target sequence is in accord with the intended design and no unwanted sites appear in the finished DNA sequence. Implementation of the method of Figure 9 allows the oligonucleotides for each fragment to be saved in separate files representing each synthon or as a complete set representing the synthetic gene. The software can also produce spreadsheets of the oligonucleotides in step 986 that are in a format that can be used for commercial orders, and as input to the robots of an automated system. Spreadsheets input to an automated system can include (a) oligonucleotide location (e.g., identity such as barcode number of a 96-well plate and position of a well on the plate); (b) name or designation of oligonucleotide; (c) name or designation of module(s) synthesized using oligonucleotide; (d) identity of synthon(s) synthesized using oligonucleotide (identifying those oligonucleotides to be pooled for PCR assembly); (e) the number of synthons within the module; (f) the number of oligonucleotides within the synthon; (g) the length of the oligonucleotide; (h) the sequence of oligonucleotide. The entire gene design process involving user interaction can be achieved in a few minutes. GeMS achieves end to end integration using a high-throughput pipeline structure. In one embodiment, GeMS is implemented through a web browser program and has a graphical interface.

[0192] At least one set of rules to guide the design process are input and stored in the memory of the system. The design software operates by means of a series of discrete and independently operable routines each processing a discrete step in the design system and comprised of one or more sub-routines.

[0193] These functions are described in greater detail below. Successful designs are rechecked for sequence integrity, restriction site errors and silent mutations.

5.2 GeMS ALGORITHMS

[0194] A method in accordance with the present invention comprises algorithms capable of performing one or more of the following subroutines:

[0195] 1. *Codon Randomization and Optimization* -- GeMS uses codon randomization and optimization sub-routines a schematic example of which are shown in Figures 10A and 10B. In one embodiment the optimization-randomization program can be bypassed with a manual selection of codons or acceptance of the natural nucleotide sequence.

[0196] A codon optimization process shown in the schematic of Figure 10A starts with an input 1010 of host codon frequencies (Faa = frequency per 1000 codons) of different amino acids from a codon preference database 1012 of a selected host organism. Then the codon preference (N) for each codon is calculated in step 1014. In one known codon optimization routine (CODOP) the codon preference N is calculated as follows: $N = Faa_1 \times n / (Faa_1 + Faa_2 + Faa_3 + \dots + Faa_n)$, where n is the number of synonymous codons (codons for the same amino acid) and Faa_1 to Faa_n are the proportions per 1000 codons of each synonymous codon. (see Withers-Martinez *et al.*, 1992, *Protein Eng* 12:1113-20.) A cut-off value for codon optimization is selected by an user in step 1020. In one embodiment, the value is 0.6. The cut-off value can vary based on the GC-richness of the host expression system or can be different for each amino acid based on metabolic and biochemical characteristics. The rationale is to choose a cut-off value that eliminates most rare codons. In one embodiment, this is done by visual inspection of the modified codon tables and selecting a cut-off value that eliminates most rare codons without affecting the preferred codons. Each codon is tested for a codon preference value above the cut-off value in step 1022. All codons with N below the user-defined cut-off value are rejected in step 1024. For each amino acid, codons with N values above the cut-off value are pooled and the N values normalized in step 1030 such that the sum of the N values is one (1). A codon preference table for the synthetic gene is generated in step 1040.

[0197] Use of the optimized codons in generating a randomized and optimized synthetic gene sequence is shown in the schematic of Figure 10B. For an input amino acid sequence 1052, the number of codons for each amino acid is calculated in step 1050 based on the synthetic gene codon preference table 1054. For each amino acid in the sequence 1052, a codon is randomly picked in step 1060 from the selection of optimized codons for the amino acid. The randomly

selected codon is used to generate a new synthetic gene sequence in step 1070. Each time a codon is used in the synthetic gene sequence it is eliminated in step 1062 from the selection of optimized codons for the amino acid in the synthetic gene codon preference table 1054. The synthetic gene sequence is validated by comparison of its translated amino acid sequence with the input amino acid sequence in step 1080. If the sequences are identical 1082, the randomized and optimized synthetic gene sequence is reported in step 1090. If the sequences are not identical, the errors in the synthetic gene sequence are reported in step 1084. In one embodiment, the user has the option to accept a substitution of a similar amino acid. In another embodiment, the errors are analyzed for implementation in correcting subsequent randomization routines.

[0198] 2. *Restriction site prediction* -- In one embodiment, a restriction enzyme prediction routine is performed at this stage. The restriction site prediction routine predicts all restriction sites in a nucleotide sequence for all possible valid codon combinations for the corresponding amino acid sequence. The program automatically identifies unique restriction sites along a DNA sequence at user-specified positions or intervals. This routine is used in the initial design of the modules and/or synthons and optionally in checking errors in the predicted sequences.

[0199] Following execution of these routines the user indicates acceptance of the output according to one embodiment. If the list of restriction sites generated are accepted by the user, the process is transferred to the GeMS codon-optimization routine. If the result is not acceptable to the user, the sub-routine is repeated while allowing the user to modify the parameters manually. The process is repeated until a signal indicating acceptance is received from the user. After the user accepts the restriction sites, the sequence is transferred to the next routine in the GeMS module to perform the subsequent procedures.

[0200] 3. *Removal of Restriction Sites* -- Restriction sites that are selected in steps 932 or 938 of the GeMS program (see Figure 9) are cleared from the codon optimized gene sequence as shown schematically in Figure 11.

[0201] A sub-routine of the present process removes selected restriction sites that are specified and input 1100 with the randomized-optimized gene sequence. The sub-routine identifies the pre-selected restriction sites in the codon-optimized gene sequence and identifies their positions in step 1110. At each given position the open reading frames comprising the recognition site are examined for the ability to alter the sequence and remove the restriction site without altering the amino acid encoded by the affected codon at the restriction site in step 1120.

If the reading frame is open, the first codon of the recognition site is replaced with a codon encoding the same or a similar amino acid in a manner that removes the restriction site sequence. If however, the first codon is unsuitable for replacement, the sub-routine shifts to the next available codon and continues until the restriction site is removed. Since a restriction site may encompass up to 6 nucleotides, removal of a site may involve analysis of up to three amino acid codons. Removal of restriction sites is performed in a manner which retains the identity of the encoded amino acid in step 1130. The sub-routine generates a randomized-optimized gene sequence from which selected restriction sites have been removed without altering the amino acid sequence 1140.

4. Insertion of Restriction Sites -- The next sub-routine performed by the process introduces restriction sites. This step substitutes nucleotide bases at selected positions to generate the recognition sites of selected restriction enzymes without altering the amino acid sequence as shown in the schematic of Figure 12. In this sub-routine a randomized-optimized gene sequence from which selected restriction sites have been removed is input along with selected restriction sites and their positions for insertion into the sequence in step 1210. The selected insertion positions are identified in the sequence and nucleotide(s) are substituted to generate in step 1220 the selected restriction site at the selected position. In one embodiment, only the sequence of an overhang created by a restriction site is inserted instead of a restriction site. When a such sequence is present in the synthon, it can be cleaved remotely by a Type IIS restriction enzyme and the overhang thus generated is available for ligation with a DNA fragment which has been cleaved with a Type II restriction enzyme to generate the complementary overhang. The substituted sequence is translated and the resulting amino acid sequence is compared in step 1230 with the sequence of the reference amino acid (see 1052 in Figure 10B). The substituted sequence is translated and the resulting amino acid sequence is compared in step 1230 with the sequence of the reference amino acid (see 1052 in Figure 10B), comparing the sequences for identity of the amino acid sequences. If in step 1240, the amino acid specificity of a codon overlapping the substituted sequence is found to be changed, the codon table may be reexamined in step 1240A for codons compatible with both the amino acid sequence and the substituted sequence, and compatible with the desired pattern of restriction sites and sequence motifs or other patterns. If any compatible codons are found, one is chosen from the list of such codons according to user preference (for example, by use of relative probabilities in a codon table), and

inserted as replacement for the undesired codon; the program returns to step 1240. If the amino acid sequence is altered, and not repairable by the procedure described in step 1240A, the program proceeds to step 1242. The user in step 1242 has the option of rejecting the output in step 1244 and repeating the process of nucleotide substitutions at the selected position. In one embodiment the user replaces in step 1246 an amino acid with a similar amino acid and manually accepts the output. The sequence generated following introduction of the restriction sites is then checked for translational errors in step 1250. A randomized-optimized synthetic gene sequence with selected restriction sites removed and other selected restriction sites inserted is provided in step 1260. As noted above, sequence motifs other than restriction sites can be "inserted" or "removed" (i.e., the oligonucleotides, synthons and genes can be designed to include or omit the sequence motifs from particular locations). For example, regions of sequence identity are useful for construction of multisynthons (see, e.g., Exemplary Construction Method 2 in Section 6.4.3, below) and can be included at specified locations of synthetic genes).

[0202] 5. *Generation of Oligonucleotides to Comprise Synthetic Genes or Synthons* – The input to GeMS has each of the restriction sites tagged as either a domain edge or synthon edge along with their positions. Based on these criteria, this step 1320 (see Figure 13) of the program pipeline divides the entire gene sequence into a number of synthons in one embodiment. In another embodiment, a preferred synthon size is input. Overlapping oligonucleotide sequences are generated in step 1320 to comprise the synthon coding region as well as the synthon flanking sequences.

[0203] The generation of oligonucleotides for a synthetic gene is shown in the schematic of Figure 13. A synthetic gene sequence 1312 is input along with parameters in step 1310 specifying lengths of oligonucleotides and the extent of overlap between adjacent oligonucleotides. The synthetic gene sequence is divided in step 1320 into a plurality of oligonucleotide sequences of specified length with overlaps allowing a selected number of bases to pair with adjacent strands. Each oligonucleotide is aligned with the synthetic gene sequence 1312 and the extent of alignment is determined in step 1330. The extent of alignment (match score) is compared in step 1332 to a predetermined sequence specificity cutoff value for acceptable degree of alignment. A decision is made based on the match of the sequences in step 1340. If the match score is less than the specificity cutoff value the invalid oligonucleotide is identified and the errors are identified in step 1342. The output may be discarded or adjusted

manually. In one embodiment, the lengths of the oligonucleotides are increased or decreased to adjust the overall extent of alignment of the oligonucleotide. If the match score exceeds the specificity cutoff, a list of validated oligonucleotides are generated.

[0204] In one embodiment, the synthetic gene is a synthon. Oligonucleotides comprising a synthon include oligonucleotides specific for the synthon coding region as well as the synthon flanking sequences. Each synthon is comprised of oligonucleotides designed as a set of oligonucleotides each having overlaps of complementary sequences with its two adjacent oligonucleotides on either side. The selection of the length of oligonucleotides take into account several factors including, the efficiency and accuracy of synthesis of oligonucleotides of specific lengths, the efficiency of priming during assembly PCR, annealing temperatures and translational efficiency. In a preferred embodiment, a 40-mer size of each oligonucleotide is selected with an overlap of about 20 nucleotides with adjacent oligonucleotides. Each oligonucleotide is designed as two approximately equal halves (in this instance, two 20-mer sections), wherein each half must meet the criteria for interactions (e.g., annealing, priming) with the two adjacent oligonucleotides that overlap with either half. the selection of a 40-mer sequence further reflects the accuracy of chemical synthesis of oligonucleotides of that length.

[0205] While the present invention relates to assembly of the overlapping oligonucleotides by a PCR reaction, it is contemplated that the oligonucleotides may be assembled enzymatically by a combination of DNA ligase and DNA polymerase enzymes. In such an embodiment, longer oligonucleotides may be used with shorter overlaps. It is contemplated that the overlaps may leave gaps of 5, 10, 15, 20 or more nucleotides between the regions of an oligonucleotide that are complementary to its two adjacent oligonucleotides. Such gaps can be repaired by a DNA polymerase enzyme and the synthon comprised by the oligonucleotides can then be assembled by a DNA ligase mediated reaction.

[0206] *6. Oligonucleotide Design Criteria:* The design of suitable oligonucleotide sets are based on a number of criteria. Two criteria used in the design are annealing temperature and primer specificity.

[0207] *6A. Optimum Annealing Temperature:* User-defined ranges for annealing temperature (preferably 60 – 65°C) and oligonucleotide overlap length are input. To increase temperature, the size of the oligonucleotide overlap length is increased and vice-versa. The GeMS program designs the oligonucleotides within specified annealing temperature boundaries. The criterion is

an uniform (preferably, narrow range of) annealing temperature for the entire set of oligonucleotides that are to be assembled by a single PCR reaction. Annealing temperature is measured using the nearest neighbor model described by Breslauer (Breslauer et al., 1986 "Predicting DNA Duplex Stability from the Base Sequence." *Proceedings of the National Academy of Sciences USA* 83:3746-3750.) and Baldino (Baldino, 1989, "High Resolution In Situ Hybridization Histochemistry" in *Methods in Enzymology*, (P.M. Conn, ed.), 168:761-777, Academic Press, San Diego, California, USA.). An additional method for narrowing the melting temperature range of designed oligonucleotide duplexes, by automatically adding or removing bases from oligonucleotide components, is also implemented.

[0208] *6B. Primer Specificity:* - Each of the overlapping oligonucleotide sequences generated for each synthon (or synthetic gene) is subjected to primer specificity tests against the entire synthon. In order to ensure optimal priming, each of the oligonucleotide sequences in a synthon are tested by alignment against the entire synthon sequence. Alignment is determined by comparing the numbers of matches and mismatches between the oligonucleotide sequence and the sequence of the synthon. Oligonucleotides that align with a degree of alignment higher than a predetermined value are selected for synthesis. In one embodiment, this is performed by aligning the oligonucleotide sequence against the synthon sequence starting at position 1 and sliding it across the length of the synthon sequence one base at a time.

[0209] In one embodiment, an oligonucleotide sequence is determined to be unsuitable for use according to the following series of steps:

[0210] Step 1: align the last three (3) bases of both the oligonucleotide sequence and synthon reference sequence such that they are identical;

[0211] Step 2: count the number of matches and mismatches in the aligned sequences with matches being identical bases in both sequences at the same position;

[0212] Step 3: calculate the ratio of matches to the total number of bases forming the overlap or alignment.

[0213] If the ratio is greater than a user-defined threshold value of 0.7 (or 70%) the oligonucleotide is suitable for synthesis. In one embodiment, oligonucleotides whose threshold value fall lower than the user-defined value can be subjected to manual modification of its sequence to increase the extent of alignment and meet the threshold requirement.

[0214] *7. Oligonucleotide Quality Testing:* The software checks for any undesired degree of aberrant priming among the oligonucleotides of each synthon. If present, it repetitively redesigns synthons in which this occurs until the design is improved. In difficult cases, it reports the results and prompts user to manually repair the errors.

[0215] *8. Input Validation Routines:* One or more user input validation routines can be implemented to run independently in parallel with the synthon design routines. These perform validation checks on instructions input by the user. These routines validate instructions typically input by a user during a step of the GeMS process and include validation of restriction site positions based on the site prediction algorithm, frame shifts and synthon boundaries. Identification of errors at the input stage prevents the user from providing any input that results in a faulty design.

[0216] *9. Output Validation Routine --* A program output validation routine can be used to reduce the time to validate the designed synthons. This allows the end-to-end design process to operate in a high-throughput manner. This program reassembles the designed synthons while maintaining the correct order and recreates a synthetic gene. The new synthetic gene is then translated to its amino acid sequence and compared with the original input protein sequence for possible errors. The restriction site pattern for the assembled sequence is verified as being the one desired. The restriction site pattern for each designed synthon (including the synthon-specific primers) is verified as well. Other quality tests can be preformed, including tests for undesired mRNA secondary structure and undesired ribosome start sites.

[0217] *10. User Interface.* An optional web-based software implementation provides a graphical interface which minimizes the number of steps needed to complete a design. Where applicable the user is provided on-screen links to web sites and/or databases of gene sequences, gene functions, restriction sites, etc. that aid in the design process.

[0218] This concludes the pipeline and outputs a list of suitable oligonucleotides for each synthon of the synthetic gene.

5.3 SOFTWARE IMPLEMENTATION

[0219] In one embodiment, the GeMS software is implemented to execute within a web-browser application making it a platform-neutral system. Its design is based on the client-server model and implemented using the Common Gateway Interface (CGI) standard.

[0220] All CGI scripts and the application programming interface (API) for GeMS was implemented in Python version 2.2. Development, testing and hosting of the application was performed on a 1.0 GHz Intel Pentium III based processor server running RedHat Linux version 7.3. The web interface runs on the Apache HTTP Server version 2.0.

[0221] The annealing temperature module in the GeMS API utilizes the EMBOSS software analysis package (Rice, P. Longden, I. and Bleasby, A., 2000, "EMBOSS: The European Molecular Biology Open Software Suite" *Trends in Genetics* 16:276-77) and implements the nearest neighbor model described by Breslauer (Breslauer *et al.*, 1986, *Proc. Nat'l Acad. Sci. USA* 83:3746-50) and Baldino (Baldino Jr., 1989, In *Methods in Enzymology* 168:761-77).

[0222] Publicly available software such as DNA Builder (Bu *et al.*, "DNA Builder: A Program to Design Oligonucleotides for the PCR Assembly of DNA Fragments." Center for Biomedical Inventions, University of Texas Southwestern Medical Center), DNAWorks (David M. Hoover and Jacek Lubkowski, 2002. "DNAWorks: an automated method for designing oligonucleotides for PCR-based gene synthesis." *Nucleic Acids Research* 30, No. 10, e43), and CODOP (Withers-Martinez *et al.*, 1999. "PCR-based gene synthesis as an efficient approach for expression of the A+T-rich malaria genome." *Protein Eng* 12: 1113-20) can be configured by the skilled practitioner to accomplish some (but not all), of the tasks used by GeMS for automated design of polyketide modules.

[0223] In one aspect, the invention provides a computer readable medium having computer executable instructions for performing a step or method useful for design of synthetic genes as described herein.

6. MULTIMODULE CONSTRUCTS AND LIBRARIES

6.1 INTRODUCTION

[0224] Synthetic genes designed and/or produced according to the methods disclosed herein can be expressed (e.g., after linkage to a promoter and/or other regulatory elements). In one aspect of the invention, a synthetic gene is linked in a single open reading frame with another synthetic gene(s) to encode a "fusion polypeptide." It will be recognized that the DNA encoding the fusion polypeptide is itself a synthetic gene (generated from the linkage of smaller genes). In a related aspect, multiple different open reading frames can be co-expressed (or their protein products combined *in vitro*) to form multiprotein complexes. This is analogous to naturally

occurring polyketide synthases, which are complexes of several polypeptides, each containing two or more modules and/or accessory units.

[0225] Thus, in the context of production of polyketides, the present invention contemplates

(A) producing synthetic genes that encode polypeptides comprising combinations of PKS modules and/or accessory units;

(B) expressing two or more different polypeptides of (A) which associate with each other to form a multipolypeptide complex.

[0226] Methods for producing polypeptide-encoding synthetic genes comprising combinations of PKS modules and/or accessory units include by designing and stitching together synthons that together encode a gene encoding the combination, using methods discussed above, (e.g., in Section 4). Alternatively, two or more synthetic genes that can encode different portions of the single polypeptide may be joined by conventional recombinant techniques (including ligation independent methods and linker-mediated methods, and other methods) using sites or sequence motifs located (e.g., engineered) at particular locations in the gene sequences (e.g., in regions encoding termini of modules, domains, accessory units, and the like). One important new benefit of the design and synthetic methods of the present invention is the ability to control gene sequences to facilitate the cloning of modules, domains, etc. A particularly useful ramification of these methods is the ability to make multiple large libraries of genes encoding structurally or functionally similar units (for example modules, accessory units, linkers, other functional polypeptide sequences), in which restriction sites or other sequence motifs are located at analogous positions of all members of the library. For example, a PKS module gene can be synthesized with unique restriction sites at the termini (e.g., Xba I and Spe I sites) facilitating cloning into the same sites in a vector.

[0227] In a related aspect, the invention provides multiple large libraries genes encoding polypeptides comprising regions (linkers) that allow the polypeptides to associate with other polypeptides encoded by members of the library or by members other libraries.

[0228] In a related aspect, the invention provides, for example, vectors and vector sets that can be used for manipulation, expression and analysis of numerous different polypeptide segment-encoding genes. For example, the invention provides useful vectors (referred to as ORF vectors) that facilitate preparation of libraries of genes encoding multimodule constructs.

[0229] The following sections describe exemplary methods for making and using vectors and vector libraries comprising ORFs encoding PKS modules and accessory units. Section 6.2, below describes how libraries can be used to analyse interactions between modules and other polypeptide units. This section is intended to illustrate how libraries can be used, and make the description of library construction more clear. Section 6.3 discusses module and linker combinations. Section 6.4 describes certain ORF vectors and methods for constructing them.

6.2. EXEMPLARY USES OF ORF VECTOR LIBRARIES

[0230] In one aspect, the invention provides methods for expression of PKS module-encoding genes in combinations not found in nature. Such novel module architecture enables production of novel polyketides, more efficient production of known polyketides, and further understanding of the “rules” governing interactions of PKS modules, domains and linkers. Combinations of “heterologous” modules (i.e. modules that do not naturally interact) may not be productive or efficient. For example, at a heterologous module interface, the product of the first module may not be the natural substrate for the second or subsequent modules and the accepting module(s) may not accept the foreign substrate efficiently. In addition, inter-module transfer of the polyketide chain (from the ACP thiol ester of one module to the KS thiol ester of the next) may not occur efficiently. See U.S. Patent Publication No. US20030068676A1: Methods to mediate polyketide synthase module effectiveness. The present invention provides methods for vectors, libraries, and methods for evaluating the ability of modules, domains, linker and other polypeptide segments to function productively.

[0231] In one aspect of the invention, libraries of vectors are prepared in which different members of the library comprise different extension modules. In one aspect of the invention, libraries of vectors are prepared in which the members of the library comprise the same extension module(s) but comprise different accessory units (e.g., different loading modules and/or different linker domains and/or different thioesterase domains). Thus, the invention provides methods for synthesizing an expression library of PKS module-encoding genes by: making a plurality of different synthetic PKS module-encoding genes (e.g., as described herein) and cloning each gene into an expression vector. In one embodiment, the library includes at least about 50 or at least about 100 different module-encoding genes. In one aspect of the invention,

such libraries are used in pairs to identify productive interactions between pairs or combinations of PKS modules.

[0232] For illustration, one application of libraries of the present technology can be illustrated by describing two (of many possible) ORF vector libraries. The skilled practitioner, guided by this disclosure, will recognize a variety of comparable or analogous libraries that can be made and used. A first ORF library comprises vectors comprising an open reading frame encoding a loading domain (LD), a PKS module (Mod), and a left linker (LL) and where different members of the library encode the same LD and LL, but different modules, i.e.:

[LD-Mod-LL]_n [Exemplary Library I]

where n is usually > 20. A second ORF library comprises vectors comprising an open reading frame encoding a right linker (RL), a module (Mod), and a thioesterase domain (TE), where different members of the library encode different modules, i.e.:

[RL-Mod-TE]_n [Exemplary Library II]

[0233] The terms "right linker" (RL) and "left linker" (LL) refer to interpolypeptide linkers that allow two polypeptides to associate. For construction of polyketide synthases which contain more than one polypeptide, the appropriate sequence of transfers can be accomplished by matching the appropriate C-terminal amino acid sequence of the donating module with the appropriate N-terminal amino acid sequence of the interpolypeptide linker of the accepting module. This can be done, for example, by selecting such pairs as they occur in native PKS. For example, two arbitrarily selected modules could be coupled using the C-terminal portion of module 4 of DEBS and the N-terminal of portion of the linking sequence for module 5 of DEBS. Alternatively, novel combinations of linkers or artificial linkers can be used.

[0234] In one embodiment, for illustration, each of the two libraries shown contains four members, each member containing a gene encoding a different module, i.e., module A, B, C or D ("ModA," "ModB," "ModC," "ModD"). Using a library of the 8 exemplary vectors shown below, all possible combinations of Modules A, B, C and D ("ModA," "ModB," "ModC," "ModD") can be tested for functionality after transfer to appropriate expression vectors.

LD-ModA-LL	RL-ModA-TE
LD-ModB-LL	RL-ModB-TE
LD-ModC-LL	RL-ModC-TE
LD-ModD-LL	RL-ModD-TE

[0235] To test for functionality of combinations of modules (e.g., pairwise combinations) from Library I and Library II can be co-transfected into a suitable host (e.g., *E. coli* engineered to support PKS post-translational modification and substrate Co-A thioester production) and product triketides may be analyzed by appropriate methods, such as TLC, HPLC, LC-MS, GC-MS, or biological activity. Alternatively the library members may be expressed individually and Library I – Library II combinations can be made *in vitro*. Affinity and/or labelling tags may be affixed to one or both termini of the module constructs to facilitate protein isolation and testing for activity and physical interaction of the module combinations.

[0236] When productive combinations are identified, the productive pair can be combined and tested in new pairwise combinations. For example, if LD-ModA-LL + RL-ModD-TE was productive, the construct LD-ModA-ModD-LL could be synthesized and tested in combination with members of Library II. Similarly, a third library, containing [LL-Mod-RL]_n constructs, can be used. A number of other useful libraries made available by the methods of the present invention will be apparent to the practitioner guided by this disclosure.

[0237] In a complementary strategy, the interactions of accessory units and modules can be assessed by keeping the module gene constant and varying the accessory units (e.g., using a library in which different members encode the same extension module(s) but different loading modules or linkers).

[0238] It will be apparent that gene libraries can be used for uses other than identification of production protein-protein interactions. For example, members of the ORF libraries described herein can be used for production, as intermediates for construction of other libraries, and other uses.

6.3 MODULE AND LINKER COMBINATIONS

[0239] This section describes in more detail how module genes can be expressed with native or heterologous linker sequences. As is described below, useful fusion proteins of the invention can include a number of elements. Examples include:

construct #	structure
1.	LD-Mod1-LL
2.	LD-Mod2-LL _H
3.	RL-Mod3-TE
4.	RL _H -Mod4-TE
5.	RL-Mod5-Mod6-LL
6.	LD-Mod7-* - Mod8-LL

where, "LD" refers to a PKS loading module, "TE" refers to a thioesterase domain; "RL" and "LL" refer to PKS interpolypeptide linkers, subscript "H" means a "heterologous" linker, "*" indicates that a heterologous AKL (ACP-KS Linker, see definitions, Section 1) is present, and "Mod" refers to various PKS modules. The modules can differ not only with respect to sequence and domain content, but also with regard to the nature of the interpolypeptide and intermodular linkers. A general discussion of PKS linkers is provided in Section 1, above, and the references cited there. Briefly, PKS extension modules in different polypeptides can be linked by "interpolypeptide" linkers (i.e., RL and LL) found (or placed) and multiple PKS extension modules in the same polypeptide can be linked by AKLs.

[0240] Extension modules used in the constructs can correspond to naturally occurring modules located at the amino terminus of a naturally occurring polypeptide or other than the amino-terminus, and be placed at the amino terminus of a polypeptide encoded by a synthetic gene (e.g., Mod3) or other than the amino-terminus (e.g., Mod 6).

[0241] It will be apparent to one of ordinary skill in the art that in an ORF comprising a synthetic gene encoding a module, the module can be joined to a variety of different linkers. For example, a module corresponding to a naturally occurring module can be associated with a sequence encoding an interpolypeptide or other intermodular linker sequence associated with the naturally occurring module, or can be associated with a sequence encoding an interpolypeptide or other intermodular linker sequence not associated with the naturally occurring module (e.g., a

heterologous, artificial, or hybrid linker sequence). It will be apparent that depending on the final construct desired, a synthetic module may or may not include the AKL of the corresponding naturally occurring module. Conveniently, Spe I and Mfe I sites optionally placed in a synthetic module-encoding gene or library of genes of the invention can be used to add, remove or swap AKLs for replacement with different AKLs.

6.4 EXEMPLARY ORF VECTOR CONSTRUCTS

[0242] As noted above, modules may be cloned into "ORF (open reading frame) vectors," for construction of complex polypeptides. Although a number of alternative strategies will be apparent, it is generally convenient to have specialized vectors serve different roles in the synthesis and expression of synthetic genes. For example, in one embodiment of the invention, synthon stitching is carried out in one vector set (e.g., assembly vectors), genes encoding modules and/or accessory units are combined in a different set of vectors (e.g., ORF vectors), polypeptides are expressed in a third set of vectors (expression vectors). However, a other strategies will be apparent to the reader guided by this disclosure. For example, ORF vectors of the invention can be configured to also serve as expression vectors.


[0243] It is often convenient, when cloning from assembly vectors to ORF vectors to use assembly vectors that include useful restriction sites flanking the multisynthon of the assembly vector. Accordingly, useful assembly vectors may contain restriction sites in addition to those described in Section 4 positioned on either side of the SIS (and thus on either side of the module contained in the occupied assembly vectors). Since these flanking restriction sites ("FRSs") are usually absent from the sequences synthetic module genes (i.e., "removed" during gene design) it is generally advantageous to use rare sites (e.g., 8-bp recognition sites).

[0244] In the descriptions of the methods described below, the following abbreviations are used for illustration only: 1=Nde I site, 2=Xba I site, 3=Pac I site, 4=Not I site, 5=Spe I site, 6=Eco RI site, 7=Bbs I site, 8=Bsa I site, * = a common sequence motif. When considering the illustrations below it is important to keep in mind that useful vectors are not limited to those with the specific restriction sites shown. For example, any of the sites shown can be substituted for by using a different site (able to function in the same manner). For example, any of a large numbers of sites recognized by Type IIS enzymes can be used for sites 7 and 8; any of a variety of sites can be used for sites 3 and 4, although rare sites (e.g., with 7 or 8 basepair recognition

sequences) are preferred. Similarly, any number of sites can be used in place of Xba I and Spe I, provided that compatible cohesive ends are generated by digestion of the sites (and preferably, neither site is not regenerated upon ligation of the cohesive ends). Further, although all of these sites are useful, not all are required for the present methods, as will be apparent to the reader of ordinary skill. In many embodiments one or more of the sites is omitted. In the discussions below, a multisynthon transferred from an assembly vector to an ORF vector is sometimes referred to as, simply, a "module."

6.4.1 ORF VECTORS COMPRISING AMINO- AND- CARBOXY TERMINAL ACCESSORY UNITS OR OTHER POLYPEPTIDE SEQUENCES

[0245] To synthesize a multimodule gene construct, an ORF vector having the following structure can be used for manipulation:



where $\equiv\equiv\equiv$ and $\equiv\equiv\equiv$ indicate a nucleotide sequence encoding a structural or functional polypeptide segment such as a non-PKS polypeptide segment (e.g., NRPS modules) or PKS accessory unit. For example, $\equiv\equiv\equiv$ can be a gene sequence encoding a loading module or interpolypeptide linker and $\equiv\equiv\equiv$ can be a gene sequence encoding a thioesterase domain, other releasing domain, interpolypeptide linker, and the like. For example, an ORF vector in which the 1-2 fragment comprises a methionine start codon and a synthetic gene sequence encoding the DEBS loading domain, the central region comprises a synthetic gene sequence encoding DEBS modules 2 and 3, and the C-terminal region comprises a synthetic gene sequence encoding a DEBS TE domain would encode a polypeptide comprising the DEBS N-LM-DEBS2-DEBS3-TE-C (all contiguous synthetic polypeptide-encoding gene sequences described herein are in-frame with each other).

[0246] Coding sequences of accessory units are known (see, e.g., GenBank) and synthetic accessory unit genes can be made by synthon stitching and other methods described herein. Exemplary methods for construction of ORF vectors with such N-terminal and C-terminal regions is described below.

6.4.2 ORF VECTOR SYNTHESIS

[0247] This section describes "ORF 2" type vectors useful for construction of a gene libraries of interchangeable elements. Three general types of vectors include

Internal type-	4-[7-*]-[*-8]-3
Left-edge type-	4-[7-1]-[*-8]-3
Right-edge type-	4-[7-*]-[6-8]-3

The brackets are used to refer to the fact that the required distance from 7 to * is fixed once 7 is picked; similarly the required distance from * to 8 is fixed once 8 is picked; and the remaining bracketed pairs [7-1] and [6-8] optionally can be chosen to be usefully proximate to each other, as described below. To use the three vectors the enzymes whose recognition sites are 7 and 8 have mutually compatible overhang products at all locations marked [7-*] or [*-8], preferably accomplished by having a) equal overhang lengths (which may be zero); b) by having cut sites creating identical overhangs (if any) at those locations [with the identical sequences within the module or accessory gene fragment at the overhangs (if any) being labelled *]; and c) the cut sites are required to be similarly compatible with the open reading frame [so the two occurrences of * (if any) initiate at the same positions with respect to the frame; or if the enzymes whose recognition sites are 7 and 8 are blunt cutters, the cut sites must be equivalently placed with respect to the frame].

[0248] The site labelled 1 becomes the left edge of the construct, and can be chosen to be a restriction recognition site for an enzyme cutting within its site (e.g., Nde I). Similarly, the site labelled 6 becomes the right edge of the construct, and can be chosen to be a restriction recognition site for an enzyme cutting within its site (e.g., Eco RI). This pair of sites can be usefully chosen to be pairs convenient for moving the final construct into various expression vectors as desired. The construction method itself does not require either 1 or 6 to be a restriction enzyme recognition site, but simply a place at which cuts can be created with the following conditions:

- the cut at 1 in the assembly (library) vector is compatible with a cut which can be created at site 1 in the ORF construction vector family during ORF construct creation;
- the cut at site 6 in the assembly (library) is compatible with a cut which can be created at site 6 in the ORF construction vector family during ORF construct creation;

- c) in each case, after transfer of the library ORF element to the ORF construction vector, the recognition sites for the Type IIS enzymes chosen for sites 7 & 8 are unique (if present) in the vector product.

[0249] For example, the Type IIS enzyme for 7 could be used to cut at site 1, creating an overhang at 1 which could be used for transfer.

Construction of an ORF vector with an initial defined N-terminal region:

[0250] A library vector of left-edge type (with site pattern 4-[7-1]-[*-8]-3) is cut at 1 and at 3, and the fragment 1-[*-8]-3 is saved; an ORF vector (initially with site pattern 1-3-4-6) is cut at 1 and 3, and the fragment 3-4-6-1 is joined to the donor fragment 1-[*-8]-3 to create a fragment with pattern 1-[*-8]-3-4-6.

Construction of an ORF vector with an initial defined C-terminal region:

[0251] A library vector of right-edge type (with site pattern 4-[7-*]-[6-8]-3) is cut at 4 and at 6, and the fragment 4-[7-*]-6 is saved; an ORF vector (initially with site pattern 1-3-4-6) is cut at 4 and 6, and the fragment 6-1-3-4 is joined to the donor fragment 4-[7-*]-6 to create a fragment with pattern 1-3-4-[7-*]-6.

[0252] The construction of a left edge by an equivalent method can be done in the presence of a previously constructed right edge. In this case, the donor is again a library vector of left-edge type (with site pattern 4-[7-1]-[*-8]-3); and the acceptor now an ORF vector with site pattern 1-3-4-[7-*]-6; once again, the donor fragment 1-[*-8]-3 replaces the acceptor fragment 1-3.

[0253] Similarly, the construction of a right edge by an equivalent method can be done in the presence of a previously constructed left edge. In this case, the donor is again a library vector of right-edge type (with site pattern 4-[7-*]-[6-8]-3); and the acceptor now an ORF vector with site pattern 1-[*-8]-3-4-6; once again, the donor fragment 4-[7-*]-6 replaces the acceptor fragment 4-6.

[0254] Once either a left or a right edge has been added, that edge can be extended arbitrarily many times by the standard internal extension procedure without interfering with the potential for extension at the other edge. At any time after a left and right edge have been added, together with arbitrarily many extensions at the left and/or right by library gene fragments of internal type, the procedure can be terminated by cleaving the ORF construction vector at [*-8]

and [7-*], and joining the overhangs (or blunt ends, in the blunt-end type IIS case) created at the two * sites.


[0255] It will be apparent from the foregoing that Internal type, Left-edge type, and Right-edge type-constructs can also be made in "ORF 1" type vectors described in the next section, using modifications of the method above that account for the differences in the restriction sites in the ORF1 and ORF2 vectors.

6.4.3 EXEMPLARY ORF VECTOR CONSTRUCTION METHODS


[0256] This section described three exemplary methods for constructing multimodule genes. The examples given show construction in ORF vectors such as those described above, but it will be apparent to the practitioner that many variations of each approach are possible and that the cloning strategies shown can be used in other contexts. For simplicity, the methods below are shown without the presence of sequences encoding the amino and carboxy-terminal regions (e.g., accessory units) discussed above in Section 6.4.3. However, the possible inclusion of such regions will be apparent to the reader.

Exemplary Construction Method 1

[0257] In this exemplary method, assembly vectors are used in which a unique Not I site (4) and a unique Eco RI site (6) flank the synthon insertion site. Accordingly, the module genes, each of which is designed so that (a) the module gene contains no Not I or Eco RI sites. In addition, it is assumed for this example that each module gene in the library is designed with unique Spe I (5) site at the 5'/amino-terminal edge of the module and a unique Xba I site (2) at the 3'/carboxyterminal edge of the module (see Figure 6). The structure of the module-containing assembly vector can be described as:



where "module" refers to a module gene and the boxed region indicates the module boundary (i.e., in this example, sites 5 and 2 are within the module gene). A library of such module-containing assembly vectors (containing different modules A, B, C, ...) can be described as:



—4—5—moduleC—2—6—

etc.

A module-containing assembly vector in a library can be called an “assembly vector” or a “library vector.”

[0258] To synthesize a multimodule gene construct, an ORF (“open reading frame”) vector is used for manipulation. In this example, the ORF vector can have the following structure:

—1—2—3—4—5—6— [ORF 1]

The Nde I site (1), which contains a methionine start codon is convenient because, as will be seen, it can be used to delimit the amino terminus of the open reading frame; however, it is not required in all embodiments (for example, the methionine start codon can be designed in the module rather than provided by the ORF vector). The Pac I site (3) in this construct is useful for restriction analysis but also is not required. (The absence of the Pac I site in the final ORF construct indicates that the region delimited by 3-4 has been successfully removed during the production process; see below.)

[0259] To insert a first module gene (e.g., a module A gene) into the ORF vector, the ORF vector is digested with Not I (4) and Spe I (5), the library vector is digested with Not I (4) and Xba I (2), and the 4-2 fragment of the library vector is cloned into the ORF vector, producing:

—1—2—3—4—5—moduleA—2/5—6—


[0260] Restriction sites 2 and 5 have compatible cohesive ends that when ligated destroy both sites (2/5). To insert a second module, the process is repeated; the ORF vector containing module A is digested with Not I (4) and Spe I (5), and the 4-2 fragment of a second library vector is cloned into the ORF vector, producing:

—1—2—3—4—5—moduleB—2/5—moduleA—2/5—6—




Additional modules, accessory units, or other sequences can be added in a similar manner.

Exemplary Construction Method 2

[0261] In a second exemplary method, Type IIS restriction enzymes are used (as described above in Section 4). In this case, the structure of the module gene-containing assembly vectors in the library can be described as:




for example,




where 7 and 8 are recognition sites for Type IIS enzymes which can form a cohesive and compatible ends (e.g., having the same length and orientation overhang) and * is a common sequence motif as described below. For the sake of clarity, in the discussion below 7 will be Bbs I and 8 will be Bsa I. In this case, the modules are designed so that (a) the module gene contains no Bbs I (7) sites or Bsa I (8) sites as well as being free of Not I (4) sites.

[0262] The generation of cohesive and compatible ends by action of the Type IIS enzymes 7 and 8 requires that a common sequence motif be present at each end of a module and the Type IIS recognition sites be positioned to produce overhangs having the sequence of the common sequence motif. In one embodiment, restriction sites for Xba I and Spe I, positioned at different ends of the module (e.g., as in Figure 6) are used for convenience. In this embodiment, the common sequence motif is 5'-CTA G-3', the central region of both the Xba I (5' - T[^]CTAG A-3'/3'-AGATC[^]T-5') and Spe I sites (5'-A[^]CTAG T-3'/3'-TGATC[^]A-5'). Cleavage by Bbs I and Bsa I produces compatible cohesive ends (5'-NNNNCTAG-3'). Importantly, it will be recognized that the common sequence motif need not be a restriction site (or any particular restriction site) and any number of motifs can be used. It will also be recognized that the introduction of the common sequence motif into the module sequence should not disrupt the function (e.g., biological activity) of the polypeptides encoded by the library. As discussed elsewhere herein, introduction of the Spe I and Xba I sites is expected to fulfill this requirement; an alternative would be, for example, motifs encoding (in combination with the surrounding gene sequence) Ala-Ala.


[0263] To synthesize a multimodule construct, an ORF vector with the following structure can be used:




[0264] To insert a first module (e.g., module A) into the ORF vector, the ORF vector is digested with Not I (4) and Bbs I (7), and the library vector is digested with Not I (4) and Bsa I (8). The module containing fragment (with a Not I cohesive end and a second cohesive end compatible with Spe I) is cloned into the ORF vector, producing:



[0265] To insert a second module, the assembly vector is digested as for the first module (resulting in e.g., $\text{---}4\text{---}7\text{---}\boxed{*\text{---moduleB---}*}$) and the ORF vector containing module A is digested with Not I (4) and Bbs I (7), producing




This construct can be cut with both Bbs I (7) and Bsa I (8) to produce:






Exemplary Construction Method 3

[0266] In this exemplary method, assembly vectors in which a unique Not I site (4) and a unique Pac I site (3) flank the synthon insertion site are used to make a library of PKS module genes, each of which is designed so that (a) the module gene contains no Not I or Pac I sites. Further, the module gene has a unique Spe I (5) site at the 5'-edge of the module gene and an Xba I site (2) at the 3'-edge of the module gene.

[0267] The structure of the module gene-containing assembly vectors in the library can be described as:




A library of such assembly vectors can be described as:




etc.

Using Exemplary Method 3, module genes can be assembled bidirectionally in a vector. For example, to generate a vector containing genes for modules A-B-C-D-E, the module genes could be individually added to the vector in the order A, B, C, D, E; E, D, C, B, A; C, B, D, E, A; etc.


[0268] Using an ORF vector having the sites




the first module gene (A) can be introduced by cutting with Not I (4) and Xba I (2) in the module, and digesting the ORF vector with Not I (4) and Spe I (5) resulting in




or cutting with Spe I (5) and Pac I (3) in the assembly vector and Xba I (2) and Pac I (3) in the ORF vector to obtain the resulting construct




To add a second module gene, the module B gene, to the left of the module A gene in construct III, the assembly vector containing module B is digested with Spe I (5) and Pac I (3), and the ORF vector containing the module A gene is digested with Xba I (2) and Pac I (3), resulting in



Additional modules can then be added to construct (V), either next to the module B gene or module A gene. For example, the constructs




or



can be made. Constructs (V)–(VIII) can be digested with Spe I (5) and Xba I (2) to remove the 2-5 fragment, producing a gene encoding a polypeptide containing contiguous modules in a single open-reading frame.

[0269] The module-containing open reading frames made using these methods can be excised from the ORF vector and inserted into an expression vector. For example, in the example shown above, the open reading frame can be excised using the Nde I (1) and Eco RI (6) sites.

[0270] It will be appreciated that the examples shown above are merely to illustrate the ability to use libraries of assembly modules for production of multimodule constructs. It will be recognized that a variety of other combinations of restriction sites, enzymes, common sequence motifs and cleavage sites can be used to accomplish the results illustrated in the preceding paragraphs. For example, a library (or toolbox) can contain incomplete ORFs comprising various combinations of four modules plus accessory units (for example, constructs such as [VI] and [VII] above



Such libraries could contain, for example, combinations of modules known or believed likely to be productive. Using such a library, the activity of a PKS or NRPS module, or other polypeptide segment, can be tested in a variety of environments. It will be clear from the discussion above that a number of useful libraries are made possible by the methods disclosed herein.

7. MULTIMODULE DESIGN BASED ON NATURALLY OCCURRING COMBINATIONS

[0271] An alternative, or complementary, strategy for design of synthetic genes encoding polyketide synthases is based on that described in Khosla *et al.*, WO 01/92991 (“Design of Polyketide Synthase Genes”) in which the starting point is a desired polyketide (e.g., a naturally occurring polyketide or a novel analog of a naturally occurring polyketide). In one strategy, the structure of a desired polyketide is assigned a polyketide code (string) by converting the

polyketide into a "sawtooth" format (*i.e.*, it is linearized and any post-synthetic modifications are removed) and assigning a one-letter code corresponding to each of the possible 2-carbon ketide units found in polyketides to create a string that describes the polyketide. The ketide units of desired polyketide are converted to a module code by determining possible modules that could produce the polyketide. The module code is then aligned with those corresponding to known polyketide synthases (preferably by computer implemented scanning of a database of such structures) to identify combinations of modules that function in nature.

[0272] In one embodiment of the present invention, potential sources of module sequences are selected based on the alignment of conceptual modules that could produce the desired polyketide with known PKS modules. Alignments can be ranked by, for example, minimizing non-native inter-module and/or inter-protein interfaces. For example, to synthesize a gene with the structure LD-A-B-C-D-E-F, where LD is a loading domain, and A-E are PKS modules, the alignment might produce in the output shown in Table 6.

TABLE 6
HYPOTHETICAL ALIGNMENT OF PKS MODULES

Target	LD	A	B	C	D	E	F
PKS 1	LD	A	C	D	A		
PKS 2	D	A	B	C			
PKS 3			B	C			
PKS 4					D	E	F
PKS 5			D	E	D	E	F

[0273] In this example several sources are identified for each of the following module sequences: LD A, B-C, D-E-F. The junctions A-B and C-D are connected to form a functional PKS. Some module sequences may serve the purpose better than others. For example, sequences #2 and #3 may both serve as sources of B-C; however, in sequence #2 the native substrate of B is the product of A, and may therefore be more likely to be productive.

8. DOMAIN SUBSTITUTION

[0274] In some embodiments, the invention provides libraries of synthetic module genes that contain useful restriction sites at the boundaries of functional domains (see, e.g., Figure 4).

Because these sites are common to the entire library, "domain swaps" can be easily accomplished. For example, in module genes having a unique Pst I site at the C-terminus of the KS domain and a unique Kpn I at the C-terminus of the AT domain (see, e.g., Figure 4), the AT domains of these modules can be removed and replaced by different AT domain encoding genes bounded by these sites can be exchanged.

[0275] For example, using the methods of the invention, a library of 150 synthetic module genes, each corresponding to a different naturally occurring module gene, can be synthesized, in which each synthetic gene has a unique Spe I restriction site at the 5' end of the gene, an Xba I site at the 3' end of the gene, a Kpn I site at the 3' boundary of each KS domain encoding region, and a Pst I site at the 3' boundary of each AT domain. Any of the 150 modules could then be cloned into a common vector, or set of vectors, for analysis, manipulation and expression and, in addition, the presence of common restriction sites allows exchange or substitution of domains or combinations of domains. For example, in the example above, the Kpn I and Pst I sites could be used to exchange domains in any modules having a KS domain followed by an AT domain.

9. EXEMPLARY PRODUCTS

9.1 SYNTHETIC PKS MODULE GENES

[0276] In one aspect, the invention provides a synthetic gene encoding a polypeptide segment that corresponds to a reference polypeptide segment, where the coding sequence of the synthetic gene is different from that of a naturally occurring gene encoding the reference polypeptide segment. For example, in one embodiment, the invention provides a synthetic gene encoding a PKS domain that corresponds to a domain of a naturally occurring PKS, where the coding sequence of the synthetic gene is different from that of the gene encoding the naturally occurring PKS. Exemplary domains include AT, ACP, KS, KR, DH, ER, MT, and TE. In a related embodiment, the invention provides a synthetic gene encoding at least a portion of a PKS module that corresponds to a portion of a PKS module of a naturally occurring PKS, where the coding sequence of the synthetic gene is different from that of the gene encoding the naturally occurring PKS, and where the portion of a PKS module includes at least two, sometimes at least

three, and sometimes at least four PKS domains. In a related embodiment, the invention provides a synthetic gene encoding a PKS module that corresponds to a PKS module of a naturally occurring PKS, where the coding sequence of the synthetic gene is different from that of the gene encoding the naturally occurring PKS. In one embodiment, the polypeptide segment encoded by the synthetic gene corresponds to at least about 20, at least about 30, at least about 50 or at least about 100 contiguous amino acid residues encoded by the naturally occurring gene [0277] Differences between the synthetic coding sequence and the naturally occurring coding sequence can include (a) the nucleotide sequence of the synthetic gene is less than about 90% identical to that of the naturally occurring gene, sometimes less than about 85% identical, and sometimes less than about 80% identical; and/or (b) the nucleotide sequence of the synthetic gene comprises at least one unique restriction site that is not present or is not unique in the polypeptide segment-encoding sequence of the naturally occurring gene; and/or (c) the codon usage distribution in the synthetic gene is substantially different from that of the naturally occurring gene (e.g., for each amino acid that is identical in the polypeptide encoded by the synthetic and naturally occurring genes, the same codon is used less than about 90% of the instances, sometimes less than 80%, sometimes less than 70%); and/or (d) the GC content of the synthetic gene is substantially different from that of the naturally occurring gene (e.g., %GC differs by more than about 5%, usually more than about 10%).

[0278] In the above-described approaches, the amino acid sequences of individual domains, linkers, combinations of domains, and entire modules can be based on (i.e., "correspond to") the sequences of known (e.g., naturally occurring) domains, combinations of domains, and modules. As used herein, a first amino acid sequence (e.g., encoding at least one, at least two, at least three, at least four, at least five or at least six PKS domains selected from AT, ACP, KS, KR, DH, and ER) corresponds to a second amino acid sequence when the sequences are substantially the same. In various embodiments of the invention, the naturally occurring domains, linkers, combinations of domains, and modules are from one of erythromycin PKS, megalomicin PKS, oleandomycin PKS, pikromycin PKS, niddamycin PKS, spiramycin PKS, tylosin PKS, geldanamycin PKS, pimaricin PKS, pte PKS, avermectin PKS, oligomycin PSK, nystatin PKS, or amphotericin PKS.

[0279] In this context, two amino acids sequences are substantially the same when they are at least about 90% identical, preferably at least about 95% identical, even more preferably at least

about 97% identical. Sequence identity between two amino acid sequences can be determined by optimizing residue matches by introducing gaps if necessary. One of several useful comparison algorithms is BLAST; see Altschul et al., 1990, "Basic local alignment search tool." *J. Mol. Biol.* 215:403-410; Gish et al., 1993, "Identification of protein coding regions by database similarity search." *Nature Genet.* 3:266-272; Altschul et al., 1997, "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs." *Nucleic Acids Res.* 25:3389-3402. Also see Thompson et al., 1994, "CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice," *Nucleic Acids Res.* 22:4673-80. (When using BLAST and CLUSTAL W or other programs, default parameters are used.)

[0280] In one aspect, the invention provides a synthetic gene that encodes one or more PKS modules (e.g., a sequence encoding an AT, ACP and KS activity, and optionally one or more of a KR, DH and ER activity). In some embodiments, the synthetic gene has at most one copy per module-encoding sequence of a restriction enzyme recognition site such as Spe I, Mfe I, Afi II, Bsi WI, Sac II, Ngo MIV, Nhe I, Kpn I, Msc I, Bgl II, Bss HII, Sac II, Age I, Pst I, Kas I, Mlu I, Xba I, Sph I, Bsp E, and Ngo MIV recognition sites. In an embodiment, the invention provides a synthetic gene encoding a PKS module having a Spe I site near the sequence encoding the amino-terminus of the module-encoding sequence; and/or b) a Mfe I site near the sequence encoding the amino-terminus of a KS domain; and/or c) a Kpn I site near the sequence encoding the carboxy-terminus of a KS domain; and/or d) a Msc I site near the sequence encoding the amino-terminus of an AT domain; and/or e) a Pst I site near the sequence encoding the carboxy-terminus of an AT domain; and/or f) a BsrB I site near the sequence encoding the amino-terminus of an ER domain; and/or g) an Age I site near the sequence encoding the amino-terminus of a KR domain; and/or h) an Xba I site near the sequence encoding the amino-terminus of an ACP domain. A synthetic gene of the invention can contain at least one, at least two, at least three, at least four, at least five, at least six, at least seven, or at least eight of (a)-(h), above.

[0281] In a related aspect, the invention provides a vector (e.g., an expression vector) comprising a synthetic gene of the invention. In one embodiment, the invention provides a vector that comprises sequence encoding a first PKS module and one or more of (a) a PKS extension module; (b) a PKS loading module; (c) a thioesterase domain; and (d) an interpolypeptide linker. Exemplary vectors are described in Section 7, above.

[0282] In an aspect, the invention provides a cell comprising a synthetic gene or vector of the invention, or comprising a polypeptide encoded by such a vector. In a related aspect, the invention provides a cell containing a functional polyketide synthase at least a portion of which is encoded by the synthetic gene. Such cells can be used, for example, to produce a polyketide by culture or fermentation. Exemplary useful expression systems (e.g., bacterial and fungal cells) are described in Section 3, above.

9.2 VECTORS

[0283] The invention provides a large variety of vectors useful for the methods of the invention (including, for example, stitching methods described in Section 4 and analysis using multimodule constructs as described in Section 7).

[0284] Thus, in one aspect the invention provides a cloning vector comprising, in the order shown, (a) SM4 – SIS – SM2 – R₁ or (b) L – SIS – SM2 – R₁ (where SIS is a synthon insertion site, SM2 is a sequence encoding a first selectable marker, SM4 is a sequence encoding a second selectable marker different from the first, R₁ is a recognition site for a restriction enzyme, and L is a recognition site for a different restriction enzyme). In one embodiment, the SIS comprises N₁–R₂–N₂– (where N₁ and N₂ are recognition sites for nicking enzymes, and may be the same or different, and R₂ is a recognition site for a restriction enzyme that is different from R₁ or L). The invention also provides composition containing such vectors and a restriction enzyme(s) that recognizes R₁ and/or a nicking enzyme (e.g., N. BbvC IA).

[0285] In one aspect, the invention provides a vector comprising SM4 – 2S₁ – Sy₁ – 2S₂ – SM2 – R₁, where 2S₁ is a recognition sites for first Type IIS restriction enzyme, 2S₂ is a recognition sites for a different Type IIS restriction enzyme, and Sy is synthon coding region. In one aspect, the invention provides a vector comprising L – 2S₁ – Sy₂ – 2S₂ – SM2 – R₁. In an embodiment, Sy encodes a polypeptide segment of a polyketide synthase. In one embodiment, Bbs I and/or Bsa I are used as the Type IIS restriction enzymes. In an embodiment, the invention provides a composition containing such a vector and a Type IIS restriction enzyme that recognizes either 2S₁ or 2S₂.

[0286] In a related aspect, the invention provides a kit containing a vector and a type IIS restriction enzyme that recognizes 2S₁ or 2S₂, (or a first type IIS restriction enzyme that recognizes 2S₁ and a second type IIS restriction enzyme that recognizes 2S₂).

[0287] In one embodiment, the invention provides a composition containing a cognate pair of vectors. As used herein, a "cognate pair" means a pair of vectors that can be used in combination to practice a stitching method of the invention. In one embodiment the composition contains a vector comprising SM4-2S₁-Sy₁-2S₂-SM2-R₁ digested with a Type IIS restriction enzyme that recognizes 2S₂, and a vector comprising SM5-2S₃-Sy₂-2S₄-SM3-R₁ digested with a Type IIS restriction enzyme that recognizes 2S₁. In another embodiment the composition contains a vector comprising L-2S₁-Sy₁-2S₂-SM2-R₁ digested with a Type IIS restriction enzyme that recognizes 2S₂, and a vector comprising L'-2S₁-Sy₂-2S₂-SM3-R₁ digested with a Type IIS restriction enzyme that recognizes 2S₁. (SM1, SM2, SM3, SM4 are sequences encoding different selection markers, R₁ is a recognition site for a restriction enzyme, L and L' are recognition sites for two different restriction enzymes, each different from R₁, 2S₁ and 2S₂ are recognition sites for two different Type IIS restriction enzymes, and Sy₁ and Sy₂ adjacent synthons which, in some embodiments, can encode polypeptide segments of a polyketide synthase.)

[0288] In a related embodiment, the invention provides a vector containing a first selectable marker, a restriction site (R₁) recognized by a first restriction enzyme, a synthon coding region flanked by a restriction site recognized by a first Type IIS restriction enzyme and a restriction site recognized by a second Type IIS restriction enzyme, where digestion of the vector with the first restriction enzyme and the first Type IIS restriction enzyme produces a fragment containing the first selectable marker and the synthon coding region, and digestion of the vector with the first restriction enzyme and the second Type IIS restriction enzyme produces a fragment containing the synthon coding region and not comprising the first selectable marker. In one embodiment, the vector has a second selectable marker and digestion of the vector with the first restriction enzyme and the first Type IIS restriction enzyme produces a fragment containing the first selectable marker and the synthon coding region, and not containing the second selectable marker, and digestion of the vector with the first restriction enzyme and the second Type IIS restriction enzyme produces a fragment comprising the second selectable marker and the synthon coding region, and not containing the first selectable marker. In an embodiment, the vector can contain a third selectable marker.

[0289] In a related aspect, the invention provides vectors, vector pairs, primers and/or enzymes useful for the methods disclosed herein, in kit form. In one embodiment, the kit

includes a vector pair described above, and optionally restriction enzymes (e.g., Type IIS enzymes) for use in a stitching method.

9.3 LIBRARIES

[0290] In an aspect, the invention provides useful libraries of synthetic genes described herein ("gene libraries"). In one example, a library contains a plurality of genes (e.g., at least about 10, more often at least about 100, preferably at least about 500, and even more preferably at least about 1000) encoding modules that correspond to modules of naturally occurring PKSs, where the modules are from more than one naturally occurring PKS, usually three or more, often ten or more, and sometimes 15 or more. In one example, a library contains genes encoding domains that correspond to domains from more than one polyketide synthase protein, usually three or more, often ten or more, and sometimes 15 or more. In one example, a library contains genes encoding domains that correspond to domains from more than one polyketide synthase module, usually fifty or more, and sometimes 100 or more.

[0291] In some aspects of the invention, the members of the library have shared characteristics, e.g., shared structural or functional characteristics. In an embodiment, the shared structural characteristics are shared restriction sites, e.g., shared restriction sites that are rare or unique in genes or in designated functional domains of genes. For example, in one embodiment a library of the invention contains genes each of which encodes a PKS module, where the module-encoding regions of the genes share at least three unique restriction sites (for example, Spe I, Mfe I, Afi II, Bsi WI, Sac II, Ngo MIV, Nhe I, Kpn I, Msc I, Bgl II, Bss HII, Sac II, Age I, Pst I, Bsr BI, Kas I, Mlu I, Xba I, Sph I, Bsp E, and Ngo MIV recognition sites). In one embodiment, a library of the invention contains genes that encode more than one PKS module each, where each module-encoding region shares at least three unique restriction sites. In some embodiments, the number of shared restriction sites is more than 4, more than 5 or more than 6. Exemplary sites and locations of shared restriction sites include a) a Spe I site near the sequence encoding the amino-terminus of the module-encoding sequence; and/or b) a Mfe I site near the sequence encoding the amino-terminus of a KS domain; and/or c) a Kpn I site near the sequence encoding the carboxy-terminus of a KS domain; and/or d) a Msc I site near the sequence encoding the amino-terminus of an AT domain; and/or e) a Pst I site near the sequence encoding the carboxy-terminus of an AT domain; and/or f) a BsrB I site near the sequence encoding the

amino-terminus of an ER domain; and/or g) an Age I site near the sequence encoding the amino-terminus of a KR domain; and/or h) an Xba I site near the sequence encoding the amino-terminus of an ACP domain.

[0292] In one aspect, genes of the library are contained in cloning or expression vectors. In one aspect, the PKS module-encoding genes in a library also have in-frame coding sequence for an additional functional domain, such as one or more PKS extension modules, a PKS loading module, a thioesterase domain, or an interpolypeptide linker.

9.4 DATABASES

[0293] In one aspect, the invention provides a computer readable medium having stored sequence information. The computer readable medium may include, for example, a floppy disc, a hard drive, random access memory (RAM), read only memory (ROM), CD-ROM, magnetic tape, and the like. Additionally, a data signal embodied in a carrier wave (e.g., in a network including the Internet) may be the computer readable storage medium. The stored sequence information may be, for example, (a) DNA sequences of synthetic genes of the invention or encoded polynucleotides, (b) sequences of oligonucleotides useful for assembly of polynucleotides of the invention, (c) restriction maps for synthetic genes of the invention. In an embodiment, the synthetic genes encode PKS domains or modules.

10. HIGH THROUGHPUT SYNTHON SYNTHESIS AND ANALYSIS

10.1 AUTOMATION OF SYNTHESIS

[0294] The gene synthesis methods described herein can be automated, using, for example, computer-directed robotic systems for high-throughput gene synthesis and analysis. Steps that can be automated include synthon synthesis, synthon cloning, transformation, clone picking, and sequencing. The following discussion of particular embodiments is for illustration and not intended to limit the invention.

[0295] As illustrated in Figure 19, the invention provides an automated system 10 comprising a liquid handler 12 (e.g., Biomek FX liquid handler; Beckman-Coulter), and a random access hotel 14 (e.g., Cytomat™ Hotel; Kendro) coupled to the liquid handler 12. Liquid handler 12 includes a plurality of positions P1 through P19 which can accept microplates and other vessels used in system 10. As discussed below and as shown in Figure 19, a number of

the positions include additional functionality. The random access hotel 14 is capable of storage of one or more source microplates 16 each carrying oligonucleotide solutions one or more PCR plates 18 comprising synthon assembly wells, and one or more (optional) sources 20 of LIC extension primers (e.g., uracil-containing oligonucleotides), and is capable of delivery of plates and pipette tips to liquid handler 12. In some embodiments, the hotel contains > 5, > 10, or > 20 microplates (and, for example >50, >100, or >200 different oligonucleotide solutions). In the example of Figure 19, source 20 includes a micro-centrifuge tube. Source 20 could also be a vial or any other suitable vessel. Random access hotel 14 is used for primer mixing, PCR-related procedures, sequencing and other procedures. In one embodiment, liquid handler 12 comprises a deck 21 with heating element 22 at position P4 and cooling element 23 at position P12. Deck 21 can also include an automatic reading device 24, such as a bar code reader, located at position P7 in the example of Figure 19. System 10 also includes a thermal cycler 26, a plate reader 28, a plate sealer 31 and a plate piercer 30. The reading device 24 is capable of tracking data, and enables hit picking for library compression and expansion as discussed in section 6 above. Hit picking can be useful, for example, for rearranging clones from a library according to user input.

[0296] Random access hotel 32 provides plate storage needed for high-throughput primer (oligonucleotide) mixing, and decreases user intervention during plasmid preparations and sequencing. Plate reader 28 includes a spectrophotometer for measuring DNA concentration of samples. Data taken from plate reader 28 is used to normalize DNA concentrations prior to sequencing. Thermal cycler 26 serves as a variable temperature incubator for the PCR steps necessary for gene synthesis. The reading device 24 is integrated for sample tracking. System 10 also includes robotic arm 40 for transporting sample and plates between different elements in system 10 such as between liquid handler 12 and random access hotel 14.

[0297] For illustration and not as any limitation, synthesis can be automated in the following fashion:

[0298] **Primer Mixing.** Robotic arm 40 is coupled to the liquid handler 12 and transports one or more source microplates and PCR plates from random access hotel 14 to liquid handler 12. Liquid handler 12 dispenses appropriate amounts of each of about 25 oligonucleotides from source microplates 16 into a "synthon assembly" well of a PCR plate 18 such that each well contains equimolar amounts of the primers necessary to make a synthon. Since each primer mix contains a different primers (oligonucleotides), as described above, a spreadsheet program is

optionally utilized to identify the primer and automatically extract the data necessary for liquid handler 12 to determine which primers correspond to which synthon assembly well. In one embodiment, data from the GEMS output identifying oligonucleotide primer locations and destinations is used to generate corresponding transfer data for the liquid handler 12. Creation of such transfer data from location and destination data is well understood in the art. In embodiments, the hotel 14 carries at least about 50, at least about 100, at least about 150, at least about 200, or at least about 1000, oligonucleotide mixes in different wells of microwell-type plates).

[0299] Synthon Synthesis by PCR. Once the PCR plate 18 is loaded with primer mixes, the liquid handler 12 delivers the assembly PCR amplification mixture (including polymerase, buffer, dNTPs, and other components needed for "synthon assembly") to each well, and PCR is performed therein. Robotic arm 40 moves PCR plate 18 to plate sealer 31 to seal the PCR plate 18. After sealing, PCR plate 18 is moved by robotic arm 40 to thermal cycler 26.

[0300] LIC extensions containing uracil are added by liquid handler 12 to the PCR products (amplicons) by a second PCR step. In the second PCR step, the primers containing LIC extensions are added (LIC extension mixture) to each well to prepare the "linkered-synthon."

[0301] A synthon cloning mixture is prepared by combining the linkered synthon and a synthon assembly vector in liquid handler 12. Each synthon cloning mixture is then transferred to a sister plate containing competent *E. coli* cells for transformation, which are positioned at cooling element 12. After transformation, cells in each well are spread on petri dishes, which are incubated to form isolated colonies.

[0302] Following incubation of the bacterial cell culture, the plates are transferred by robot arm 40 from an incubator 54 to an automated colony picker 50 (e.g., Mantis; Gene Machines). Automated colony picker 50 identifies 5 to 10 isolated colonies on a plate, picks them, and deposits them in individual wells of a deep-well titer plate 52 containing liquid growth medium.

[0303] Liquid growth medium is used to prepare DNA for sequencing, e.g., as described above. The liquid handler 12 then sets up sequencing reactions using primers in both directions. Sequencing is carried out using an automated sequencer (e.g., ABI 3730 DNA sequencer).

[0304] The sequence is analysed as described below.

10.2 RAPID ANALYSIS OF CHROMATOGRAMS (RACOON)

[0305] A bottleneck in the gene synthesis efforts can be the analysis of DNA sequencing data from synthons. For example, sequence analysis of a single synthon may require sequencing 5 clones in both directions. In one embodiment, a typical PKS gene might involve analysis of 100 synthons, with 5-forward and 5-reverse sequences each (1000 total sequences).

[0306] To ensure accuracy in synthesis of large genes, a rapid analysis of the results is performed by a RACOON program as shown in the schematic of Figure 14. A sequence of a synthetic gene, wherein the synthetic gene is divided into a plurality of synthons, sequences of synthon clones wherein each synthon of the plurality of synthons is cloned in a vector, a sequence of the vector without an insert is entered in the program 1912. In addition, DNA sequencer trace data tracing each synthon sequence to a particular clone are also provided 1912. For all reads, the nucleotide sequence is analyzed (by base calling) 1910 for each cloned sample and vector sequences that occur in the sample sequence are eliminated 1920. To improve accuracy of data processing software in high-throughput sequencing and reliably measuring that accuracy, a base-calling program such as PHRED is used to estimate a probability of error for each base-call, as a function of certain parameters computed from the trace data. A map depicting the relative order of a linked library of overlapping synthon clones representing a complete synthetic gene segment is constructed ("contig map") 1930 and the contig sequences are aligned against the reference sequence of the synthetic gene 1940. The program identifies errors and alignment scores for each sample 1950 and generates a comprehensive report indicating ranking of samples, substitution-insertion-deletion errors, most likely candidate for selection or repair 1960.

[0307] Preparation of a single synthon might entail sequencing five clones in both directions. The sequences are called and vector sequence is stripped by PHRED/CROSS_MATCH. Next, the sequences are sent to PHRAP for alignment, and the user analyzes the data: the correct (if any) sequence is chosen by comparison to the desired one, and errors in others are captured and analyzed for future statistical comparisons.

[0308] The Racoon algorithm has been developed to automate tedious manual parts of this process. PHRED reads DNA sequencer trace data, calls bases, assigns quality values to the bases, and writes the base calls and quality values to output files. PHRED can read trace data from SCF files and ABI model 373 and 377 DNA sequencer files, automatically detecting the

file format. After calling bases, PHRED writes the sequences to files in either FASTA format, the format suitable for XBAP, PHD format, or the SCF format. Quality values for the bases are written to FASTA format files or PHD files, which can be used by the PHRAP sequence assembly program in order to increase the accuracy of the assembled sequence. After processing sequences by PHRED, Racoon consolidates the forward and reverse sequences of each clone, and sends the composite to PHRAP for alignment with others from the same synthon. The software calls out the correct sequences, and identifies and tabulates the position, type (insertion, deletion, substitution) and number of errors in all clones. It also detects silent mutations, amino acid changes, unwanted restriction sites and other parameters that can disqualify the sample. The user then decides how to use the data (error analysis, statistics, *etc.*).

[0309] The features of Racoon include: (i) reading multiple data formats (SCF, ABI, ESD); (ii) performing base calling, alignments, vector sequence removal and assemblies; (iii) high throughput capability for analysis for multiple 96 well plate samples; (iv) detecting insertions, deletions and substitutions per sample, and silent mutations; (v) detecting unwanted restriction sites created by silent mutations; (vi) generating statistical reports for sample sets which results can be downloaded or stored to a database for further analysis.

[0310] The Racoon system is implemented using the following software components: Phred, Phrap, Cross_Match (Ewing B, Hillier L, Wendl M, Green P: Base calling of automated sequencer traces using phred. I. Accuracy assessment. *Genome Research* 8, 175-185 (1998); Ewing B, Green P: Basecalling of automated sequencer traces using phred. II. Error probabilities. *Genome Research* 8, 186-194 (1998); Gordon, D., C. Desmarais, and P. Green. 2001. Automated Finishing with Autofinish. *Genome Research*. 11(4):614-625); Python 2.2 as integration and scripting language (Python Essential Reference, Second Edition by David M. Beazley); GeMS Application Programming Interface (Kosan proprietary software); Apache Web Server version 2.0.44 (<http://httpd.apache.org>); and Red Hat Linux Operating System version 8.0 (<http://www.redhat.com>).

RACCOON ALGORITHM

[0311] *Step I: Data population.* The user inputs into the Racoon program raw sequencing data, vector sequence, and a look-up table that maps the sample to a specific synthon. The program creates run folders for each sample and correctly puts the sequencing files (forward and

reverse directions) in its folder, along with the desired synthon sequence. The program uses the look-up table to find the related synthon sequence from a database containing the synthetic gene design data.

[0312] *Step II: Base calling, vector screening and sequence assembly.* Multiple reads can be analyzed using base-calling software such as PHRED and PHRAP (see, e.g., Ewing and Green (1998) Genome Research 8:175-185; Ewing and Green (1998) Genome Research 8:186-194; and Gordon *et al.* (1998) Genome Research. 8:195-202) to obtain a certainty value for each sequenced nucleotide. A python script is executed on each sample folder containing the chromatogram files for a particular synthon. This script in turn executes the following programs in succession:

[0313] PHRED: a base calling software to determine the nucleotide sequence on the basis of multi-color peaks in the sequence trace. PHRED is a publicly available computer program that reads DNA sequencer trace data, calls bases, assigns quality values to the bases, and writes the base calls and quality values to output files (see, for example, Ewing and Green, Genome Research 8:186-194 (1998). After calling bases, PHRED writes the sequences to files in either FASTA format, the format suitable for XBAP, PHD format, or the SCF format. Those skilled in the art will be able to select a nucleotide sequence characterization program compatible with the output of a particular sequencing machine, and will be able to adapt an output of a sequencing machine for analysis with a variety of base-calling programs.

[0314] CROSS_MATCH: an implementation of the Smith-Waterman sequence alignment algorithm. It is used in this step to remove the vector sequence from each sample.

[0315] PHRAP: a package of programs for assembling shotgun DNA sequence data. It is used to construct a contig sequence as a mosaic of the highest quality parts of reads. The resulting assembly files are candidates for comparison and analysis.

[0316] *Step III: Error detection, ranking of samples.* A python script reruns CROSS_MATCH with the purpose of determining variation between the original synthon sequence and the resulting assembly files for each sample.

[0317] Each synthon folder has a collection of sample folders and the associated files generated by PHRED, PHRAP and CROSS_MATCH. A python program detects each of the related samples and associates them with a synthon. It looks for the required information from

the output files and ranks the samples. The program looks for silent mutations; checks freshly introduced restriction sites; and generates a report that can be used for further analysis.

[0318] Racoon is capable of processing large datasets rapidly. About 200 samples can be analyzed in less than 2 minutes. This included the base calling, vector screening, detection of errors and generation of reports. The results can be saved as HTML files or the individual sample runs can be downloaded to the desktop for further analysis.

11. EXAMPLES

EXAMPLE 1

GENE ASSEMBLY AND AMPLIFICATION PROTOCOLS

[0319] This example describes protocols for gene assembly and amplification.

Assembly

[0320] The assembly of synthetic DNA fragments is adapted from a previously developed procedure (Stemmer et al., 1995, *Gene* 164:49-53; Hoover and Lubkowski, 2002, *Nucleic Acids Res.* 30:43). The gene synthesis method uses 40-mer oligonucleotides for both strands of the entire fragment that overlap each other by 20 nucleotides.

[0321] Equal volumes of overlapping oligonucleotides for a synthon are added together and diluted with water to a final concentration of 25 μ M (total). The oligo mix is assembled by PCR. The PCR mix for assembly is 0.5 μ l Expand High Fidelity Polymerase (5 units/ μ L, Roche), 1.0 μ l 10 mM dNTPs, 5.0 μ l 10 x PCR buffer, 3.0 μ l 25 mM MgCl₂, 2.0 μ l 25 μ M Oligo mix, 38.5 μ l water. The PCR conditions for assembly begins with a 5 minute denaturing step at 95 °C, followed by 20-25 cycles of denaturing 95°C at 30 seconds, annealing at 50 or 58°C for 30 seconds, and extension temperature 72°C for 90 seconds.

Amplification

[0322] Aliquots of the assembly reaction are taken and used as the template for the amplification PCR. In the amplification PCR, regions of the primers used contain uracil residues, for use in LIC-UDG cloning. The primers are: 316-4-For_Morph_dU:
5'GCUAUAUCGCUAUCGAUGAGCUGCCACTGAGCACCAACTACG 3' [SEQ ID NO:1]
and 316-4-Rev_Morph_dU:
5'GCUAGUGAUCGAUGCAUUGAGCUGGCACTTCGCTACTACACC 3' [SEQ ID NO:2].

Uracil-containing regions are underlined. As noted, a common pair of linkers can be used for many different synthons, by design of common sequences at synthon edges.

[0323] The reaction mix for the amplification PCR is 0.5 μ L Expand High Fidelity Polymerase, 1.0 μ L 10 mM dNTPs, 5.0 μ L 10 x PCR buffer, 3.0 μ L 25 mM $MgCl_2$ (1.5mM), 1.0 μ L 50 μ M stock of forward Oligo, 1.0 μ L 50 μ M stock of reverse Oligo, 1.25 μ L of assembly round PCR sample (template), and 37.25 μ L water. The program for amplification includes an initial denaturing step of 5 minutes at 95°C. Twenty-five cycles of 30 seconds of denaturing at 95°C, annealing at 62°C for 30 seconds, and extension at 72°C of 60 seconds, with a final extension of 10 minutes.

[0324] The amplification of samples is verified by gel electrophoresis. If the desired size is produced, the sample is cloned into a UDG cloning vector. When amplification does not work, a second round of assembly is performed using a PCR mix for assembly of 16 μ L first round assembly 0.5 μ L Expand High Fidelity polymerase, 1.0 μ L 10mM dNTPs, 3.3 μ L 10 x PCR buffer, 2.0 μ L 25 mM $MgCl_2$, 2.0 μ L oligo mix, and 35.2 μ L water. The PCR conditions for the second assembly are the same as the first assembly described above. After the second assembly an amplification PCR is performed.

EXAMPLE 2

LIGATION INDEPENDENT CLONING METHODS

[0325] Protocols for cloning of synthons into a stitching vector are described below with reference to vectors pKos293-172-2 or pKos293-172-A76. The reader with knowledge of the art will easily identify those changes used to accommodate vectors with different restriction sites, different synthon insertion sites, or different selection markers.

Exonuclease III Method

[0326] *Vector preparation:* To prepare vectors for UDG-LIC, 10 μ L of vector (1-2 μ g) is digested with 1 μ L Sac I (20 units/ μ L) at 37°C for 2 h. 1 μ L of nicking endonuclease N. BbvC IA (10 units/ μ L) is added and the sample is incubated an additional two hours at 37°C. The enzymes are heat inactivated by incubation at 65°C for 20 minutes, and then a MicroSpin G-25 Sephadex column (Amersham Biosciences) is used to exchange the digestion buffer for water. The samples are treated with 200 units of Exonuclease III (Trevigen) for 10 minutes at 30°C and

purified on a Qiagen quik column, eluting to a final volume of 30 μ L. Samples are checked for degradation by gel electrophoresis and used for test UDG-cloning reaction to determine efficiency of cloning.

[0327] *UDG cloning of fragments:* To clone the synthetic gene fragments, they are treated with UDG in the presence of the LIC vector. 2 μ L of PCR product (10 ng) is digested for 30 minutes at 37°C with 1 μ L (2 units) of UDG (NEB) in the presence of 4 μ L of pre-treated dU vector (50 ng) in a final reaction volume of 10 μ L.

[0328] The resulting mixtures are placed on ice for 2 minutes, and the entire reaction volume (10 μ L) is transformed into DH5 α *E. coli* cells, and selected on LB plates with 100 μ g/mL carbenicillin (*i.e.*, SM1). The plasmids are purified for characterization and subsequent cloning steps.

Endonuclease VIII method

[0329] *Vector Preparation:* The vector is linearized by digestion with Sac I. Nicking endonuclease (100 units N. BbvC IA) is added and the mixture incubated at 37°C for 2 h. DNA is isolated from the reaction mixture by phenol/chloroform extraction followed by ethanol precipitation.

[0330] *UDG Cloning:* 20 ng linearized vector, 10 ng PCR product, and 1 unit USER enzyme (a mixture of endonuclease VIII and UDG available as a kit from New England Biolabs) are combined and incubated 15 m at 37°C, 15 m at room temperature, and 2 m on ice, and used to transform *E coli* DH5 α . Endonuclease VIII is described in Melamede et al., 1994, *Biochemistry* 33:1255-64.

EXAMPLE 3

CHARACTERIZATION AND CORRECTION OF CLONED SYNTHONS

[0331] *Identification of clones:* To identify clones containing the correct PCR product (*e.g.*, not having sequence errors), plasmid DNA is isolated from several (typically five or more) clones and sequenced. Any suitable sequencing method can be used. In one embodiment, sequencing is carried out using DNA obtained by rolling circle amplification (RCA), using phi29 DNA polymerase (*e.g.*, Templicase; Amersham Biosciences). See, Nelson *et al.*, 2002, "TempliPhi, phi29 DNA polymerase based rolling circle amplification of templates for DNA

sequencing" *Biotechniques* Suppl:44-7. In one embodiment, each colony containing a plasmid to be sequenced is suspended in 1.4 mL LB medium and 1 μ L is used in the amplification/sequencing reaction.

[0332] *Sequence analysis:* After sequencing, the results can be aligned and compared to the intended sequence. Preferably this process is automated using a RACOON program (described below) to identify the correct sequences after aligning the sequences corresponding to each synthon.

[0333] *Storage of clones:* Clones of interest can be stored in a variety of ways for retrieval and use, including the Storage IsoCode® ID™ DNA library card (Schleicher & Schuell BioScience).

[0334] *Site-Directed Mutagenesis to Correct Sequence Errors:* Synthon samples can be sequenced until a clone with the desired sequence is found. Alternatively, clones with only 1 or 2 point mutations can be corrected using site-directed mutagenesis (SDM). One method for SDM is PCR-based site-directed mutagenesis using the 40-mer oligonucleotides used in the original gene synthesis. For example, a sample with only one point mutation from the desired target sequence was corrected as follows: The overlapping oligonucleotides from the assembly of the synthons that corresponded to that part of the synthon were identified and used for the correction of the synthon. The error-containing sample DNA was amplified using a Pfu based PCR method using overlapping oligonucleotides (nos. 1 and 2) that cover the area of the mutation (see Fischer and Pei, 1997, "Modification of a PCR-based site directed mutagenesis method" *Biotechniques* 23:570-74). The reaction mixture included DNA template [5-20 ng], 5.0 μ L; 10 x Pfu buffer, 0.5 μ L; Oligo #1 [25 μ M], 0.5 μ L; Oligo #2 [25 μ M], 1.0 μ L; 10mM dNTPs, 1.0 μ L; Pfu DNA polymerase, and sterile water to 50 μ L. PCR conditions were as follows: 95°C 30 seconds (2 minutes if using Pfu with heat sensitive ligand), 12-18 cycles of: 95°C 30 seconds, 55°C 1 minutes, 68°C 2 minutes/kb plasmid length (1 min/kb if Pfu Turbo). Next, the methylated (parental) DNA was degraded by adding 1 μ L Dpn I (10 units) to the PCR reaction and incubating 1 hr at 37°C. The resulting sample was transformed into competent DH5 α cells. Plasmid DNA from four clones was isolated and sequenced to identify desired clones.

EXAMPLE 4

IDENTIFICATION OF USEFUL RESTRICTION SITES IN PKS MODULES

[0335] To identify useful sites in PKS modules, the amino acid sequences of 140 modules from PKS genes were analysed. A strategy was developed for identifying theoretical restriction sites (*i.e.*, that could be placed in a gene encoding the module without resulting in a disruptive change in the module sequence) that fulfill some or all of the following criteria:

1. Sites were about 500 bp apart in the gene and/or are at domain or module edges,
2. Compatible with high-throughput assembly of modules from synthons (often by virtue of being unique within a module),
3. Similarly placed among different modules, and
4. Do not disrupt the function (activity) of the PKS.

[0336] Two types of restriction sites were identified. The first set of sites are those located at the edge of domains (including the Xba I and Spe I sites at the edges of modules). The second set of sites could be located at synthon edges, but were not generally found at domain edges.

[0337] It will be understood that the restriction sites described in this example are exemplary only, and that additional and different sites can be identified by the methods of disclosed herein, and used in the synthetic methods of the invention.

[0338] The amino acid sequences of selected regions of 140 modules taken from some 14 PKS gene clusters were aligned (*see* Table 9). Then, regions of high homology near edges of domains that, when reverse translated to all possible DNA sequences, revealed a 6-base or greater restriction site were identified. In specified cases, a conservative change of the amino acid in order to place the restriction site was allowed, provided that change was found in many of the PKS modules. In a few cases, restriction sites were placed in putative inter-domain sequences that required change of amino acids. In such cases there was experimental evidence that the modified amino acid sequence did not disturb functionality in some PKSs.

[0339] The results of the gene design for the four common variants [(KS+AT+ACP); (KS+AT+ACP + KS); (KS+AT+ACP + KS +DH); (KS+AT+ACP + KS+DH+ER)] of PKS modules are shown in Figure 4 and Tables 7-11. The positions of the restriction sites are referenced to the homologous amino acid target sites within a domain where possible, and to module 4 of the 6-DEBS gene or protein (which contains all six of the common domains). For the latter, numbering of the amino acid and nucleotide sequence used for reference begins at the

first residue of the EPIAIV found on the N-terminal edge of the KS domain; homologous motifs are found at the N-terminal edges of all 140 KS domains in the sample.

TABLE 7
RESTRICTION SITES NEAR DOMAIN EDGES

Restriction Enzyme	Domain / Terminal Orientation	Nucleotide Position of site in ery mod4 *	AA Sequence near site in ery mod4	Amino acid motif in ery mod4
Spe I	ACP (C)	54 bp before KS		VG-not conserved
Mfe I	KS (N)	5-10	PIAIVG	PIA
Kpn I	KS (C)	1243-1248	GTNAHV	GT
Msc I	AT (N)	1590-1595	PGQGAQ	GQ
Pst I	AT (C)	2611-2616	PRPHRP	PR-not conserved
BsrB I	ER (N)	4075-4080	PLRAGE	PL
Age I	KR (N)	5029-5034	TGGTGT	TG (initial TG)
Xba I	ACP (C)	6001-6006	FADSAP	FA (not conserved) from DEBS2 near terminus

* Numbering for each module begins at the N-terminus of the KS domain taken to be the amino acid at the site homologous to that of the glutamate (E) of the E-P-I-A-I-V of module 4 of erythromycin.

[0340] An Mfe I site is incorporated near the left edge of the KS coding sequence using bases 2-7 of the 9 bases coding for the tripeptides homologous to the PIV of the initial motif of the KS. 70% of the 140 KSs need no change in amino acids; the remaining 30% require only conservative changes [81% V->I, 17% L->I and 2% M to I]. On the right edge of 100% of the 140 KS domains, there is a conserved GT (nt 1267 - 1272) that can be encoded by the sequence for a Kpn I restriction site.

[0341] An Msc I site is incorporated near the left edge of the AT coding sequence (nt 1590-1595) at the site of the GQ dipeptide found in 100% of the sampled ATs. A Pst I site was placed at the right side of the AT (nt 2611 - 2617) at a position where Pst I and Xho I had been previously placed without loss of functionality after domain swaps. This variable sequence region is identified in many modules by a Y-x-F-x-x-x-R-x-W motif where "x" is any amino acid; in others, alignments always produce a well-defined equivalent position. The two amino

acids to the immediate right (C-terminal to W) of this motif are modified to introduce the Pst I site.

[0342] For modules containing a KR, an Age I site was placed at the TG dipeptide (nt 4894 - 5542) found in 100% of the 136 KRs in the test sequences. When an ER domain is present in the module, a Bsr BI site is placed at its left edge, which codes for the conserved PL dipeptide (nt 4072 - 4929) found in all but one of the 17 ERs in the test sequences (the remaining ER is the only ER domain in the sample without activity). Since the ER and KS domains are separated by only 4 to 6 amino acids, the Age I site of the KR serves as the other excision site for the ER.

[0343] At the carboxy end of the module, a Xba I site was placed at a well-defined position adjacent to the carboxy side of the ACP of the module. There are two leucines (L) at positions 36 and 40 to the right of the active site serine (S) of all ACPs. The codons of the two amino acids following the leucine at position 40 (normally positions 41 and 42 after the active site serine) were changed to the recognition sequences for Xba I (C-terminal end).

[0344] In modules that naturally followed another, a Spe I cloning site was incorporated as the amino terminus site. This site is analogous to that described for the Xba I, above (normally positions 41 and 42 after the active site serine), and is followed by the intermodular linker to the MfeI site in the KS. In modules that exist at the N-terminus of proteins (*i.e.* no ACP to the left), the Spe I to MfeI linker sequence is not needed, and the segment of the module synthesized consists of only the MfeI-Xba I body.

[0345] It will be appreciated by the reader that the present invention provides, *inter alia*, a method for identifying restriction enzyme recognition sites useful for design of synthetic genes by (i) obtaining amino acid sequences for a plurality of functionally related polypeptide segments; (ii) reverse-translating said amino acid sequences to produce multiple polypeptide segment-encoding nucleic acid sequences for each polypeptide segment; (iii) identifying restriction enzyme recognition sites that are found in at least one polypeptide segment-encoding nucleic acid sequence of at least about 50% of the polypeptide segments. Preferred restriction enzyme recognition sites are found in at least one polypeptide segment-encoding nucleic acid sequence of at least about 75% of the polypeptide segments, even more preferably at least about 80%, even more preferably at least about 85%, even more preferably at least about 90%, even more preferably at least about 95%, and sometimes about 100%. Examples of functionally related polypeptide segments include polyketide synthase and NRPS modules, domains, and

linkers. In one embodiment, the functionally related polypeptide segments are regions of high homology in PKS modules or domains (i.e., rather than the entire extent of a module or domain).

[0346] The invention also provides a method of making a synthetic gene encoding a polypeptide segment by (i) identifying one, two three or more than three restriction sites as described above, and (ii) producing a synthetic gene encoding the polypeptide segment that differs from the naturally occurring gene by the presence of the restriction site(s) and (iii) optionally differs from the naturally occurring gene by the removal of the restriction site(s) from other regions of the polypeptide segment encoding sequence.

TABLE 8
RESTRICTION SITES BY MODULE TYPE

module type	# synthons	# modules of this type in list	sites required (see list below)
DH/KR/ER	14	17	1-11, DH1&2, ER1&2
DH/KR	12	48	1-11, DH1&2
KR only	10	72	1-11
no KR	7	3	1-7&11
total modules in list:		140	

TABLE 9
PATTERN OF RESTRICTION SITES USED FOR MODULE DESIGN

				#	# currently	% currently				
site	synthon	Restriction		required	designed from	from	domain	edge	use	
1	yes	SpeI	ACTAGT	1	-4	140	140*	100.0%	yes	ACP cter
1a		MfeI	CAATTG	3	-4	140	140	100.0%	yes	KS nter
2	yes	set#1	see Table 7 1 or 2	-4 or 2	140	140	100.0%			
3	yes	NheI	GCTAGC	1	-4	140	140	100.0%		
4	yes	KpnI	GGTACC	1	4	140	140	100.0%	yes	KS cter
4a		MscI	TGGCCA	2	blunt	140	139	99.3%	yes	AT nter
5	yes	set#2	see Table 7 1 or 2	-4 or 2	140	140	100.0%			
6	yes	AgeI*	see Table 4	1	-4	140	98	70.0%		
7	yes	PstI	CTGCAG	1	4	140	140	100.0%	yes	AT cter
8	yes	KasI or MluI	see below	1	-4	137	121	88.3%		pre-reductive region nter
9	yes	AgeI	ACCGGT	1	-4	137	132	96.4%	yes	KR nter
10	yes	set#2	see Table 7 1 or 2	-4 or 2	137	109	79.6%			
11	yes	XbaI	TCTAGA	1	-4	140	140*	100.0%	yes	ACP cter
DH1	yes	SphI	GCATGC	2	4	65	54	83.1%		
DH2	yes	set#3	see Table 7 1 or 2	-4	65	65	100.0%			
NgoMIV or										
ER1	yes	BspEI	see Table 7	1	-4	17	17	100.0%		
ER2	yes	XbaI*	see Table 8	1	-4	17	17	100.0%		

[0347] In one embodiment, each site #1 can be joined to site # 11 of a second module (or an equivalent Xba I from another upstream unit); and each #11 to an Spe I. Thus #1/#11 in the final construct is only a single location, coding for the dipeptide SerSer (this location has previously been successfully used in cases where the native amino acids were replaced with the homologous dipeptide ThrSer). No amino acid changes are required in sites other than #1a, #7 and #1/#11. At each of these three sites, a history of previous successful exchanges is available.

[0348] In site #7, any native dipeptide is replaced with LeuGln. In reported sequences this site is not well conserved, except that the first amino acid is often of large hydrophobic type (as is Leu). [L->I, V->I, M->I]

[0349] In one aspect, the invention provides a PKS polypeptide having a non-natural amino sequence, comprising a KS domain comprising the dipeptide Leu-Gln at the carboxy-terminal edge of the domain; and/or an ACP domain comprising the dipeptide Ser-Ser at the carboxy-terminal edge of the domain.

[0350] Restriction sites used for synthon edges, but not domain edges, do not require that the restriction site be compatible between modules. At certain sites in Table 10 a list of restriction enzymes is provided, such that the stated number of cases for each site (see Table 9) one of the list is compatible with the amino acid sequence.

TABLE 10
LISTS OF RESTRICTION SITES FOR CERTAIN SYNTHON EDGE LOCATIONS

set#1 (at site #2):		frame	overhang
AflIII	CTTAAG	2	-4
BsiWI	CGTACG	2	-4
SacII	CCGCGG	1	2
NgoMIV	GCCGGC	1	-4
set#2 (at sites #5 and #10):			
BglII	AGATCT	1	-4
BssHII	GCGCGC	2	-4
SacII	CCGCGG	2	2
set#3 (at site #DH2):			
AgeI	ACCGGT	2	-4
AflIII	CTTAAG	2	-4
BspEI	TCCGGA	1	-4
NgoMIV	GCCGGC	1	-4
site #8:			
Kas I	GGCGCC	1	-4
Mlu I	ACGCGT	1	-4
site #ER1:			
Ngo MIV	GCCGGC	1	-4
Bsp EI	TCCGGA	1	-4

TABLE 11
SITES USING PAIRS OF COMPATIBLE RESTRICTION ENZYMES.

	site #6 ("AgeI*):		frame	overhang
5'synthon	AgeI	ACCGGT	1	-4
3' synthon	NgoMIV	GCCGGC	1	-4
	(alternates to NgoMIV: XmaI or BspEI)			
	site #ER2 ("XbaI*):			
5'synthon	XbaI	TCTAGA	1	-4
3' synthon	AvrII	CCTAGG	1	-4

[0351] In certain cases (see sites #6 and #ER2) the constructs are designed by using one restriction site for the 5' synthon, and a second with compatible overhang for the 3' synthon. This allows use of certain restriction sites for the synthons that are not desired in the final product (e.g., the Xba I at site #ER2 would interfere with the use of the 3' Xba I site at #11 for gene construction).

TABLE 12
SOURCES OF 140 MODULES IN INITIAL ANALYZED SET

cluster	accession #	source (genus)	source (species)	# extension modules
erythromycin	M63676/M63677	Saccharopolyspora	erythraea	6
megalomicin	AF263245	Micromonospora	megalomicea	6
oleandomycin	AF220951/L09654	Streptomyces	antibioticus	6
pikromycin	AF079138	Streptomyces	venezuelae	6
niddamycin	AF016585	Streptomyces	caelestis	7
spiramycin		Streptomyces	ambofaciens	7
tylosin	AF055922	Streptomyces	fradiae	7
geldanamycin		Streptomyces	hygroscopicus	7
pimaricin	AJ278573	Streptomyces	natalensis	12
pte	AB070949	Streptomyces	avermitilis	12
avermectin	AB032367	Streptomyces	avermitilis	12
oligomycin	AB070940	Streptomyces	avermitilis	16
nystatin	AF263912	Streptomyces	nodosus	18
amphotericin	AF357202	Streptomyces	noursei	18
				total: 140

[0352] Other sequences of domains, modules and ORFs of PKSs and PKS-like polypeptides can be obtained from public databases (e.g., GenBank) and include, for illustration and not limitation, accession numbers sp|Q03131|ERY1_SACER; gb|AAG13917.1|AF263245_13; gb|AAA26495.1; pir|S13595; prf|I1702361A; sp|Q03133|ERY3_SACER; gb|AAG13919.1|AF263245_15; ref|NP_851457.1; dbj|BAA87896.1; ref|NP_851455.1; gb|AAF82409.1|AF220951_2; gb|AAF82408.1|AF220951_1; ref|NP_824071.1; ref|NP_822118.1; gb|AAG23266.1; ref|NP_821591.1; sp|Q07017|OL56_STRAT; pir|T17428; gb|AAF86393.1|AF235504_14; gb|AAF71766.1|AF263912_5; ref|NP_821593.1; dbj|BAB69304.1; ref|NP_824075.1; gb|AAB66507.1; ref|NP_824068.1; ref|NP_821594.1; dbj|BAB69303.1; gb|AAF86396.1|AF235504_17; ref|NP_823544.1; ref|NP_822117.1; pir|T17463; gb|AAK73501.1|AF357202_4; dbj|BAC57030.1; emb|CAB41041.1; ref|NP_336573.1; emb|CAC20920.1; ref|NP_822114.1; gb|AAC46028.1; emb|CAC20921.1; ref|NP_855724.1; dbj|BAC57031.1; ref|NP_216564.1; gb|AAB66504.1; ref|NP_824073.1; gb|AAG23262.1; gb|AAG23263.1; ref|NP_824072.1; gb|AAO06916.1; gb|AAG23264.1; gb|AAF86392.1|AF235504_13; gb|AAP42855.1; ref|NP_630373.1; gb|AAB66508.1; pir|T30226; gb|AAK73514.1|AF357202_17; gb|AAB66506.1; pir|T17410; pir|T30283; gb|AAP42874.1; pir|T17464; ref|NP_822113.1; gb|AAC01711.1; gb|AAG09812.1|AF275943_1; ref|NP_733695.1; pir|T30225; ref|NP_824074.1; gb|AAO06918.1; pir|T30221; gb|AAM81586.1; pir|T30228; pir|T17409; gb|AAC46026.1; gb|AAC46024.1; gb|AAO65800.1|AF440781_19; gb|AAK73513.1|AF357202_16; gb|AAM54078.1|AF453501_4; gb|AAK73502.1|AF357202_5; gb|AAP42858.1; pir|T30223; gb|AAM81585.1; gb|AAF71775.1|AF263912_14; gb|AAG23265.1; gb|AAP42856.1; emb|CAC20919.1; pir|T17412; pir|T17467; gb|AAF71776.1|AF263912_15; pir|T17411; gb|AAO65799.1|AF440781_18; ref|NP_821590.1; dbj|BAC54914.1; gb|AAF71768.1|AF263912_7; gb|AAO65796.1|AF440781_15; ref|NP_824069.1; gb|AAO61200.1; gb|AAP42859.1; gb|AAO65806.1|AF440781_25; gb|AAF71774.1|AF263912_13; gb|AAL07759.1; ref|NP_851456.1; ref|NP_821592.1; pir|T30224; gb|AAO06917.1; gb|AAO65797.1|AF440781_16; gb|AAK73512.1|AF357202_15; ref|NP_301229.1; gb|AAC46025.1; ref|NP_856616.1; emb|CAB41040.1; gb|AAC01712.1; pir|T17465; gb|AAP42857.1; gb|AAK73503.1|AF357202_6; gb|AAO65801.1|AF440781_20; gb|AAO65798.1|AF440781_17; pir|T17466; pir|S23070; sp|Q03132|ERY2_SACER;

gb|AAG13918.1|AF263245_14; emb|CAA44448.1; ref|NP_794435.1
gb|AAM54075.1|AF453501_1; gb|AAA50929.1; gb|AAP42860.1; dbj|BAC57032.1;;
dbj|BAC57028.1; dbj|BAA76543.1; gb|AAP42873.1; ref|NP_855341.1; ref|NP_216177.1;
gb|AAM54076.1|AF453501_2; gb|AAP40326.1; gb|AAC46027.1;
gb|AAM54077.1|AF453501_3; gb|AAN63813.1; emb|CAD43451.1; gb|AAK19883.1;
ref|NP_630372.1; gb|AAO65807.1|AF440781_26; gb|AAA79984.2;
gb|AAF26921.1|AF210843_18; emb|CAD43448.1; ref|NP_794436.1; gb|AAB66505.1;
gb|AAF43113.1; gb|AAF62883.1|AF217189_6; dbj|BAC57029.1; pir|T03222; gb|AAP42867.1;
ref|NP_822727.1; emb|CAD43450.1; gb|AAD03048.1; gb|AAP45192.1; gb|AAO61221.1;
gb|AAF82077.1|AF232752_2; ref|NP_486720.1; gb|AAO65790.1|AF440781_9;
ref|NP_485688.1; gb|AAM81584.1; emb|CAD43449.1; ref|NP_00108795.1; ref|NP_302534.1;
gb|AAP42872.1; pir|T28658; ref|NP_00105790.1; ref|NP_217447.1; ref|NP_337514.1;
emb|CAD19091.1; ref|NP_856601.1; gb|AAF19810.1|AF188287_2; ref|NP_00110107.1;
ref|NP_00110105.1; ref|NP_217449.1; ref|NP_337516.1; gb|AAF62880.1|AF217189_3;
gb|AAK57188.1|AF319998_7; ref|NP_00108802.1; ref|NP_00110106.1; ref|NP_217450.1;
ref|NP_856604.1; pir|T30871; gb|AAF26919.1|AF210843_16; ref|NP_00107887.1;
ref|NP_856602.1; ref|NP_217448.1; emb|CAD19092.1; ref|NP_336931.1; ref|NP_216898.1;
gb|AAO62584.1; ref|NP_00108796.1; pir|S73013; ref|NP_302535.1;
gb|AAM70355.1|AF505622_27; gb|AAF26922.1|AF210843_19; gb|AAK57186.1|AF319998_5;
gb|AAK57187.1|AF319998_6; emb|CAD19090.1; ref|NP_302536.1; ref|NP_00108803.1;
emb|CAD19087.1; gb|AAF62884.1|AF217189_7; pir|T17421; ref|NP_302533.1; pir|S73021;
gb|AAO64405.1; gb|AAF19813.1|AF188287_5; ref|NP_602063.1; emb|CAD19088.1;
gb|AAO64407.1; gb|AAF00959.1|AF183408_7; gb|AAF26923.1|AF210843_20;
emb|CAD29794.1; gb|AAF19814.1|AF188287_6; emb|CAD29793.1; ref|NP_00108797.1;
gb|AAF62885.1|AF217189_8; dbj|BAB12210.1; ref|NP_00074381.1; gb|AAO62582.1;
ref|NP_214919.1; ref|NP_630013.1; ref|NP_334828.1; gb|AAK57189.1|AF319998_8;
ref|NP_00110108.1; ref|NP_739315.1; gb|AAM33470.1|AF395828_3; emb|CAD19086.1;
emb|CAD19089.1; ref|NP_217456.1; ref|NP_486719.1; ref|NP_856610.1; pir|B44110;
ref|NP_00107886.1; ref|NP_485689.1; gb|AAF00958.1|AF183408_6; ref|NP_301233.1;
ref|NP_854867.1; ref|NP_215696.1; ref|NP_335661.1; ref|NP_218317.1; ref|NP_00107888.1;
emb|CAD19085.1; ref|NP_857467.1; ref|NP_301199.1; pir|T17420; ref|NP_218342.1;

gb|AAK57190.1|AF319998_9; dbj|BAB12211.1; gb|AAM77986.1; gb|AAC49814.1;
ref|NP_522202.1; ref|NP_870253.1; ref|NP_301890.1; ref|NP_216043.1; ref|NP_855206.1;
dbj|BAA20102.1; emb|CAD19093.1; ref|ZP_00130214.1; gb|AAK26474.1|AF285636_26;
gb|AAK48943.1|AF360398_1; ref|NP_867299.1; ref|NP_828360.1; dbj|BAB69235.1;
ref|NP_349947.1; ref|NP_519927.1; gb|AAC23536.1; ref|XP_324222.1; ref|NP_841435.1;
ref|ZP_00107678.1; sp|P22367|MSAS_PENPA; ref|NP_854075.1; ref|NP_630898.1;
gb|AAN85523.1|AF484556_45; ref|NP_389599.1; emb|CAB13589.2; gb|AAB49684.1;
ref|NP_389603.1; emb|CAB13604.2; gb|AAN85522.1|AF484556_44; ref|ZP_00102851.1;
gb|AAO62426.1; gb|AAM12913.1; dbj|BAC20566.1; gb|AAN17453.1; ref|ZP_00126161.1;
ref|ZP_00065888.1; ref|XP_325868.1; ref|NP_216180.1; ref|NP_855344.1; gb|AAD34559.1;
ref|ZP_00050081.1; ref|ZP_00074378.1; ref|ZP_00126160.1; gb|AAL27851.1; dbj|BAB69698.1;
gb|AAB08104.1; pir|T44806; dbj|BAC20564.1; pir|T31307; ref|XP_330288.1;
ref|NP_851435.1; gb|AAN60755.1|AF405554_3; ref|ZP_00103294.1;
gb|AAD39830.1|AF151722_1; ref|XP_330106.1; gb|AAF19812.1|AF188287_4;
ref|NP_085630.1; ref|XP_329445.1; gb|AAF26920.1|AF210843_17; emb|CAB13603.2;
ref|NP_534177.1; ref|NP_356936.1; gb|AAM12909.1; ref|NP_792409.1;
gb|AAG02357.1|AF210249_16; ref|NP_384683.1; gb|AAF62882.1|AF217189_5;
emb|CAB13602.2; ref|NP_389600.1; ref|NP_822424.1; gb|AAK15074.1; ref|NP_356944.1;
ref|NP_754352.1; gb|AAO52333.1; ref|NP_851438.1; ref|ZP_00130212.1; ref|ZP_00110270.1;
ref|NP_389601.1; ref|NP_721710.1; gb|AAM33468.1|AF395828_1; emb|CAC94008.1;
ref|XP_324368.1; gb|AAO52327.1; ref|NP_486686.1; ref|ZP_00111186.1; ref|NP_851434.1;
ref|ZP_00110255.1; emb|CAD70195.1; ref|ZP_00124542.1; ref|ZP_00110274.1;
ref|NP_856605.1; ref|NP_217451.1; ref|ZP_00108701.1; ref|ZP_00126162.1;
gb|AAD43562.1|AF155773_1; ref|NP_519931.1; ref|NP_754319.1; pir|T30342;
ref|NP_405471.1; gb|AAM12911.1; ref|ZP_00012847.1; gb|AAN74983.1; ref|ZP_00110275.1;
ref|ZP_00108808.1; ref|ZP_00110898.1; ref|NP_486675.1; dbj|BAB88752.1; ref|NP_302532.1;
ref|ZP_00074380.1; gb|AAF15892.2|AF204805_2; ref|NP_492417.1; ref|ZP_00106167.1;
emb|CAA84505.1; emb|CAC44633.1; sp|P12276|FAS_CHICK; ref|ZP_00110267.1;
gb|AAO62585.1; ref|NP_823457.1; ref|XP_322886.1; gb|AAN32979.1; sp|P12785|FAS_RAT;
ref|NP_059028.1; emb|CAA46695.2; sp|Q03149|WA_EMENI; emb|CAB92399.1;
ref|NP_821274.1; gb|AAA41145.1; ref|NP_851440.1; dbj|BAB12213.1; ref|NP_754362.1;

gb|AAF00957.1|AF183408_5; gb|AAM93545.1|AF395534_1; ref|NP_828538.1;
ref|NP_004095.3; pir|G01880; emb|CAB38084.1; pir|S18953; emb|CAD19100.1; pir|S60224;
ref|ZP_00083375.1; ref|XP_126624.1; sp|Q12053|PKS1_ASPPA; ref|NP_608748.1;
emb|CAC88775.1; ref|NP_822020.1; dbj|BAC45240.1; gb|AAO64404.1;
gb|AAD38786.1|AF151533_1; emb|CAA76740.1; gb|AAC39471.1; ref|NP_754360.1;
sp|Q12397|STCA_EMENI; ref|NP_670704.1; ref|NP_819808.1; ref|XP_319941.1;
sp|P36189|FAS_ANSAN; gb|AAN59953.1; dbj|BAB88688.1; gb|AAO25864.1;
emb|CAD29795.1; gb|AAO51709.1; gb|AAM12934.1; gb|AAO51707.1;
sp|P49327|FAS_HUMAN; pir|T18201; ref|ZP_00102377.1; ref|NP_624465.1; ref|NP_828537.1;
ref|ZP_00124458.1; ref|NP_647613.1; dbj|BAB88689.1; ref|ZP_00089514.1; ref|NP_624466.1;
gb|AAO52142.1; ref|NP_754345.1; gb|AAD31436.3|AF130309_1; gb|AAM12925.1;
gb|AAO51578.1; emb|CAA31780.1; ref|XP_316979.1; ref|XP_321166.1; gb|AAG10057.1;
ref|ZP_00052686.1; gb|AAO51589.1; gb|AAA48767.1; ref|NP_754350.1; ref|NP_389604.1;
gb|AAF31495.1|AF071523_1; gb|AAK16098.1|AF288085_2; gb|AAN75188.1;
ref|NP_508923.1; gb|AAO25858.1; emb|CAA65133.1; gb|AAO25899.1; gb|AAN79725.1;
pir|T30183; gb|AAO39786.1; gb|AAO50749.1; ref|ZP_00109665.1; gb|AAO25874.1;
gb|AAO25848.1; gb|AAK72879.1|AF378327_1; ref|NP_489391.1; gb|AAO25869.1;
gb|AAM94794.1; dbj|BAA89382.1; gb|AAD43312.1|AF144052_1;
gb|AAL01060.1|AF409100_7; emb|CAA84504.1; gb|AAD43307.1|AF144047_1;
gb|AAO25844.1; gb|AAO25836.1; ref|ZP_00108217.1; gb|AAD43310.1|AF144050_1;
gb|AAO25852.1; ref|NP_717214.1; ref|ZP_00068117.1; gb|AAO39778.1; gb|AAO39788.1;
gb|AAO25904.1; gb|AAL06699.1; gb|AAO25889.1; gb|AAO25884.1;
gb|AAD43309.1|AF144049_1; ref|NP_485686.1; pir|T30937; gb|AAO39787.1;
gb|AAO39780.1; gb|AAF76933.1; gb|AAO25879.1; ref|NP_851482.1; gb|AAO39781.1;
gb|AAO39790.1; ref|NP_630000.1; gb|EAA46042.1; gb|AAO51629.1; gb|AAO25894.1;
gb|AAL01062.1|AF409100_9; 181 2c-44; gb|AAN28672.1; gb|AAD43308.1|AF144048_1; and
gb|AAO39107.1.

EXAMPLE 5

SYNTHESIS OF DEBS MODULE 2

[0353] DEBS Module 2 is a 4344 bp module. The module was designed to give 10 synthons of varying length (range, 350-700 bp). Each of the synthons was prepared, and the composite results are provided in Table 13. The ten synthons of DEBS Module2 were assembled by conventional methods (e.g., 3-way ligations) into a single module and secondary sequencing was performed to verify the presence of the desired sequence. Synthons for which the correct sequence was not obtained the first attempt were used for optimization and error determination and the numbers in parenthesis in Table 13 represent the second set of results.

TABLE 13

SUMMARY OF SYNTHESIS OF MODULE 001 (DEBS MODULE 2)

Synthon	Fragment Size	Correct	Total Sequenced	Percent Correct	Errors/kb
001-01	419	0 (31)	26 (85)	0 (36)	8.4
001-02	527	1	12	8	4.8
001-03	485	1	19	5	6.6
001-04	739	3 ^a	12	25	1.9
001-05	383	0 ^b	24	0	8.5
001-06	404	1	14	7	6.8
001-07	392	0 (15)	19 (95)	0 (16)	6.3
001-08	326	0 ^b	24	0	5.9
001-09	517	1	45	2	6.7
001-10	617	0 (6)	12 (17)	0 (35)	8.1

^a Oligos used in the assembly of synthon 001-04 were partially purified by HPLC. Different polymerase was also used for the assembly of this synthon.

^b Correct amino acid sequences were obtained for synthons 001-05 and 001-08 using samples that contained only silent mutations that had acceptable codon usage.

EXAMPLE 6

EXPRESSION OF SYNTHETIC DEBS MOD2 IN *E. COLI*

[0354] The DEBS Mod2 gene in an *E. coli* strain having high 15-Me-6dEB production was replaced with a synthetic version (Example 5) and protein expression and polyketide titer were compared. The strain employed expresses a DEBS Mod2 derivative (with the KS5 N-terminal

linker) from a stable RSF1010-based vector and DEBS2&3 from a single pET vector. The background strain (K207-3) has genes required for pantetheinylation and CoA thioester synthesis integrated on the chromosome. T7 promoters control Mod2 and DEBS 2&3 expression. Induced cultures are fed with propyl diketide to yield 15-Me-6dEB.

[0355] Synthetic (2) and natural (1) sequence Mod2 expressing strains produced indistinguishable levels of 15-Me-6dEB after 25h (8mg/L) and 42h (25mg/L) of expression. Quantitative PAGE analysis of the soluble protein fraction showed considerably higher protein expression from the synthetic Mod2 gene versus the natural sequence gene (Figure 15). Approximately 3.2-fold more Mod2 protein was observed from the synthetic gene after 42h of expression at 22°C. Equivalent titer despite higher expression level suggests that Mod2 is not production limiting in the strain used, as expected from previous work (unpublished).

[0356] *Methods: Expression strain construction* The ORF for synthetic DEBS Mod2 was assembled in the following way. The Spe I-Eco RI fragment of MPG011 (LLK1) was ligated into the ORF assembly vector (pKOS337-159-1). The NotI-Xba I fragment MPG001 (DEBS Mod2) was then ligated into this vector at the NotI-Spe I site. The AatII-MfeI fragment of the resulting plasmid was replaced with that from MPG009 (DEBS Mod5) to add the KS5 N-terminal linker sequence. The NdeI-EcoRI fragment of this plasmid (pKOS378-014) containing the Mod2 ORF was inserted into an pRSF1010 backbone to create the expression vector pKOS378-030. The *E. coli* host strain used was K207-3, which has *sfp*, *prpE*, *pccB*, and *accA1* genes for ACP pantetheinylation and CO-A thioester synthesis integrated on its chromosome. K207-3 harboring the pET vector pBP130 [Pheifer *et al.*, 2001, *Science* 291:1790-92], which expresses genes for DEBS2&3 under T7 promoter control, was transformed with pKOS378-030 and pKOS207-142a (WT Mod2 in pRSF1010; from J. Kennedy) to create synthetic (2) and WT (1) Mod2 strains, respectively. The protein sequences of the synthetic and WT Mod2 constructions are identical except for 4 substitutions in the synthetic gene required for restriction site engineering (L914Q, G1467S, T1468S, and P1551G)

[0357] *PKS expression and polyketide analysis* For the expression of Mod2 + DEBS2&3 genes, strains grown at 37°C to mid-log phase. Expression was induced with the addition of IPTG to 0.5mM and fed with the addition of 500mg/L 2-methyl-3-hydroxyhexanoyl-N-acetylcysteamine thioester (propyl diketide), 5mM propionate, 50mM succinate, and 50mM

glutamate. Induced cultures were incubated at 22°C for the time indicated. At each sampling, culture supernatants were extracted with ethyl acetate and 15-Me-6dEB titer was quantitated by LC/MS (Ref). Cells were harvested, lysed with BPERII reagent (Pierce), and soluble protein was quantitated (Coomassie Plus; Pierce) and analyzed by SDS-PAGE. Gels were stained with Sypro Red (Molecular Probes) and quantitatively imaged with a Typhoon imager (Molecular Devices).

EXAMPLE 7

SYNTHETIC DEBS GENE EXPRESSION IN *E. COLI*

[0358] The complete 30,852 bp of the DEBS PKS gene cluster (loading di-domain, 6 elongation modules, and thioesterase releasing domain) was successfully synthesized. Using the GeMS software developed in this laboratory, the component oligonucleotides for each module and TE were designed; in total, approximately 1600 ~40mer oligonucleotides were designed and prepared. The design utilized codons optimal for high *E. coli* expression and incorporated restriction sites to facilitate assembly and module interchange. Sixty-seven synthons ranging from 238 to 754 bp were prepared and cloned as described above. We observed >90 success rate in UDG cloning, and error rate of gene assembly was 3 in 1000. An average of 22% of clones sequenced were correct. Synthons were assembled into modules using the stitching sewing method, with approximately 75% of clones containing the desired vector. Module 001 (DEBSmodule2) was used for initial testing of gene synthesis and therefore the error rate (avg of ~6.5 errors/kb) was higher for these synthons.

[0359] Module 2 was prepared as described in Example 5. The multi-synthon components of the remaining modules were then stitched together and selected according to the strategy shown in Figure 16 and Figure 17.

[0360] In an example experimental set of 10 ligations with the DEBS gene, seven gave 7/8 or 8/8 correct ligants, one gave 6/8, and two gave 3/8 and 1/8 correct; the incorrect samples were all that of the donor vector, which must have survived uncut.

[0361] All DEBS subunit genes have been fully synthesized and assembled into complete ORFs. These genes are transformed into an *E. coli* host strain for activity and expression testing. Synthetic and natural DEBS components are co-expressed in various combinations to determine the effects of gene synthesis codon usage and amino acid substitutions on individual subunit

activities (Figure 4-2). Synthetic DEBS1 has been successfully expressed in active form in *E. coli*. Total DEBS1 expression is >3-fold higher for the synthetic codon-optimized subunit than the natural sequence subunit. Synthetic DEBS1 co-expressed with natural DEBS 2 & 3 subunits supports similar levels of 6-dEB product as the natural DEBS1 construct.

[0362] The sequence of the three DEBS open reading frames of the synthetic genes are shown below in Table 14B. (Each of the sequences includes a 3' Eco R1 site which was included to facilitate addition of tags.) Table 14A shows the overall sequence similarity for the synthetic sequence and the reported sequences of DEBS2 and 3, and a corrected sequence for DEBS1.

TABLE 14A
COMPARISON OF SYNTHETIC AND NATURALLY OCCURRING SEQUENCES

	NATURALLY OCCURRING GENE SEQUENCE ¹		#bp	#aa	SYNTHETIC GENE SEQUENCE		
	Naturally Occurring DNA Sequence (accession #)	Naturally Occurring Polypeptide Sequence (accession #)			# aa changes compared to nat. seq.	% identity vs nat. seq.	% identity vs nat. seq.
DEBS1	Corrected M83676 ²	Corrected AAA26493 ¹	10632	3544	9	99.75%	76%
DEBS2	M63677	AAA26494	10701	3567	9	99.75%	76%
DEBS3	M83677	AAA26495	9510	3170	5	99.84%	76%

1. As reported in GenBank accession nos., except as noted
2. DEBS1 was resequenced and the following changes relative to M63676 were used in the design of the synthetic DEBS1 gene: An early frameshift has the effect of replacing the initial 18 aa of AAA26493 with an alternate 71-aa N-terminal sequence; there are changes in an approximately 100-bp region include complementing frameshifts, which have the effect of replacing 32 aa in the reported sequence with a different 33 aa segment.

TABLE 14B
SEQUENCE OF SYNTHETIC DEBS1-3 (SEQ ID NO: 3)

DEBS1
ATGGCAGATCTGAGCAAACTCTCGATTCTCGCACCGCCAGCCGGGCGCATCGTCCGCCCCATGGCCGC
TGTCGGCTGCAATGAATTCGCAATTGCGTCTCGCGCCCGGCAGCTTCGGGCACACCTGGACCGTTTCC
GGACGCGGGCGTGGAGGGCGTGGGTGCGGCATTGGCCACGACGACGAGCGCGGACGACAGGTCCGCATCGT

GCGGTGGTGTGCTTCATCGAAGCTCAGAACTACTGGATGGTCTGGCCGCGGTGGCCGATGGTCGCCCGC
ATGCGAGCGCTCGTACGCGGGGTTCGCGCTCCTTCTGCCCGGTAGTGTGTTGTTTCTCGGCGAGGGGGC
ACAGTGGGCGAGGTATGGCGGGCGAGCTGCTTGGCGAGTCCGCGGTGTTTCGCTGCGCCCATGGACGCTGT
GCTCGCGCTTCGAACCTGTGACAGACTGGACGCTTGCACAGGTCTGGATGATCCCTGAACAAAGCCGCGC
GCGTTGAAGTGGTCCAGCCAGCGCTTATTGCGCGTGCACAACTTCGCTAGCGCGCTCTGGCGTTCCCTTGG
CGTGACCCAGATGCTGTGGTTCGCCATTCAATTGGTGAATTAGCAGCGCGCATGTTTTCGCGGTGCCGCA
GGTCCGCGGATGCAGCGCGCGCGACGCGCATCTGGAGTTCGCGAGATGATTTCGCTGGTGGGCAACGGCG
ACATGGCCGCTGTGCTCTGTGCGGAGATGAAATTGAACACAGTATCGCGCGCTGGGACGATGACGCTGT
GCTGGCGGGCGTCAACGTTCCGCGGTCCGCTCTGTGTGACAGGGTCACTGAACCCGTAGCTCGTGTGTG
CAGGAAGTGAAGCGCGAGGGCGTACGCGCCAGGTAACTCAATGTTAGCATGGCTGCGCATAGCGCTCAGG
TTGATGACATCGCTGAGGGTATGCGTAGTGCCCTGGCGTGGTTTTCGCCAGGCGGCTCCGAAGTTCGCTT
TAGCCCTCACTGACCGCGGTGCGGTGTGATACCGGTGAGTTAGTAGCCGATTACTGGCGTGGTTCTTTT
CGGCTACCGGTAGCTTGTGTAAGCGATCCGAGTGCCTTGGAAAGTAGGCGCGGTAGCTTGTGCGAAG
CGAGCCGCGATCTGTGTTGGCGGGCGGCTGCAACAGACCTGGATGCGGAAGGTTCAAGCGCGGTGT
TGTACCTACACTGCAGCGTGGTCAAGGGGCGATGCGTGCCTTCCTGTTGGCCGCGGCGAGGCTTCACT
GGCGCGTTCGCGGTGAGTTCAGGCGCGCTTACGATGATGTTGGTTCGGAACAGGTTTCGCTGCTGAGT
TCGCTCCGCGCGAAGAGAGGACAGCGCGCGAGTCCGGGTTGATTGGAAACGACCGCGACAGTGTCT
CCGCGAAGCGGTGCTGGCTGTGGTGAACGGGGAGACCGAGCTCTTGAGCGCGCGGATGCTGTCGAGAG
GCGACCTTTCGCGAATTAGGTCCTGATTCTGTGTTAGCAGCCAGCTCGCGCGGAAGTCAAGCGCGGCA
TTGGCCGTGAAGTGAATTCATGCGCTGTTATATGACCACTCAACCCCGCGTGCATCTGCGAGGCACTGCTC
TAGTGGGACCGAAGTACGACGAGAGACTGCGCGCCGTAACAGCGAAGCTGCACCTGGCGAACAATT
CGGTTAGTAGCGATGCACTGTGCTTACCGGGCGGTGTATCGACCCCTGAAGAATTCTGGGAGTGTGTT
CAGAAGCGCGGATGCGGTGCGGGGCTTCGACTGACAGAGGGTGGACCTGGATAGCTGCTTCCACCC
GGATCAACTCGTTCCGCGCACCGCCATCAGCGGGCGGTGGGTTCCTGACCGAGGCGAGCGCTTGTAT
CCGGCTTCTTGGTATGAGCCCGCGCGAGGCGTTAGCCGTGGATCCTCAGCAGCGCTGATGCTGCGAAC
TTTCTTGGGAAGTCTTAGAACGTCGCGCATCCCGCGACTTCCCTACAGGCAAGTCCGACGGGTGTTTT
CGTCCGGCTGATTCCGCGAGGATCAGGCCCACTGCTGGCGGAAGCGCGGAAGGGGTGGAAGGCTACCTG
ATGACGGGCACGACTACATCGAGTAGCGTCCGCTCGTATCGCGTACACTTAGGTTTGGAGGGCCGACTA
TCAGTGTGATACGCGCTGTCTTCCTGCTACCTGCTAGCCGTACATCTCGCGTGCAGAGCGTTCGCGCGTGG
CGAAGCTCTCTCGCCATGGCGGGCGGTGTTACGCTGATGCCGACACCGGGGATGCTGTTGATTTCG
CGCATGAACAGCTTGGCGCCAGATGTTGCTGCTGCAAGCGTTCCTGCTGGTGGGGAACGGTTTCGCGATGG
CTGAAGGCGCGGGCATGCTGCTGCTGGAACGCTTATCTGACGCCGCTCGTAATGGGCAACCAAGTGTGCG
AGTGTGCTGCTGGCACCGCTGTGAATAGCGATGGCGCTAGCAACGGGCTGCTCGCTCCAAATGGTCCGGCC
CAAGTCCGTGTGATCCAGCAGCGCTTAGCGGAATCAGGTTTGGGTTCGCGGACATGATGTCGTTGAAG
CGCATGGGATGGAACCCGCTTGGGTGATCCGATTGAGGCCCGTGCAGCTTTGAAGCTTACGCGCGCGA
CCGTGAGCAGCCACTGCTATCTGGCAGTGTCAAAAGTAACCTTAGGCAACACCGAGGAGCGCTGGCGTA
CGAGGAGTAATCAAAATGTTGCTTGCAGTGCAGCGCGGGCACCTTACCGCGCACTTCCATGCAAGCGAGC
GTAGCAAGAACTCGACTGAGCAGCGCGGTGCTATTTCGCTGTGACGAACTGAGCTGCGAGCGCGCTGG
TGCCCGCGCGCGCTGCCGGGTGAGCAGCTTTGGCATCAGCGGTACCAATGCCATGCAATTATCGAG
GAAGCCCCACAGGTTGTAGAAGGGGAACGCTGTTGAGGCTGGCGATGATGTTGACCGGTGGTATTCAG
CCTCTCAGCGGAAGTCTTCGCGCACAGGCGCGCGTTCGCGAGCGCACTGCGCGGAACACCTGGGCA
GGAACCAAGTACATCGCGTACAGCTGGCTACAGGCGCGCGCGCTGCCACACCGTGGCGCTTTTGG
CGGTTGGACCTCCGAGCGCTGCGCTTCGATGGCTGGCAGCGCTGGCAGCGAGCGAGCGAGCGCGCTGG
TGGGTACAAGCCGGGCTCAACAGCGTGTCTCTTCGTGTTCCCTGCGCAGGCTGGCAGTGGCGGGCAT
GGCGCTCGACCTCTGAGACCAAGTCCGCTGTTCCGAGCGCGCTCCGTGAGTGTGACAGTCCCTGGAA
CCACTCTGGATTGTAAGTCAATTCCGTTTTCAGTCCGAGGCGCGCGCGCGAGCAGGACGCGGCT
TGATGATCGGAAGTGTGGATGTGTGCAACCTGTGATGTTTGCAGTATGGTTCTCTGCGATCCATGTG
GCGCGCGCAAGCGCTGCAACCGCGAGCGGTGATGGGCAAGCGAAGTGGCAATGCTGCGCATCGGTT
GCAGGGGCACTGTCTCTGATGATGCGCGCGCGTGTGCGCCTGAGATCTCGCGTGTGCTATCTATGC
CAGGCAACAAAGGATGGCTCAATCGCGCACAGCGCGGGGAAGTGGTGCACGATTTGGCGATCGTGT

GGAGATTGCGCGCTGTTAATGGCCACGCTCGGTGGTAGTGGCCGGTGACAGCGATGAATTAGATCGTCTC
GTCGCATCTTGTACTACCGAATGTATTGCGCGGAAACGCTCTGCGCGTAGATTATGCGAGCCATTTCATCTC
ACGTAGAAACGATTCGCTGAGCGCGCTGCATGCCGAATTAGGTGAAGATTTCATCCATCGCTCGGCTTTGT
CCCTTTTTTTTCGACCGTGACCGGCCGTTGGACCCAAACGAGAACCTGGACGCTGGTTATTGGTATCGT
AATCTCCGTCGCGCGGTGCGCTTTGCAGATGCGATACGGGCCCTGGCAGAAACAGGGCTATCGCACGTTTC
TGGAGGTGAGTGGCATCCAATCTGACAGCGCGATTAGGAGATTGGTGATGGCAGTGGCGCGACCT
GTCCGCAATCCATAGCCTGCGTCGCGGCGACGCGAGCCTGGCGGATTGGTGAAGCTCTGATGCTGTGCA
TTCGCGCTGGCGTGGCATGCGATTGGGAGTCTGTACACCTGGGCATGGTGGCGCGCGCTACCGCTGC
CGACCTATCGCTTTCAGCGCGAACGCGCTGTGGCTGCAGCGGAAACCTGTGGCTCGCCGCTATCCGAGGT
TGATGAAGTCTCTGCGCTGCGCTACCGTATCGAGTGGCTCCAACCTGGCGCGGTGACCGCGACGCTTGT
GATGTTAGCTGGCTTGTAGCTAAATATGCGGCGACAGCGATGAACGAGCACTGCGGCGACGCGAAGCGC
TGGAATCCGCTGGGCGCCGTGTGCGCGAATCTGTGTCGATGCCCGCTGTGGCGCGGATGAATTAGCAGAG
ACGCTCGCGTTCGCTCGCGCGAAGTCGCGCGGTGTTCTGAGCTTACTCGCCCTCGATGGCGCGACGAGAG
GAAGCGCGCTGGCACTGGCAAGCTTAGCAGATAAGCTGAGCTGGTTTCGATATGGTATCCGCGGAAC
TGGGTGCGCGCTGTGGACAGTGACCGAATCAGCAGTGGCTACGGGCCGCTTCGAACTGTTTCGTAATGC
CGCACCGGTGCGCTGTGGGGGTAGGTGCTGTTATCGCGCTTGAGAACCCGCGCGTCTGGGCGCGTCTC
GTTCGACGTACTTCGCGTAGCGTGGCGGAGCTTGGCGGCCACTTAGCCGCGCGTGGTTTCGGGGCGCGAG
GCGAAGATCAACTGCGCTGCTGCTGCTGATGGGTTTACGCTCGTGGTGGCGCGCGACGAGCGAGCG
AACGAGTGATGAATGGAAACCGACGGGGACCGTCTGTTGACCGGTGGCATGGTGGTGTAGGCGGCGAA
ATCGCCGCTGTGGACAGTGGCGGTGCTCTCACTTCTCTGTTAGCGCTAGCGGCCGCGATGCTG
ATGCTGCGCGCAACTGGTTCGAGAACTTGAAGCCCTGGGGCGCGTACCAGCGTTTGGCGATGTGACGT
GACGGACCGGAGTCTGTGCGCGAGCTGTTGGCGGTATGGCGATGACGTACCGTTATCAGCGCTCTC
GCGACCGCGCAACTTGGATGACGGCACCGTCGATCTCTGACAGGTGAACGCGATTGAACCGCGAAGCC
GCGCCAAAGTGTTAGGGCGCGCAATCTGCATGAGCTGACAGTGAAGTCTGACCGCGTCTGCTGCT
GTTTTCAGTTTTCGCTGCGCTTGGTGCAACGCGCTCTCGCGGTATGCGCGAGGCAACGCTTACCTG
GATGGTTTGGCCGACGAGCTAGATCTGATGGTCTGCTGCTACCGCGTGGCATGGGGAGCGTGGCGG
GCTCAGGTATGGCCGAAGGGGCGGTAGCCGATCGCTTTCGCGGTCAAGCTGTTATGAATAAGCGCGCTGA
AACCGCTGTGCTGCTTACAGAATGCTCTGGAATCGCGCAGAAGTCTGCGCGATGGTATCGATGTTCTG
TGGGACCGCTTTTATTAGCTACACCGCGCAGCGTCCAACACGCTGTTTGTATGAATTTGACGATGCC
GCCGGCGGCCCGCAGCGCCCTGTCTGAGCAACGCTAGGTGCGCTGCCCTCCCTCCCGCTCCAGAGCG
GGAAGAAGCGCTGTTCAAACTGGTGCCTCACATGCGCGCGCAGTCTGGGCGCGCTGCGAGGACCG
GTCCTGCTGACCAAGCTTTCGCGAGTGGGTGTGGATTCTCTTTCAGCGCTGGAATTCGCTAACCGCT
TAGGCGCGCGCAGCGGTGTGCGTCTTCAACCAACGACAGTGTTCGATCAGCCAGATGTTTCGTACGTTGGC
CGCCCATCTCGCGCGGATATTGTCTAGTGCAACCGCGCGGAAACAGCGGCACCTCGACGAGTCTGCGCG
GTCTGATGAACCAATTGCTTCTCGGTATGGCTTGTGCGCTGCGCGGTGAGGTGGACTCACCAGAACGCT
TTTGGGAATTAATTACCTCTGGCGCGGACTCTGCGCGGAGGTTCCAGACGATCGCGGTGGGTGCTGTA
TGAGCTGATGGCTAGTGACGCTGCGGGGACCGGTGCACATGGGAACCTTCATGGCAGGTGCGCGTGACTCT
GATCGGCTTTTTCGCGCAATGACCCGCGTGAAGCACTGGCGATGGATCCGACAGCGCGCGCGCTGG
AAACGACCTGGGAAGCGTTGGAAGTGCAGGCATTCTTCGCGAAACCTTAAGGGGTAGTGACAGCGGTGT
TTTGTGGGTATGCTCTACACGGGCTACGCAACGGGCGTCCACGCTCGGAAGACGCGGTGACGCGTTAT
CTTTTAAACCGGCAACCGCAAGTGTGCGAGTGGGCGTATGCGCTATGCTTGGGTTGGAGGCGCCCG
CACTTACTGTGCGACACCGCATGTTCCAGCAGTCTGCTGGCTTGCACACCGCGTGTGGAGATTACGGGA
CGGTGATTGCGCACTGGCTGTGTGCGGTGGCGTCTCAGTAATGGCGCGGCCGGAAGTATTTACGAGTTCT
TCGCGTCAAGGTGCGCTGTCCCGGATGGCGCGTGAACCGTCTTTCGATGAAGCTGATGGCTTCGGG
TGGCGAAGGTAGCGCGTTCGTTTTTTACACGCTCTGTCGATGCGCGCGCTGAAGGTGCGCGCTGTTT
AGGTGTGCTCGCAGTTCGCGCGTGAACAGGATGGCTAGCAACGCTTCTGCGCTCTTTCGCTGTGA
GCTCAGCAGCGGTGATCCGTGCGCGCTGGCTCTGTCGGGTATACGGGAGCCGATGATGCGGTGTTGG
AAGCGACCGAAGCTGTAAGTCTGCGCGATCAGTTGAGGCGCGGCCGCTGCTGGCTACTTACGGCA
ATCAGCGCGCAGCTGTTCCGCTGCTGCTGGGCTGCTCAATCCAATATTGCTCATGCCCAAGCGCGC
GCTGGCGTGGCGGCGTATCAAAGTCTGCTTGTCTTGAACGGGGCGTGGTTCCGCTTATGCTGTGCC

T

DEBS2 (SEQ ID NO: 4)

ATGACAGACAGTGAAGAAAGTTGCTGAGTATCTGCGCCGCGCCACCTGGATCTTCGTGCGGCACGCCAGC
GCATCCCTGAACTGGAAAGTGATCCAATTGCTATTGTGAGCATGGCGTGTGCGCTGCCAGGGGGTGTAA
TACGCCACAGCGCTTGTGGGAGTTACTGCGTGAGGGTGGCGAAACTCTGTGCGGCTTTCTTACTGACCGGT
GGCTGGGACCTGGCAGCTCTGCACACACCGGATCCAGACAATCCGGGAGCGTCACTAGTGAGATAAAGGCG
GTTTCTTGGACGACGCCGAGGCTTCGACGCCGAGTTTCTTTGGTGTGAGCCCGCGTGAGGCTGCGGCGAT
GGATCTCTAGCAACCGCTTGTACTTGGAAACCTCTTGGGAACCTGGTGAAAGACGCAAGGTATCGACCCGCAC
AGCTTAAGAGCATACGCGACGCGGTGCTTCTCGGTGTGCTAAATTTGGCTATGGTGAAGATACCGCGC
CTGCGGAGGACGTAGAAGGGTACTCGGTGACCGGGTGGCGCCCGCGGTGGCGTCCGCGCGATTTCTCTA
CACTATGGCGCTGGAGGGCGCGTCGATTAGCGTCGATACCGCTTGCTCTCTCCTCATTAGTTGCGGTACAC
CTTGCCGTTGAGTCTCTGCGTAAAGGGGAGAGCAGCATGGCGGTGTGTCGGTGGCGCGCGCTCATGGCAA
CACCTGGCGTTTTCGTCGATTCTCTCGCCAACCGTGCACTCGCAGCGGATGGTTCGGAGCAAAGCCTTTGG
CGCGGGCGCCGATGGTTTCGGCTTTAGCGGAAGGTGTAACTTGGTTCTGCTGGAGCGCTCTGTCCGAAGCG
CGGCGCAACGGCCATGAAGTGCTGGCTGTCTGTCGTGGGAGCGCACTGAACCAAGATGGCGCTAGCAATG
GCTTAGCGCTCTCTTCCGGGCGACACAGCGCCGTGTAAATTCGCCAAGCGCTGGAAGAGCTGGCGTCTCGA
ACCAGGCGATGTGGACGCGGTAGAAGCACACGGCAGCGGCGACGGCTCTGGGTGATCCGATTGAGGCAAC
GCTTTGCTGGATACCTATGGCGGTGATCGTGTGAGACCGGCCACTTTGGCTGGGCTCTGTTAAATCAA
ACATCGGCCATACCCAGCGCGCGCAGGCGTGACTGGCTTACTGAAAGTGGTTCTGGCGTTAGCACAACGG
CGAGCTGCCCGGACCTGTCATGTTGAAGAACCGACCTCACGTGGATTGAGATTTCGGGCGGGCTCGCG
CTTCTGGCGGGAACGACCATGCTGCGCCGTGCGCAACGACGCGCGCGCGCTGTTTTCGCCATTTGCGA
TTTCTGGTACCAACGCACTGATTGTGGAAGAAGCACCGGAGCGTGAACCTCGTGAAACCCCGCTCA
CGACGCGACACCTGTCCGCTGGTTGTGACGCGCCGCACTACAGCGGCTCTTCGCGCACAGGCGCGCTCAG
ATCGCTGAGCTGTAGAGCGTTCGGACGCGGATTTAGCGGGGTGGGCTTGGGTTTGGCGACCAACGCG
CCCGGCACGAGCATCGCGCCGCGTGGTGGCTTCCACCCGGGAAGAGCGGTGCGTGGGCTGCGCGAAAT
TGTGCTGGGCGCGACTGCGGATGCACTGGTTCAGGGGGTTACTGAAGTAGACGCTCGCAATGTAGTC
TTTTTATTCCTTGGCCAGGGCTCCAGTGGCGGGTATGGGCGCGGAATTGCTGTCCAGTTCAACCGTCT
TCGAGGTAAATTCGCGCTGTGACGAAAGCATGGCGCCAATGCAGGATTGGAAGTTTCAGATGTGCT
GCGTCAGGCTCCAGGGGCGCGAGGTCTGGATCGTGTGATGTTGTACAACAGTTCTGTTTGGCGTAAATG
GTTAGCTTAGCGAGCTCTGGCGCAGCTATGGCGTGAACCGGCGCGGTGCTGGGTCATTTCGAGGGCG
AGATTGCGGCAGCATGTGCTGGGCTCTCACCTCGAAGATGCTGCCAAATTAGTAGTGGTAGATC
TCGTTTGATGCGCTCTTATCTGGGAAGGGGGATGGCTGCCGTGGCATTAGGCGAGGCGAGCATTTGCG
GAGCGTCTGCGTCCGTGGCAGGATCGCCTTCTGTTGCGCGCAATGAATGGCCCGCGTAGCGCTTGTGTAT
CAGGCGAGCGAGTGCTCTGCGCGTTCGAGAAAGATTGCGCGCGCGAGGGATTTCGCGTGGTGACAT
CGATGTAGATTATGCAAGCCATTCTCCGAGATCGAAGCGGTCGCGAAGAGCTGCTGGAGACAGCGCGC
GATATTGCTCCGCGTCCGCGCGGTGTGACCTTCCACAGTACCGTTGAATCGCTTCGATGATGGCACCG
AACTTATGTCGCGTATTGGTATGCAATTTCGGGAACACGGTCCGCTTTCGGGATGCGGTCACAGTCT
GGCAGAAATCTGGTTATGATGCTTCTATTGAGTTAGTCTCTCATCCGTTGGTGGTTTCAGGCAATGGAGAG
GCGTGTGAGGAAGCTGACGCGCTGAAGACGCGGTGGTTGTGCGTAGTCTTACCGCGACGTCGCGAGCC
TGAGCGGTTCCTTGTGTCGATGGCAACGGCACAGTAAAGCGGTGGGACATCCGTGGGATGTAGCGCT
TCCGGGGCTGCCCCATTGCTTTACTACGTACCTTTTCAACGCAACCGTACTGGCTGCAGCCAGCG
GCACCTGCTGCGCGAGGATGAACCTGGGTACCGCTTCTAGGACACCTATTGAAGAACACGAGAGCG
GTAATCTGGAATGCTGATTGGTTGGTTGTGACCCCGCTGATCTACCGGAATGGACTGAGATGCTGTGTA
AGCAATCAACGCTACAGTGTGCGCGCGCCCTGCGTTGCGAAGTCGACACAAGCGCATCTCGACCGGATG
GCTCAAGCGGTTCGCGAGGCTGGCACGGGTTTTCGCGCGTGTCTGAGCCTTTTATCCTCCGATGAAGTG
CCTGTGCGCCGGGCGTCCCTGCCGTCGCTGGGTTGCTGACGCTTGTCCAGGCCCTAGGCGACGCGAG
TGTAGACGCGCGGTGGTGGCTGACTCAAGTTCGCGTACCGACCCCGGACGAGCATGATTAGACGCT
CCGCGCAGACCAACGCCCATTGGTTTGTCCAAAGTGGCGGGCCTGGAAATTGCCAGCGCGTGGGGGGTG
TAGTTGATCTGCCAGAGTCTGTAGATGACGAGCACTGCGTCTTCTGGTGGACATCTTGGCGGGTGGCGG

TCGTGCGGAGGAGTCATCTGGCCCGTCCGTGATGGTCGTCTCCATGGTCGCCGCGTAGTGAGAGCTAGTCTC
CCAACAATCCGGGTAGTGCAGCACTGGACCCCTCAACGGCACAGTGTGGTTATACCGGTGCGCAAGCCCGGTGCG
GCGATCAACTGGTCCGTTGGCTGGCCGACCGTGGCGCTGAACGCTCTGGTTCTGGCAGGCGCATGCCCGGG
GGATGATCTGCTTGCGCCCGTTGAAGAAGCTGGCGCGTCAGCGGTCTGCTGTGTCGCAAGACGCCGCGCG
CTGCGTGAAGCTTTAGGCGACGAACCCGTGACTGCTTTAGTGCAAGCTGGCACTCTGACGAACCTTTGGCT
CTATTTTCGAGGTGACTCCGGAAGAAATTCAGAAACCATCGCGGCGAAACATGCGCTCTGGCCGCTCT
GGATGAGGTTCTGGGTGATCGCGCGTGAACCGCAAGTATATTGCTGCTGTGGCCGCTATTGGGGC
GGTGCGGGGATGGCACTTATGAGCGGGTTTGGCATAATTTGGACGCGTCTGGCTGAACCACTATGGGCAC
GCGGTCTGTTATGCACTCTCGTTGCTTGACGCCATGGGCGTTCGCCGGCGGTGCGCTTGATGATGGCTA
CTTAAGAGAACCGGTTTGGCTTGGCTTACTGTGCGCTGACGCGCGATGCGTACTGGGAACGTTTCTGCGCA
GCAGGCCCGGTGCTCGCTGCGCGTCGCCGACGTAGATTGGCCGTTGCTGTGAGAAGGTTTCGCGCGACCC
GTCTTACTGCTCTTTCGAGAACTGGCGGGCCGCCGGGTGAGGCAGAACCGCAACCGGACAGTGGTCC
GACCGTCAGCCCTGTCAGCGCTTGGCTGGGTTGTGCGCGACGAACAGCAGCAAAACCTCTGCGGAATTA
GTTGCCAATGCGGTTTGGCGAAGTTTtagGCCATGAGTCCGCGCGGAGATCAACGTGCGCCGGGCATTTA
GCGAGCTGGTTTtagGCTTTAAATGCAATGGCGCTCGCAACCGCTCAGCGCGACGACCGGCTGCG
CTTACGCGGCTGCTCTGTTTCGATCATCCGACTGTCACGGCTTAGCCCAACACTCTCGCGCTCTGCTCT
TCTATGTGACCGGCTCAGCGCGGTTCGCGTTTGGGGCGCAGCGGATGAAAGCGAGCCAATTGCCATTG
TCGGCATCGGCTGCTTTCCGGGTGGCATCGGCTCTCTGAACAGCTGTGGCGGCTTCTTGCGAAGG
GGCAATCTGAGCAGCCGGCTTCCGCGCAGATCGCGGCTGGGACATCGGCCGCTGTACCATCTCAGAACCG
GATTAATCCGGCGAGCTGCTTATGTGCGACAAGGTGGCTTCTCACCGACGACGCGGATTTGATCCGGGTT
TTTTGGTATTACACCGCGGAGCTTTGGCAATGGACCCGACGAGCGCTTAATGCTTGAAACAGCATG
GGAGGCACTGCAAGCTGCGGGCATTGACCCGGATGCCTTAAGAGGCACCGGACACAGGCGTTTTCGTAGGC
ATGAACCGGTCAAGGTTACATGCTACTGGCAGGTGAAGCGGAGCGGTAGATGGTTACCAAGGCTTAG
GCAACAGCGATCTGTTTtagAGTGGTGGTATCGCTTATACGTTTGGTAGGGAAGCCGGCGCTGACTGT
TGATACGCGCTTTCGCTTCTGTTGGTTGGTATTCTATGCGCAATGCAAGCTCCGCTCGCTGGGAATGC
TCTCTCGCCCTGGCTGGTGGTGTACCGTCATGTGAGCCGTTATACCTTCGTGCACTTCTCGACCCAGC
GTGGTCTGGCTAGTGATGGTTCGTGTAAGCGTTTCTCAGCGCGGGCTGATGGTTTCGCGCTTTCGGAAG
CGTGGCCGCTCGTGTGGAACCGCTTAGCCGTCGCGTGCACCGGGCACCAAGTCTGGCGGTGCT
CGTGGTTCTGCGCTTAACAGGATGGGGCTAGCAATGGCTGGCCGCCCAACCGGTCATCGCAGGAAC
GTGTATCCGTCAGCGCTCGCCGACGCGGGTGCCTGTGCTGACGTGGATGTGTTGGAAGCGCACGG
CACTGTGACAGAATTTGGCGGACCAATCGAGGCGGGTGTCTGATCGCAACGTAGCGGCGAGGATCTGTAC
CGCCCGCTGCGTTTGGGAGCGTGAAACCAACATTTGTTATACCAAGCAGCAGCGGGGGCCGAGGG
TAATTAAGTAGTGTCTGGCGATGCGTCATGGTATGCTGCCGCGTAGCTGCAAGCTGACCAACTGTCTCC
TCATATCGATTGGGAGTCAGCGCTGTGGAGTCTCTGCGTGAAGAAGTACCGTGGCCCGCAGGCGAACCG
CGCGCCGCGCGGGTGTTCCTCTTCGGCGTTTCAGGTACCAACCGCACGTTATTGTGGAAGCGCACGG
CGGCCGAACAGGAAGCGGCTCGTACGGAACGCGGCCGCTGCCGTTCTGTCTGGCGCTCCGAAGC
TTGTGGTAGCCGCGCAGGCCCGCGCACTTGTCTGAGCACTTACGCGACACCCGAGCTGGGGCTGACCGAT
GCTGCGTGGACTCTGGCGACCGCGCGCTGCACGTTTCGACGTGCGCGCGCGGATTTGGGCGATGATCGCG
CTGGTGATATGCGCGGAACCTGATGCTTATGCGGAAGTCGCGCGCTCTGCGGATGCGGTGGCAGCAGTAC
CTCCGCGGCTGACCAACCGACGTCTGCTGTTTCCCTGGCAGGGGCCAGTGGGTGGTATGGCCCGGAC
TTACTGGAAGTTCTGAGTCTTTGCGGAGTCGATGAGCCGCTGCGCGGAAGCGCTGTGCGCTCACACTG
ATTGGAACCTTCTGAGTGTGCGTGGTGTAGTGGTCCAGATCCGCGACGAGCGGTGAGACGCTTACAC
CCCGGCTGCTTTTCCATTATGGTCTCTCTCGCGGAACCTGGCGGTGCCACGCGTGACTCCGCGCGCT
GTTGTAGGTCACCTCTCAGGCGGAAATTCGAGCGCACAGTGGCGGGTGGCTTAAGCTTTGGAAGCCGCGAG
CTAAAGTGGTGGCTTCTGAGTCTCTCAAGTACTGCTGAGCTTGATGATCAGGCGGGATGGTTTCTAGTAGG
GGCATCTCGGGATGAACCTGGAACCGTGTCTGCGACGCTGGGACGCGCGCTAGCAGTGGCCGCTGTGAAT
GGTTCAGGAGACCTCAGTTGTGCGAGGCCCTACTGCGCAATTTGATGAGTTCTTTGCGGAAGCCGAAGCCC
TGAAATGAAACCAACCGGATGCGAGTTCGTTATGCGAGCCATTCGCGAAGTGCACGATTTGAAGA
TCGTCTGGCAGCCGAACCTCGGTACAATTACCGCGCTTCGCGGCGAGCTACCTCTGCGATAGCAGGTTGCC
GGCGAAGTAATTGATACGACGCGGATGGACGCGCTTTATTGGTATCGTAACCTTGCGCCGCTCCGCTTTTGT

TTGAACAAGCCGTCGCTGGTCTCGTCGAACAGGGGTTTGACACATTTGTCGAGGTTTCCCCACATCCGGT
TCTGCTGATGGCAGTGGAGGAGACAGCAGAAATCGCAGGGGCGGAAGTCACCTGTGTTCTACGCTTCGT
CGCGAGCAGTCCGGCCCGCATGAGTTTCTGCGGAACCTGCTGCGGCCCATGTCCACGGGCTTGGCGCCG
ATCTCGCTCCGCGTGTGTCGCGGCCGTCGCGTGAATTACCAACTTACCCGTTTCGAACATCAACGTTT
TTGGCTGCAGCCGACCGCCAGCAGATGTTAGCGCCTTAGGCGTACCGCGGGGAGAGCAACCTCTGCTC
CTGGGACCGCGTTCAGCTTCGGGTCAACGTCGTCGCTTTTACCGGGCGTCTGTCTACGAGCAGAGCAGC
CGTGGCTGGTCCGAACATGTCGCGGGCGTCTGTAACCTGGTGCCGGTTCCGTGCTGGTGGAACCTGGCGCT
GGCGGCCGCTGAAGATGTAGGGCTGCGCGTATTGGAAGAATTGGTTTACAACGCCCACTGGTACTGGCA
GGTGCGGGCGCTCTCTTCGCTATGTCGCTGGCGCTCCGATGAATCAGGCCGCGCTACTATTGATGTCC
ACCGCGCAGAGATGTAGCGGCACCTCGCGGACGCCAGTCGAGCATCGCAGCATCGCATGCTATTGGCGCA
AGGCGTCGCGCTGGCCCTCGGGATACCGAACAGTGGCGCCCTGAAGATGCGGTTCGCATCCCGCTTGAT
GACCATTTATGACGGCTTGGCAGAACAGGGCTACGAGTATGGTCCGTCTTTCAGGCGCTTACGTGCGGCCCT
GGCGCAAGATGACTCTGTCTACGCGAAGTTTCAATCGCGCGGACGAGAGGGGCTACGCGTTTACCC
GGTGCTGCTGACGCGGTAGCTCAAACGCTGAGCTTAGGGGCACTCGGTGAACCGGGTGGCGGAACTT
CCATTTGATGGAATACGGTGACCCTTCAACGAGTGGCGCACTTCGCTTCGTGTAGTGGCGACCCAG
CTGGTGGCATGACTACGGCCCTGCTGTGAGCGGATCCGCGAGTCATTAGTGCTACCGTTGATTTCTCT
TGTGTCCTGCTCACTGGTGAAGATGGGAACAACCGGAACCGCGCGGGCGAGTGGGAGCTTCATGCA
CTGGACTGGGGCCGCTTGGCGGAACAGGCTCTACTGGTGGTGTGATGACAGCTGACGCCAGCGATTAG
ACGCGCTCTTAAGTCTGTGTAACCGGAGCGAGATGCCGTTTATGTTGTTACGAGCCGGAGGGGTGATGA
TCTCTCGGCTCGCGCACCGCACGGTGTGCTGTGGGCTGCGCGCTGGTTTCGCCCTGGCTGGAAACAGGAG
GAACTCGCGGCCCGCACGCTGGTGATCGCAACGTCAGGGGCGTCACTGTGAGTGATGAGCATTTCTGTT
CGAGGCGCGGCCCGCGCTGAGTGGGGCTCATTCGCTGCGCGAAGCGGAATCCCGCGGATCTGTTCTGT
ATTGTTAGATACTGATGCCAGGCTGGTATGCTGCCGTGCGGTGCCAGACAATCCGCAACTTGGCGTTCGG
GGTGACGACGTGTTTGTGCTCTGCTGAGCCGCTCGCGCCGAGTGCCCTGACGCTGCCAGCAGGACCC
AACGCCCTTGTCCCGGGCGATGGCGCTATTGATTTCTGTGGCAITCGAACTGCGCGGACCTGCGCGGACCTG
TCTGCGCGCGGCTGAGGTACGGGTGATGTGCTGCGACCGCGTAATTTTCTGTGATGTTTGTAGCC
CTGGCATGTATCTCGCAAAAGCGATATGGGTACGAAGCAGCGCGGTAGTGACTGCGGTAGGCCGACG
ATGTTGATGCCCTTCGCCCTTGGTATCGGGTGCTTGGCCTGTTCCAAGGCGCGTTCGCGCAATCGCTGT
TACAGACCATCGCTTGTATGACAGCTGTTCTGATGGTTGGTCGATGCCGACGCTCGCGCCGTCTCTATC
GCCATACAACGTGACATTATGCCCTGATGATCTGCGCGGCTTGC CGCGCGGTGAGAGTGCTCTTATTC
ACGCTGCGCTGGTGGTGTGCTGATGGCAGCTGTAGCTCTGGCAGCTCGGCTGCGCCGAGGTGCTTAGC
TACCCTGGCTCGGCTAAACACGGCACTCTGCTGCGCTCGGCTGATGATGAGCATTTGCGAGTTCT
AGGGAGACTGGTTTCGCCCGTAAATTTCTGTAACGCACAGGCGGGCGTGGGTTGACGTTGTGCTCAACT
CCTTGACTGGCGAATCCTGGATGAGTCAGCAGACCTCCTTGTGTAAGATGGCGTGTGTTGATAGATGGG
CAAAACCGATCTGCGTACGCGCGGGGACTTTCGTGGGCGCTACGCGCATTGTGATCTGGGGGAGGAGGAG
GATGATCTGTGGGTGAATTTCTCCGTGAAGTAGTGGGCTTACTTGGGCGAGGCGAATTTGATCGGCTGCG
CGTAAAGTGCTAGTAAATTTGGGGTCCGCGCTGCCGCTCCAGCACGCTCGCGGTGCTCACTAGG
TAACTTTGACTGACCAGCGCTGCGCGGTGACCCCTGACGCGCACTGTGTTAATCACCGGTGGTAGCGC
ACCTCGGGGCGTTTGTAGCACGCCATCTGGTGACGGAAATGGTGTGCGGCATCTGTGCTGCTGTAGTC
GTGCTGTGCTGAGCGCGCGGCTCGATGAACTGCGCGCAGAAATTTGAGGATTTGGGTGCGCAGGCGGA
AATTGCGGCGTGCGCACAGCGGATCGCGACGCCCTGAGTGCCCTGCTGGATGTTTGGCCCGGCGCTGTG
ACCGGGGTGTGTCAGCCAGCGGCTGTGCTGGCGATGGCTTGGTGACAAGCATCGTAACCGCGCGGTGG
AACCGGTTCTGCGGCTCAAAAGTCGATGCGCGGTGGAACCTTCACTGAATGACCCGAAATACCGGCTTGAG
CTTCTTTGCTGTTTCACTTCTGCGGCAAGCGTGTAGCAGGCCCTGGGCAAGGTGTGTGTCGCGCGCG
AATGAAGTCTGATGATGCAITGAGCGCTCTGCTGCGCACCGCGGTTTGTCTGCGCAAGCGCTGGGTGGG
GCCTCTGGGCGCCAGCGCTCGGAATGACTAGCGGTCTGGGTGACCGCACTTGGCGGTACAGGTGTGCGCG
GTTGCCGACCGAAGCTGCTCTGCGCCTGTTTCGACAGCGCAATTGCGTTCGCGGGGTGAGGTGGTTTTCG
CTGTCAATCAACCGCTCAGCGCTGCGCGCGCTGAAATTTGATCAAGAGGTCTGCGGTGATGATGATGCTG
CAAACTCTCGGCTGTGCGGAGGCTGAAGCTGCGGGCCAAACGTAGTTGACCGCTTACCGCGCTGATG
CGAATCGATCAGGTGCGGGGCTCGCGAACTGGTGGGTGACCGATGACCGCGGTGATGGTTGATGCGG

AGCGCCGATCAGTTGCCGGAAAGCGAAAGCGTTTAAAGACTTGGGCTTCGATAGCCTGGCGCGCTCGAGC
TCCGCAACCGCCTTGGGACAGGCCAGGCGTGC GGCTTCCAGGACGCTGGTGTGTTGATCATCCGACGCC
GTTGGCGGTAGCGGAGCATCTCGGGACCGGCTGTCTAGTGCCCTCGCGGCTGTTGACATCGGGGATCGG
CTGGATGAATTGGAAAGACATCTGGAAGCCCTGTGACGCGAGGATGGCCATGATGATGTGGGCGAGCGTC
TGGAGCGCTGCTTTCGCGCTGGAAACAGTCAGTCCGTCTGTCGGACGCGCGCTGCTCTGCGATTCTGAAGA
CGCTAGCGATGATGAATTATTTAGCATGCTCGACCAACGCTTTGGTGGTGGCGAGGACCTGGGGAATTCCG

DEBS3 (SEQ ID NO: 5)

ATGTCCTGGTGATAATGGCATGACGGAAGAAAAATTACGTCGCTACTTGAACGCGACCGTTACCGAGCTCG
ATTCGCTTACCGCCCGTTTGC GCGAAGTCGAACACCGCGCAGGTGAGCCAATTGCGATCGTAGGTATGGC
CTGTGCTTTCCGGCGGATGTGGACTCTCCAGAATCTTTTGGGAATTTGTTTTCGGCGGGGCGGATCGG
ATTGACGAGCGCCAGCGGATCGTGGCTGGGAGCCTGATCCAGATGCGCGCTTAGGCGGATGTTAGCTG
CGGCGGGCGAATTTTGATGCGAGTTTTCGCGCATTTCCGCGCGTGAAGCCCTTGCGATGGATCCACAACA
GCGGATTATGCTGGAATTTTCATGGGAAGCCCTGGAACGGGCGCGTCAGATCCGGTGTGCTGCGTGGC
TCCGCAACGCGGTATTCTACTGGGTTGGTACAGTCGATTATGGCCCTAGGCCATGAGCGCCCTGATG
AAGTCTCTTGGTTACGTTGGCAGGGCAGCGCATCATCGTGGCCAGTGGTGTGATAGCCTACTGCCTTGG
CCTTAGGGGCGCCCATGACCGTGGATACGGCATGCTCATCGGCCCTACCGCCCTGCATTTGGCTATG
GAATCCCTCGCGCGGACGAATGTGGTTAGCGCTGCGCGGCGGGGTTACGGTTATGAGCTCTCTTGGCG
CGTTACAGAAATTCGCTCGAGGGGGGTTTGGCCGCGGATGGTGTGTGTAACCGTTTCAGTAAAGCGGC
AGACGGCTTCGGGCTTCGAGAGGGGGCGGGTGTCTTGGTTACAGCGCTCTGTCAGCTGCTCGCGGTGAG
GGGCGCCCGTACTGGCCGTCTGCGCGGCGAGTGCCGTAATCAGGATGGTGTGATAGCAAGCGCTTAAACGG
CACCAAGCGGCCACGCCACAACAGTGAATTCGTGCTGCACTGGAGAACCGCGGCGTTGCGGGGGGA
TGTAGATTACGTAGAAGCGCACGCGACAGGCACTCGTTTAGGCGACCAATCGAAGTCCACGCTCTGCTG
TCGACGTATGGTGTGTAACGTGATCTGATGACCCGTTATGGATTGGTTTCGGTTAAATCCAAATCATCGGC
ATACCAAGCTGCGCGTGGCGTGGCGGGCGTTATGAAGCGGTACTGGCCCTACGGCACGGCGAGATGCC
ACGCAACCTGCATTTCGAGCAACCAAGTCTCAGATTGAATGGGACCTTGGGGCAGTTAGCGTAGTTTCT
CAGGCACGTTCTGTGGCCGCGAGCGAGCGTCCGCGCGTGCAGGCGTTAGTTCTTTTGGCAATTAGCGGTA
CCAACGCGCATGTGATTGTTGAGGAAGCCCTGAAGCCGACGAACCGGAGCCCGCGCGGATTTCGGTCC
GGTCCCTCTGGTGCTTAGCGGTGCGGATGAACAGGCCATGCGGGCACAGGCGGGTTCGCTTAGCCGATCAC
CTGCGCTCGGGAACCAAGAACTCTCTGCGTGACACAGGTTTACCTTGGCTACGCGCGCGAGCGCTGGG
AATATCGCGCTGTTGTGGTGGGCGATCGTGTATGATGCGCTGGCGGCTTCGCGCGCGTGGCGGACGGTGG
TATTGGCGATCGTACTCGACTGGTACAGGCGCGCACGCGTCCGCGTGTGGCTATGCTGTTCTTGGCCAG
GGTGCGAATGGCAGGCGATGGCGGTGACCTGCTTCGTGAAAGCCAGGTTTTTGGCGATAGTATTTCGG
ACTCGGACAGCTGCCCTTGGCACCGCACGCTAGATTGGAGTCTGACTGATCTGCTGTCTGGGCTCGTCCGCT
GGATCGTGTGAAGCTGGTGACGCTGCCCTGTTTGGCGTTATGGTGTGATAGCCGCGCTGTGGCGGTTCA
CATGGGCTAGAGCCCGCAGCGGTCTGAGGCCACAGTCAAGGCGAAATTCGACCGCGCATGTTTGGCGGGG
CTCTCGATTAGAGGATGACATTAATTTGGTTGCAAGTAAAGTCTGTTTAGCCGTTTGGCGGGTCA
GGGCGGCTAGGCGTCTGTTCCGCTGGGTACGGAACAGGCTGCGGAACGGATTGGCGGTTTTCGCGGCGCC
TGTCATTCGCGAGCGTTAACCGGCCACGTTCTGTGTTGGTAGCAGGGGAATCTGGCCCTCTGGATGAAC
TGATCGCCGATGTCGAAGCGAAGGATATACCGCACGCGGTATCCAGTGGATTATGCGAGTCACTCCC
TCAGGTGAATCTCTGCGGAGAGAACTCTGACTGAGCTGGCGGGCAATGACCCCTGTGAGCGGAGATGTC
GCCCTGTATTCCAGACGACGCGCGCAGCGGATCGACGCAACCATGAGTACCGCGATTGTGATGACAA
ATCTCCGTGAGCAGGTGCGCTTCCAAGACGCTACGCGTCAACTGGCCGAAGCCGGTTTTGATGCTTTCGT
GGAAATGATCTCCATCATCCGCTCTGACTGTGGGTATTGAGGCCACTCTTGATAGTGCAATTGCCAGCAGAT
GCAGCGCATGCGTGTGGTACGCTTACGCGGTGATCGTGGCGGCTGGCAGACCTTTCATACGCGATTAG
GCGAGGCTGATGCGCCAGGCGGTGGAGGTGGATTGGTCACTGCTCTTTCGGGATGCGCCCGCATGGAAAT
ACCAATGATTCGTTTTCAGCTGAGCTTACTGGCTGACGATTCCGACAGTGGCGGGCTGGCGGCTGATGACGA
GATGATGATTGGCGTTATCAGGTGCTTTGGCGTGAAGCGAATGGGAGTCTGCTGCCCTCGCGGTCGCG
TGCTGCTGGTAACCGGCCCGGGTGTACCATCTGAGCTGTCCGATGCCATCCGGTCAGGGCTGGAGCAGTCT

GGGGGCAACGCTTTTGACATGCGACGTGAAAGCCGTTCCACGATCGGCACGGCGTTGGAAGCTGCTGAT
 ACTGATCGCTGAGCACCGCTAGTATCGCTGTTAAGCCGTGATGGCCAGGCTGCTGATCTCGATCTCGATG
 CTCTGGCTTTGGTGCAGGCCCTAGTGTCTGCTGGCGTGAAGCAACCGCTGGTGGTCTGGAACCGTAAATGC
 TGTCCAGGTGCTGATGGTGAAGCTGCTGGATCTGCTGCCAAGCCATGGTGGGCGGGCTGGGCCGCGTGGT
 GGTATCGAAACAACCGGGTCTGCTGGGGCGGCTGGTGCAGCTGGTTGACGCCGACGAGCTTCCATCCGT
 GTCTTGCTGCGGTCTCGCGGATCGCGTGGTGAGGAACAAGTTGCCATCCGTGCGATGGTATCAAAGT
 GGC CGCCTGGTTCCAGCACCGGCTCGCGCGCACGTACCCGGTGGAGCCCTCGCGGTACGGTGTCTGGTA
 ACCGGTGGACAGCTGGCATCGGGCACACGTGACAGCTGGCTGGCGCGCAGTGGTGGCGAACATCTGG
 TCTCTTCTGGGCGCGCGTGGCGCGCACGCGCAGGCGCCAGCGAACTCCGCGAAGAACTGACCGCGCTGGG
 CACGGCGTGACTATTGCACTTGGACGTTGGCGATCGCGCTCGGTTAGAAGCAGTATTGGCAGCGGAA
 CGCGCGGAAGTGGTACCGTCTCTGCGGTTATGCATGCCGCGGGTGTGTCAAACGACACC CGCTGGATG
 ATTTAACCGAAGCCGAGTTACAGGAGATCGCTGACGTGAAAGTCCGGGCGACCGTTAACTTGGAGCAGCT
 GTTTCGCGGACCTGGATGCGTTCTGTTCTTTCTGTCAAATCTGGCGTTTGGGGTCTCGCGGTCTGGCG
 TCTTACGCGCTGCGAACCGGTTTCTTGATGGTTTGCACGCGCGCGAGATCTGAAGGCGCACCCGCTCA
 CGAGTATCGATGGGTTGTGGGCGGTCAGAACATGGCGGGTGAAGGCGGTGATGCTATCTCGTAG
 CCAGGGCTGCGCGCAATGGACCCAGATCGTGGGTGGGAAGAACTGCATATCAACGCTGGATCACGGTGAG
 ACCTCCGTCTCAGTGGTGCATATGGACCGTCCGCGTTTGTGGAGTTGTTCAACGCTGCCCGTCAACGCC
 CTTTGTGTTGATGAAATCGGGGTGACGGGCGAAGCTCGCAGAGTGAAGAGGGGCGCTCGGCTGGCGTA
 CGCTCTGGCGCGCATCTCTACCGCGAGCGCGCGAGACCTGGGCAACCTGATCTCGTGGCGAAGTGGCA
 CGCGTTCTGGTCAACGCGAGATCGCGCGATGACCGCGATCGTGCGATTGCGATCTGGGGTTGACT
 CCATGACGTCCGTTGACTTGCACCAACCGTCTCGCGAGCGGTACGCGGGGTACGTGAGGCTGCCACAGTTGT
 ATTTGACCATCCAAACGATCACGCGCTTGGCGGATCATTATTTGGAGCGTCTCTCTAGTGCCTGGAAGCG
 GAAAGCGCCCGCTGGCTGCTGCGAAGTTCCAAAGATGCGGATGACCCAACTGGAGTCTGGTGGCATGG
 CGTGCGGTTTCTGGGCGGGGTTCACAAACCGGCGAGCTGTGGGAGTTTATCGTAGGCGGTGGCGATGC
 CGTAGCGAAATCGCTACCGACCGGGGTGGGATTTAGTGCACTGTGTCAGATCGGACGCGAGCTCAC
 GGAACCTCTTATCTCGCCATGGTGCCCTTTAGATGGTGC CGCAGATTTTGAACGCGGCTTTTTTGGCA
 TTTCACTCTGTGAGGCGTTGGCAATGGATCCACAGCAGCGTCAGGTGCTGGAAACCACTGGGAGTTATT
 CGAAAACGCGGATCGATCGGCAACGCTTAAGAGGTTAGATACGGGTGTGTTTTGGGCGCTGCGCTAT
 CAAGTTATCGGTGAGTATCGGTGGTCCAGAGGATAGCGAGGGGTATCTGTGACGGGGAACCTGCTG
 CCGTGTGTGCGGCGCGCTGAGCAACGCTGCTGGCTTGAAGGTCGCGCGGTAAACGCTGGACAACGCGATG
 CTCTTCCAGCTCTGGTGGCTTACACTCCGCTTGTGGCTCCCTGCGCGACGGTGATGCGGGTTAGCGGTC
 GCCGTTGGCGTCTCGGTGATGGCAGGGCCTGAAGTCTTCACTGAGTTGACGCGCAGGGGTGGCTGGCGG
 TGGATGGCGGTTGAAGCGTCTCTGCGGAGGCCGATGGTTTCTGTTTGGCGAGGGCGTGGCTGGCGG
 ACTGCTTCCAGCGCTCTGAGCGATGCAACGCGGGCGGGCGCCAAAGTCTCGGTTGTGGTGGCGGTTCCGCC
 ATTAATCAGACCGGTGCTAGCAACCGTCTGGCGCGCCAAAGCGGTGGGCGCAACCGTGTGATTCTGTA
 AAGCATGGGCTCGCGCGGTATTACTGGTGAGACGTGCGGTGGTTGAAGCGCATGGGACTGGGACCCG
 CCTTGGTGATCCAGTTGAAGCGTCTGCGCTGTGGCTACTACCGGGAATCCGCTGGCAGCTCAGGTCCG
 GTACTGCTGGGCTCTGTGAAAAGCAATATCGGCAACGCCAGCGCGCGCGCTGGCGTTGCTGGGTTATCA
 AAGTAGTGTAGGTCTGAACCGGGGCTCGTTCCGCGATGCTGTGCGAGGCGAAGCTTCCCGCGTAT
 CGGTGAGCAGTGTGGTGGTGGAGCTCGCGAAGCTGACGCCGTTGCGCGCGGCGGCAACCGCGCGCTT
 CGGAGGGCAGGCGTGTCTGCGTTCCGCGTGAGCGGTACCAACGCTCATGTCAATTATGCGGAGCCGCCAG
 AGCTCGGAGCGCTGCGCAGAACCGGGGCGGTCGCTGTACTCGCGCTCGAATAGTGTTCGCGTTCTCT
 TAGCGCCGACCGAACAACCGGCTGGCTGTCACAAACGCGCTGTGGAAAGCGCGTGAAGCTTGGT
 CCATGACGCGCTTGGCTCTCGCTCTGGCTACCGGCGCGGCCACCTTCCGCTGCGCGGCTCTGTGTAG
 CAGGTGACCAACGAACAACCTGGGGGTGAGTGTGCTGCTGACGTGGCGGCGGAGGTTGCAACGCGGCGGAC
 GACAGGTAACGCGTCCGAGGTGGTGTGCTTTTGTCTTTCTGGCCAGGGCGCCCAATGGGAAGGTATG
 GCTCGGGGTTGCTGAGTGTGCCAGTTTTCGCGCAATCGATCGCGCAATGTGACCGCGTTCTGAGTGAAG
 TTGACAGGTTTTCAGCTTCAGAAGTTCTGGAACAGCGCGCTGATGACCGCTCACTCGAACCGGCTGAGCT
 TGTGCAACAGTGTCTCTCTGTTATGGTTAGTTTACCGCTTATGGGCGCGTGTGGGGTGAACCCG
 TCAGCCGTTATCGGTATAGTCAGGCGAAATGCGGCGCGCGTGTGGCCGCGCTTCTGAGTTTGGAGG

ATGGCGTTTCGTGTGGTCGCGTTGCGCGCGAAAGCCCTCGTGCATCGCGGGCAAAAGCGGCATGGTCTC
CTTGGCGGCCCTTGGCGAACGCGCCCGTGGTGTGATTGCCCGGTGGGAAGACCCGATCAGTGTGGCGGCG
GTAAACAGTCCCTAGCGGCTGTAGTTAGCGGTGATCTGAAAGCACTTGCAGGACTGGTAGCGGCTTGGC
AAGATGAAGGCGTTCCGCGCCAAAACGCTCCAGTGGACTATGCGAGCCATTCTCGGCACGTTGGAAGAGAT
TCGCGAAACAATCTTGGCGGACTGGATGGTATCTCTGCACGTCTGCGCGGATCCCGCTGTACAGCACC
CTTCATGGCGAGCGTGCAGACGGGGCGGATATGGGGCCCGGTATTGGTATGACAATTTGCGCAGTCAAG
TCCGTTTCGATGAAGCGGTTTTCAGCGGCCGTTGCCGATGGTCATGCCACCTTTTGTGGAATGAGCCCGCA
CCCGGTTCTGACCGCGCGCTGCAGGAGATCGCGGCCGATGCCGTGGCGATCGGTTCTCTGCACCGTGAT
ACGCTCAGGAGCAATTAATTGCCGAATTAGCACGCGCTCATGTACACGGCGTGGCTGTGATGGCGCA
ACGTTCTTTCAGCGGCACCAACCCGTGGCTCTGCGGAACTACCCGTTCGAGCCGCGAGCGTCTAGCTGCA
GCCGAGGTGTCTGACCAGCTGGCGGACTCCCGGTATCGCGTGGATTGGCGTCCACTGGCGACAACGCCG
GTGGATCTGGAAGGCGGTTTCTGTGTGCACGGCTCAGCGCCTGAATCACTCACCTCCGAGTAGAGAAAG
CAGCGCGCGCGTAGTTTCCAGTGGCGAGCGCCGATCGGGAAGCCTCTGCTCGCTTGGCTGAGGCTCCGC
CGAAGTGGCTGGCGTCTGTCTGGTGACACTGGCGCCGCTACTCACCTGGCGCTGCACCAAGTCCCTAGGC
GAAGCAGGTGTGCGCGCCCGTTATGGTTAGTGACACGCGGTGCCGTGGCGCTCGGTGAATCCGAAACG
TTGATCTCGGAACAAGCGATGGTGTGGGGCTGGCGCGGTTATGGGGCTGGAACCCCGGAGCGTGTGGGG
CGGCTTAGTAGATTGCGCGGCGAACTGCCCTGGGGATGGCGAAGCCTTGTGCGATGCTTGGCGCG
GATGGTCAAGGATCAAGTCGCGATTCTGATGATCACGCGCGCTTATGGCGCGCGTCTGGCTGAGGCTCCGC
TGGTACTCTGGGAGGACGCTGGGAACCGCGCGGTACTGCATTGGTGACCGGTGGCAGCGGGCGGTGGG
TGCTCAGTGGCTCGCCATCTGGCCCGCTGCGCGCTCGAGGACCTGGTGTCTGGTCAGCGCTGGTCTGGTGT
GACGCCCCGGGCGCGCGGAGCTGGAAGCTGAGCTTGTGGCGCTGGCGCCAAAACGACAATTACGGCAT
GCGATGTAGCGGATCGTGAAACAGCTGTGCAAACTTTTAGAAGAAATTACGTGGCGAGGTCGTCGCGTGCG
CACAGTCGTTTCACTGCGGGCGTCCCGGAATCACGCCGCTGCATGAGATTGGGAATTGGAATCTGTG
TGCGCCGCAAAAGTTTACCGGCGCCCGCTGCTTGACGAACTGTGCTGATGCGGAGACTTTTGTGTTGT
TTAGCTTCCGGGCGGCGCTGTGGGGCTCCGCAAAATTAGGCGCATATTCCGCGCAAACTGCTGCTCGA
TGCTCTGGCTCATCGTCCGCGCGCAGAAGGCCGCGCAGCCACAGTGTGCTTGGGGCGTGGGCGCGC
GAAGCATGGCAACGGGCGACTTAGAAGGCTGACGCGCGCTGGCTTGCGCCGATGGCGCGGAGCGGG
CAATTCCGGGCGTCCACCAAGCTCTGGAACAATGGTGACACTTGGCTCTCTATTGCCAGCTCGACTGGGA
GGCGTTCGCTGTGGGTTTACCGCGCACGTCGCGCTCCACTGCTCGATGAATGTGTCAGCGCGCGCTGAC
GGTGCAGTACCACTGCTTTCAGCGGCTCCAGCCGCTGAATGACTAGCCAAGAAGCTGTGGAGTCTGATGC
ACTCGCATGTTGCCGAATCTTGGGTCATAGCAGTCCGGATGCCCTCGGCCAAGACCAGCCGTTTACGGA
ACTGGGTTTCGATAGTCTGACTGCCGTTGGCCTGCGGAACCAAGCTACAGCAAGCAACTGGTCTGGCGTTA
CCGCGCAACTTAGTCTTTCGAACATCCGACAGTACGCGCTTGGCCGATCAGTCCGCGCAACAACCTGTCTA
GTGGCACCCCGGTCGGGAAGCGTCTAGTGCTCTGCGCAGACGGGTATCGTCAGGCTGGCGTCTGGGGCG
GCTACGCACTTACTTGGATTCTCTGCGAGGCTTTCCGACTTCCGCGCAAGTATTTCGATGGTCTGATGGC
TTTAGCCTTGACCTGGTGGATATGGCCGATGGTCCAGGCGAAGTGACGGTCATCTGCTGTGCGGGACCG
CGGCCATTTCAGGCCCGCACGAGTTTACTCGTCTGCTGGCGCATTGGCGGGCATTGCTCCTGTGCGGTGC
AGTTCCGCAACCAAGGCTATGAGGAAGGCGAAACCACTGCGAGCAGCATGGCCCGCTGGCCGCGGTGAG
GCTGATGCACTTTCGCAACCAAGGTGACAAACCTTTCTGGTATGACAGGCGACAGCGCCGCGCATCTA
TGGCCATAGCTCTGCGAGCCAGCTGTTGGATCGTGGTCAACGCGCAGCGGGGTGCTGATGATGATGT
ATACCCGCCGGGCCACCAAGACGCTATGAACGCTGGCTCGAAGAATTGACCGCCACGTTATTTGACCGT
GAGACCGTAGCATGAGCAGCATCGTTGACCGCGCTGGGTGCGTAGCAGCCGCTGACAGGTCAAGTGGC
GTCCGCGCAAAACGGGTCTGCGCAGACTTCTGGTGTCTGCGGGCAACCTATGGGCCCATGAGCCGGATGA
TTCGTGGAACCGACCTGCGCGTTTGAAGCATGACAGTGGCTGTCCAGCGCAACATTTACAGATGGTT
CAGGAACACGCGGATGCGATTGCTGTCATATCGACGCTGGCTTGGAGGCGGGAATTCG

EXAMPLE 8

METHOD FOR QUANTITATIVE DETERMINATION OF RELATIVE AMOUNTS OF TWO PROTEINS

[0363] A double-mAb technique was developed to quantitatively determine the relative amounts of two or more PKS proteins expressed in the same cell. According to this method, different epitope tags are used for each PKS protein, and they are quantitated simultaneously by Western blot using a mixture of two differently labelled antibodies (*e.g.* labelled with CY3 and CY5). The ratio of dyes provides an assessment of the relative stoichiometry of the two proteins expressed.

[0364] As a model system to develop this technology, we used a protein that was labelled with two different epitope tags (cmv-c-AtoC-FLAG-BRS-His) on either end (the 55 kDa AtoC). This provided a protein in which the two tags are present in a known ratio.

[0365] In our initial experiments, we had difficulties obtaining reproducible ratios of two Mab's bound to the protein after Western blot, especially with sub-microgram quantities. We therefore made the effort to develop the methods of analysis needed using dot-blot of cmv-c-AtoC-FLAG. In the data shown below, two fluorescently labelled antibodies (cmv-c-AlexaFluor488 and FLAG-Cy5) were used simultaneously to quantitate a dot-blot of the AtoC construct mentioned above. The blot was scanned using a Typhoon 9410 Fluorescent Imager, and analysis was performed using ImageQuant software. Results are shown in Table 15.

TABLE 15
RESIDUAL ANALYSIS OF DOT-BLOT DATA

ng on blot	cmv-c-AlexaFluor488		FLAG-Cy5		ratio of areas (AF488/Cy5)
	predicted ng	% error	predicted ng	% error	
10	5.80	42.02	4.17	58.34	0.151
50	48.28	3.44	41.97	16.06	0.139
100	109.01	9.01	119.99	19.99	0.125
250	243.78	2.49	260.24	4.09	0.132
500	504.70	0.94	491.97	1.61	0.146
1000	998.43	0.16	495.34	50.47	0.284

[0366] The cmyc-AlexaFluor488 antibody provides a very accurate range of quantitation in the 50-1000 ng range. The FLAG-Cy5 antibody is accurate across a range of 50-500 ng, and clearly suffers from signal saturation at the 1000 ng level. The ratios of the peak areas are also stable across the 10-500 ng range, allowing for detection of N-terminal or C-terminal degradation, as well as stoichiometric analysis of protein levels.

[0367] Epitope-tagged DEBS proteins have now been expressed and purified for use as epitope tagged standards for quantitative Western analysis.

TABLE 16

Protein	Epitope Tags	Configuration of tags
DEBS module 2	HA, flag, brs, his	HA-mod2-flag-brs-his
DEBS module 2	c-myc, flag, brs, his	cmec-mod2-flag-brs-his
DEBS module 2	HA, his	mod2-HA-his
DEBS2	c-myc, his	DEBS2-c-myc-his

A synthetic DEBS module 2 protein (mod2) was expressed in *E. coli* K-207-3 as a fusion protein (c-myc-mod2-flag-brs-his). Cloning of the module 2 gene into an expression vector in frame with genes encoding the tag sequences was facilitated by inclusion of an Eco RI site in the synthetic gene. DEBS module2 with N- and C-terminal epitope tags was co-expressed with DEBS2 and DEBS3 in an *E. coli* k-207-3. At 20 and 40 hours, samples from production cultures were subjected to SDS-PAGE (two colonies of each strain were tested). Gels were either stained with sypro red or subjected to Western blotting, using fluorescently-labeled antibodies directed against the epitope tags, c-myc, flag and biotin. Monoclonal antibodies were labeled with fluorescent dyes (alexa 488 and alexa 647) such that two fluorescent signals could be monitored simultaneously.

EXAMPLE 9

EPOTHILONE PKS GENE SYNTHESIS

[0368] The complete 54,489 bp epothilone synthase gene (loading didomain, 9 elongation modules, and thioesterase of the DEBS gene) was synthesized, and assembled.

[0369] The gene was designed by using a version of GeMS software developed. Modules were synthesized using Method R and Type II vectors. To synthesize the approximately 55 kb of DNA, the gene cluster was broken down into 118 synthon fragments ranging in size from 156 to 781 bp. The 3000 oligonucleotides were pooled into oligonucleotide mixtures using the Biomek FX and the assembly and amplification were performed using the conditions described in Example 1. They were cloned into a UDG-LIC vector (Method R and Type II vectors were used) and a >90 success rate in UDG cloning. Eight colonies for each synthon were picked into 1.5mL LB/carb and aliquots were taken for use as template for the RCA reaction to provide samples for sequencing. Clones were obtained that contained the correct sequence for all 118 synthons that make up the Epo gene cluster. The average error rates for the 118 synthons was 2.4/1000 and on average 32% of the samples sequenced were correct. This was an improvement from the DEBS gene cluster numbers of 3 errors per kb and only 22% correct. Correct samples for 104 of 118 (88%) were obtained from this first round of sequencing eight samples; for the remaining 12 synthons, correct sequences were found after sequencing additional clones. After the correct clone was identified through sequencing, the plasmid DNA was isolated from stored cultures and the assembling the synthons into modules was performed using the stitching strategy aforementioned.

[0370] The sequences of synthetic ORFs encoding epothilone synthase polypeptides EpoA- are shown below in Table 17B. (Each of the sequences includes a 3' Eco R1 site which was included to facilitate addition of tags.) Table 17A shows the overall sequence identity between the DNA sequences of the synthetic genes and the reported epothilone synthase sequences.

TABLE 17A

SIMILARITY OF SYNTHETIC AND NATURALLY OCCURRING SEQUENCES

NATURALLY OCCURRING GENE
SEQUENCE¹

SYNTHETIC GENE SEQUENCE

epothilone PKS	Naturally Occurring DNA Sequence (accession #)	Naturally Occurring Polypeptide Sequence (accession #)	#bp	#aa	# aa changes compared to nat. seq.	% identity vs nat. seq. (aa)	% identity vs nat. seq. (dna)
EpoA	AF217189	AAF62880	4263	1421	4	99.72%	75%
EpoB	AF217189	AAF62881	4230	1410	2	99.86%	75%
EpoC	AF217189	AAF62882	5496	1832	4	99.78%	75%
EpoD	AF217189	AAF62883	21771	7257	15	99.79%	75%
EpoE	AF217189	AAF62884	11394	3798	8	99.79%	74%
EpoF	AF217189	AAF62885	7317	2439	5	99.79%	75%

1. As reported in GenBank accession nos. shown.

TABLE 17B
SEQUENCE OF SYNTHETIC EPOTHILONE SYNTHASE

EpoA (SEQ ID NO: 6)

ATGGCCGACCGCCGATCGAACGTGCAGCGGAGGATCCAATTGCGATTGTAGGCGCGGGCTGCCGCCCTGCGGGCGCGGTGATTGACCTCTCGGGCTTCTGGACGCTGTTAGAAAGGCTCCCGCGACACCGTCGGTCAAGTCCCAGCGGAGCGGTGGGATGCTGCGGCGTGGTTCGATCCGATCTGGATGCACCTGGCAAAACACACAGTGAACCGCGCCAGCTTTTTTAAGCGATGTCGCTGCTTCGATGCCTCTTTTTTCGGGATCAGTCCGCGCGAAGCCCTTCGCATGGATCCGCGCCACCGGCTGCTGCTGGAAGTGTGCTGGGAAGCATTGGAAAACGCAGCTATTGCCCGCTCGGCCCTGGTTGGCACGGAACTGGCGTCTTTATTGGCATCCGTCGAAGCGAATATGAAGCGGCATCTGCTAGGGCTACTGCCAGCGCAGAAATTGATGCTCAGCGCGGCTGGGCACGATGCCTTCAGTTGTGTCAGGTCTGATTTCATACGTCCTGGGCCCTTCGTGGTCCGTGTGTGGCGGTGGACACCGCATATAGTTC TAGCTTAGTCGCAGTACACCTGGCGTGTGAGTCGTTACGTTCCGGCGAATGCTCGACCCGCGCTTCAGGTTGGGTCAGCCTTATGCTGTCCCGAGCACTTATGTCGTTGAGCAAGACACGTCGCTTGGCAACCGACGTCGCTGCAAGCCCTTCAGCGCGAGGCCGATGGGTTTGGTCTGGCGAAGGTTGCGCAGTGGTCTGCTGAAGCGTGTGTCGCGCGCACGTGCGGATGGGGACCGCATCTTCGCGATTATCCGCGGCTCGGCCATCAACCATGATGGTGCCAGCTCCGGTCTCACTGTTCCGAAACGTTCTTCACAGGAAATTGTACTGAAACCGCCCTTAGCCGATGCTGGTTGCGCGCATCTTCGGTGGGGTACGTCGAAGCTCATGGGACGGGTACTACCTTAGCGATCCGATGGAATTCAGGCGCTCAATGCCGCTCTACGGCTGGGTCCGGATGTCGCGACCCCTTTGCTGATCCGGGTCTCAAGACTAACCTCGGCATCCAGAGTATGCTCCGGGATCACTGGTCTGCTGTAAGGTTGTTGTTGCTCTGCGACACGGTCAAATTCGCGCGCACCTCCATGCTCAGGCGTTAAATCCGCGCATTAGCTGGGGCATCTGCGCTGACCGTTACCGTGTCTCGGACCCCGTGGCTGACTGGAACAACCGCTCGCGCGCGGGCGTCTCCTCGTTTGGCATGAGTGTACCAATGCCAGTGTGTTCTGGAGGAAGCCCGAGCAAGCTGCACCCCGCAGCCCGCAGAACGTCACGCCGAATTTGTTAGTGTCTGTCGCGTACCGCTGCCGCTCTGGA CGCATGCGGCGCGTTTGGCGGACCACTTTAGAAACATACCCGTCACATGTTTAGGTGACGTTGCCCTTCTCGCTGCGCACTACCGTAGTGCATGGAACATCGCCTGGCGGTGGCGGCTACGCTCTCGGAGGTCGCTGTCGCGGCTTAGAGCGCGCAGTCTCAGGTCAGACCCCGCGGGTGTGTCGCTGGTATCGCAGACTCGCTTCGCGGCAAACTGGCTTTTCTGTTTATCGCCAGGGTGCCAGAGCTCTGGCATGGCGCGGGCTGTACGATGTTGGGCTGCTTTTCGCGAAGCGTTTGATTTGTGTGTGCGCGCTTTTACCAGAACTGGATCGCTCGCTGCTGAAGTAATGTGTTGGCATGGAACCAACGATCAGTAGATGCCGCACTTTTAGACCAGACAGCTTTTACACAGCCAGCGCTTTTACGTTTGAGTATGCTCTGGCTGCACCTGGAGATCTTGGGCGTAGAACCAAGAACTGGTGGCGGGTCACTCGATTGGCGAAGTGGTGGCGGTGCGTTCGCGGTGTGTTTCAGTTTGGAGGACGCCGTGTTCTGGTTCGCGCGCAGCGGCTGCTCATGTCAGGCGCTGCTGCTGCTGGTGTGCAATGCTGCTATGCGGCGCCAGAAGCGGACGTCGCGCGCGGCTGCGGCTCATGCGCATCAGTAAGTATCGCGGCTGTT

AATGGCCAGACCAAGTGGTAATCGCGGGCGCAGGGCAGCCGGTGCATGCGATCGCCGCTGCAATGGCGG
CGCGCGGTGCCCGGACCAAGCGCTTCACGTGAGCCACGCGTTCACAGTCCACTGATGGCACCAGATGTT
AGAAGCGGTTTGGCCGCGTGTGCTGAATCCGTAAGTTATCGTCTGTCGAGCATCGTACTCGTTAGTAATCTG
AGCGGCAAGCAGGGACAGATGAAGTATCCAGCCCTGGCTATTTGGGTGCGTCATGCTCGGGAGGTTGTGTC
GTTTCGCGAGATGGCGTGAAGCGCTCCATGCGCGCAGGTGCGAGCACGTTTGTGAAGTGGGTCCGAAGTCT
TACTCTTTTGGGTTTAGTTCCGGCGTGTTTGCCAGACGCTCGTCCGCGCTTCTGGCAAGTCTCTGTGCC
GGGCGCGATGAACCGCCACTGTTCTGGAAGCTCTGGGGGGTCTGTGGGCGGTTGTTGTTGTTGATCGT
GGGACAGTCTGTTTCCGAGTGGCGGTGCGCGCTGCTCTGCGGACGTATCCGTTGGCAACGTGAGCGTTA
CTGGCTGCGACCAAGCGGATGACGCGACGCGCTGTTGATCGGCGAGCACCGGTTGCGGGCCATGACGAA
GTCGAAAAGGCGGGGCGGTGACAGGTGGGGATCGCGCGAGCGCCGTTTGGATCATCCACCGCCAGAGA
GCGGACGCGGTGAAAGGTTGGAGGCGAGCGGCGACCGTCCGTTTCGTTTGGAGATTGATGAGCCTGGCGT
GCTGAGCCGCTCGTTCTGCGGTGTACGAGCGTTCGCGCACCGGGCTTAGGTGAGGTGAAATTTGCTGTA
GACGCGGTGCGTTTGGCTTGGCGGCGAGTACAGTGGGCGCGTCTGGGTATGGTTCCGATGATCTGCGGGTA
AACCAGATTCGCGCGCTGCTGTAGGCGGGGAATGTGCCGGCCGCTATTGTGGCGGTTGGGGAAGGCGTAA
TGCTCTGGTTGTAGGTACAGCCGGTGATGCACTGAGCGCTGGTGTCTTCGCAACCCATGTCAACCGCTCA
GCGCGCTGTGTCGCCACGCTTACGCGCTGTTCGCGACCGAGGCGCGAGCTATGCCAGTGGCATATC
TCACCGCGTGGTATGCTCTGGATGGCATGCCCCGCTTCAACCTGGCGAGCGCGTGTCTGATCATGCGGCG
CAGCGGTGGCGTTTGGCTTGGCGGCGAGTACAGTGGGCGCGTTCGAGTTCACGCTACTGCGTACGCG
GGTACGCGCAGAAACGCGCTTACCTTGAAGCTCGGGGTTGTTACGTTTCAGATTCTCGCAGCGACC
GCTTTGTAGCAGATGTGCGGCGCTGGACCGGCGGGAAGGCGTTGATGTGTTCTGAACTCTCTGTCAAG
TCAACTGATTGATAAGTCACTTCAACTTACTGCGGTCTCATGGTGGTTTTCGAACTCGGCAAGCGCATG
TGTTATGCTGATAATCAGCTCGGCGCTTCCGCGCTTCTGCGCTAACCTTTCATTTCTTTGGTTGATCTGCG
CGGCGATGATGCTGGAGACCGCTGGCGACGTGTGCGTGCCTTGTGGAGGAGCTGCGGTTTAAATTTGCGCG
TGTTGTGTTTACCCCGCGCGCATGCGCACGCTTCTCTATTGTCTCGCGTGGCGGACGCGCTTCCGTTGATG
GCGCAAGCAGCATTTAGGCAAACTCGTACTGACCTTAGGGGATCCGAGGTTCCAAATCCGATTTCCGA
CACACGCGGGGGCGGTCCGTTACCGCGACCGGGACCTGCTGGATCGTCTTCGCGATGCTGACACCGGC
GGCTCGTGGCGGCGCTTAGAAGCTTTTTCGCGCACCCAGGTGTGCAAGTGTGCGCACACCTGAAAT
AAAGTAGGGGCTGAAGCTTTGTTTACACGCGTGGGTATGGATCCCTGATGGCAGTGGAACTTCGTAATC
GTATTGAGGCGAGCTTGAAGCTGAAATATCTACAACCTTCTCTAGCAGGAGCCGAACATCGCCCTGCT
GACCCAAAATCTGTTGGATGCACTCTCTAGTGCAATTAAGTTTGAAGCGTGTTCGCGCGGAGAACCTCGCG
GCGGCGCTCAATTCGCACTTTGTGTCGTAGGGGCGGATCAGGATTGGGAAATCACTGTCTGGG

EpoB (SEQ ID NO: 7)

ATGACCATTAATCAGTTACTGTAATGAATTAGAACACCGGGCGTTAAATTTAGCCGCGAGATGGGGAGCGCC
TCCAGATTCTAGGCGACAAAATGCGCTGAACCCGAACTTGTAGCACAGTACTTCTGAACATAAATCCAC
GATCTTAACCATGCTGCGCGAGCGCTTTCGCGGGAAGTCTATGTGCCAGCCCCAGCGGAACGGCATGTG
CGGTTCCCTCTGACCGACATCAGGGCTCTATTGGCTCGGTCGACTGGTGCCCTTACGGTTCCGTCGG
GCATCCATGCGCTACCGTGAATATGATTGACCGGATCTGGACGTGGCCCCGGCTTAGTCGTGTCATTCCGTAA
AGTGGTTGACCGGCATGATATGCTGAGGGCTCATACCTTCCCGGATATGATGACAGTGATCGAACCTAAA
GTAGATGCGGACATCGAATCATTGACCTGCGTGGCTCGATAGATCTACACGCGAAGCTCGGTTGGTGT
CCCTGCGTGACCGCATGTCTCACCGGATTATGATACGGAACGCCCGCGCTGTATCAGTTGTGGCCGT
TCGCTTAGATGAACAACAGACCGCGCTGGTGTGAGCATTGATCTGATTAACTGTGACCTGGGCGAGTCTG
AGCATTATCTTTAAAGATTGGTTGAGCTTTTACGAAGATCTGAAACCTCGCTGCCAGTGTGGAACCTGA
GTGACCGGACATACGCTTCGGGTTGGAATCGCGTAAAAAATCGGAAGCCACACGCGCTCAATGGACTA
CTGGAACCGCGGTGTGCTGAACTCCACCAACCGCAATGCTGCCAATGAACAGTCCGTTGAGTGTG
CGTGAATTCGTTCCGTCATACGGAACAGTGGCTCCGCTGTGATAGTTGGTGGCGTTTAAACAACGTTG
TAGGCGAACCGGGCTTGACCCCAACCGGTGTAATCTTCGAGCTTTCTCTGAGGTGATCGGCGCTGGT
CGCTAGCCCGCGCTTTACCTTCAACATCACTTTATTCAACCGTCTCCCTGATCACTCCCGGCTCAATGAT
ATTACTGTTGATTTTACAAGCATGGTGTCTGTTGACATTGATACGACGCGCGCAAAATCACTTCGAACAGC

GTGCTAAACGCATTACGGAACAGCTGTGGGAAGCCATGGACCACCTGCGCATGTTTCTGGGATTGAAGTACA
GCGCGAAGCGGCACGTGTGCTGGGCATTCAACGCGCGGCACCTGTTCCCGGTAGTACTGACCTCAGCCCTC
AATCAACAGGGTGTGGGGTATGCGCTCTGCAACGCTGCGGCACCCGGTTTACACGAGCAGTCAAGTCTC
CGCAGCTCCTGCTCGATCATCAGCTGTACGAAACATGACGGTGACCTGGTCTGCGCGTGGGATATTGTGGA
TGGCGTGTTCGCGCGGATCTGCTGGATGATATGTTAGAAGCCTATGTGCGCCTTTTACGTGCGCTGACG
GAGGAACCGTGGTCTGAACAAATGCGCTGCGCCTGCGCCCGCTCAGTTAGAGGCACGTGCATCCGCCA
ATGAACCTAACTCACTGCTGTCTGAACATACTCTGCATGGTCTGTTTGCCGCTCGGGTGGAGCAGTTACC
GCTGACGCTTCGAGTGGTTAGGCGCTCGTAAACCCCTGACGTATGAGGAATTGTCCTCGCGCTCGCGCGG
CTGGGTGCGCCGCTCGCGGAAACAAGCGCAGCGCCGAATACCTTGGTCGCGCTGTTATGGAGAAAGGTT
GGGAACAAGTGTTGCGGTCCTTGGCGTGTGGAAGCGCGCGGCTTATGTTCCGATTGATGCGGACCT
GCCAGCAGAACGTATTCACTACCTGCTTGATCAGCGTGAGGTTAAATTTGGTGTGCTGACTCAACCGTGGCTG
GATGGCAAACTTAGCTGGCGCGCAGGGATCAGCGTCTGCTGGTAAGCGACGCGCGGCTCGAAGGGGAGC
GCGCAACCTGCGGATGATGCGGATTGAGACCCCATCGGACTTAGCATACGTCACTACACCGATGGTTT
GACTGGTTTGCAGAAAGGTTGTTATGATTGATCAGCGTGGCGCTGTCAATACAATTTTGGACATCAACGAG
GCGTTTGAGATTGGTCTCGGGGATCGCGTGTGCGCCTGTCTCACTTTCTTTTGATCTGCTGGGTTATG
ACGTTTTTCGTATCCTCGCGCGCGCGGACCAATTGTGTGCCAGATGCGTCAAACTGCGTGACCCAGC
CCACTGGGCTGCTATTATGAACCGCAAAAAGTCACTGTGTGGAATAGTGTACCGGCATGATCGGTATG
CTGGTCGAACTCTTTCTGAAGGCGGCCCTGATTGCTGCGACGTAGCTGCGCCTCAGCGCTGAGTGGTG
ATTGATCCCTGTGGGGCTCCCGGGTGAACCTTCAAGCTATCCGTCGCGCGCTCAGTGTTATTAGCTGGG
GGGTGCCACAGGCTAGCATCTGGAGCATGGCTATCCGTGTCGCAACGTGGACCCGCTGCTGGGCATCA
ATTCCGATATGGCGCCCGCTTCGCAATCAGACGTTCCACGTGCTTGACGAGGCGCTGGAGCCACGCGCG
TATGGGTCCAGGCCAACTGCTATATCGGTGGCGTGTGCCCTGCGCCTGAGCTGAGGCTATGGCGTGACGAGGAAAA
AAGCTCGAATCTTTCTGCTGCATCCGGAACCGGGGAAACGCTGTATGAACACCGGGGATCTCGGCGC
TACTTTCGGAATGGCAATATGAATTTATGGGCGCGAGGATAACCAATTAACCTCGGGGCTATCGCG
TGGAAATGGGTGAAATCGAAGAAACCTGAAAAAGCCATCTAACGTGCGCATGCGGTCACTGCGCGT
TGGCAATGATGCCGCAAAATAAATTAAGTCTGCTGTATGTGTACCGGAGGGACCCCGCCCGTGTGCGCG
GAACAGGACGCATCACTTAAGACGGAACGTGTGATGCGCGTGGCGATGACGACCAAGCGGACGGCCTGA
GCGACGCTGAGCGCGCTCCAGTTCAAATGGCACGTCACTGGCCTGCGTCGCGATCTGGATGGCAACCGGT
GCTAGACCTGACGCGTCTGCTATCCGCGCGAAGCGGGGCTGGATGATATGCTCTGCTGCTGCTGCTGCGC
ACTTTCTTAGAGGCAACGATCCGCTTCGTAGAATTTGGTGTGCTTCTGCTCTGCTTAGCTTAGCTGGAGC
CTGATGGCGCAGCTCTCCCTAAATCCGTTACCCTTCGGCGGTAGTACCTACCCGGTCCAAACATACGC
CTATGCGAAAGCGGCGGTATCGAGGGGTGAGACGAAGGCTTCTATTACTATCATCTTCGAGCATCGT
CTGCTGAAAGTTAGTGATCAGGTTATTGAACGTGGCGCGCACGTGCGCGCAAGACTTCGACGCTTTTGACG
AAGCTGCTCTGTTTACTCTTTGTTGGCCGTATCGATGCGATCGAGAGCCTGTACGGGTCAATGAGCCG
CGAATTTTGTCTGTTGAAGCTGGTTATATGGCCCACTGTCTATGGGACGAAGCGCGCTGTGCAACATT
GGGCTCGCCCTGTAGGGCAGTTTGATTTTGAACAGGTACGCCAGTTCTTGATTATCGCCATTCGATG
TTTACGTACACGGTATGCTGGGCGGTGCGCTGGATCTCGCCAGTTTCAGGTCTGTACCTTCGGCCAGGA
TTCCAGGCCAGCTGTGCTACGACGCGCGGTGCCCCACCGGGTCCGCGACCAACATTTTGTGATCACTCT
CGGGACTTTCTTCGCACTAACTGCCGGAATATATGATACCGACCGTTTTCGTGCGATTGGACGCGTTAC
CGCTCACTTCAACGCGCAAGTGGATCGCAAGCGCTGCGGGAACGAAGACATCATGCTCCGCGGCA
CTCCGGTCACACCGCCCGCGTGATGCTCTGGAAGAGATTCTGGTCGCGCTGTTGCTGTAAGTTCTCGGT
CTGGAAGTTGTGCGGCTGCAACAGTCTTTTGTAGACCTGGGTGCTACTTCCATCCATATCGTTCGTATGC
GCAGCGTGTTCGAGAAACGCTGGACCGGAAATTGCCATTACAGAACTTTTCAGTACCAATCCGCTGGG
TTCGTTAGCCAGCGGCTTTCTAGTGATAGTAAGATTTAGAACACCTCGGAATATGCAGGACCGCGTCT
GAGGCTCGCCCAAGGCGCGGCTCGTTACAGGAATTC

EpoC (SEQ ID NO: 8)

ATGGAAGAACAGAATCCAGTGCATTTGCCGTGATTGGCATGTCAAGTCCGTTCCAGGGGCGCGGATC
TGGATGAGTTCTGGCGCAATCTGCGCGACGCGCACCGAGGCGCTCCAGCGCTTTAGTGAGCAGGAATCGC

GGCGTCGGGCGTTGATCCGGCTCTTGTGTTAGATCCGAACCTATGTGCGGGCAGGTAGCGTTCTGGAAGAT
GTCCGATCGTTTGTAGTCCGCTTTCTTTGGTATCTCCCCGCGTGAAGCGGAACCTGATGGACCCGAGCACC
GGATCTTATGGAAATCGCGTGGGAAGCACTCGAAAAACCGCGCTATGACCCGAGCTGCATACGAGGGTAG
CATCGCGCTGTATGCGGGGGCCAAATGAGCAGTTATTTAACTTCAATTTACATGAACATCCGCGGATG
ATGCGTTGGCGGGCTTGGTTCCAGACGCTGATCGGGAAACGATAAAGATTACTTGGCAACGACAGTGTCCT
ACCGTCTGAACCTTGCCTGGCCGAGTATCTCCGTCCAAACCTGCGTCTCAACCTCGCTTGTGCTGTCTCA
TTTAGCTTGTATGAGCCTCTTGGACCGGGAATGCGACATGGCACTGGCAGGCGGCATCACCGTCCGCATC
CGCACCGCTAGCTGGTTATGTGTACGCGGAAGGCGGTATTTCTCACGAGATGGTCAATTGTGCGCGATTG
ATGCCAAGGCTAATGGAACCAATATGCGCAATGGCTGCGGCGTGTGCTGCTGAAGCGCTTAGATCGTGC
GCTGTCGAGCGAGCCCTTCCCTCAACTTCGAGCGCTAATTCTGGGACGCGGACCAATATGACGGTGGCGCAAG
ATTGGGTTTACCOCGCTTCCAGAGTGGGTGAGGCGCAAGCGATCATGAGGCGCTGGCGCTGGCGGGTG
TTGAGGCGCGTATGATCCAGTACATTTGAAACACATGGCACCGGCACACTGCTCGGGGACGCAATCGAAAC
GGCAGCTTACGCGCGGCTTTTGCATCGCGACGCGTGCATCGCGCTCTTGGCCCATCGGCTTCTGATAAA
ACCGGCTCGGTCACTGGAATCTGCGCTGGCATTGCTGGTTTGATTAGAACCGTACTGGCGCTTGAAC
ATCGTCACTGCGCTTCCCTCAACTTCGAAAGCCCAATCCGTCGATCGATTGCGCTCATCTCCATT
CTACGTGAACACGTCACGTGAAGACTGGAACTGCTAGCACACCGCCGCGCGGGGTATCAAGCTTT
GGTATTGGCGGTACCAACGCCCATCTGGTGCTGGAAGAAGCTCGCGCAGCCAAATGGCAGCTCGCGCTC
CAGCGCTTACGCGCGGCTTTTGGTGTGCTGAGTAAATCAGCAGCAGCTTGGATGGAGCGCTTGTGGCGG
TCTGCGGATCACTGCAAGCTCACCAGGGTTTGTCCCTGGGCGATGTGCGCTTTAGTCTGGCTATCA
CGCTCCCTATGGAACATCGTTTGGCAATGGCGGCGCGGAGTCGGGAAGCACTGCGAGGGTTTGGATG
CGGACGCGCGTGGACAAACGCTCTCGGCGGGTCCGCGGTGTTTCCCTGGCAACGCTCCGAAAGT
CGTCTTCGCTTTCTGGGCGAGGTAGCCAGTGGGTGGGTATGGGTGCTCAGTTGTTGGCCGAAGAACA
GTTTTTATGCGCGCTTTCGCGCTGGCATCTGCAATCCAAGCTGAAGCTTGGATGGAGTTTGTGGCGG
AACTGGCTCGCGATGAAGGTTTAGCCAGATCGAAAGCTATTGACGTGGTGCAACAGTCTCTGTCGCTT
AGCAGTAGCATTCGCTGCCCTGTGGAGATCTTGGGGCGTTGGTCTGACGTCGATCGGCAATAGCATG
GGTGAGTTGCACTGCTCAAGTTGCAAGCGCTCTGTCCTCGAAGACGCGGTGGCAATCATTTGTGCGC
CGAGCGCTGCTGCGCGCTATTTCCGGTCAAGGCGAGATGGCTGTTACTGAATGAGCTCGCGGAAGC
AGAAGCCGCGCTGCTGGCTATGAAGACCGTGTCTCGGTGCGGTGAGCAATAGCCCGCGCTCTACCGTG
CTGTGGGTGAACCTGCGCAATCGGGAGGTTTGTCCAGCTTAAACGCGAAGGGGGTATTTGTGCTC
GGGTGAAAGTAGATGTGGCTAGCCACTCACCACAGGTAGATCCATTACGTGAAGACTGCTGGCAGCGCT
GGGTGGCTTACGCCCGGTGCGGCGCGCTGCCGATGCCGTCAACTGTCTACTGGTGCATGTTGGCAGGC
CCGGAACCTGGGCGCTAACTACTGGATGAATAATCTGCGCAACCAAGTTTCGCTTGGCGAAGTTGTTCAAG
CGCAGCTCAGGGCGGTACCGTCTGTTTGTGAAATGTCCTCCGATCCGATTCTGACCACTCGGTGCA
GGAAATGCGTGGGCGGCGCAACGCGCAGGCGCGCAGTTTGTAGCTTACGTCGCGGCGAGGATGCAAGG
CCCGCATGCTGGAGGCGTTAGGGGCGCTGTGGGCCAAGGTTATCCAGTTTCGTTGGGGGCGCTTTTTC
CGGACGGCGCGCGCGGTTCGGTGGCGCACTTACCCTTGGCAGCGTGAACGCTACTGGCTGCGAGGCGC
AGCCAAAGCGCGCAGGCGATCTGCGCGGTGTTCTGTCGAGGCGGCCATCGCTCTTGGGCGAAATGCA
ACCTTATCAAGCAACGCTCTACCCGCGCTGAGGAAACCACTTGGATTGAAGAGCTTCCGATCGCTGG
GTGATCATCGGTCCAGGGCGCAGTGGTGTTCGCGGTGCGGCTATCTGAGATGGCTATTTCTCGGG
TGCTGAAGCCCTGGGCGATGGTCCGCTACAGATTACGACAGTGTGTTCTGGCGGAGGCACTTGGTTCGCG
GGCAGCGTTCGCGTACTGGTTCAGGTGGTGAAGCAGAACCGGAGCGGGCGCTTACAGTTTCAGATTG
CAAGCGGTGCGCGGTGCGGCGCACGCGAGTTTTCGTTTCAACGACGCGGCGCTTATACGTGTAGA
GCGCACTGAGGTGCTTGGGGCTTACGCTTCTGCGGCTCGGGCTCGAGGCTTATGCGGCTGATGCGCC
GCAGCGATGATGCGAACTTACGGAAGTGGGCTCCAGTACGCGTCCGCTTTCAGGGCATGCGCAAC
TGTGGCGCGCGAGGGGCGAGGCAATTGGGCGCGCTACGTTTTCGCGAGCGCAGCGGGAGCGCGCAATA
TCGGCTCATACAGCGCTGCTGAGTGTGCTTTCAGTGGTGGTTCCTTATTGTCGGCGTGGGGAG
GCTACCCCGTGGGTGCGCGTGAAGTTGGTTCCTGCGCTCTGCTCAACGCTCTTGGGGAATATGGT
GTCAGCAGCGGTAGTTGAACCTGGCGCTCAGACTCGGAGCTCAGGCTCGGCTTTCGGGTAGTCGA
CAGCAGTGGCGCGTGGTAGCGGAAGTGATGGCTTGGTGGCACAGCGTTTGCCTGGCGGTGTCGCGCT
CGCGAAGAAGATGACTGGTTTCTTGAAGTTGAGTGGGAGCAGCGCCGCTCGGACGGCTAAGGTTAATG

CGGGTCGGTGGTTGCTCCTGGGTGGCGGTGGCGGGCTGGGTGCTGCACATTCTGTTGATGCTGGAAGCTGG
 CGGTACAGCGGTTGTGCATGCGGCCGAGAGCAATACATCTGCGCGGGGCGTCCGGGCCCTGCTAGCGAAG
 CGGTTGATGGGCAAGCTCCACAGCCGTTGTTCACTGGGCTCGCTGGATGGCGGTGGCGAACTTGACC
 CGGGCCTGGGGGCAAGGGGCGCTGGATGCTCCTCGTAGTGCAGATGTGTCGCGAGATGCACCTGGATCC
 GGCCCTGGCTGCGCGGTGCGTAGTGTACTGTGGACGGTCCAAGCGTGGCAGGTATGGGCTTTGCGCAG
 GCCCCGCGCTGTGGTTTGCTGACTCGGGGTGCCAGGCGGTAGGGCCGGTGACGTGAGTGTGACCCAGG
 CACCGCTGCTCGGTTTGGGTGCTGTTATTGCCATGGAACACGCTGACCTCCGTTGTGTCGCGTGGATCT
 GGATCCTACCCCGTCCGGATGTTGAACTGGGTGCGCTGCTTGCAGAACTCCTTGCTGATGATCCGAAGCC
 GAAGTTGCCCTTACGTGGCGCGAGCGCTGTGTGCTCGCATTTGTTCCCGCTCAGCCGGAACCCGCCCTC
 GCGGTGCGATCGAAAGCTGCGTCCCAACTGATGTGACAATCCGTGCAGATAGCACCTATCTGCTCACC
 TGGTCTTGGCGGCTTAGGCTTGTGCGTTTGGCTTGGCTCGCGAGCGGGTGACGATCATCTGGTCTGT
 GTAGGCCGTAGCGGTGCGCCTCTGTGGAGCAGAGGGCTCGCGTGGCAGCTTTGGAAGCACCGCGGGCGC
 GTGTGACCGTGGGCTAAAGCTGACGTAGCTGATCGCGCCAGTTAGAACGCACTTTTACGGGAAGTGAAGC
 CTCGGGCATCGGTTACGCGGCTCGTTTATGCGCGCGGATTCGTGATGACGGGTTACTGATGACGAA
 ACGCCCGCACGCTTTCTGTAAGTAGTGCGCCAAAGGTTCAAGGCGCACCTCCATCTTCATGCACCTACGC
 GCGAGGCACCGCTGAGTTTATTTTGTCTCTACGCTCCGCGGTGCGGCTGTGGGTTCTCGGGTGACGG
 GAATTTATGCGGGCGGCAATACCTTCTTGGATGCGCTGGCGCACCAACCGTCTGCTCAGGGTTACCAAGC
 TTAAGTGTGATTTGGGGCTGTTTCGCGGAGGTTGGTATGGCTGCGCAGCAGAAAGACCGGGGTGCGGTC
 TGGTATCGCGCGCATGCGCTCGCTGACCCCGGACGAAGGTCGTAGCGCTCTGGCTCGTCTCTTGAATC
 GSGCCGTGTTCAAGTGGGGTTCATGCGCAGTGAACCTCGCCTGTGGGTGGAGTTGTATCCGCGCGCTGC
 AGTTCACGATGCTGCTGCTGCTGCTAACAGCACATCGTGATCCGCTGCGCGCCCTGCGGCGCACGGCG
 ATCTTCTGCGTCTGCTGCTGCTGCGCGGAGCCTTTCGCGACGTTTCGGGTTCATGGAACGCTCTCTTCGCG
 CAGAGTTTACAGAGTGTGCGGCTCCAGAGGGCAAAATGAGGTAGATCGGCCCATCGACATCCCTGGGC
 ATGAACAGTCTCATGGTCTGGAGCTGCGGAACCGTATTGAAGCCATGTTGGGCATTACGGTTCGCGCA
 CTCCTTCTTGGACGATATCCGACCGTAGCAGCACTTTCGGGGCAGTTAGCGCGTGAAGCATCTAGTGTGCG
 GCGGTGGAGAGTCCGCATACACCGCAGATAGCGCAGTTGAATCGAAGAAATGTCCAGGATGACCTG
 ACTCAACTGATTCCGCGGAAATTTAAGCCCTGACGGGGAAATTC

EpoD (SEQ ID NO: 9)

ATGACACACAGTGGGCCGACCGCTCAACAAAAATCCACTGAAACAAGCAGCAATTATCATTCAGCGCCTTG
 AAGAACGCTTGCAGGTCTGGCAACGCGGAACCTGGAGCGTACTGAGCCAATTGCGATCTGAGGCATCGG
 GTGTGCTTTTCCGGGTGGCGCAGACGCGCCGGAAGCATTTCTGGAACATGCTCGATGCTCAGGCGGACGCC
 GTTCAGCGTTTGGACCGTTCGCTGGGCACTGGTTCGGGTAGCGCCAGTGGAAAGCGTCCCTCATTTGGGCGG
 GTTTATTGACCGAACCGATTGACTGTTTTCGATGCGGCCCTTTTGGTATTTTCGCCGCTGAAGCAGTAG
 CTTGGATCCGCAACGACGCTGTCTCTTGAAGTAGCATGGGAGGGGCTGGAAGACGCGCGCATCCACCG
 CTGTAGCATTTGACGGCTCTCGCACTGGTGTCTTTGTGGGTGCGTTACCGCCGATTTATGCCGCTACTGTTG
 CTCGCTGCTGCTGTTGAAGAACGCGACCGGTACAGCGCAGCAGGTAACATGTTATCCATCGCGCTGGCGG
 TTTGTGCTATAGCTTGGGCTTCAGGGCCCGTGTGTTGACGTTGATACGCAATGCTCGTCTCTTGTGTT
 GCTATTTCATCTGGCTGCGGCTCCTTTCGGGCTTGGCGAAAGTGACCTGGGCCCTTGCAGCGCGGCTCTCGA
 CGTTGTTTATCACTGATATGATGGAAGCGCGCGCACGCCAGGCCCTGTCCCGGATGCGCGCTGTGCG
 TACTTTTCATGCGTGGCGAATGGCTTTGTACGTGGTGAAGGTTGTGGTCTGCTGCTCTCAAAAGCTTGA
 TCCGAGCGCACGCGTGACGGCGACCGCTATTGCGGCTTAATCCGCGGCTCAGGAGTTAATCATGACGGTC
 GCTCCACGGGCTGACGCTGCGGCTTCAGGCGCAACGCTCTTGCAGGAAACGGTCTGCGCGAAGCAGCTCGTAGTGC
 GCACGTTGAAGCAGGGGCGGTGGATTACGTGGAGACTCATGGCACCGGCACCGCTGGGCGATCCGATC
 GAAGTGGAGGGCTTGAGAGCCACCGTCCGCCCGAGCCGAGCGACGCTACTCGCTGTGTGTTAGGCGCGG
 TAAAACGAACTTGGACACTTGGAGGCGAGCGCTGGTGTAGCTGGGCTGATTAAAGCTTGCCTGTCTCT
 AAGCGCACAGCACTCCGCGTAACCTGAACCTTCTGACCTTGAACCGCGGTATCCGCTCTTGAAGGCTCT
 GCATTGGCGCTCGCAACGAGCGCAGTTCTTGTGGCCGCGACAGATCCGCGACGCTTGTCCGCTGTGAGTT
 CATTTGGCATGTGCGGTACCAATGCTCAGTGGTACTGGAGGAGGCTCCGGCCGTGGAATGCTGGGCTCG
 GCGCGCGAAGCTTCCGTGAACCTGCTGGTGTGAGCGGCAAACTGAAGGTGCCCTGGATGCTCAAGCT

GCCCGCTCTGCGTGACATTTGGACATGCACCCGGAACCTGGGGTTAGCGCATGTGGCTTTCTCCCTGGCAAC
CGACCCGCTCTGCGATGACACATCCGTTGGCTGTTCGCGTAACCTCCCGCGAAGCTCTGTTGGCCGCCCTT
GTCAGCGGTGTCACAGGGCCAAACGCCAGCAGCGCGCTGCACGGTGCATTGCGAGCTCTAGTTCGCGGTAAAG
CTGGCTTCTGCTGTTTACTTGGCCAGGGCGCCCAAACTCCGGGATGGGTGCGCGGCTTATGTGCGCGCTTGGC
CCGCTTTCTGTGAAGCCTTTGATCGCTGTGTAAACGTTATTTGACCGGTGAGCTGGATCGGCCACTGCGGGA
GGTTATGTGGCGCGAAGCTGGGTCCGCCGAATCATTACTGTTAGAACAGACCGCGTTTCAACGAGCCCGCG
CTGTTGCGTGTGCAATGTCCTCTGACGGCGCTCTGGAGATCTTGGGGTGTCAACAGCAAGCTGCTGGTTG
GACACTCTATTGGCGAACTGGTTCGCGCGCTGCGTGGCTGGCGTTTCTCTCTGGAAGACGGTGTGGCGCT
CGTGGCGGCTCGGGGTCCGCTCATGTCAGGGGCTGAGCGCTGCGCGCGCCATGGTGTCACTGGGTGCTTCA
GAGCGAGAAGTAGCAGCAGCCGCTGCACACCATGCGGCATGGGTTTCAATCCCGCGCTAAATGGCCGAG
AGCAGGTAGTTATTGACGGCGCTGAAACAGCGGTGACGGCAATCGCCGAGGGTTTGGCGCGCGCGCGCT
CGCATAAACGCCCTCCACGTCCTCATGCTTTCACTCCCGCTGATGGAACCAATGCTGGAAGAGTTC
GGTTCGCGTGGCAGGCTCTGTTAACTACCGTCTGCTTAGCGTCTGTTCAACCTGAGTGGTTAAAG
TGGTTACTGACAGCTGACGCGCCCGAGGCTACTGGGTTGCTCATGTGCGCGAAGCGGCTCCGTTTGTCTGA
TGTTGTGAAGACCTTGACAGCGCGCGCGCGGCACTTTCTGGAAGTCCGCTCAACCGCCGCTGCTGCTG
GGCTCTGCTCCCGGCTGCTGCTGCAAGAGCAGAACCTACGTTATTAGCGAGCTTTGGGGCGGGCCGTTAAG
AAGCAGCGGCTGCTTGGAGGCCCTTTGGGCGTTTGTGGGCGGCGAGGCGGTTCCGTTTCTTGGCTGGCGT
TTTTCAACCCGCTGCTGTCGCGGTGTCGCTTCCGACCTATCCGTGGCAAGCTGAGCGATTTGGCTGAG
GCACCGGCGGAAGGGCTCGGGTGGCAGTGCAGCGAGATGCGTTAGCCCAAGTGGTTTATCGCTGGATTGGC
CGAAATGCGACCGGATGGTTGATTTCTCGCGGTGCGCGTTCGGCGCGCTGGCTTGTCTCTGGCGGACCG
TGGCGGGGTGGCGAAGCAGCGCGCAGCGCACTAGTAGTCAAGGCTGCTCATGTGCGGTGTTACATGCT
CCGCGGGAGCGCTCGCCGTCGCGAACAGGTGACCCAGGCGCTGGGCGGGCGCAATGATTGGCAGGGCG
TCTGTGACTTTGTGGGCTCTGAGTCAGTCTGTCGAGGCGGGCGCATCCGAGAGGAGTGCAGAGAAAGTGAAC
ACACCTGGCGACCGCTCGCGTGTAGCACTGATTGAGCGCGCTGGGACTGGCCCGCGCAGCCCTCGCGCT
GCGATTGCAACCGCTGGGGCTGTACGCTGCTGCGAGCGCGGATGCTGCCCTGTCTGAGCTCAGGCTCATGT
GGGGATGGGTGCTGTCGACGCTTTGGAACATCCGGGCTCTCGGGTGTGCTGGTTGATCTGATCCGGA
AGAATCTCAACGGAAGTAGAAGCGCTGGTGGCTGAACTGCTGTCTCCGGATGCGAAGATCAGCTCGCA
TTTCTCAAGGCGCTGCTGTCGCGCCCGCTTGGTCGCGCGCCACCGGAGGGCAACGAGACCGCGGTGT
CGTTAAGCGCGAAGGTTCTATTTGGTTACCGGTGGTCTGGGCGCTCTGGGTCTGCTGCTGGCTGCTG
GCTGGTGGAAACGTGGTGCGGGTCACTGGTTTTAATCTCTCGGCAAGGGCTCTGATCGCGAAGAAATGG
GGCGGTGATCAACCACTGAGGTACGGGCGCGTATCGCAGCGATTGAGGCGCTCGAAGCTCAAGGCGCAC
CGTAACCGGTTGCCCGCTGGATGTTGCAGACGCTGAGGGGATGGCGCTCTTTTAGCAGCGCTGGAGCC
GCCACTGCGCGCGTGGTCCATGCGCTGGCTGCTGAGCAGCGCTCTGTTAGCGCACCAAGGATGTCAGGT
CGCTGGCTCGGGTGTACGTCGCGAAAGTTGAAGGTGCTTGGGTTCTGCATACCTGACCCGCGAGCAGC
CTCTTGATCTGTTTGTCTTGTAGCTTCGCAAGTGGTGTTCGGGTTCCACTGCCACAGGGCTCTTATGCG
GGCAGGAACGCAATTTTGGATGCTCTGCGGATCTGCGTCTGACAAAGGCTTGGCGGCTTAAAGCAAT
GCATGGGGCTGTGGGCGGAAGGGGGTATGGGCTCACAAGCCAGCGCGCGAGCATGAGGCAATCCGGTA
TCTGGGCGATGCGCGAGCTCTGCGCCCTGGCGGCAATGGAATGGCTCCTGGGCAACCGCGCACGAGCG
TGTGGTAAATTCAGATGGAATCGGCTCAGCGGGTGCAGCACACCGGATGCTTCCAGAGGGCGTTTCTGG
GATCGCTGCTAACCGCTCACCAAGCAGCTAGTACAGTGTCTGTCGCCGAGCTTGAACGCTTGGCGGCTC
CAAGCGTGTGCAAAACCGGTTCCGCTCTGTATGAGCTGTGTCGCGCGTGGTAGCAGGTGTGATGGGTT
TACTGATCAAGGCACATTAGATGTCGCGCGCGGCTTTGACAGACAGGGTTTATAGATGCTCATGCGGGTT
GAAATTCGTAAACGCTGCAAGCGAGCTGGGATGTCGCTCCGCAATTGGCGTTCGATCATCCGAC
CCGTGAAGCGTTTGGTGGAAATTTTACTTAGCCAAAGCGCTAGTTTACAGGACCGTACGAGTATCGCGCT
GTGCGTCTGCAACCGCTCACCAAGGAAATCAATTGCGATTGTGGGCGGCTGCGGCTTTTCTGGGTGCGT
GAGGACCTGGAATCTTACTGCGAGTTGTGACGGAAGGTGTGCTGTTTCTACCGAAGTACCGGCGAGCC
GTTGGAAACGGGCGGACGGCGTGGCCCTGGCAGCGGTGAAGCACCGCGCAGACCTATGTTCCGCGCGG
TGCGCTTCTCCGCGAAGTCGAACTTTGACGCGGCTTCTTTCACATCTCTCCGCTGGAAGCTATGCTC
CTGGACCCGCGACAAACGCTTGTGTTAGAACTCTGTTGGGAAGCAATCGAACGTCGCGGCGAGGATCCGA
GTGCCCTGCGTGAATCTCTACTGGAGTGTGTTGTGGGTGCGGGCCGCAATGAGTATGCAGAACGTTTCA

GGACTTAGCTGATGAAGCAGCAGGGCTCTACTCCGGAACCTGGCAATATGCTGAGCGTCGCGCAGGGGGCT
CTTTCCTTTTTTTGGGGTTACACGGGCCGACCTCGGCAGTGCACACTGCCTGTAGTAGCAGTCTGGTTCG
CGTTGCACTTTGGCTGTCAATCACTGCGCCGTGGCGAGTGTGACCAAGCTTACCTTGGGGGGGGCTTAATAT
GTTACTGTCCCCAAAAACAGTTTGCCCTGCTTTCACGCATGCGATGCGCTGTCACTGGTGGAGCGTTGTAAG
ACTTTCTCGCTGACGCTGACGCGGTATGCCGCGCGCGAAGGCTGTGCGCTGTGCTCCTGAAGCGGCTGT
CTGATGCAACAAGGGATCGCGATCCGATCTCGGCAGTAATCGCGGTAACAGCAATTAACCATGATGGTCC
GAGCAGTGGCTTGACAGTGGCTCGGGTCGCGCACAGGAAGCCTTACTTTCGTCAGCGCTGGCACATCGC
GGCGTAGTGCCCTGATGTGGACTTCGTTGAATGCCATGGCACGGGGAACGCGTTTAGTGATCCGATTG
AGGTTCCGCGCATGTCGCGAGTATACGGTCAGGCCCGCGCGCGGATCGTCCGCTCATTCTGGGCGCGGC
CAAAGCGAATCTCGGCACATGGAACCGGCAGCAGGCTTAGCTGGGCTGTTGAAGGCCGTGCTGCGGCTG
GGCCAGGAACAATTCGGCTCAGCCTGAACCTGGGTGAACCTGAACCCGCTGCTGCCATGGGAAGCCCTGC
CCGTGGCGGTGGCACGTGCGGCGGTCCCGTGGCGCGCACCGATCGTCCGCGTTTTCGAGGTGTGAGTTC
GTTCCGATAGCGCGGTACCAACCGCGCATGTTGTCCTTGAAGAAGCGCCCGCGCTTAGTAATTTGGCTAGCG
CGCGCGGAACGCTCGCGGAATTTGCTGGTTCTTCTGGCAAGAGCGAGGGCGCACTGGACGCGCAGGCGC
CACGCTCGGTGAACACTTAGACATGCATCCGGAACCTGGGCTGGGCGATGTAGCCTTCTCCCTGGCAAC
AACCGCGCAGCGCATGAACCATCGTCTGGCGGTGGCTGTGACGAGTCCGCAAGGCTTATTAGCAGCTCTG
AGGCGCGTTCGCGAGGCTCAAACCGCGCGGTGGCGCTCGTTGCATTGCGAGCTCAAGCCGTGGTAAGC
TGCCCTTTCTGTTCTGCTGCTGAGCCAGGGGGCGCAGACCCCGGTATGGCGCTGTGGTAGTATTTGGCTAGC
GCTTCTCCGCGAAGCATTTGATCGTCTGCTGCGCTTGTGTTGATCGCAACTGTGAACGCGCGCTGTGTGAG
GTTATGTGGCGGAGCGGGTTCGGCGGAACTCTCTGTTACTCGATCAACAGCACTTACTCAGCCAGCCC
TGTTTACGGTAGAATATGCCCTGACCGCGCTGTGGAGATCTGGGGCGTGAACCTGATCGGTGGCGGG
GCATCAGCGGGGCGAATCGTGGCAGCTGTGTAGCTGTGTGTTCTCTGGAAGATGGTGTCCGCTT
GTGCGCGCGAGTGGCGCGCTGTGAGGGTCTGTGCGCTGGTGGCGCGATGGTTAGTCTGGGTGCTCGG
AGGCGGAAGTTGCTGCGCGCTGAGTCCACATGCGGCTTGGGTATCAATCGCAGCGGTAAATGGTTCGGA
ACAAGTTGTCATTGTCAGGGCTGGAACAGGCACTCAGGCAATCGCGCGGGTTTCGCGCAGCAGCGGGGTC
CGTACGAAACGGCTGCACTGTTAGTCTAGTACGCACTCTCCTCTGATGGAACCCATGCTGGAGGAGTTGC
GCCGCGTGTGCTGCTTCTGTTACTACGCGCCGCGCATCTGTGTGCTGGTTAGCAACCTGAGTGGTAAGGT
GTGACCGATGAACCTTTCTGCCCCGGGTACTGGGTCGCTCACGTGCGTGAAGCGGTCCGCTTTGCGGAT
GGTGTGAAGCGTTACATGAGGCTGGGCTGGTACGTTTCTGGAGGTAGGGCCCTAAACGACCCCTCCTGG
GCCCTCTGCCAGCATGCCCTGCCGAAGCGGAGCCGACGCTGTGGCGAGCCTTCGCGCAGGACGTGAGGA
AGCAGCAGGCGCTTAGAGGCGCTGGGTGCTTTTGGGCGCGGAGGAAGCGTCTCGTGGCCCGGTGTG
TTTCGACCGCTGCGCGCGCTGTCCGCCCTTCAAACCTATCCTTGGCAACGCGCAGCGCTACTGGCTGCAGA
TGAACCTGATATGCTGCTGAGCGCGCGCGGATCCGACACAAGGTTGGTTTACGCGCTGGATTGGCC
GGAATTTCTCGGAGTCTCCAGAAGTCAGAGGAGGCTTACGCTGGGAGCTGGCTGTTCTGCGCATATAA
GCGCGTGTAGCGCAAGCGGTTGCGCGGCTCTGTCTACACGCGGGTTACCGTGGGTTGTCTGCTATGCC
CAGCGGAACCTCAGGCACTCGGAGCTGGTGACGAGGCTCGCGCGCTCGCAGCGATTGGCAGGTTGT
GCTGTATTATTGGGGCTTGTAGCGGCTCGTGGTCTGAAGCAAGTATCGATGAATTTGGGATGCTACT
CGTGGCGGACGCGCCCGGTTCTGGGCTCGCGCGCTTCTGTGACGCTTGTAGTTAGTGGCCCTCGGCTGT
GGGTTGTTACACGCGCGGTGCATCGTTGGTGATGAGCCCGCATCGCGCGGTGCCAGGCACTGTG
GGGATGGGTCGCGTTCGCGCACTTGAACACCTGGCGCATGGGGGGGCTCGTGGATTGGATCCGCGA
GCGTCTCCGCTCAGGCTTACCAATCGACGCTGAATGTTAGTTACTGCAACTGTAGTCAAGAAACCG
AAGTACAGTTGCGTTTCGCGCAGCGCGCGCCATGCCGCTCGCTCGTATGCGCGCCACGCGTGGGGA
GGCAGCGCTGCGTCTTGAAGCGCGAAGCAAGTTACCTGGTGACCGGTGGGCTGGTGGGCTTGGCTTG
ATTGTCGCGCAGTGGCTGTTGGAATTAGGCGCGCTCATCTGTGCTGACTTCACTGTCGCGGTTGCCG
ATGCTCAGGCTTGGCGCAACAGCAACACCAGAAATCCGCGCTCGTATCGCGCTGTGGGAAGCACTGGA
AGCTCTGGTGGTCCGCGTTATCTGTAGCAGCGCTGGATGTGCGAGATGCGAACCATGACCGCCCTCGT
TCTCAGTGAACCCGCGCTGCGCGGTGTTGTCCAGCTGCGGGCGCTCGGTTATGCGTCCGCTGCGCTG
AAACAGCATGACGATGAGTTAGATCTGTGCTGCTCCTAAGGTGGCGGAGCGTGGTTATGTCATCGCT
GCTGCACGCGCGTCTGCTGGACCTGTTTGTGCTGTTCTCAAGCGGTGCGCGGTTTGGGCGAGTCAAGC
CAGGGTGCATGCTGCTGCAACCGCTTTTTGGATGGCTGGCACATCTGCGTCTCAGTCACTGC

CCGCCCTTAAGCGTAGCCTGGGGTCTCTGGGCCGAAGGTGGCATGGCGGATGCTGAGGCGCATGCCCGCTT
ATCAGATATTGGTGCTCTCCAATTGTCAGACCTCTGCTGCCCTTATCCGATTGCAAGCGTCTGGTGAAACCC
GGCGCAGCACAAOCTACTGTTCACGCGGATGGACTGGGCCCGCTTTGGCCAGTGTACACGGCACGTGGCC
GTCGTAACCTGCTGAGCGCTTTAGTGGCTGGTCCGGATATTATTCGCGCTAGCCCTCCGCGAGCTGCTAC
ACGTAAATTGGCGGGCCCTCAGTGTCCGCGAGGCCCGCATGGCGCTGCATGAAGTGGTGCATGGTGCAGTT
GGCGGTGTTTTAGGCTTTTTGGAGCCCTTCTGCACTGGATCCGGGCATGGGCTTTAAACGAACAAGGTTTTGG
ACTCTCTGATGGCGGTGGAGATTTCGGAACCTTTTGCAAGCAGAACTGGACGTGCGTCTCTCAACGACATT
AGCGTTCGATCACCTTACTGTGCGAGCGCTGGTGGAGCATCTGCTCGTGGATGTGTCTAGTTTGAAGAC
CGCTCTGATACGACGATATTGCGCTCGCTGGCCCTCCGACGAGCCAAATTGCAATCGTGGCGCTGCTCGCC
GTTTTCTGGGCGCGCTGGGAAGACTTGAAGACTATGGCAGTTACTGCGAGAAGGGGTAGTGGTTTCGGC
CGAAGTCCCTGCGGACCGCTGGGACGCGGCCGATTGGTACGATCCGGATCCGGAATCCAGGCGCGAGC
TATGTTACCAAAAGGCGGTTTTTGCGCGATCTTCAAGCCTGGATGCCACGTCTCTCCGATTAGCCCGC
GTGAGGCTGATGACCTCGACCCGACAGCGCCTGCTTTTGGAAAGTGTCTGGGAAGCGGTGAGAGCGC
CGGATCGCCCCGACACCTTGCCTGACAGTCCGATGCTGCTCTCGTAGGTGGCGGCCAAACGAGTAT
TACACGCGAGCGGTTACGGGTTTTACTGACGGCCCGCTGGTCTCTAAGTGGCACTGGCAACATGCTCT
CTGTGGCAGCAGGGCGCCTTTGTTTTTTTTAGGCTTGACGGGCCGACATTGGCGATGGACACGGCGTG
TTCGAGCTCGTTAGTAGCGCTTTCATCTGGCTTGTCACTGCTGCTGCTGGGTGAATCCGATCAGGCATTG
GTTGGCGGCTGAACTGCTCTTTTAGCGCCGGAACCTTTGCTCTGCTGTCACTGTATGCGTGGCTTGTCA
CAGATGGTCTGTGTAAACCATTCAGCGCGGATGCGATGGTACGCAAGTGGTGAAGGCTGTGCTAGTGGT
GTTCTGAAACGCTCTCCGTGATGCGCAGAGGCCGCTGACTCGAATTTCGGCGCTGATCCGCGGTAGTGT
GTAAACCATGATGGTCCGTCCTCGGGTCTGACCTGCTAATGGTCCGGCGCAACAGGCACTTTCGCTC
AGGCTCTGAGCCAGGACAGTGTGTCCCCTGTGGATGTTGATTTCGTGCAATGCCATGGCACTGGTACCGCT
TCTGGGTGACCCGATTCAGCTCTGAGTGAAGTATACGGTCCGGTCTGATGAGGATGAGGATCGCCCT
CTCGTATTAGGCGCGCTTAAAGCCAAATGTTGCCCACTTGAAGCAGCAGAGCGGCTGGCATCATTTACTGA
AAGCGGTGCTTGCCTTACCGTACGCAACAGATTCCAGCGCAGCCAGAGCTCGGGGAGCTGAACCCGCACTT
GCCGTGGAATACTCTCCCAGTGGCGGTTCCACGTAAAGCGTGCCATGGGCGCTGGCGCTGCTCGCGC
CGTGGCGCGTGAGTGCTTTGGTTTATCGGGTACCAACGTTTCACTGTGGTGTAGAAAGAGCGCCGGAG
TAGAGTTAGTGCCAGCTGCACCTGCGCGTCCGGTTCGAACCTGGTGGTGTGTAGATGCGAAAGCGCTGCGGC
TCTGAGCGCTGGCGCAGAACGCTGAGCGCCCATCTGAGCGCACATCCGAGAGCTGTCTGTGGGCGATGTA
GCCTTTATGTGCTACTACTCTGCGAGCCCGATGGAACACCGCCTGGCGATTGCGACACCAAGTCCGGAAG
CCTTACGTGGTGCCTGGATGCGCGCAGCCAGCGCCAGACCCCGCAAGCGCTGCGCGCGCAAGCCGT
ATCCAGCGCAGGCAAAATTAGCCTTCTGTTTACTGCGCAGGGGGCCAGATCGCGGATAGGGGCGCGGC
CTGTACGAAGCTTGGCCTGCTTCCGCGAGGCGTTTGACCGCTGCGTAGCGCTTTGACCGTGAACCTGG
ATCAGCGTGTGCGTGAAGTATGTTGGGCGGCGCCAGGTTTGGCGCAAGCTGCGCGTTTAGATCAAACTGC
CTACGCGCAGCCAGCCCTGTTTGCACTTGAATACGCACTGGCTGCGCTGTGGAGATCTTGGGCTGTGAA
CCTCACGTTCTTCTGGGTGATTCGATTGGTGAACCTGTTGCGCGTGTGCGTGGTGTATTAGCTTAG
AGGACGCTGTGCGCCTTGTGGCCGCAACGCGGCGCTGTGATGAGCGCTGCGCGCTGGTGGCGCATGCT
GCTCTCGAGCGAGTGAAGCGGAGGTAGCGGAGTGTGCTCCACAGCAGCCACGCTGAGTATGCGA
GCCGTTAATGGTCCGATGCGGTGATGTCAGGCGCGGAAGTTTCAAGTTTTCGGGTTGGGTGTCTACCT
TCGGCGCGCGGAGTCCGTACGAAACGCTGCGCCGTATCTCACGCCCTTTCATTACCGTTGATGGAATCC
TATGCTGGAGGATTTTCAACGCTGCGCGCAGCACTGCTATCGTGACCGGATCGTCCGGTAGTGTGCG
AACGTTACTGCTCAGGTGCGAGGTCCGGAGATCGGACACCTGAATATTGGGTTTCGTCACTGTGCTGAG
CGGTTGCTGTTTGGCGATGCTGCTAAAGCCCTTCAAGCTGCGGCGCAGCAGTGTGTAGAATTGGGCC
GAAACCTGATTGCTGGGTCTGCTGCGAGCTTGCTGGCGAAGCGGACGCGTACTTGTGCCAAGTTTA
CGCGTCACTGCTCAGAGTGCAGAGTGGTGTGCGCAGCATTAGGCACATGGTACGCTGGGTGGCGCAG
TGGATCGGAAGCGCTATTTCGAGTGGGCGCGCGCGTGTGCGCTGCGCTGCGCTGCGCTGCGCGCAG
ACGTCATTGGCTCGAGCTGACACCTGTTCTGCGGCTCCAGCGGGCATTCGCGGCTGTTGGCGCTGGCG
GGCGTGGGCTTTGATGCTGCGTCACTGCTGCTCCATCAGTGTGCTCAATAGGGCCACGTCATCAGCAT
TCTGGGTGACCATCTGTGTGTTGGTAAAGTGTGCTGCGGCTGCAATTCATGTGGCGGTGATTCTGAG
TATCGCAGCGGAACGCTGGCTGAACTGCAATCGAAGTGCAGGCGTTGAATTTCTGAAAGCCATGCT

ATGGAGCCGGATCAGGAAGTGAAGTGCATGCTGTCTTGACGCCGAGGCGGCAGGGGACGGGTATCTGT
TCGAACTGGCAACCTTGGCGGCACCGAAGAACTGAGCGTTCGTGGACGACCCATGCTCGCGGCCGTGTGCA
ACCGACAGATGGGGCACCAGGGGGCTTACCGCGTTTAGAGGTGTTAGAAGATCGGCCATTCAACCTTTG
GACTTTGGCGGGCTTCTCGGATCGGCTCTCAGCAGTCCGCATTGGCTGGGGCCGCTGTGGCGGTGGGCTTC
AGGATGGTCTGTGGGATCAAGCCTAGCCTGGGACGCTGGTGGCCGACTATTCACAAAGCCCATAGCT
GGCGCCGCTGCACCCGATTTTGTGTAGATAACGGTTTCGCGGTGTCACTGTGTGGCGACCCGGTCGGAACCA
GAAGACGATGGTACTCCACCGCTGCCGTTTGTGTGTGAACGCGTGGCGCTGGTGGCGTGCACCTGTGGT
GTGTCCGCTGTGGGGCGCTTCGCGCTCACAGGCATTGGCGCTCTCTTCGTCGTACTGTGGACGAAC
TGGTGAAGTTGTGCTGAGGTGGAAGGCTTTGTGTGTGCGCGGCTCTCGCGAAGTCTTTCTGCGTCAG
GAATCGAGGGCGTCTACGCTGTCCCTGTATGCGCTTGGATTGGCGTGAAGGCGCGCTGCGCGATGCGGAC
CTGAGCGGATGGAAGAATCATGGTGGTGTGTGCGAGCTCCGGGGTCGGAATGGCAGCGCATGTGGCTAC
GCGCTCAACCGCTGCGTGTCTGCGCGAACCTAAGGTCTGGAGGCGGCATGGCAGGGCTTAGCGCTGCC
GGTGTGATTTGGCTGTGGGAACCTGGCGCGCATGAAGAAGCACTGGCGGACGCGCAGCGTGTGCGCACGG
AAGGTCTGTCCGTGTCGAGGCATTCGTGATCGCGCGTACGCTGTGGTGGTTAACACAGGGGCTGT
GGCGGTGGAAGCTGCTGAGCGCGTGCAGGTTCGCACTGCCCGCTCTGGGGGCTCGCGCGCACCGTGTG
CAAGAGCGTCCGGAACGTCTTGTACGTTAGTGGATCTGGAACCGGAAGTCGATGACGCGTAGCGCGG
ACGTTCTGTGCTCGGGAATTAGGCGCGTGGGATGATGAAACGCGAGTGTCTCCGTTCCGCGGAACGCG
TGTGCTCGCTGGCTGGTCAAAGCGACACACCGGAAGTCTTCTGTGGCGGACGCGCGGAATCTTATCGTCT
GAGCAGGTGAGAAAGCACCCTGGATCAGCTGCGGTGGCACAGCCCAACGGCGGGCTCCGGGCCGAG
CGGAAGTGAATCAAGATGAACCGGAGCGCGCTGAATTTCCGTACTGTTCTGCTGTTCTGGGGATGTA
TCTTGTGACGCGAGGCCGATGGGCGGGGATTTGGCGCGGATCGTCAACGCGTGGCGGCGGTGCTCAT
CACCTGAGCGTAGGTGAGCGCGTGTGATGAGCTTAGGCACATTACACGTTTGTGACGCTGGATGCTCGGC
TGTGTTGTTCTGCAACCGGCTGGCTGTGATCTTGGCCCAAGCTCGCAGCGCTCCGGTTGATTTCTGATG
GTGGCTGGCACGTGATGATCTGGTAACCTCCGTGTTGGTGAACGCGTGTGATTCATGCGCGCGAGGT
GGCGTGGGATGGCGCGCTCAAATCGCAGCGTGGATCGCGCGGAAGTTTTCGCCACCGCTCTCCGT
CCAAATGGGCGCGTCTTTCAGGCGATGGGTGTGCGCGTACGCACATTGCCAGTTCTAGGACTCTGGAGTT
CGCTGAACCTTCCGCAAGTTACGGGTGGCGGTGGTGTGATGTTGTACTTAATGCTTTGGCGGGCGAG
TTTGTGGATGCATCTCTGAGCCTCTTGACCACTGGTGGTGGTTTCTGGAGATGGGCAAAACGGACATT
GCGATCGCGCGCGTCTGCTGCGCCACCCAGGGGTGCGTACCGCGTATTGACATCTTAGAGCTGGC
GCCAGATCGGACCCGTGAGATCTTGAACGCGTCTTGAAGGTTTCGACGGGGCCATCTCCGCGCTTTG
CCGTTGCATGCGTTTGCATATTACAAAGCGAAGCGCGCTTCGTTTACGGCGCAGGCTCGGCACCAAG
GCAAGTCTGCTCTGCTCCTCGCGCAAGCGCGGCCCACTGGCCCCAACGGGGACGGTTCTGCTGACCGG
TGGCTTAGGGGCGCTCGGTTTGCATGTGGCACGCTGGTTGGCTCAGCAGGGCGGCTCACACATGGTCTG
ACGGGTGCGCGTGGTTTGGATACCCAGGGGCGGCCAAAGCGGTTGCCGAATTTAGGCTCTTGGTGGC
GTGTCACTATTGCCGATCTGATGTGGCTGATCGCAACGCTCTGGAGGCGGTTTACAAGCAATCCGAGC
GGAATGGCGCTGCAAGCGGTGATTATGCGGCTGGCGCACTTGATAGTGCTGCTCGGTCAGGCGTGGCAAC
ACGACCGTTCTCAGCGGTGTATTAGCCCCGAAGTAACCTGGCGCTGGAACCTGCACGAGTTAACTGCGG
GGAATGATCTGCTGCTTTTGTGTGTTTGTAGCTCAATGAGTGTCTGCTCGGTGAGTGTGCTGAGTGGAA
CTATGCGCGCGCAACACCTTTCTGGATGCGCTGCGGCTCACCGCGCGCAGAAGGGCTGGCAGCTCAG
TCGCTAGCTTGGGGTCCGTGGAGTGTGCGGATGAGCGGCGGGTCTTTGAGCGCGCTTCAAGCAGCT
TTGACGACCGATGAGGCGGCTTTCGCCGCGCGCAGGGCACGCGCTCGGTCAGGCTGAGCGTGGCAAC
CCGGAACCTCAGCTGGGTCTGATGCTCTTGTATGTGAGAGCGGCTCCGAGCGCTCGCGCGCGCAGTTC
CCTCAGTTTGGCGTCCCTGCGGTGCGAGGCTCGCCATGCGCGCGCGCTGAGTGAAGCTTATGCGTCTAG
CGGCAGCGCTCGGGGCTTTGCTGAAGCCGCGCGCGGACGAAGTGGCGGAAGTTGTTCAAGCCGAAT
TGCAACCGTGTCTCAGCTGGGGGCGCGAGCGCGTACCCGTTGATCGCCGCTGTCTGATCTGGGTTTA
GATTCATTACAGCTGTGCAATACGCAATGTTCTCGGCCAGCGTGTGGTGTGCAACCTGCCAGCGACCT
TTGCGTTGATCAACCAACTGTAGAGCAGCTGACCGTGTGGCTCTGGAACAAAGTTTCTAGTGTGGCAGA
ACCTTCGCTCCCGACGCAAAAGCTCTCCGAGGTTGGCTCGATGAACCAATTTGGCTATTATGGTCTAG
GGTTGCGCGCTTTCGGGTGGTGTACCGATCCGGAAGCTTCTGGCGCTGCTGGAAGAAGGTAGCGATG
CGGTGTTGAGGTCCCGCATGAGCGCTGGGACATCGATGCGCTTCTATGACCCAGATCCGGATGTGCGTGG

GAAAACTGACTACGCGGTTTGGCGGGTTTGTGTCGGATATTGACCGCTTCGAACCTGCATTTTTCGCGCATT
TCCCCGCGCGAAGCTACGCCATGGATCCGAGCAGCGCCTGCTGCTGGAAACGAGCTGGGAGCGTTTG
AGCGTGC CGGCATTCTCCCGAGAGCGTCTTATGGGTTCCGATACGGGTGCTCTTTGGGGTCTTTTCTATCA
GGAATATGCGCGCCTCGCTGGTGGTATTGAAGCAATTGACGGTTATCTGGGGACCGGCCACCGCGCATCC
GTCGCGAGCGGCGGTATCTCGTATGTTCTGGGCTTAAAGGTCCGTGCTTGACTGTTGATACGGCGGTGTA
GTTGTCGCTGGTGGCGGTACATCTGGCATGCCAAGCGCTCCGGCGGGCGAATGCAGTGTGCGCTTAGC
AGGTGGGGTGGCTTTGATGTTGACCCAGCTACATTTGTTGAGTTTCAGTCGTCTGCGCGGCTTTGGCGCGG
GACGGTGTGGTACAAATCATTCGAGCGCTGCGCGAGATGGTGTGGTGGTCCGAGCGGTGCGGATGCTGC
TCCTCAAACCGCTGCGCGATGCCCAAACGCGACGCGCATCCGATCTTAGCGGTGATCCGCGGAGACCGCGCT
AAACCAAGATGGCGGTAGCAACGGTTTAAACGGCGCTAATGGCTCCAGCCAGCAGGAAGTCATCCGTCGC
GCATTAGAGCAGGCAGGCTTAGCGCCAGCCGACGTGAGTTATGTGTCAGATGTCATGGTACGGGAACACCC
TCGGTGATCCGATCGAAGTGCAAGCGTTGGGTGCGCTATTAGCACAGGCGCGCCGAGTGATCTGTCGCT
GGAATTTGGTAGCGTCAAAGCAACATTTGGGCATACCAGGCTGCGCGAGCGGTGGCGGCTGTGATCAAA
GTAGCTCTGGCTCTCGAAACGGGCGCTGATTCTCGCGCTCTCTGCATTTTGATGCCCGAACCCGACATTC
CGTGGTCCGAACCTGGCGGTGAGGTGCGCGCCAAACCTGTGGAGTGACACGCAACGCGCGACCGGTGCG
CGCAGGCGTATCGAGTTTGGTGTGAGCGGTACCAATGCCCAAGTGTGTTAGAGAAGCCCCAGCAGCG
GCCTTCGCAACCGGCGCGCGCGGTGAGCGAGTGTGTTGTCGTGTCGCGGAATCTGCGCGCGCGCTGG
ATGCCAGCGGCGGCAAGTCTTTCTGCGCATGTGTTGCACATCTGAGTGGGCTTAGGCGATCTGATCAAA
TAGTCTGGCGACTACCGCTCAACATGACGTATCGCTTAGCAGTAGCTGCGCACAGCGCGGAGCGGTG
TCTGCGCGCTGATACCGCTGCGCGCAAGGCAAGCACTCAGCTGTCGTCGCGGTGTCAGCGAGTACTG
GCTCGCGCGCGAAGTTGTATTTGTGTTCCCTGGCCAAAGGAGCAATGGTTAGGTATGGGCGAGAACTG
GCTGTCCGAAGAACCTGTATTCGCTGACGCTCTGTGAGTTCGCGATCGTGCAGTTCAAGCGGAGGCTGGG
TGGTCTTATCTGCGAGACTCGGACGAGATGAACCAACCTCAGCTGAGGTGCGATTGATGTGGGATCG
CTGGCTTTTGGCATCGAAGTGGCACTGAGCGCGCTGTGGAAGTCTTGGGGTGTGGAACCGGATGCCGT
TGTGGTCAITTTATGGCGAAGTGGCGCGGCCCACTAGCAGCGCCCTTAGTCTGGAAGACGCGGTA
CGCATCATTTGCAGGCGCAGCCTTTTGTGTCGCGCTATTAGCGGGCAAGCGGAATGGCAGTGGTCAAC
TGTCCCTGGCTGAAGCGGAAGCGCGCTGCTGGGTTATGAAGACCGCTTAGAGCTTGTGTTTCGAACCT
GCCACGCTCAACCGTCTTGGCGGCGAGCCCGCTGCGCTGGCGGAAGTTTATGCGATCTCGGCGCAAAA
GGCGTCTTCTGTCGTGCGGTGAAAGTAGATGTAGCTAGCCACAGCCCTCAGATTGATCCATTAGCTGACG
AATCTGTTAGCGCTCTGGCGCAACTGGAACCACTGAGCCACGCTCTATGCGGTCCACAGTACAAG
CACGATTGTGGCGGGCCCGAAGTGGTGGCGAGCTATTGGGCAGATAATGTGCGCAACCTGCGCTCCGCTTC
GCGGAAGCGGTGCAATCTCTCATGAAGGCGGGCATGGCTGTTTGTGCAAAATGTGCGCGCACCTATT
TGACCACCAAGCGTCAAGAAATCCGTCGGGCTACTAAACGTGAAGGCGTGGGTAGGGTCTGCTGCGT
CGGCCAAGATGAACCGTTGTCTATGCTGGAAGCGCTGGGCGCACGTGGGTGTCATGGGCGAGCTGTAGT
TGGGAACCGCTGTTTATGGCGGGCGGCGAGGCTGCGCGTTCATTACCAACGTACCCTGGGCGAG
GCGAACGCTATTGGCTGCAGGACCAACAGGTGGTGGCGGAGCGAGCGCGTATTGGCATGCTGGGT
GCATCTGCGCTCTGGGTGAAATGCAGACCTTAGTACCCAGCGTAGCACCGCGCTGGGAGACCACTC
GATCTGAACCGGCTGCGGTGGGTGGTATCAAGCGGCGTGTAGTTTTCGCGGTGCTGCGCT
ATCTGGAATATGGCGTGTAGTTTCGGTGGGAGGCTCTGGGGATGGTCTCTCCAGGTTAGTGTATGTGT
TGGCGGAACCGCTCGCTTTCGCGGACGACACCCGCTGGCTGTGTCAGTAAATGGTACGGAAGCGT
CCGGGCGGTTTACAATTTTCATGTGGGCTCACGTGTTCCGGGCGAGCGCGCGTCTTTCGCTCTCACG
CACGCGGCGTCTTCTGTCAGACGAGCGCGCAGAGGTGCCAGCACCGCTGGACCTGGCCGCGCTGCGCG
ACGCTTTCAGGCGAGTGGCGGCTGCGGCCACCTACGACGCGCTGGCGGAAATGGGTTTAGAATACGCG
CCTGCTTTCAGGTTTATGTTGAATCTGGCGGGGTGAGGGCGAGGCGCTGGGTGCGCTACGTCTTCCGG
AGGCGCTGGCAGCGCCGCGCGCTTGTGCTGTCATCCAGCACTGCTGGAAGCTGCTTTCACGTTTCTTC
TGCCTTTGCTGATCGCGGGAGGCCACCTTGGGTGCGGTAGAAATCGGTTCTTGCGCTGGTTTCAG
CGGCGCTGAGGCGGCTTTGGTGTTCATGCCGCTAGCGTATCCATGGCAACACTACGCTGATCGCGCT
CAACAGACTTTTGGGTGTTGACTCGACTGGCGCGATCTGGCGAGATTCCGGGTGGTTGACAGCG
TTTGGCAGGCGGCTTCTGTCGCGGGAAGAGGACGATTGGTTTCATGGAACCTGCTTGGGAGCCACAGCT
GTGCTGCTCTGAAGTTACTGCGGCGCTTGGCTGTTGATTGGGTGGGTGGTGGGTGCGAGCC

TGTATAGTGCTCTGACGGAAGCAGGCCACAGCGTGGTCCACGCCACCGGCCACGGCACCAGCGCGCGGG
 CTTCAGGCTCTGCTGACGGCATCGTTTACAGCGTCAGGCTCCGATAGCGTCGTTTCACTAGGTTCACTG
 GATGAACCGCGGTTTCTTGTAGCCGACGACCGCTTTGATGCTGACGCCCTGGAAAGATGCTGGTGGCGG
 GCTCGGATCCGCTACTGTGGACCGCTCCAGGCGGTTCAGGTCGGGGTTTCGTTGATCGCCACGCTTTT
 GTTAGTGAACGCTGGGCGCAGGCCATTTGGCGCGGTGATGCTCTGTGGCGCAAGCCCATGCTGGGT
 CTCGGCCGTGTGATCGCATTTGGAGCAGCCGAACCTGCGTTTGGCCCGCATCGACCTGGATTCGGGCGGTC
 GCGAGCGCGAAGTCGATGAGCTTTCTTGAGAGCTGTGGCTGACGATCCGAGGAAGAAGTTGCGTTTCG
 CGGCGCGGAACGCGCGGTGGCCCGCTCGTGCGTCTTTTACCGGAGACAGATTGCTGCGTGAAGAAATCGAA
 CCAGCTGAAGGCGCGCTTTTCTGCTGGAGATTGACGGTTTCAAGTGTCTCTGGAGATTGGTTCTGCGGTG
 CCACGGAACGTGCTCTCGGCGCCCGGGGAAGTTGAAGTCGCCCTGGAAGCCCGCGCTGAATTTTTT
 GGAATGTGATGCGTGAATGGGCATTTACCTGGTTCGGGCGACGCTCCAGTAGCATGGGCGCCGAATGT
 AGTGGTCGTAATTTTGTCTATGGGCGAAGGCGTCGAAGCCCTTCGATCGGCCAAGATGTCGTCGCGCTCG
 CACCTTTCTTTTGTACTCATGTGACAATCGATGCCGATATGGTCGCCCGCGCTCAGCGCGCTGAC
 CGCAGCGCAGGCGGCTGCCCTGCCCTGTGGCTTCATGACGCGCATGGTATGGTTTAGTGATCTGGTGGT
 CTGCGTCGGGCGAAGCTGTTTGTATTATAGCGCCACTGGCGGCATGGCCCTTGGCGAGTACAAATCG
 CGCGCCATCTCGGGGCGGAGATATTTGCGACAGCAGGCACCCCGAAAAACGCGCATGGCTCCGCGAACA
 AGGATATTGCGCATGTAAATGGATTCTAGGTCACTTAGACTTTGCTGAACAGGTCCTGGCCGCGACAAAGGT
 GAAGCGGTGGATGGTTTAAACTCCCTGTCCGGTGGCGCAATCGATGCTTCATTAGCCACTTTAGCTTC
 CAGACGCGCGTTTCACTGCAACTGGTAAACCGGACATTTACGCCGATCGACGCTGGGCTGGCCCACTT
 CGCAAAAGCCTTTTCTACAGCGCAGTCGATCTGGCTGGTTTAGCGGTTTCGGGCGCCGGAGCGTGTGCG
 GCTCTGCTTGTGAGGTGGTAGACCTGCTGGCAGTGGTGCGCTTCAGCCGTTGCCCGTAGAAATCTTTCT
 CTTTGAAGCGCGCGCGCGGACGCTTTGCGAAAAATGGCACAAGCTCAACACTGGGTAAATTTGGTCTGGG
 ATTAGGAGATTCGGAATGCGCATTCGCGTCCAGCGCAGAGTGGGGTAGCAATTTCGCGCAGACGCGCAG
 TACCTGCTGACCGGTGGTTAGGTGGCTGGGTCTTAGCGTAGCGGGTTGGTTGGCCGAACAGGGCGCGG
 GCCATCTGGTTCTGGTTGCTGCTCGGTGCGTCCGTCAGTGCAGAACACAGACCGCGCTAGCGGCCCTGGA
 AGCACAGGGGCTCGCGTTACAGTTGCTCGTGCCAGCGTTGCGGATCGTGACAGATCGAAAGCTATCCTT
 CGCGAAGTGACCGCGTCGGGCACTCGGCTTCGTTGGTGTGGTGCATGCGAGCTGGCATCTGGATGACGGCC
 TGCTGATGCGCAGACACCCGGCAGCTTTTCGCGCAGTTATGGCTCGAAAGTCAGAGTGGCCCTCACTT
 GCATGCGCTGACCCGTGAAGCGCCACTGAGTTTTCGTTTATATGCGAGTGGTGGCGGCTTTTGGGT
 AGTCCAGGCGAGGCAACTATGCCCGCGGAACACTTTCTTAGATGCATTAGCACACCACCGCGCGCGC
 AGGCGCTCCAGCCTTAAGTATGACTGGGGTCTGTTGCTGATGTGGGGTTGGCGGCTGGACAGCAGAA
 TCGCGGCGCGCGCTTGGTAACAGCTGGGACTCGCAGTTCGACCCCGGATGAAGGTCTGTGGGCACTTGA
 CGTCTCCTGGATGGCGATCGGACTCAGGCGAGGGTGTGCGGTTTCGACGTGCGCCAAATGGGTGGAGTTCT
 ATCCGGCGCTGCTTCTTCACTGCGCTGAGTGGTCTGGTTACCGCCCGCGCTGTGGCGAGCGGCGCTCT
 GCGAGGCGATCGCATCTCTTAGAGCGCTCGCTACGCGCAGAAGCGGGTGCCCGTCAGGTATGCTCCAG
 GAAGTTGTTTCGCGCAAGTGTCTCAAGTGTCTCGTCCGGAAGGGAACCTTGACGTTGACGTCGCCG
 TGACCTCCCTGGGCACTGGATAGCTTGTAGGGTCTTGAATTGCGTAACCGCAATTGAAGCTGTTTGGGGAT
 CACCATCTGCGACCTGCTGTTGGGACTTATCCTACCGTCGCGGCGCTGAGTGGCTGCGCTGGCGCTCCAT
 GTGTCTAGTACTGGTGTGAGGAGTCTGCCCGTCCACCGGACACAGGTAATGTTGCCCTATGACCCATG
 AAGTGGCGTCTTAGATGAAGATGGTGTGTTGCTCTGATCGACGAATCCTTGGCGCGCGCAGGCAACG
 CGGGAATTC

EpoE (SEQ ID NO: 10)

ATGACCGACCGTGAAGGCGCAGCTTTTGAACGCGCTGCGTGAAGTGACGTTGGCCCTCGGGAATACTCTGA
 ACAGCGCGGATCACTTTAGATTAGAAAAAACGGAACCAATTGCCAATTGCGGCACTGGCTGCGGCTTTTCC
 AGGCGGTGCGGGGACTCCGGAAGCTTTTGGGAGCTGCTGGATGATGGTGTGATGCGATGCGGACCTT
 GAGAGAGCGGTGGCGCTGGTGGGGTCGATCTTGGTGTGATGACGTCACCACTGGGCTGGCTCTCTGACTG
 AAGCGATTGACGGCTTTGACGCGGCTTCTTTGGCAATTGCGCGCGCGGAAGCCCGCTCTCTGATCCTCA
 GCACCGGCTGCTGTTGAAGTTGCATGGGAAGGTTTGAAGACGCGCGCATCCCGCGCGTATGCTGGT

GGGAGTCGCACGGGTGTCTTCGTAGGCGTAITGTGCAACAGAAATATTACATGCGGGCGGTGGCTACCAGC
CGCGCGAGGAACGCGATGCTTTATAGCAACACGGGTAAACATGTTGCTATTGCGCGGTGGCGCTTGTGCATA
CACGCTTGCCCTTCAGGGCCCTTGCTGTGACAGTTGACACAGCGCTGCTCTTCGAGTCTGTGGTGGCGATCCAC
CTGGCGTGTGCTCTACTTCGCTGCGCGTGAATCCGACTTAGCGCTGGCGGGTGGCGTCAATATGCTGTATTAT
CTCCTTGACACCATGCGCGCCCTTGCTCGTACCCAGGCATTGTCCCGAACCGGTGTTGTGTCAAACCTTCGA
TGCAAGCGCGAACGGTTTGTCCGGGGCGAGGGTGTGGCTGATCGTGCTTAAACGCTCTCTCCGATGCG
CGTCCGGACGGCGACCGTATTTTGGGCCCTGATCCGCGGCAGCGCTATTAACACCGATGCTGCTCCACAG
GTCTGACCGCACCGGAATGTACTGGCTCAGGGCGCACTGCTGCGTGAAGCTTTACGTAATGTCAGGGGTGGGA
AGCCGAAGCTATTGGCTAGACTCGAGACTCATGCGCGCGCGACTCTCTTTAGGGGATCCGATGAGATCGAA
GCCCTGCGCACTGTGGTGGGCCCGCGCGCTGATGGCGCCCGTTCGCTGCTCGCGCGGTGAAACCA
ACCTGGGCAATTGGGAAGCGCGCGGGGTGCTGGGCTGATCAAAGCAACCTGTCTTTGCACCATGA
ACGTATTCCGCGCAACCTGAATTTCCGTACACTTAATCCGCGTATCCGCAATTGAAGGACGGCATTAGCC
CTCGCTACCGAACCGATTCCATGGGCTCGCACCGGCCGTACGCGTTGCGCGGTGTTTCAAGCTTTGGCA
TGTCCGGTACCACTGTGCGCATGTGTCTCTGGAGGAAGCCCTGCTGTTGAGCGGAGGCGAGCGCGCGGA
ACGGCTGCGGCACTGTGTTGTGTTAAGTGCAGAAATCAGTTGCCGCCCTGGATGCCAAGCAGCGCGCTG
CGTGATCACTCGAATAAATCATGTGAATCGGCTCTGTGTGACGTGGCACTTAGCCCTGGCGACTACCCGTA
GCGCAATGGAAACATCGCCTGGCCGTGGCAGCGAGCTCTCGTGAGGCGCTGCGCGGGGCCCTGTGCGCTGC
CGCCCAAGGCCACACGCCGCCGGCGCGGTGCGGGGCCCGCGCATCCGTTGGGTGACGCGCAAAAGTGGTCA
TTCTGTGTTCCCTGGCCAGGGTTCACGATGGGTAGGGATGGGCGGTAAACTGATGGCGGAAGAACCTGTCT
TTCCGCGAGCGCTGTGGAGGCTCGGACCGTGCCTCGAAGCAGAAGCGGTTGTGCTCTGTTAGTGAGCT
GTCCGAGATGAAGCGCAGCGCAGCTTTGGCCGTATCGACGTTGTCCAGCCGCTACTGTTTGTCTATGGAA
GTGGCCCTTATCGGCCCTGTGGAGATCTTTGGGGTGTGGAGCCAGAGCGCGTAGTGGGTCACTCAATGGGGC
AGGTAGCCGCTGCGCATGTGGCAGGTGCGCTGTCTCTGGAAGACCGGTGAGTATTATTTGCGCGTCTC
ACGCTGCTCCGCTCGATCTCGGGCAGGTGAAATGGCACTCGTGGAGCTGTCCCTGGAGGAAGCGCGAA
GCGAGCTGCGCGGCAATGAAGCTGCTGTCTGTGCTGTGCTCAAATAGCCACCGCAAGCAGCTGATGG
CCGTTGAACCGGCCGCACTGTGCGAAGTTCTGCGAGCGTTGACCGCGAAAGCGCTTTTCTGCGCTCAAGT
TAAAGTCGATGTGGCTAGCCACTCGCCGCGAGGTGGACCCGTTGCGTGAAGAACTCATTTGCCGCCCTGGGT
GCCATCGCCCCACGCGCAGCCGCTGTTCCAATCGGTTCCACCGTGACCGCGCGTGTATTGCGAGGCCGG
AATGGGCGCGCTCTTATTGGGCTGATAACTTGCGCCAACCCGTAACGTTTTCGCGCTGCGCGCAGCACT
CTCGGAAGGTGATCCGACGCTGTTTCATCGAAATGAGTCGCGCATCCGATCTTGTCTCGCCGCTTGGATGA
ATTCAAGCGCGGTGCAACAGAGTGTGTCAGCGGTTGGGTCACTGCGCCGTTGGTCAGGACGAGCGTGCAA
CTTTACTGGAAGCACTGGGGACCTCTGGGCCCTCGGGCTACCCGATATCGTGGGCTCGTCTGTTTTCAGC
GGGGGTGCTGCGGTACCGCTTCCAACGTATCCGTGGCAACACGAGCGTGTGTTGGCTGCGAGTTGAACCA
GATGCTCGTCTTATGCTGCTGCCGACCAACGAAAGATTTGGTTCTATCGCACTGACTGGCGGAAGTCT
CTCGCGCCGCCCCGAAAGTGAACAGCACAAGGAGCTGGCTTCTCTCGCTGACCGTGGCGCGCTGG
TGAGGCGGTGCTGCGGCACTTAGCACCGTGGCCTGAGTTGTACCGTGTACATGCGTCCGCTGATGCA
TCGACCGTTTGCAGGCAAGTGTAGCGAAGCGCGCAGCGCTCGCAACGATTTGGCAGGGGGTATTGTATCTCT
GGGCTCTGAGATGCTGTGTTGATGCTGGCGCAGTGCAGATGAAGTTTCGGAAGCGCAACGCCCGCGCAAC
CGCGCCGCTGTAGGTTTGTGCGCTTCTGTGAGCTGCGCCGATCCTCCCGGTTTGGGTTGTGACC
AGAGGTGTGCGCACCGTTGGCGGGGAGCTGAAGTTAGTCTGTGTCAGGCGCGTGTGGGGTGTGAC
GTGTGTGAGCGCTTGAACATCCGCGCGCTGGGGTGGCTGTGTCGATCTGATCCGAGAAATCACCGAC
CGAAATGAACCACTGGTGGCTGAGCTGTGAGCCCTGATGCCGAAGACAGTTGGCTTTTGTGATGGC
GCTGATCACGACGCGCGCTGTGTCAGCGCGCGCGGAAGGTGATGTGCGCGCATGCTCTTAGTGGCGG
AAGGCTCTTACTTAGTCACCGGTGGCTGGGTGGTCTGGGTCTTCTGCTGGCGCGCTGTTGGTATGAGCG
TGGGGCCCGCGCACTGGTTCTGATCTCCGCACTGGCTGCTGCAAGCTCAAGCATCGGTTGTGAAC
CGCGCGGAAGCCGCGCGACGATTTGCCGCCGTGGAAGGTCTGGAAGCTCAGGGGGCAGTGTTACCGTAG
CGCGGTTGGACGTAGCTGAGGCGGACCTTATGACGGCCTTGTAGCTGCTATTGAGGCTCATTTGCGCGG
TGTGTTACGCGCGCAGGTGTGTTTCGGTGTCGCTCGCTGAACTGATGAGGCCCTCTTAGAAGAG
GTATTACGCCCTTAAAGTTGCGGTTAGTTGGTTACTGCACTGGCTTCTGCGTGAACGCTCTTGGATTGT
TTGTACTCTTTCAGCAGCGGGCGCGCACTCTGGGGGGCAAGGCCAGGGCGCGTATGCGACGCAATATG

GTTCCTGGATGGCTTGGGCACATCATCGTCGCGCACATTCTCTGCCAGCCTTAAGTCTCGCATGGGGCCCTG
TGGGCGGAGGGGCGGCGTGGTTGATGCCAAGCGCATGCGCGCTTATCTGACATCGGCGCTTCCCAATGG
CGACGGGCGCGGCTCTCAGCGCGCTCGAAACGCTTAGTGAAACACAAGTGCGGGTGCAGCGCACGCTCACACG
CATGGATTGGGCGCGCTTGCACCAGTCTACGCCGCTCGTGGTGGCGGTAACTGCTTTCCGCGCTGGTT
GCGGAAGATTGAGCGCACGGCGAGCCCTTCGGTTCCAACCGCAATGCATTTGGCGCGGTCTGAGCGTAG
CGGAATCACGCTCGGCGCTGTATGAACGGTGGTGGTATTGTTGCACGGGTCTGGGCTTCTCCGATCC
GGGGGGCGTGGACGTGGGTTCGCGGCTTCGCGGAGCAGGGCTGGATTCACTTATGGCGTGGAAATCCGC
AATCGCTTACAGCGTGAACCTGGGTGAGCGTTTAAAGCGCACCTTAGCTTTTGATCATCCGACGGTGGAAAC
GCCTTGTGCGCGACCTGTGACTGATGTGTCTAGTCTTGAAGACCGTTCCGATACGCGCCATATCCGCGAG
CGTGGCCCGCATGACGACATCGCAATTTGCGGCGCGCATGTGCTTTCCGGGGGCGGATGAGGGGCTG
GAGACCTACTGGCGTCACTTAGCTGAGGGCATGGTCTGTTCAACCGAGGTGCCAGCAGACGTTGGCGCG
CTGCGGACTGGTATGATCCGGATCCGGAAGTACAGGTCTGTAACCTACGTCGCGAAAGGTGCCCTTCTCCG
TGACGTGCGTTCTGGTTAGATGCGGCATTTTTCATCAGTCCGCGTGAAGCTTCTGATTTGGATCCGCGAG
CAGCGCTCTGCTCGGAGGTCTCATGGGAAGCTATCGAGCGCGCGGCCAGGACCCGATGCGCTTAGCGCG
AGAGCGCCACTGGCGTCTTTGTCGGTATGATCGGTAGTGAACACGCCGAACGGGTCCAAGGTTTAGATGA
CGATGCGCGCACTGCTGTACGGCACCAACCGGAATTTGCTGTCTGTGGCAGCAGCGCGCTGAGTTTTC
CTTGGGCTGCATGGCCGACGATGACCGTGGATACCGCTTGCTCTAGCTCCCTGTCGCCCTGCACCTGG
CTTGCCAGTCACTTACGCTCTGGCGGAATGCGATCAGGCGCTGGCTGGCGGCTCTCTGTTCTGCTTTCGCC
TCGCTCATTTGTGGCGGCTCCCGTATGCGTTTGTGAGCCCTGATGGTGGCTGTAAACGTTTTCAGCGCA
GCCGCCGATGGGTTTGGCGGTGCCGAAGGTTGCGCGCTGGTGGTATTAACACGCCCTGCGTGTATGCCCAAC
GTGACCGCGACCCGATTTTGGCGGTGGTAAAGATTACAGCCATTAAACAGATGGGCCCTAGTGGGTCT
CACCGTCCGCTCTGGGCGGCCCAACAGGCACCTGTTGGGTCAAGCTCTTGCTCAAGCAGGGGTGAGCGCT
GCCGAGTTGACTTTGTTGAGGTTCACGGAACCGGGACCGCGTGGGTGATCCAAATAGAGTCTCAGCGCTT
TGGGCGCAGTGTATGGCGGTGGTGGCCGCGGAGCGCCACTGTGGTTAGGGGCAAGTGAAGCGAATCT
TGGGCATCTGGAGGCGAGCGCTGGCTTGGCAGCGGTTCTGAAAGTGTCTGCTGGCATTAGAATGAACAA
ATTCCTGGCGAACCGGAATGGATGAGCTGAACCTCATATTCATGGCGGAACTGCGGTTGCGGTTG
TCCGCGCCGAGTGCCTGGCGCTCGTGGCGCACGCGCCAGCTCGCGCGGTTGTGTCGCGATTCTCGTCTCAG
CGGTACCAACGCTCAGCTCGTGTGTTGAGGAGGCACCTGCTGTTGAACCGAGGCGAGCCGACAGCAAGT
CGCGCGAAGTCTGTTGTTCTGAGCGCTAAAGTGTGGCCGCGCTGGATGCTCAGGCCGCGCGCTGCGTG
ATCATCTGGAACCAACGTTGGAATCTGGGCTGGGCGATGTGCTTTCTATTGGCTACCAACGCTTCTG
CATGGAGCATGCTTGGCGGTTGCAGCCAGCTCTGCTGAAGCCCTGCGTGGTGGTTGATGTGCCGCGCG
CAGGGTCACTCCGCGGGGTGCCGTTTCGCGCGCGTGTCTTCTGGTGGCAGCGCCCCAAAGTAGTGTTCG
TTTTCCCTGGCCAGGTTTCGCGAGTGGGTAGGCATGGGCGCTAAACTGATGGCGGAGGCGCTGTATTTCG
TGCCGCCCTTGAAGGCTGCGATCGTGCCATCGAAGCCGAAGCAGGCTGGTCCCTGCTTGGGGAAGTCACT
CGCGATGAAGCGCCCTCTCAACTTGGCCGCTGATGATGGTCCAGCGGTTCTGTTTGGCGTTGAAGTGG
CCCTGTCTGCTCTGTGGAGATCTTGGGCGGTGAACCGGAAGCTGTTGTAGGTCATGATCGGGCGAAGT
CGCAGCGCCCATGTTGCTGGTGCTTGTCTCTGAGGAGTACGGTGGCGCATTTATCTGTCGCTCTCGC
CTGCTGCGCGGATTTCAAGCCAAAGGTGAATGGCTTAGTGGAACTGTCGTTAGAGGAAGCGGAAGCAG
CAITTCGCGGGCATGAAGGTCGTCTGAGCGTGGCAGTCTCAAACTCGCCCTGTTCTACCGTTTATGACAG
TGAACCTGCTGCTTAAGTGAAGTTTTCGCGCGGTTGACCGCCAAAGGTGCTTCTGCGCGTCAAGTGAAG
GTGATGGTTGTCAGCACAGTCCAGTGGACCCCTTTCGCGCAGGAGCTGGTAGCTGTTAGTGGCGCCA
TTCGCGCGCGCTTCGCGCGGTGCCAATGCGCAGCACCGTGACCGGGGTGTCATTGCGGCTCTCAAGT
CGTGGCTGCTTATGGGCTGATAAATTGCGCCAGCTCCGTTTGCAGCTGCAACAGCTTCTGTTGTTA
GAAGGCGGGCGACTCTCTTCAATGAAGTGTCCCGCATCCGATCCTGGTTCCGCTCTCGATGAAGTCC
AGACAGCTGTGGAACAAGGGGCTGCAGCGGTTGGTTCACTGCGCGGTGTCAGATGAACGCGCCAGCT
GCTCGAAGCTTTGGGCATCTGTGGGCGTCCGCGCTCATGGGTGTCATGGGCACTGCTTTCTGCTGGG
GGCCGCTGCTGCTGCTGCGGACATACCGGTGGCAGCATGAGCGGTATCGGCTGCAGGATCTGTATCAT
CGACAGCAACCGTCCCTTCGCGTGGCCAACTCCAAATGGTGCACAGGATCATCGGTTACTGGTGGCGC
GTTACTGCTCAGCGCGCGCTTGGTGACACCTGTGGGAACAGGCTTTGAGCGACGAACGCTGCTGCTTAC
CTGTGACAGACCGGTGTGACGCGGAAGCGGTGCTTCCAGCGCTGCGTATGTTGAGATGGCCCTTGGCG

CAGGCGTCGACTTGTATGGCGCGCGACTTTTGTCTTAGAGCAGTTGGCATTTGGAAGCGCGCTTGGCAGT
GCCTAGCGAGGGGGGCGCATTGTACAGGTGCTCTGTCTGAAGAAGGCCCGGGCGCTGCTCTTTTCAG
GTCTCGTCCCGTGGAGGAAGCGGTCGTTCTTGGGTACGTTCATGCGACTGGGCACGTCATGACGCGATCAGT
CCAGTGGCGGTGTGTGCGCTTAAGGAGGCGCGCTGGGAGATTCAACAGCGTGTGCTCTCCGTTCTGAGCTC
GGAAGCTCTGTACCGGTACTGAACGAACATGCTCTTGACTATGGGCGCTGTTTTCAGGCGGTAGAAGCAG
GTTTGGCTGGGCACTGGCGAGGTACTGGGCGCGCTCCGTCTCCGGAAGACATGGCTTCGTCCAGCGGTG
CGTACCGGATCCATCCGCGCTTGTAGACGCGTCTTTCAAGTCTGACCGCATGCTTACAAACGCCAGA
AAGTATCGAAATCCGCGCTGTCGACCGATCTGTCACGAGCCAGACCTGCCGCGTACGCGTGGCGGAGTA
AATCAGGCAGTGTAGCGATACCTGGCTGTGGGATGACAGCATGGATGCTGTCGACAGCAGTCTGCGCTCTG
TACCCGTTGACTTGGTACTTGGTTCTTTTACGCTAAATGGGAAGTAAATGGACCGTTTGGCGCAAACTTA
TATCATTCGAGCGCTTCGCACATGGAACGCTCTTTGCGCGCGCGCGAAGCTCACACTATCGACAGGTTA
TTGGTGGCTTTACAGATTAGTGGGTGTATCGCAAAGTATATAAACGCTGGATGGACCATCTGGTTCGCCA
TTGGCGCTGTGGTGGCGGATGGCGAAACATCTCGTATCATCGCAGCCACTGCCGCGAACAGCATCGGTCGGG
CGTTTGGAGGAGGCGGCCACCGTGTGTGGGACTTACAGTCTTACTGGAGTGGTGTAAATTCGCAAGT
GAACCGCTGGCTGATGTGCTACCGGCAAAACCTGGCGTTGGAATTCGTGTTACCGCGCGGATTCGTCG
ACATGGCAGAACTATTATCAGGAAGTCCCTATTCGCGGTTATAGTAACGGTATCGTCCGCTGGTGGTGGT
CGAATCCGAGCGCGCGTGTGGCGCTTGGGCGACCTTTCTATCTTAGAAATTTGGCGCAGGTACAGGG
GCAAACGACAGCGCGCGCTTCTGCTGTTCTGCTGCGCGGACCGTACGAGATTCACCTCACCGATGTATCGC
CGTCTTCTAGCTCTGTGCGGAACAAACGCTTTCGTGATCATCCGTTCTCGAAATCGGTTATTCGGATAT
TGATCAGAGACGAGCGCGCGGAGTACGCCCATCAGAAATTCGATGTGATTTGGCGAGCGAATGTGATT
CACGCGACCCGTGACATCCGTGCCACTCGGAACGTTTGTCTGAGCTTGTCTCGCGCAGGCGGGCTGCTGG
TGCTCTGTGGAAGGACCGGCCACCGCATCTGGTTTGACATTACGACGGGCTGATCGAAGGCTGGCAGAA
ATATAGGATGATGCTGCGCAGCGATCATCCGCTGTGTGCGCAGCACGCTACCTGATGCTGCTGCGCGC
TGTGGCTTCGCAGATCCGCTGAGCCTTCCGCGCGATGGGTCTCCAGCGCGGATCCCTGGGCGCAGCATGAA
GTTTCTGAGCTGCGCGCGCGCGCTGCTGTTGATCAAGTGGCGAGTCTGCTGATGCTAGTCTTCC
CGCGCGCGCGGCGCTCCGTCAAGAGTGGCGGATGTTTCGCTGATGCGGTTTACCGCATGGCGCTGGAA
CGCATGTACTTTTATCGCGCTCCAGGCGCGCAGGTTTGGGTGCACGCTCGCCTCCGTACAGGGGCGCGCG
CCTTACGAAAGCACTGACGGGCGACCTGCTGCTTTTCGAAGAAACGGGCGAGTGGTGGCTGAGGTGCA
GGGCTCGCGCTGCCGAGCTTGAGGCACTCTGCTTTTGTCTCCGCGCAGCCACGTTGAAGAGTGGTTATAC
GCTCTGAGTGGCAGCGCAAGATCCGATCCCTGAAGCGCTCGCGCAGCCTCATCCGCGGCTTGGCGGCG
CGTGGCTTGTCTTATGGATCAGGCGCGCAGCGCGCGCTTGTAGAGCTGTTTGAAGGCGAGAGTGA
AGCCTGCGTTCGCGTGGTTGCAAGCACAGCGTATGCATGCTTGGCGCTTGGCTGTATCAGGTTGATCCG
GCTCAGCGAGATGGCTTTCATACTCTGCTGCGCGACGCTTTTGGGGAAGACCGTATGTCGCGCGCGTGG
TCCACATGTGGTCACTCGATGCTAAAGCCGCTGCTGAGCGTACCAAGCGGAATCGCTGCAAGCTGACCA
GCTGCTGGTGGTCTGCTGCTTACTAGCTGCTGGTGGCGCGCTGACGCGCGCTTGGCGGATATGCGG
CGTCTTTGGCTGCTGACGCGTGCAGTGCACGCGCTGGGTGCGGAAGACGCTGCGGCTCTGTCTGCTCAGG
CACCATCTCGGGTCTTGTGTCGACACTCGCACTGGAACATCCGGAATACGGTGCATCTCTGTAGATGT
TAATCCGCGCGCTGAGCTGAGCCGTTTACTGTTGAACCGAGATGCGCGCTGTCGCGGAGATCTGAGGAT
CAGATTTGCCCTGCGCTCCAGCGGTGCTACGTTGCCCGCTGGTTGCTTCAAGTTTCTCCGCGAAGCGCG
CGACCGATGGCGCATTCGCGCGGATGGGTGATACGTCATCCGATGGATGGGCGCGGCTTGGCTGAGCTCAG
CGTTGCGCAGTGGATGGTTATGACAGGCGCGCGGCACTGTGTTCTCGTGGACCGTGGCGCGCCAGTGAT
GCCTCTCTGTGATGCACTTCGCTCGATGGCAGAAAGCTGGTGGGGAAGTACAAATCGTCAAGCGGACGTGG
CCGCGCGTGTAGATGAGCCGCTTACTGTTCTAAATTTGAACCGAGATGCGCGCTGTCGCGGAGATGTG
GTATGTGGAAGCGGTACGTTTTCAGGGGATTCAGCATGTTGGAACCTCGATGCCATCGCTTCAAAGAGTGG
ATGTATCCGAAGTGTTTGGGTGCTTGAACCTTGACGCGCTGACGCTGACGCTGAGCTTGTAGATTTTTCG
TCCTGTATAGCAGCGGTACATCTTTACTGGGCTTCCGGGTCAAGGTAGCCGCGCGCGAGGGATGCCCTT
CTTAGATCGGATTCGACATTCATCGCTGTCGCTTAGGTCTTACCAGGATGTCAATTAATTTGGGGCTGCTT
AGTGAAGCGCAGTCCGCGCCAGCCAAACGATGGTGGTGCCTCTGATACCGTGGGATGGAGAGGCG
TTACCTTGGAGCAAGGTGCGGAAGCTCTGGGTGCTTTACTTGGCGCAACCGCGCGCAGGTGGGGTTAT
GCGCTGAATCTCCGCCAGTGGCTGGAGTTTACCCGAATGCGGACGCGCTGGCATTATGGCGGAACTG

CTGAAAGAACCTGATCGCACCGATCGCAGTGCAGTAACGTAACCTGCGGGAGCGCTTCAATCCG
 CCCGCCGAGGATCGGCAGCTGGTTCTCGAAAAACACCTGTGCAAGCTGCTGGGCCGTGGTCTCCGCTCT
 GCCACCGAAGCGATTGAACGTCATGTCCCTTTAGCAACCTGGGTATGGACAGTCTCATTTGGTTAGAG
 CTGCGCTAACCGGATTGAAGCGGCCCTGGGTATTACCGTTCCTGCCACTCTGCTGTGGACGATCTCCGACCG
 TTGGCCGACTGTTCGGTAACTCTCTTGACACTTCTTCTAGTAATGCTGGCGGCGTCTCAGCTATCCCGCGAC
 CGAGCGCGAAAAAGCTTTGAAAAACGACGCCGAGATTTAGAAGCCTTGCCTGGGATGACTGATGAACAG
 AAAGATGCGTGTCTGCGGAGAACTCGCACAACTGGCCAGATCGTGGCGAAGGGAATTC

EpoF (SEQ ID NO: 11)

ATGGCGACGACGAACGCGGTAACTGGAACTGCTCTTCTGTTAATGGTAAGCTGGCGAAGAAGAACC
 CAAGTTTAGAGCAGGAACGCACTGAAACCAATTGCGATTATTGGGATCGGCTGCCGTTTTCGCGGTGGTGC
 GGACCCCGGAAGCCTTTTGGGAACCTGTTGGATAGTGCGCCGCGATGCTGTGACCGCGTACGCTCCGCGT
 TGGCGCGTGTGGCGCTCCATCCTTCAGAAAGTCCCGCGCTGGGCGGGTGTCTGACCGAGGCCGTGG
 ATGGGTTTACGCGCGCTTCTTGGTACAAGTCCGCGCAAGCGGTAGCTCGATCCGCAACAGCGCTCT
 GCTCTGGAGGTAACTCGTGGAGGTTCTGGAAAGATGCGGCATCGCACCGCAATCGCTGGATGGTAGCGCT
 ACAGCGCTCTTTCTGGGGCTTGTAGCTCCGACTATAGCCATACTGTTGGCGAGCAGCGCGCGAAGAAC
 AGGACGCTATGACATTACGGGCAACACTCTTCCGTCTGCTGCCGGGCGTCTCAGCTATACCTTCGGTCT
 ACAGGGCCCGTGCCTCACGCTAGACACTGCGTGTAGCTCATCGTTGGTGGCAATTACCTGGCGTGTGCG
 AGCCTCGCGCAGCGAGTCTGATCTGGCCCTGGCTGGCGGTGTTAATATGCTGCTGTCAAGCAAAACCA
 TGATCATGCTCGGTACGCTTCAAGCACTGAGCCCGGATGGACATTGCCGTAACCTTGTATGGCTCGCTAA
 TGGCTTGTGACGCGGCGAAGGCTCGGATATGGTGGTATTAACAACTCTGAGCGATCCCGAGCGGACGCG
 CATGCGATTTGGGCATTGATCCGCGGTTACGCCATGAACCGAGGCGCGCTTCCACCGGTTGATGGCGC
 CAAACGTCCTCGCCAGGAAGCGCTGCTGCGTACAGCGCTACAGAGCGCACGCTGGATGCTGGCGCGAT
 CGATTACGTGGAGACACATGGCACAGGCACTCGCTGGGCGATCCATAGAAGTTGACGCTCTGCGTGCA
 GTCATGGGTCCGCTCTGTGCGATGGGAGCCGTTGTGTTGGGTGCAAGTGAAGAAACAACTTAGGCCAAC
 TGGAGGGCGCGCTGGGGTGGCGGTTGTATCAAGCCGCACTGGCGCTTCCACCGAAGCAATCCTCGC
 TAATCTGCATTTCCACACACTAATCCGCGTATTCTGATTGAGGGAACCGCGCTGGCCCTGGCAACCGAA
 CCAGTTCCGTGGCTCGCGCGGTCGTCCACGCTTTGCGGGTGTGTCTGCTTTCCGCGCTGAGTGGTACCA
 ACGTGCATGTTGTGTTGGAAGAAGCACTGCCACCGTGTAGCCCCGCAACGCGCGGCGGTTCTGTGTA
 ACTGCTGTTTATTAAGCGCTAAATCCAAGCCGCTCTGGACGCAAGCGCGCGGTTATCGGCCACATC
 GCGGCATATCCGAGCAAGGCTCTGGGTGATGTGGCCTTTTCTTAGTTGCGACCCGAGTCCGATGGAAAC
 ATCGTCTCGCGCTTGC CGCACGCTCTCGCGAAGCGCTGCGTTCTGCGTTAGAGGCGCGCGCAAGGCCA
 AACCCCGCAGGCGCGCTCTGTGCTGTGCGGCTCGTCAACCGGTAAATGGCATTCTCTGTTGCTGCGC
 CAGGCGCCCCAAGTACAGGATAGGGCGGTGCTGTGGGAAGCCTGGCCCTGCGTTTCGTGTAACCTTCG
 ACCGCTCGCTTACTTTGTTGACCGTGAAGCTGCACCAACCTCTGTGTGAAGTTATGTGGCGGAACCGGG
 TAGTAGCCGTTCTGCTGCTTTAGACCAAAACGCGGTTCAACCAACAGCGCTGTTGCGCGTTGAATACGCG
 CTGCGCTCGCTGTTTATGATCTTGGGGCTGGAACCGGAACCTGATCGCGGGCCTCTTCTTGGGCGAGCTGG
 TGGCCGCGTTCGTTGCGGGCGTGTGTTTCTGCTGGAAGACGCTGTTGCGTTGGTGGTGGCACGCGGCGCCT
 GATGCAGGCGCTGCGAGCTGGCGGTGCCATGTTAGCATTGCGGCTCCGGAAGCCGATGTCGCGCGAGCT
 GTTGCAACGCAAGCGGCTAGTGCTCAATGCGCGCGTCAATGGCCCTGCTGGGCTGTGCTGCTGCTGCGG
 CGGAGAAATTTGTGCAACAAATGCGCGCTGCCCTTGTGCTGCGCGGCTGCTGCGCAACCAACCTTTGCTATG
 TTTCCAGCGCTTCCACTCCCGCTGATGGATCCAATGCTGGAAGCACTTCCGCGGCTCACTGAATCTGTG
 ACCTATGCGCGCCGCTGATGGCGTTAGTAAGCAATCTGTGCGGTAAACCGTGTACCGATGAGGTGTGTG
 CGCCTGGTTATTGGGTACGCCATGCTCGGGAAGCGGTGCGCTTCGAGATGGGCTTAAAGCGCTGCACGC
 AGCAGCGCGGGTATTTTTGTGTAAGTTGGTCCGAAACCTGCGCTGCTGGGCTGTGCTGCTGCTGCTG
 CCGGATGCGGCTCCAGTGTACTGCCAGCAAGCGCGCAGGTGCTGAGCAGGCGCGCTGAGCATGTGATG
 CACTGGGTGGGTTTGGGTGGTGGGCGAGCGTAACGTGGAGTGTGTGTTCCGCTCAGGTGTGCGCG
 GTTCTCTCTCCCAACGATATCCGTGGCAACCGGAACCGTATTGGCTGCAGGCACTGTAGACGCTGAAGCG
 GATGGTATCGCTCGCGCAAGCTGGCGATCATCAATTGCTGGGTGAAGCCTTCAGTGTGTCAACCCACG

CAGGTCTGCGCCTGTGGGAGACTACCTCGATCGTAAACGCTGCGCGTGGCTGGGTGAGCATCGGGCGCA
GGGTGAAGTAGTGTTCCTCGGGGGCAGGCTACTCTGGAATGGCCCTTTCTCCAGGCGCGAGATATTAGGG
GATGGTCCGATCGAGTTAACGGATGTTGGTGCTGATTTGAGACCCGTGACTTTTGGCTGGCGATACGGCAGTTCT
CTGTGCAGGTGTGACAACTGAAGAACGTCGCGGTCGCTCTGCGGTTCAGGTTCGCTCCCGGCAACGAGG
GGCCCGTCTGTCAGATTTTTCGATTCATGCCGCTGGTGTCTGCGTCCGCTCGCTCGTGCGGAACGCC
GCTCGTCTTAATCTCGCCGCACTGAGAGCCCGCTGTCATGCAGCAGTCCACGCCGCTGCTATCTATGGCG
CATTGGCAGAAATGGGGTTACAGTACGGGCCCTGCACTCGGTGGTCTGGCAGAACTGTGGCTGGCGAGGG
TGAAGCTCTGGGTGCGCTTCTGTCGCAAGATCCGCGGTTTCGGCGGAGCTATACGCTGCACCCGAGT
CTCCTTGATGCATGCGTACAGATGATTGTGGGCGGCTTCGCGGACCGTGATGAAGCTACGCCATGGGCC
CGGTGAGGTTCGGGAGCGTGGCTCTCTTCAACGCTCTCCTTGGGAATTTGGTGCCATGCGCGTGTGT
GTCAGACGCCAACAGGCACCGAGTCTGCGAGCGCCGACTTTGAGCTGATGGACGGCACAGGGGCTGT
GTTGCGAGGATTAGCCGTCTGGTGGTTGAACGCTTAGCGTCCGGCGTCCGCGCGCTGACGCCAGGATT
GGTTTCTGAGGCTCGATTGGGAACCGGCAGCATTAGAGGGTCGGAATAACGCGCGCTCGCTGGCTGCT
GCTGGGGAGGGTGGGGCTTGGGCGCTTCTTATGTAGTGCCTGAAGCGGCTGGTCAATGTTGTGGTA
CACGCCGACGGGATGATACGTCTGCGGCAGGCATGCTGCGTTCGGCGAACCGCTTCGATGGTGTG
CGCCGACGCGTCTGCTCCACCTCAGCTCTCTGGACGGCGCGGTCACCTGGATCTCTGGCTTGGCGCTCA
AGGCGCAITGGACGCTCCGAGATCTCCAGACGTGGACGCGAGCCCTTGATTCGCAATTAATGGCGGT
TGGCGATTCCGTGCTGAGCTCTGGTCAGGCGCTCGTCGATGGATCTGCGGAACGCAACGCTCTGTGGC
TGCTTACCGCTGGCGCAAGGCAGCTGCGCAGGCGATGTCTCGGTGGTGCAGGCTCCGCTGCTGGGGCT
GGCGCGCAGATTCGCGCTGGAAATGCAGAACTTCGCTGATCTCAGTAGATTGGATTCGCTGCAGCGC
GAAGCGAAGCGGACGCGTCTGCTGGCGAACTGCTGGCTGACGACGCGGAGGAAGAATGGCATTCGCTG
GTGGTGAACGCTTTGTGGCAGCTTGGTTACCGCTTGGCGGAAGCGCAACGTCGGGAAAAAATTCGCC
AGCGGCGACCCCGCTTTCCTTTGGAATCGATGAACCCGGGTGTTTAGATCAGTTAGTCTTCCTGTGCA
ACGGGTCCCGCTGCGCCGGGCGCGGCGAAGTCAGATCGCGCTAGAGGCTCGCGGCTCGGATTCTATTG
ATATTGAGCTGCGCTCGGGTACCGCAACGCACTTGCTGGCGGGAGATCGCGCTCGCTGGG
TAGTGAATGCGCCGCGCCGATCGTAGCAGTAGGTGAAGCGTGAATGGTGGTAGTGGGTGAGCCGCT
ATTGCCCTTAGCGGCGGGTGTTCGCGACGATGTTAGCACTTCGCGACCTTGGTGTCTCGCGGCTCGC
TCCGCTTACGCGCAGCGAAGCGCGCGCATGCCATTGGCGTATCTTACCGCTTGGTATGCGCTTGATA
AGTGTCTCACCCTTACGCGAGCGAAGCGTGTCTGATTCGCGCGAGGCGCGGGGCAATGGTCTGTGCGCC
TCCGCTGGCGCGCAGCGCTTGGTGTGATGAGTCTATGCGACCGCGCACGCAAAAAAGCTGCTTACC
TTGAGTCTGCTGGGTGTGCGCTACGTGAGCGATCCTAGGCTCTGGTTCGCTTCGCGAGCGGATGTCATGCGTG
GACCGATGGGGAGGGCGTTGATGTGGTTCTGGAATCTCTGTCGCGGCAACATATCGATAAAAGTCTGATG
GTTTTACGCGCATGTGGCGGCTCGTTAAACTGGGTTCGCGTGACGATTGCGCTGACACCCACCGAGGCG
TGCCACCGCTGTGTGCGCACTTTTCAATTTCTCAGGTGGATCTGCGTGGCATGATGCTGAGCACCGCGC
CGGATTTGCTGCTCTTCTGAGTGAATGTTTGGCGTGGTGGCGCGGTCGATTTCCCTTTTAGGGAGC
GGTCTGCGGGTTGGTGGCAGCCTGACCCCGCCACCTGTGCAAACTTCCCAATTAGTCTGTCGCGCTGAAG
CATTTCGTCGCATGCGCGAGGCTCAGCATCTCGGTAACCTGGTCTGACCCCTGGATGATCCAGAGGTTCTG
TATTCGTGCGCGCAGCGAAGCAGCGTGGCAGTTCTGTCGATGGCACCTTATTTAGTTACCGGTGGTTTA
GGTGGCTTGGGCTTACGTTGTGCTGGCTGGCTGGCAGAACCGGCTGCTGGGCAAGTTAGTGTAGTGGGGC
GTAGCGCGCTGCTCTCGGAGAACAGAGAGCGCGCTGGCGCGCTTGGGCGCCATGCGGCTGCGCTAC
CGTAGCTAAAGCTGATGTAGCGGATCGTTCAAAATTAAGCGGTAAGTCTGCGGAAAGTACGCGCTTCCGGC
ATGCGCTGCGGGGCGTTGTCCAGCGCTGTTTAGTAGACGAGCGCTGTTGATGCAACAGAGCCCGG
CCCGCTCTGTAAGTAAATGGGCCCTAAAGTGCAAGGTCGCCCTTCACTGTCACACTCTGATCTCGGAAGC
ACCTTTATCTTCTTGTGTTCTGATGCAAGTGACAGCGGTTATTCGCGAGCGCGGCTGCGGCTTAATAC
CTGCTGCAAAACGCTTTTCTGATGCGCTGAGTCATCACCGCGCTGGCGCTGGTTCAGGCGCTTAAGCA
TTGACTGGGGCATGTTTACCGAAGTGGGGATGGCGGTGCGCAAGAGAACCGTGGCGCACGCCCTTATAG
TCGGGCGCATGCGCGTATTAGCGCGCAAGAGGGCTGTACGCGTTCGCGCGCTCTCGAAGGTGATCTGT
GTTTCAACCGGGTATCCGGTATACCGCGTCAAGTGGTGGAGTCTTATCCGCGCACAGCGCGCAAGT
GTGCTCTAGCGCGCTGCTCAAACTCAGCGTTCGCGTCTGATGCGCACCGCGCGGATCGCGATCTCCT
CGAACAGTTGGCCTTCGCGGAACCATCGCTCGGGCTGGCCTGTTGCAAGATGTGATACGCGTGCAGGTG

TCGCATGTGCTCCGCTGCCGAGGATAAAATCGAGGTGGACGCACCGTTATCCAGTATGGGTATGGATA
 GTTTGATGTGCTGGAATTACGCAATCGTATCGAAGCCGCGCTGGGCGTAGCCGCTCCGCGAGCTCTGGG
 TTGGACTTACCCGACGGTGGCAGCTATTACCCGTTGGTTACTGGATGATGCTCTTTCTAGTCGCTTAGGC
 GGC GGAGCGGATACGGATGAATCCACTGCATCGGCGGGTAGCTTTGTTTCACGTCCTGCGCTTTTCGCCCGG
 TAGTAAAAACCGCGTGACGCCCTGTTTGTGTTTTCACGGTTCGGGGGGTTCTCCAGAAGGCTTCCGTAGCTG
 GTCCTGAAAAATCAGAGTGGAGTGACCTCGAAATGTGCGCATGTGGCATGATCGTTCCCTTGGCATCTGAG
 GATGCCCGCGGCAAAAAATATGTTTCAGGAAGCTGCCAGTCTCATCCAACATTATGCGGATGCCCATTTG
 CTCCTGTGGGTTTCTCTTTGGGTGTTGCTTTGTAATGGGCACAGCGGTGGAGCTGGCTTCTCGGAGTGG
 GCGCCAGCACCATTTGGCGGTGTTTCGCACCTGGGTGGCTCCCTGATTTTCAGCAGCGAAATCACTCCGGAG
 ATGGAGACCGATATTATCGCGAACTGTTTTCGTAACGCGCGCGGTTTCGTGCGCTCAACAAGCAAG
 TCCAGGCTGACGCCCGCGGATAAAGTGATTACTGATACCATGGTCGCCCTGCGCGCGGTGATAGCAA
 AGAACCCCGTCAAAAAATCGCGGTGCCGATCGTTGCAATTGCCGTTTCGGATGACGTGATCGTCCCTCCA
 TCGGACGTTTCAGGACTTACAGAGCCGTACCAACGAAACGGTTTACATGTCATCTGCTGCGGGCGACCATG
 AGTTCCTGGTTGACCGCGGGCGTGAAATTATGCATATTGTAGATTACACCTTAATCCGCTGTTAGCTGC
 CCGCACACGTCAGTGGCCCGGCTTCGAAGCAAAAGGGAATTC

[0371] All publications and patent documents cited herein are incorporated herein by reference as if each such publication or document was specifically and individually indicated to be incorporated herein by reference.

[0372] Although the present invention has been described in detail with reference to specific embodiments, those of skill in the art will recognize that modifications and improvements are within the scope and spirit of the invention. Citation of publications and patent documents is not intended as an admission that any such document is pertinent prior art, nor does it constitute any admission as to the contents or date of the same. The invention having now been described by way of written description, those of skill in the art will recognize that the invention can be practiced in a variety of embodiments and that the foregoing description are for purposes of illustration and not limitation.

WE CLAIM:

1. A synthetic gene encoding a polypeptide segment that corresponds to a reference polypeptide segment encoded by a naturally occurring gene, wherein the polypeptide segment-encoding sequence of the synthetic gene is different from the polypeptide segment-encoding sequence of said naturally occurring gene, wherein
 - a) said polypeptide segment-encoding sequence of said synthetic gene is less than about 90% identical to said polypeptide segment-encoding sequence of said naturally occurring gene, and/or
 - b) said polypeptide segment-encoding sequence of said synthetic gene comprises at least one unique restriction site that is not present or is not unique in the polypeptide segment-encoding sequence of said naturally occurring gene, and/or
 - c) said polypeptide segment-encoding sequence of said synthetic gene is free from at least one restriction site that is present in the polypeptide segment-encoding sequence of said naturally occurring gene.
2. The synthetic gene of claim 1 wherein the polypeptide segment is from a polyketide synthase (PKS).
3. The synthetic gene of claim 2 wherein the polypeptide segment comprises a PKS domain selected from AT, ACP, KS, KR, DH, ER, and TE.
4. The synthetic gene of claim 3 that encodes one or more PKS modules.
5. The synthetic gene of claim 4 comprising at most one copy per module-encoding sequence of a restriction enzyme recognition site selected from the group consisting of Spe I, Mfe I, Afi II, Bsi WI, Sac II, Ngo MIV, Nhe I, Kpn I, Msc I, Bgl II, Bss HII, Sac II, Age I, Pst I, Kas I, Mlu I, Xba I, Sph I, Bsp E, and Ngo MIV recognition sites.

6. The synthetic gene of claim 1 wherein the polypeptide segment-encoding sequence of the synthetic gene is free from at least one Type IIS enzyme restriction site present in the polypeptide segment-encoding sequence of said naturally occurring gene.

7. A synthetic gene encoding a polypeptide segment that corresponds to a reference polypeptide segment encoded by a naturally occurring PKS gene, wherein the polypeptide segment-encoding sequence of the synthetic gene is different from the polypeptide segment-encoding sequence of said naturally occurring PKS gene and comprises at least two of:

- a) a Spe I site near the sequence encoding the amino-terminus of the module;
- b) a Mfe I site near the sequence encoding the amino-terminus of a KS domain;
- c) a Kpn I site near the sequence encoding the carboxy-terminus of a KS domain;
- d) a Msc I site near the sequence encoding the amino-terminus of an AT domain;
- e) a Pst I site near the sequence encoding the carboxy-terminus of an AT domain;
- f) a BsrB I site near the sequence encoding the amino-terminus of an ER domain;
- g) an Age I site near the sequence encoding the amino-terminus of a KR domain;
- h) an Xba I site near the sequence encoding the amino-terminus of an ACP

domain.

8. A vector comprising a synthetic gene of claim 1.

9. The vector of claim 8 that is an expression vector.

10. A library of vectors each comprising a synthetic gene of claim 1.

11. The vector of claim 8 that comprises an open reading frame encoding a first PKS module and one or more of:

- a) a PKS extension module;
- b) a PKS loading module;
- c) a thioesterase domain; and
- d) an interpolypeptide linker.

12. A cell comprising an expression vector of claim 9.
13. The cell of claim 12 comprising a polypeptide encoded by the vector.
14. The cell of claim 13 that comprises a functional polyketide synthase, wherein said PKS comprises a polypeptide encoded by said vector.
15. A method of making a polyketide comprising culturing a cell of claim 14 under conditions in which a polyketide is produced, wherein the polyketide would not be produced by said cell in the absence of said vector.
16. A gene library comprising a plurality of different PKS module-encoding genes, wherein the module-encoding genes in the library have at least one restriction site in common, said restriction site is found no more than one time in each module, and the modules encoded in said library correspond to modules from five or more different polyketide synthase proteins.
17. The library of claim 16 wherein said module-encoding genes comprise at least three restriction sites in common.
18. The library of claim 16 wherein the unique restriction is selected from the group consisting of consisting of Spe I, Mfe I, Afi II, Bsi WI, Sac II, Ngo MIV, Nhe I, Kpn I, Msc I, Bgl II, Bss HII, Sac II, Age I, Pst I, Bsr BI, Kas I, Mlu I, Xba I, Sph I, Bsp E, and Ngo MIV recognition sites.
19. The library of claim 16 wherein said at least one restriction site in common is:
 - a) a Spe I site near the sequence encoding the amino-termini of the modules;and/or
 - b) a Mfe I site near the sequence encoding the amino-termini of KS domains;and/or
 - c) a Kpn I site near the sequence encoding the carboxy-termini of KS domains;and/or

- d) a Msc I site near the sequence encoding the amino-termini of AT domains;
and/or
- e) a Pst I site near the sequence encoding the carboxy-termini of AT domains;
and/or
- f) a BsrB I site near the sequence encoding the amino-termini of ER domains;
and/or
- g) a Age I site near the sequence encoding the amino-termini of KR domains;
and/or
- h) a Xba I site near the sequence encoding the amino-termini of ACP domains.

20. The library of claims 16 wherein said genes are contained in cloning or expression vectors.

21. The library of claim 20 wherein each PKS module-encoding gene also comprises coding sequence for

- a) at least a second PKS extension module, or
- b) a PKS loading module, or
- c) a thioesterase domain, or
- d) an interpolypeptide linker.

22. A cloning vector comprising, in the order shown,

- a) SM4 – SIS – SM2 – R₁ *or*
- b) L – SIS – SM2 – R₁

where SIS is a synthon insertion site, SM2 is a sequence encoding a first selectable marker, SM4 is a sequence encoding a second selectable marker different from the first, R₁ is a recognition site for a restriction enzyme, and L is a recognition site for a different restriction enzyme.

23. A vector of claim 22 wherein SM2 and SM4 are genes conferring drug resistance.

24. A composition comprising a vector of claim 1 and a restriction enzyme that recognizes R_1 .

25. The cloning vector of claim 22 wherein the SIS comprises $-N_1-R_2-N_2-$ where N_1 and N_2 are recognition sites for nicking enzymes, and may be the same or different, and R_2 is a recognition site for a restriction enzyme different from R_1 or L .

26. A composition comprising a vector of claim 25 and a nicking enzyme.

27. A vector comprising

a) $SM4-2S_1-Sy_1-2S_2-SM2-R_1$ or

b) $L-2S_1-Sy_2-2S_2-SM2-R_1$

where $2S_1$ is a recognition site for first Type IIS restriction enzyme,

where $2S_2$ is a recognition site for a different Type IIS restriction enzyme, and Sy is synton coding region.

28. The vector of claim 27 wherein Sy encodes a polypeptide segment of a polyketide synthase.

29. A composition comprising a vector of claim 26 and a Type IIS restriction enzyme that recognizes either $2S_1$ or $2S_2$.

30. A composition comprising a cognate pair of vectors, wherein said cognate pairs are:

- a) a first vector comprising $SM4-2S_1-Sy_1-2S_2-SM2-R_1$ digested with a Type IIS restriction enzyme that recognizes $2S_2$, and
a second vector comprising $SM5-2S_3-Sy_2-2S_4-SM3-R_1$ digested with a Type IIS restriction enzyme that recognizes $2S_3$;

or

- b) a first vector comprising $L-2S_1-Sy_1-2S_2-SM2-R_1$ digested with a Type IIS restriction enzyme that recognizes $2S_2$, and

a second vector comprising L'-2S₃-Sy₂-2S₄-SM3-R₁ digested with a Type IIS restriction enzyme that recognizes 2S₃,

wherein SM1, SM2, SM3, SM4 are sequences encoding different selection markers, R₁ is a recognition site for a restriction enzyme, L and L' are recognition sites that are the same or the same or different, and each different from R₁, 2S₁, 2S₂, 2S₃, and 2S₄ are recognition sites for Type IIS restriction enzymes, wherein 2S₁, 2S₂ are not the same, 2S₃, and 2S₄ are not the same, and digestion of the first vector with 2S₂ and the second vector with 2S₃ results in compatible ends.

31. The composition of claim 30 wherein 2S₁ and 2S₃ are the same and 2S₂ and 2S₄ are the same.

32. The composition of claim 30 wherein Sy₁ and Sy₂ encode polypeptide segments of a polyketide synthase.

33. A vector comprising a first selectable marker, a restriction site (R₁) recognized by a first restriction enzyme, and a synthon coding region flanked by a restriction site recognized by a first Type IIS restriction enzyme and a restriction site recognized by a second Type IIS restriction enzyme

wherein digestion of the vector with said first restriction enzyme and said first Type IIS restriction enzyme produces a fragment comprising said first selectable marker and said synthon coding region, and

digestion of the vector with said first restriction enzyme and said second Type IIS restriction enzyme produces a fragment comprising said synthon coding region and not comprising said first selectable marker.

34. A method for joining a series of DNA units using a vector pair comprising
a) providing a first set of DNA units, each in a first-type selectable vector comprising a first selectable marker and providing a second set of DNA units, each in a second-type selectable vector comprising a second selectable marker different from the first,

wherein said first-type and second-type selectable vectors can be selected based on the different selectable markers,

b) recombinantly joining a DNA unit from the first set with an adjacent DNA unit from the second set to generate a first-type selectable vector comprising a third DNA unit, and obtaining a desired clone by selecting for the first selectable marker

c) recombinantly joining the third DNA unit with an adjacent DNA unit from the second set to generate a first-type selectable vector comprising a fourth DNA unit, and obtaining a desired clone by selecting for the first selectable marker, or

recombinantly joining the third DNA unit with an adjacent DNA unit from the second series to generate a second-type selectable vector comprising a fourth DNA unit, and obtaining a desired clone by selecting for the second selectable marker.

35. The method of claim 34 wherein step (c) comprises recombinantly joining the third DNA unit with an adjacent DNA unit from the second set to generate a first-type selectable vector comprising a fourth DNA unit, and obtaining a desired clone by selecting for the first selectable marker, said method further comprising

recombinantly combining the fourth DNA unit with an adjacent DNA unit from the second series to generate a first-type selectable vector comprising a fifth DNA unit, and obtaining a desired clone by selecting for the first selection marker, or

recombinantly combining the third DNA unit with an adjacent DNA unit from the second set to generate a second-type selectable vector comprising a fifth DNA unit, and obtaining a desired clone by selecting for the second selection marker.

36. The method of claim 34 wherein step (c) comprises recombinantly joining the third DNA unit with an adjacent DNA unit from the second series to generate a second-type selectable vector comprising a fourth DNA unit, and obtaining a desired clone by selecting for the second selectable marker, said method further comprising

recombinantly joining the fourth DNA unit with an adjacent DNA unit from the first set to generate a first-type selectable vector comprising a fifth DNA unit, and obtaining a desired clone by selecting for the first selection marker, or

recombinantly joining the third DNA unit with an adjacent DNA unit from the first set to generate a second-type selectable vector comprising a fifth DNA unit and obtaining a desired clone by selecting for the second selection marker.

37. The method of claim 34 wherein the desired clone comprises a sequence encoding a PKS domain.

38. A method for joining several DNA units in sequence, said method comprising
a) carrying out a first round of stitching comprising ligating an acceptor vector fragment comprising a first synthon SA_0 , a ligatable end LA_0 at the junction end of synthon SA_0 and an adjacent synthon SD_0 , and another ligatable end la_0 ,

and a donor vector fragment comprising a second synthon SD_0 , a ligatable end LD_0 at the junction end of synthon SD_0 and synthon SA_0 , wherein LD_0 and LA_0 are compatible, another ligatable end ld_0 , wherein ld_0 and la_0 are compatible, and a selectable marker,

wherein LA_0 and LD_0 are ligated and la_0 and ld_0 are ligated, thereby joining said first and second synthons, and thereby generating a first vector comprising synthon coding sequence S_1 ;

b) selecting for said first vector by selecting for the selectable marker in (a);
and,

c) carrying out a number n additional rounds of stitching,
wherein n is an integer from 1 to 20,
wherein S_n is the synthon coding sequence generated by joining synthons in the previous round of stitching, and

wherein each round n of stitching comprises:

1) designating said first or a subsequent vector as either an acceptor vector A_n or a donor vector D_n

2) digesting acceptor vector A_n with restriction enzymes to produce an acceptor vector fragment comprising a synthon coding sequence S_n , a ligatable end LA_n at the junction end of synthon S_n and an adjacent synthon SD_{n+100} , and another ligatable end la_n ; and,

ligating the acceptor vector fragment to a donor vector fragment comprising synthon SD_{n+100} , a ligatable end LD_{n+100} at the junction end of synthon SD_{n+100} and synthon S_n , wherein LA_n and LD_{n+100} are compatible, another ligatable end ld_{n+100} , wherein la_n and ld_{n+100} are compatible, and a selectable marker,

wherein LA_n and LD_{n+100} are ligated and la_n and ld_{n+100} are ligated, thereby generating a subsequent vector, or

digesting donor vector D_n with restriction enzymes to produce a donor vector fragment comprising a synthon coding sequence S_n , a ligatable end LD_n at the junction end of synthon S_n and an adjacent synthon SA_{n+100} , another ligatable end ld_n , and a selectable marker; and

ligating the donor vector fragment to an acceptor vector fragment comprising synthon SA_{n+100} , a ligatable end LA_{n+100} at the junction end of synthon SA_{n+100} and synthon S_n , and another ligatable end la_{n+100}

wherein LA_{n+100} and LD_n are compatible and are ligated and la_{n+100} and ld_n are compatible and are ligated,

thereby generating a subsequent vector

d) selecting the subsequent vector by selecting for the selectable marker of said donor vector fragment of step (c)

e) repeating steps (c) and (d) n-1 times thereby producing a multisynthon.

39. The method of claim 1 wherein the selectable marker of step (d) is not the same as the selectable marker of the preceding stitching step and/or is not the same as the selectable marker of the subsequent stitching step.

40. The method of claim 37 wherein la_0 , ld_0 , la_n , ld_n are the same and/or La_0 , Ld_0 , La_n , and Ld_n are created by a Type IIS restriction enzyme.

41. The method of claim 37 wherein said synthons SA_0 , SD_0 , SA_{n+100} , and SD_{n+100} are synthetic DNAs.

42. The method of claim 37 wherein any one or more of synthons SA_0 , SD_0 , SA_{n+100} , or SD_{n+100} is a multisynthon.

43. The method of claim 37 wherein the multisynthon product of step (e) encodes a polypeptide comprising a PKS domain.

44. A method for making a synthetic gene encoding a PKS module, comprising

- (i) producing a plurality of DNA units by assembly PCR, wherein each DNA unit encodes a portion of said PKS module;
- (ii) combining said plurality of DNA units in a predetermined sequence to produce PKS module-encoding gene.

45. The method of claim 44, further comprising combining said module-encoding gene in-frame with a nucleotide sequence encoding a PKS extension module, a PKS loading module, a thioesterase domain, or an PKS interpolypeptide linker, thereby producing a PKS open reading frame.

46. A method for identifying restriction enzyme recognition sites useful for design of synthetic genes, comprising the steps of

- obtaining amino acid sequences for a plurality of functionally related polypeptide segments;
- reverse-translating said amino acid sequences to produce multiple polypeptide segment-encoding nucleic acid sequences for each polypeptide segment;
- identifying restriction enzyme recognition sites that are found in at least one polypeptide segment-encoding nucleic acid sequence of at least about 50% of said polypeptide segments.

47. The method of claim 46 wherein said functionally related polypeptide segments are polyketide synthase modules or domains.

48. The method of claim 46 wherein said functionally related polypeptide segments are regions of high homology in PKS modules or domains.

49. A method for high throughput synthesis of a plurality of different DNA units comprising different polypeptide encoding sequences comprising: for each DNA unit, performing polymerase chain reaction (PCR) amplification of a plurality of overlapping oligonucleotides to generate a DNA unit encoding a polypeptide segment and adding UDG-containing linkers to the 5' and 3' ends of the DNA unit by PCR amplification, thereby generating a linked DNA unit, wherein the same UDG-containing linkers are added to said different DNA units.

50. The method of claim 49 wherein said plurality comprises more than 50 different DNA units.

51. A method for designing a synthetic gene, the method comprising the steps of:
providing a reference amino acid sequence;
reverse translating the amino acid sequence to a randomized nucleotide sequence which encodes the amino acid sequence using a random selection of codons which have been, optionally, optimized for a codon preference of a host organism;
providing one or more parameters for positions of restriction sites on a sequence of the synthetic gene;
removing occurrences of one or more selected restriction sites from the randomized nucleotide sequence; and
inserting one or more selected restriction sites at selected positions in the randomized nucleotide sequence to generate a sequence of the synthetic gene.

52. The method of claim 51, further comprising:
generating a set of overlapping oligonucleotide sequences which together comprise a sequence of the synthetic gene.

53. The method of claim 54, wherein:
one or more parameters for positions of restriction sites on a sequence of the synthetic gene comprises one or more preselected restriction sites at selected positions.
54. The method of claim 51, wherein the inserting of restriction sites comprises:
identifying selected positions for insertion of a selected restriction site in the randomized nucleotide sequence;
performing a substitution in the nucleotide sequence at the selected position such that the selected restriction site sequence is created at the selected position;
translating the substituted sequence to an amino acid sequence;
accepting a substitution wherein the translated amino acid sequence is identical to the reference amino acid sequence at the selected position and rejecting a substitution wherein the translated amino acid sequence is different from the reference amino acid sequence at the selected position.
55. The method of claim 54, wherein a translated amino acid sequence identical to the reference amino acid sequence comprises substitution of an amino acid with a similar amino acid at the selected position.
56. The method of claim 51, wherein the reference amino acid sequence is of a naturally occurring polypeptide segment.
57. A system for designing a synthetic gene, including a computer processor configured to:
provide a reference amino acid sequence;
reverse translate the amino acid sequence to a randomized nucleotide sequence which encodes the amino acid sequence using a random selection of codons which have been, optionally, optimized for a codon preference of a host organism;
provide one or more parameters for positions of restriction sites on a sequence of the synthetic gene;

remove occurrences of one or more selected restriction sites from the randomized nucleotide sequence;

insert one or more selected restriction sites at selected positions in the randomized nucleotide sequence to generate a sequence of the synthetic gene; and

generate a set of overlapping oligonucleotide sequences which together comprise a sequence of the synthetic gene.

58. A computer readable storage medium containing computer executable code for designing a synthetic gene by instructing a computer to operate as follows:

provide a reference amino acid sequence;

reverse translate the amino acid sequence to a randomized nucleotide sequence which encodes the amino acid sequence using a random selection of codons which have been, optionally, optimized for a codon preference of a host organism;

provide one or more parameters for positions of restriction sites on a sequence of the synthetic gene;

remove occurrences of one or more selected restriction sites from the randomized nucleotide sequence;

insert one or more selected restriction sites at selected positions in the randomized nucleotide sequence to generate a sequence of the synthetic gene; and

generate a set of overlapping oligonucleotide sequences which together comprise a sequence of the synthetic gene.

59. A method for analyzing a nucleotide sequence of a synthon, the method comprising:

providing a sequence of a synthetic gene, wherein the synthetic gene is divided into a plurality of synthons;

providing sequences of a plurality of synthon samples wherein each synthon of the plurality of synthons is cloned in a vector;

providing a sequence of the vector without an insert;

eliminating vector sequences from the sequence of the cloned synthon;

constructing a contig map of sequences of the plurality of synthons;

aligning the contig map of sequences with the sequence of the synthetic gene; and
identifying a measure of alignment for each of the plurality of synthons.

60. The method of claim 59, further comprising:
identifying errors in one or more synthon sequences; and
reporting one or more informations selected from the group consisting of: a
ranking of synthon samples by degree of alignment, an error in the sequence of a synthon
sample, and identity of a synthon that can be repaired.
61. A system for high through-put synthesis of synthetic genes comprising:
at least one source microwell plate containing oligonucleotides for assembly PCR
a source for an assembly PCR amplification mixture
a source for LIC extension primer mixture
at least one PCR microwell plate for amplification of oligonucleotides
a liquid handling device which
retrieves a plurality of predetermined sets of oligonucleotides from the
source microwell plate(s)
combines the predetermined sets and the amplification mixture in wells of
the at least one PCR microwell plate;
retrieves LIC extension primer mixture; and
combines the LIC extension primer mixture and amplicons in a well of the
at least one PCR microwell plate; and
a heat source for PCR amplification configured to accept the at least one PCR
microwell plate.
62. The system of claim 1 further comprising a source for at least two assembly
vectors.
63. An open reading frame vector having a structure selected from
a) Internal type: 4-[7-*]-[*-8]-3;
b) Left-edge type: 4-[7-1]-[*-8]-3; and

c) Right-edge type: 4-[7-*]-[6-8]-3;

wherein 7 and 8 are recognition sites for Type IIS restriction enzymes which cut to produce compatible overhangs “*” ; 1 and 6 are Type II restriction enzyme sites that are optionally present; and 3 and 4 are recognition sites for restriction enzymes with 8-basepair recognition sites.

64. The vector of claim 63 wherein 1 is Nde I, 6 is Eco RI, 4 is Not I and 3 is Pac I.

FIGURE 1




FIGURE 3

FIGURE 3A




FIGURE 3B





FIGURE 4

A4. Vector pKos293-172-2



4B. Vector pKos293-172-A76




FIGURE 5





FIGURE 6



6B.





FIGURE 7
Stitching and Selection Strategy






FIGURE 8




FIGURE 9. GeMS algorithm chart




FIGURE 10A. Codon optimization




FIGURE 10B. Generation of randomized & optimized gene sequence




FIGURE 11. Restriction site removal




FIGURE 12. Restriction Site insertion




FIGURE 13. Generation of oligonucleotides for synthetic gene.

FIGURE 14




FIGURE 15







FIGURE 16



168






FIGURE 17
FIGURE 17 A




FIGURE 17 B




FIGURE 17 C




FIGURE 17 D




FIGURE 17 E





FIGURE 18






Figure 19